HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 Linux 18NOV21:22:15:1518NOV21:22:15:15 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS ADDV SASDATA 9.4 Linux 18NOV21:22:15:1518NOV21:22:15:15 HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000006600000000000000000000 STUDYID Study Identifier USUBJID Unique Subject Identifier DOMAIN Domain Abbreviation SUBJID Subject Identifier for the Study SITEID Study Site Identifier (AGE Age ,SEX Sex 4)RACE Race 5 TRTSDT Date of First Exposure to Treatment DATE ^ TRTEDT Date of Last Exposure to Treatment DATE f ARM Description of Planned Arm n ARMCD Planned Arm Code ‰ ACTARM Description of Actual Arm ’ ACTARMCDActual Arm Code ­TRT01P Planned Treatment for Period 01 ¶TRT01A Actual Treatment for Period 01 ŃTRT01PN Planned Treatment for Period 01 (N) ģTRT01AN Actual Treatment for Period 01 (N) ō AGEGR1 Pooled Age Group 1 üAGEGR1N Pooled Age Group 1 (N) DVSEQ Sequence Number  DVSPID Sponsor-Defined Identifier ČDVTERM Protocol Deviation Term  2DVTERM1 Protocol Deviation Term 1 čDVDECOD Protocol Deviation Coded Term EPOCH Epoch 1ACTSITE Actual Site of Deviation Occurrence E!DESGTOR Visit Designator ICAPE Confirmed Analysis Population Exclusion j DVCAT Category for Protocol Deviation { DVSTDTC Start Date/Time of Deviation ˆ DVSTDY Study Day of Start of Deviation ’!ASTDT Analysis Start Date DATE š"PREFL Pre-treatment Flag ¢#TRPFL On Treatment Flag £$RANDFL Randomized Population Flag ¤%PHASE Study Phase „&PHASEN Study Phase (N) ¬'COHORT Cohort Group “(COHORTN Cohort Group (N) µ)DOSALVL Actual Dosing Level ½*DOSALVLNActual Dosing Level (N) ¾+DOSPLVL Planned Dosing Level Ę,DOSPLVLNPlanned Dosing Level (N) Ē-DS3KFL FU to 6MPD2 Ļ.AGEGR3N Pooled Age Group 3 (N) Š/AGEGR3 Pooled Age Group 3 Ų0AGEGR4N Pooled Age Group 4 (N) Ł 1AGEGR4 Pooled Age Group 4 į2HIVFL HIV Positive Subjects Flag ģ3AGETR01 Age at Vaccination 01 ķ4TRTSDTM Datetime of First Exposure to Treatment DATETIME õ5TRTEDTM Datetime of Last Exposure to Treatment DATETIME ż6TR01SDTMDatetime of First Exposure in Period 01 DATETIME 7TR01EDTMDatetime of Last Exposure in Period 01 DATETIME  8TR02SDTMDatetime of First Exposure in Period 02 DATETIME 9TR02EDTMDatetime of Last Exposure in Period 02 DATETIME $:VAX101 Vaccination 01 %$;VAX102 Vaccination 02 I$VAX202 Vaccination 04 µ?VAX20U Vaccination Unplanned in Period 02 Ł@VAX20UDTVaccination Date Unplanned in Period 02 DATE ŚAUNBLNDDTTreatment Unblinded Date DATE āBSAFFL Safety Population Flag ź HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 C4591001C4591001 1005 10051317DV100513171005AĄFWHITE DVĄDV×BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z9W1BYUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1005Potential ReVax Initial Contact NO Non-Important2021-05-13BĪDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr^¦ÄHr|ņxHr^¦ÄHr|ņx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051328DV100513281005AąFWHITE DVĄDVÖBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z9W1F3Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1005Potential ReVax Initial Contact NO Non-Important2021-05-13BĪDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr^ŠHr{¼ Hr^ŠHr{¼ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051339DV100513391005AąFWHITE DVĮDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEAMG1Other Informed Consent Informed Consent FOLLOW-UP 1005Consent NO Non-Important2021-03-04B‡DWG YYPhase 3A@ . . .N. A12-15 YearsNAąHr`ĢHsLHr`ĢHr{óHsr|pHsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051339DV100513391005AąFWHITE DVĮDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z9W1F6Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1005Potential ReVax Initial Contact NO Non-Important2021-05-13BĶDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr`ĢHsLHr`ĢHr{óHsr|pHsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051339DV100513391005AąFWHITE DVĮDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XU5CQNProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-06-09BčDWØ YYPhase 3A@ . . .N. A12-15 YearsNAąHr`ĢHsLHr`ĢHr{óHsr|pHsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051413DV100514131005AšMWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1USCBW1Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1005Potential ReVax Initial Contact NO Non-Important2021-04-01BmDWc YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§(HrĀŪHr§(HrĀŪ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWcYC4591001C4591001 1005 10051414DV100514141005AŠFWHITE DV÷DWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OT8117Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1005V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr§E Hs„²¬Hr§E HrĀņHs}"tHs„²¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051414DV100514141005AŠFWHITE DV÷DWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBFVLProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-25B£DW™ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr§E Hs„²¬Hr§E HrĀņHs}"tHs„²¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051414DV100514141005AŠFWHITE DV÷DWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YY0VDAVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-06-25BĀDWø YYPhase 3A@ . . .N. A12-15 YearsNAŠHr§E Hs„²¬Hr§E HrĀņHs}"tHs„²¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051417DV100514171005AŠFWHITE DVłDWéPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZGA15PVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-08-13BńDWé YYPhase 3A@ . . .N. A12-15 YearsNAŠHr©ōHsęFŒHr©ōHrŅœHsʶxHsęFŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĶYC4591001C4591001 1005 10051419DV100514191005AšFWHITE DVłDWTPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OT811BVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1005V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ%ĢHs"(HrŖ%ĢHrĀž¼Hsf\Hs"(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1005 10051419DV100514191005AšFWHITE DVłDWTPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UEHGUJOther Informed Consent Informed Consent OPEN LABEL TREATMENT1005Consent NO Non-Important2021-02-24BGDW? YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ%ĢHs"(HrŖ%ĢHrĀž¼Hsf\Hs"(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1005 10051419DV100514191005AšFWHITE DVłDWTPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XK5AREVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1005COVID_A1 NO Non-Important2021-06-02B©DW” YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ%ĢHs"(HrŖ%ĢHrĀž¼Hsf\Hs"(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1005 10051420DV100514201005AĄFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZH24PKNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK8 NO Non-Important2021-03-31BjDWb YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖ$(HrĀżĢHrŖ$(HrĀżĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051420DV100514201005AĄFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1VNE4OGVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK10 NO Non-Important2021-04-14BxDWp YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖ$(HrĀżĢHrŖ$(HrĀżĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051420DV100514201005AĄFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHJ095Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1005SSWAB_WEEK22 NO Non-Important2021-07-13BŅDWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖ$(HrĀżĢHrŖ$(HrĀżĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051420DV100514201005AĄFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z70K1JVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1005V4_MONTH6_L NO Non-Important2021-07-19BŲDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖ$(HrĀżĢHrŖ$(HrĀżĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051421DV100514211005AŠMBLACK OR AFRICAN AMERICAN DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBFVOProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-18B™DW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr«u0HsĻ¤Hr«u0HrĒ!¤Hssß HsĻ¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051421DV100514211005AŠMBLACK OR AFRICAN AMERICAN DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z9VJW3Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1005V103_MONTH1 NO Non-Important2021-07-19B×DWŠ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr«u0HsĻ¤Hr«u0HrĒ!¤Hssß HsĻ¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051422DV100514221005AĄMBLACK OR AFRICAN AMERICAN DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z9VJW6Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1005V103_MONTH1 NO Non-Important2021-07-19B×DWŠ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«wHsĻhHr«wHrĒ"XHssßHHsĻhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051424DV100514241005AŠMWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTC10GVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1005V2_VAX2_L NO Non-Important2021-01-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬o€HrČDHr¬o€HrČD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1005 10051424DV100514241005AŠMWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1SZFK08Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005V202_SURVEIL_SWAB|637848674981060NO Non-Important2021-03-19B\DWV YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬o€HrČDHr¬o€HrČD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1005 10051424DV100514241005AŠMWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1VIS4UEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005POT_COVID_CONVA|640515884311050 NO Non-Important2021-04-16BxDWr YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬o€HrČDHr¬o€HrČD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1005 10051425DV100514251005AŠFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZH24PNNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK6 NO Non-Important2021-04-03BkDWe YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬”LHrČCĢHr¬”LHrČCĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051425DV100514251005AŠFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHUSS7Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK8 NO Non-Important2021-04-09BqDWk YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬”LHrČCĢHr¬”LHrČCĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051427DV100514271005AąFWHITE DVžDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1SSTN91Nasal swab collected at a visit where it was not required Laboratory VACCINATION 1005COVID A NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr°zDHsŽųHr°zDHrĢ%PHsrYĄHsŽųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AąFWHITE DVžDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OTC0WAProcedure not performed as part of vital signs. Procedures/Tests VACCINATION 1005V2_VAX2_L NO Non-Important2021-01-08BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr°zDHsŽųHr°zDHrĢ%PHsrYĄHsŽųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AąFWHITE DVžDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1RVVF3JVisit conducted when not required per protocol Visit Schedule VACCINATION 1005COVID_A1 NO Non-Important2021-02-04B.DW+ YYPhase 3A@ . . .N. A12-15 YearsNAąHr°zDHsŽųHr°zDHrĢ%PHsrYĄHsŽųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AąFWHITE DVžDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R54FU9Lab performed out of window Laboratory FOLLOW-UP 1005SSWAB_WEEK4 NO Non-Important2021-03-11BQDWN YYPhase 3A@ . . .N. A12-15 YearsNAąHr°zDHsŽųHr°zDHrĢ%PHsrYĄHsŽųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AąFWHITE DVžDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1RVVUHHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK4 NO Non-Important2021-03-11BQDWN YYPhase 3A@ . . .N. A12-15 YearsNAąHr°zDHsŽųHr°zDHrĢ%PHsrYĄHsŽųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AąFWHITE DVžDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XRTK89Procedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-06-07B©DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAąHr°zDHsŽųHr°zDHrĢ%PHsrYĄHsŽųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051431DV100514311005AąMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1UEIK9LOther Informed Consent Informed Consent FOLLOW-UP 1005Consent NO Non-Important2021-02-09B2DW0 YYPhase 3A@ . . .Y. A12-15 YearsNAąHr±¶pHrĶ„ąHr±¶pHrĶ„ą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051438DV100514381005AŠMWHITE DV’DW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBFVRProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-27BDW› YYPhase 3A@ . . .N. A12-15 YearsNAŠHr±ŚLHs›!„Hr±ŚLHrĶ«ŒHsjHHs›!„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051445DV100514451005AąFWHITE DV’DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZH24PQNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK8 NO Non-Important2021-04-14BrDWp YYPhase 3A@ . . .N. A12-15 YearsNAąHr²8Hs™µLHr²8HrĶzTHs~¬Hs™µLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051445DV100514451005AąFWHITE DV’DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZHUSSBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK10 NO Non-Important2021-04-22BzDWx YYPhase 3A@ . . .N. A12-15 YearsNAąHr²8Hs™µLHr²8HrĶzTHs~¬Hs™µLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051445DV100514451005AąFWHITE DV’DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZH2CQFNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK12 NO Non-Important2021-05-11BDW‹ YYPhase 3A@ . . .N. A12-15 YearsNAąHr²8Hs™µLHr²8HrĶzTHs~¬Hs™µLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051445DV100514451005AąFWHITE DV’DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZHUSSEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK14 NO Non-Important2021-05-12BŽDWŒ YYPhase 3A@ . . .N. A12-15 YearsNAąHr²8Hs™µLHr²8HrĶzTHs~¬Hs™µLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051445DV100514451005AąFWHITE DV’DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBFVUProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-26BœDWš YYPhase 3A@ . . .N. A12-15 YearsNAąHr²8Hs™µLHr²8HrĶzTHs~¬Hs™µLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051445DV100514451005AąFWHITE DV’DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Y8SL8EProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-06-16B±DWÆ YYPhase 3A@ . . .N. A12-15 YearsNAąHr²8Hs™µLHr²8HrĶzTHs~¬Hs™µLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051447DV100514471005AąFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS2TLKOther Informed Consent Informed Consent VACCINATION 1005Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĢ$`HrēŹDHrĢ$`HrēŹD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051447DV100514471005AąFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS2TLQOther Informed Consent Informed Consent VACCINATION 1005Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĢ$`HrēŹDHrĢ$`HrēŹD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051448DV100514481005AĄFWHITE DWDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS2TM2Other Informed Consent Informed Consent VACCINATION 1005Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĢCHs™ųHrĢCHrēÜHs~šHs™ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1005 10051448DV100514481005AĄFWHITE DWDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1UEIVHJOther Informed Consent Informed Consent FOLLOW-UP 1005Consent NO Non-Important2021-03-01B2DWD YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĢCHs™ųHrĢCHrēÜHs~šHs™ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1005 10051448DV100514481005AĄFWHITE DWDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZH2CQJNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK4 NO Non-Important2021-04-02BRDWd YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĢCHs™ųHrĢCHrēÜHs~šHs™ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1005 10051448DV100514481005AĄFWHITE DWDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1UIIRQ1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK6 NO Non-Important2021-04-05BUDWg YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĢCHs™ųHrĢCHrēÜHs~šHs™ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1005 10051448DV100514481005AĄFWHITE DWDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YW5EXQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1005Consent NO Non-Important2021-05-26BˆDWš YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĢCHs™ųHrĢCHrēÜHs~šHs™ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1005 10051450DV100514501005AąMASIAN DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WTN7QNVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK10 NO Non-Important2021-04-26BjDW| YYPhase 3A@ . . .N. A12-15 YearsNAąHrĢ^Hs—mxHrĢ^HrčPHs{Å<Hs—mxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051450DV100514501005AąMASIAN DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBFW7Procedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-24B†DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĢ^Hs—mxHrĢ^HrčPHs{Å<Hs—mxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051450DV100514501005AąMASIAN DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y8SL8JProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-06-14B›DW­ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĢ^Hs—mxHrĢ^HrčPHs{Å<Hs—mxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1005 10051451DV100514511005AšFWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTTAVCProcedure/Test not performed per protocol Procedures/Tests SCREENING 1005V1_DAY1_VAX1_L NO Non-Important2021-01-11ĮDWYNYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŖ`Hrź•HrĶŖ`Hrź•..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWåYC4591001C4591001 1006 10061183DV100611831006AąMMULTIPLE DVéDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OT811HVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-07B'DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr”±°Hs,”Hr”±°HrĘĢHsv/ČHs,”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061183DV100611831006AąMMULTIPLE DVéDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OS305PVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-07B'DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr”±°Hs,”Hr”±°HrĘĢHsv/ČHs,”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061183DV100611831006AąMMULTIPLE DVéDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1POJ18NProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1006V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-09BHDW0 YYPhase 3A@ . . .N. A12-15 YearsNAąHr”±°Hs,”Hr”±°HrĘĢHsv/ČHs,”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061190DV100611901006AšMWHITE DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1XOV7IRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK4 NO Non-Important2021-04-24BDWz YYPhase 3A@ . . .Y. A12-15 YearsNAšHr—M0Hr±Į8Hr—M0Hr±Į8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061190DV100611901006AšMWHITE DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM22LNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1006SSWAB_WEEK6 NO Non-Important2021-05-12B¢DWŒ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr—M0Hr±Į8Hr—M0Hr±Į8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061190DV100611901006AšMWHITE DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YCOMHGVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-05-15B„DW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr—M0Hr±Į8Hr—M0Hr±Į8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061201DV100612011006AĄMWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z4PJFHVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006V4_MONTH6_L NO Non-Important2021-07-07BŁDWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜ōxHr“`šHr˜ōxHr“`š..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061203DV100612031006AŠFWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OSO0CLVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1006V2_VAX2_L NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™XHr±×øHr™XHr±×ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1006 10061203DV100612031006AŠFWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YCQC4RVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK6 NO Non-Important2021-05-03B˜DWƒ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™XHr±×øHr™XHr±×ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1006 10061203DV100612031006AŠFWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZMMT2FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-05-27B°DW› YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™XHr±×øHr™XHr±×ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1006 10061209DV100612091006AŠMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMMT2JVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-05-25B­DW™ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrš\Hr³čHrš\Hr³č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061214DV100612141006AąMBLACK OR AFRICAN AMERICAN DVķDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZHUT27Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK8 NO Non-Important2021-05-03B—DWƒ YYPhase 3A@ . . .N. A12-15 YearsNAąHršSHs £„HršSHr³Z¬HssŻ¤Hs £„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061214DV100612141006AąMBLACK OR AFRICAN AMERICAN DVķDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XNGGW5Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006COVID_A1 NO Non-Important2021-05-18B¦DW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHršSHs £„HršSHr³Z¬HssŻ¤Hs £„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061214DV100612141006AąMBLACK OR AFRICAN AMERICAN DVķDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YNZMAVVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-06-21BČDW“ YYPhase 3A@ . . .N. A12-15 YearsNAąHršSHs £„HršSHr³Z¬HssŻ¤Hs £„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061219DV100612191006AąMWHITE DVšDWŪPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORCDBKVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1006V2_VAX2_L NO Non-Important2020-12-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHrótHsŌ¤HrótHr“SHs˜oHHsŌ¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1006 10061219DV100612191006AąMWHITE DVšDWŪPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y29BS2Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006COVID_A1 NO Non-Important2021-06-11B»DWŖ YYPhase 3A@ . . .N. A12-15 YearsNAąHrótHsŌ¤HrótHr“SHs˜oHHsŌ¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1006 10061219DV100612191006AąMWHITE DVšDWŪPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZMMT2MVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK6 NO Non-Important2021-06-11B»DWŖ YYPhase 3A@ . . .N. A12-15 YearsNAąHrótHsŌ¤HrótHr“SHs˜oHHsŌ¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1006 10061219DV100612191006AąMWHITE DVšDWŪPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZCT7K7Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-07-30BģDWŪ YYPhase 3A@ . . .N. A12-15 YearsNAąHrótHsŌ¤HrótHr“SHs˜oHHsŌ¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1006 10061224DV100612241006AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMMT8JVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-07-07BÕDWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrž=HHr¹”ČHrž=HHr¹”Č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061224DV100612241006AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z6G6W8Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006V4_MONTH6_L NO Non-Important2021-07-08BÖDWÅ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrž=HHr¹”ČHrž=HHr¹”Č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061230DV100612301006AąFMULTIPLE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OVP24TNasal swab not collected for the visit where it is required Laboratory VACCINATION 1006V2_VAX2_L NO Non-Important2020-12-31BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŸŖpHr½½0HrŸŖpHr½½0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1006 10061230DV100612301006AąFMULTIPLE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZQO1UVNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1006COVID_A NO Non-Important2021-08-10BöDWę YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŸŖpHr½½0HrŸŖpHr½½0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1006 10061231DV100612311006AĄFWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHUT2AVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK10 NO Non-Important2021-05-26BŖDWš YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŸ°LHr¹¦<HrŸ°LHr¹¦<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061232DV100612321006AŠFWHITE DVńDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZHUT2DVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK4 NO Non-Important2021-04-13BDWo YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŸµ°Hs¢<HrŸµ°Hr»gˆHssö@Hs¢<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061233DV100612331006AšMWHITE DVńDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OT811QVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1006V2_VAX2_L NO Non-Important2020-12-29BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ“„Hs¢xHrŸ“„Hr»gÄHssö|Hs¢xPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061241DV100612411006AąFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV6XRJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-06-04B²DW£ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr ŌĢHr¹é€Hr ŌĢHr¹é€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061247DV100612471006AŠFWHITE DVóDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PAG6XISerology sample not collected Laboratory FOLLOW-UP 1006V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-28B2DW$ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢^HsŠSĢHr¢^Hr»`¼Hsn®`HsŠSĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061247DV100612471006AŠFWHITE DVóDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZH10SVVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1006V103_MONTH1 NO Non-Important2021-07-12B×DWÉ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢^HsŠSĢHr¢^Hr»`¼Hsn®`HsŠSĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061249DV100612491006AšFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMMT8MVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-11B·DWŖ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr£H°Hr½§ Hr£H°Hr½§ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1006 10061250DV100612501006AŠMWHITE DVōDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y55S2VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK6 NO Non-Important2021-05-06B“DW† YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£IdHs©ž Hr£IdHr½§ÜHsv PHs©ž Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1006 10061250DV100612501006AŠMWHITE DVōDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YY0VDNVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-06-28BČDW» YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£IdHs©ž Hr£IdHr½§ÜHsv PHs©ž Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1006 10061254DV100612541006AąFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P85LFLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006COVID_A1 NO Non-Important2021-02-02B6DW) YYPhase 3A@ . . .Y. A12-15 YearsNAąHr£rąHr¼ōHr£rąHr¼ō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061256DV100612561006AšFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMMT8SVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK6 NO Non-Important2021-05-04B‘DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr£©ōHr¼ØÜHr£©ōHr¼ØÜ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061256DV100612561006AšFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZMMT8PVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-12BøDW« YYPhase 3A@ . . .Y. A12-15 YearsNAšHr£©ōHr¼ØÜHr£©ōHr¼ØÜ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061258DV100612581006AąMNATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERDV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMN4C1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-24BĮDW· YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§$”HrÄ!\Hr§$”HrÄ!\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061259DV100612591006AšFWHITE DV÷DWoPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1VGEQO9Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-04-13ByDWo YYPhase 3A@ . . .N. A12-15 YearsNAšHr§8ųHsEZģHr§8ųHrÄ3,Hs$h“HsEZģPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW@YC4591001C4591001 1006 10061261DV100612611006AąMWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMN4C4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-22BæDWµ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§ HrÄ3¤Hr§ HrÄ3¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1006 10061262DV100612621006AšMWHITE DV÷DWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z4PJFLVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-07-07BĪDWÄ YYPhase 3A@ . . .N. A12-15 YearsNAšHr§ššHsµz\Hr§ššHrÅÖ<Hs}.hHsµz\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061267DV100612671006AšFASIAN DVųDWéPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PG7JLHNasal swab not collected by site staff prior to vaccination. Laboratory VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrØ°¬Hsę‹8HrØ°¬HrŚœ¬HsČSpHsę‹8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŅYC4591001C4591001 1006 10061267DV100612671006AšFASIAN DVųDWéPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1PG76QCProcedure not performed as part of vital signs. Procedures/Tests VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrØ°¬Hsę‹8HrØ°¬HrŚœ¬HsČSpHsę‹8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŅYC4591001C4591001 1006 10061267DV100612671006AšFASIAN DVųDWéPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QZSYM3Other lab deviation Laboratory VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-22B'DW YYPhase 3A@ . . .N. A12-15 YearsNAšHrØ°¬Hsę‹8HrØ°¬HrŚœ¬HsČSpHsę‹8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŅYC4591001C4591001 1006 10061269DV100612691006AąMWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PFF411Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006COVID_A1 NO Non-Important2021-02-10B:DW1 YYPhase 3A@ . . .Y. A12-15 YearsNAąHrØė€HrÅŚģHrØė€HrÅŚģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061269DV100612691006AąMWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1VRXXYCVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006COVID_B1 NO Non-Important2021-04-27B†DW} YYPhase 3A@ . . .Y. A12-15 YearsNAąHrØė€HrÅŚģHrØė€HrÅŚģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061269DV100612691006AąMWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZMN4C7Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-23BæDW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrØė€HrÅŚģHrØė€HrÅŚģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061269DV100612691006AąMWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YY0VDQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006V4_MONTH6_L NO Non-Important2021-06-29BÅDW¼ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrØė€HrÅŚģHrØė€HrÅŚģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061272DV100612721006AŠFBLACK OR AFRICAN AMERICAN DVłDW‘BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OXOQ5YParticipant met exclusion criterion #01 (participant having other medical or psychiatric condition) Inclusion/Exclusion VACCINATION 1006V1_DAY1_VAX1_L YES-POP2,YES-POP3Important 2020-12-16ADVł YYPhase 3A@ . . .N. A12-15 YearsNAŠHr©ļäHsr”Hr©ļäHsr”..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061274DV100612741006AąFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YBCOE9Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-05-25B”DW™ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŖ?ŠHrČ1ĄHrŖ?ŠHrČ1Ą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061274DV100612741006AąFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YV6XRNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK10 NO Non-Important2021-06-15B¶DW® YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŖ?ŠHrČ1ĄHrŖ?ŠHrČ1Ą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061274DV100612741006AąFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZD1VOBNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-07-04BÉDWĮ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŖ?ŠHrČ1ĄHrŖ?ŠHrČ1Ą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061276DV100612761006AšFWHITE DVśDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YCQC4VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK8 NO Non-Important2021-05-11B’DW‹ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«KšHs”³(Hr«KšHrÅÖ“HstŠ8Hs”³(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061277DV100612771006AŠFWHITE DVśDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZE8TSOSerology sample not collected Laboratory FOLLOW-UP 1006V201_SURVEIL_CONSENT NO Non-Important2021-03-12BVDWO YYPhase 3A@ . . .N. A12-15 YearsNAŠHr«pųHsŽ8 Hr«pųHrČpHss HsŽ8 Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061278DV100612781006AŠMWHITE DVśDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R1DHHZNasal swab not collected for the visit where it is required Laboratory VACCINATION 1006COVID_A NO Non-Important2021-01-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr«ˆ¤HrÄOHr«ˆ¤HrÄO..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¾YC4591001C4591001 1006 10061280DV100612801006AšMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z2PN6TVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK14 NO Non-Important2021-07-06BŹDWĆ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr«¬HrĒ6DHr«¬HrĒ6D..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061282DV100612821006AŠMWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XOV7IVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK10 NO Non-Important2021-05-13B“DW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬‹ÜHrČ2tHr¬‹ÜHrČ2t..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1006 10061284DV100612841006AąMWHITE DVūDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YZ24R2Subject/LAR did not sign the ICD but gave verbal consent Informed Consent OPEN LABEL TREATMENT1006Consent NO Non-Important2021-06-15B“DW® YYPhase 3A@ . . .N. A12-15 YearsNAąHr¬ąHs˜ÅLHr¬ąHrȅ0Hs|¶¤Hs˜ÅLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1006 10061286DV100612861006AąMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z7HG8IVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK16 NO Non-Important2021-07-09BÉDWĘ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr°§ųHrĢytHr°§ųHrĢyt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1006 10061287DV100612871006AŠMWHITE DVžDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y71SN1Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1006V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14B‘DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°æąHrĢ„xHr°æąHrĢ„x..Placebo Placebo .DWŽYC4591001C4591001 1006 10061287DV100612871006AŠMWHITE DVžDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y71SMXReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1006V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-11B­DWŖ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°æąHrĢ„xHr°æąHrĢ„x..Placebo Placebo .DWŽYC4591001C4591001 1006 10061299DV100612991006AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z7HG8MVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK14 NO Non-Important2021-07-16BĘDWĶ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr½°LHrŚż“Hr½°LHrŚż“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071409DV100714091007AŠMASIAN DVĀDW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1O6HZE1Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-01B)DVź YYPhase 3A@ . . .N. A12-15 YearsNAŠHrad|Hsn€Hrad|Hsn€..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071409DV100714091007AŠMASIAN DVĀDW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1OE7S8MVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2020-12-15B7DVų YYPhase 3A@ . . .N. A12-15 YearsNAŠHrad|Hsn€Hrad|Hsn€..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071409DV100714091007AŠMASIAN DVĀDW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA€1-1X12I7NVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V4_MONTH6_L NO Non-Important2021-05-10BÉDWŠ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrad|Hsn€Hrad|Hsn€..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071409DV100714091007AŠMASIAN DVĀDW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZBKAZ3Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1007Potential ReVax Initial Contact NO Non-Important2021-05-17BŠDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrad|Hsn€Hrad|Hsn€..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071409DV100714091007AŠMASIAN DVĀDW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZZ4D8ZProcedure not recorded in source documentation as having been performed. Procedures/Tests REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-27BŚDW› YYPhase 3A@ . . .N. A12-15 YearsNAŠHrad|Hsn€Hrad|Hsn€..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071409DV100714091007AŠMASIAN DVĀDW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZZ4D95Procedure not recorded in source documentation as having been performed. Procedures/Tests REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-27BŚDW› YYPhase 3A@ . . .N. A12-15 YearsNAŠHrad|Hsn€Hrad|Hsn€..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071409DV100714091007AŠMASIAN DVĀDW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZZ4DCVProcedure not recorded in source documentation as having been performed. Procedures/Tests REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-27BŚDW› YYPhase 3A@ . . .N. A12-15 YearsNAŠHrad|Hsn€Hrad|Hsn€..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071409DV100714091007AŠMASIAN DVĀDW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZZ4DCYProcedure not recorded in source documentation as having been performed. Procedures/Tests REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-27BŚDW› YYPhase 3A@ . . .N. A12-15 YearsNAŠHrad|Hsn€Hrad|Hsn€..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071414DV100714141007AąMWHITE DVĀDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTN7QVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK4 NO Non-Important2021-04-05B¦DWg YYPhase 3A@ . . .N. A12-15 YearsNAąHrao¼Hs—aHHrao¼Hr}+0Hsu|Hs—aHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071414DV100714141007AąMWHITE DVĀDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YHI2APOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BŅDW“ YYPhase 3A@ . . .N. A12-15 YearsNAąHrao¼Hs—aHHrao¼Hr}+0Hsu|Hs—aHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071414DV100714141007AąMWHITE DVĀDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YBCOECVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-06-14BģDW­ YYPhase 3A@ . . .N. A12-15 YearsNAąHrao¼Hs—aHHrao¼Hr}+0Hsu|Hs—aHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071415DV100714151007AĄMWHITE DVĀDVóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z33ZY0Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsSCREENING 1007V2_VAX2_L YES-POP2,YES-POP3Important 2020-06-03ĀDV5YNYPhase 3A@ . . .N. A12-15 YearsNAĄHrayHr”ŽHrayHr”Ž..Placebo Placebo .DWŒYC4591001C4591001 1007 10071415DV100714151007AĄMWHITE DVĀDVóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1O4BQN6Subject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1007V1_DAY1_VAX1_L NO Non-Important2020-11-06BDVŃ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrayHr”ŽHrayHr”Ž..Placebo Placebo .DWŒYC4591001C4591001 1007 10071415DV100714151007AĄMWHITE DVĀDVóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1OFD7VRProcedure not performed as part of vital signs. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-10B2DVó YYPhase 3A@ . . .N. A12-15 YearsNAĄHrayHr”ŽHrayHr”Ž..Placebo Placebo .DWŒYC4591001C4591001 1007 10071415DV100714151007AĄMWHITE DVĀDVóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1OSO0FAVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-10B2DVó YYPhase 3A@ . . .N. A12-15 YearsNAĄHrayHr”ŽHrayHr”Ž..Placebo Placebo .DWŒYC4591001C4591001 1007 10071415DV100714151007AĄMWHITE DVĀDVóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1OSO0FDVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-10B2DVó YYPhase 3A@ . . .N. A12-15 YearsNAĄHrayHr”ŽHrayHr”Ž..Placebo Placebo .DWŒYC4591001C4591001 1007 10071415DV100714151007AĄMWHITE DVĀDVóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1OT9EZAVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-07BNDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrayHr”ŽHrayHr”Ž..Placebo Placebo .DWŒYC4591001C4591001 1007 10071415DV100714151007AĄMWHITE DVĀDVóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X6ZYPNReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BĢDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrayHr”ŽHrayHr”Ž..Placebo Placebo .DWŒYC4591001C4591001 1007 10071428DV100714281007AĄMASIAN DVĀDV×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z33ZY3Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsFOLLOW-UP 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-05BÄDW… YYPhase 3A@ . . .N. A12-15 YearsNAĄHraØ°Hr}Y˜HraØ°Hr}Y˜..Placebo Placebo .DWYC4591001C4591001 1007 10071428DV100714281007AĄMASIAN DVĀDV×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZBKAZ6Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1007Potential ReVax Initial Contact NO Non-Important2021-05-13BĢDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHraØ°Hr}Y˜HraØ°Hr}Y˜..Placebo Placebo .DWYC4591001C4591001 1007 10071428DV100714281007AĄMASIAN DVĀDV×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z340H3Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-05BćDW¤ YYPhase 3A@ . . .N. A12-15 YearsNAĄHraØ°Hr}Y˜HraØ°Hr}Y˜..Placebo Placebo .DWYC4591001C4591001 1007 10071429DV100714291007AŠFWHITE DVĀDV×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y71SN4Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BĢDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHra«ųHr}\ąHra«ųHr}\ą..Placebo Placebo .DWŒYC4591001C4591001 1007 10071429DV100714291007AŠFWHITE DVĀDV×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z340H6Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BįDW¢ YYPhase 3A@ . . .N. A12-15 YearsNAŠHra«ųHr}\ąHra«ųHr}\ą..Placebo Placebo .DWŒYC4591001C4591001 1007 10071471DV100714711007AąMWHITE DVéDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZQ9454Other Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-06-14BÅDW­ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr”ÜHr°0Hr”ÜHr°0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071471DV100714711007AąMWHITE DVéDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZQ945KOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-06-14BÅDW­ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr”ÜHr°0Hr”ÜHr°0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071472DV100714721007AŠFWHITE DVéDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTN7QYVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK2 NO Non-Important2021-04-08B‚DWj YYPhase 3A@ . . .N. A12-15 YearsNAŠHr”ń¬HsŽ,hHr”ń¬Hr°jĢHsr_`HsŽ,hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071475DV100714751007AšFWHITE DVéDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ORZHPEOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-19B3DW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr•čHr°«Hr•čHr°«..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071475DV100714751007AšFWHITE DVéDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ORZHQYOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-19B3DW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr•čHr°«Hr•čHr°«..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071478DV100714781007AąMWHITE DVéDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P947RROther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B@DW( YYPhase 3A@ . . .N. A12-15 YearsNAąHr•HsĮHr•Hr°ĮHHsv`LHsĮPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071478DV100714781007AąMWHITE DVéDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P947RZOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B@DW( YYPhase 3A@ . . .N. A12-15 YearsNAąHr•HsĮHr•Hr°ĮHHsv`LHsĮPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071478DV100714781007AąMWHITE DVéDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1P947RQRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B@DW( YYPhase 3A@ . . .N. A12-15 YearsNAąHr•HsĮHr•Hr°ĮHHsv`LHsĮPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071478DV100714781007AąMWHITE DVéDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1P947RYRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B@DW( YYPhase 3A@ . . .N. A12-15 YearsNAąHr•HsĮHr•Hr°ĮHHsv`LHsĮPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071480DV100714801007AąMWHITE DVéDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZQ94OLOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-11-30ADVé YYPhase 3A@ . . .N. A12-15 YearsNAąHr•!|HsI¤Hr•!|Hr°²ĄHsrlųHsI¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071480DV100714801007AąMWHITE DVéDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XEB7A6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B©DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr•!|HsI¤Hr•!|Hr°²ĄHsrlųHsI¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071480DV100714801007AąMWHITE DVéDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7ACOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B©DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr•!|HsI¤Hr•!|Hr°²ĄHsrlųHsI¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071480DV100714801007AąMWHITE DVéDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7B2Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B©DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr•!|HsI¤Hr•!|Hr°²ĄHsrlųHsI¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071480DV100714801007AąMWHITE DVéDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7B8Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B©DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr•!|HsI¤Hr•!|Hr°²ĄHsrlųHsI¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071481DV100714811007AĄFWHITE DVźDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZQP13IICD signed by subject/LAR had not received IRB/IEC approval Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-07B½DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr–¤Hs©‘ŲHr–¤Hr±» HsśōHs©‘ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071481DV100714811007AĄFWHITE DVźDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZQOYGKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-07B½DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr–¤Hs©‘ŲHr–¤Hr±» HsśōHs©‘ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071481DV100714811007AĄFWHITE DVźDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZQP122Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-07B½DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr–¤Hs©‘ŲHr–¤Hr±» HsśōHs©‘ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071481DV100714811007AĄFWHITE DVźDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZQP12IOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-07B½DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr–¤Hs©‘ŲHr–¤Hr±» HsśōHs©‘ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071482DV100714821007AŠFWHITE DVźDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z9OU88Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-01ADVź YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr– ĢHr±Ā Hr– ĢHr±Ā ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071482DV100714821007AŠFWHITE DVźDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z6VKZXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-15BćDWĢ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr– ĢHr±Ā Hr– ĢHr±Ā ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071483DV100714831007AšFWHITE DVźDWvPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WZ6CUNOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B9DW" YYPhase 3A@ . . .N. A12-15 YearsNAšHr–`HsNģ$Hr–`Hr±Ū“Hs3ILHsNģ$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1007 10071483DV100714831007AšFWHITE DVźDWvPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WZ6XY0Other Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B9DW" YYPhase 3A@ . . .N. A12-15 YearsNAšHr–`HsNģ$Hr–`Hr±Ū“Hs3ILHsNģ$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1007 10071483DV100714831007AšFWHITE DVźDWvPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WZ6Y09Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-03-30BxDWa YYPhase 3A@ . . .N. A12-15 YearsNAšHr–`HsNģ$Hr–`Hr±Ū“Hs3ILHsNģ$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1007 10071484DV100714841007AŠFWHITE DVźDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UEGOPQOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B9DW" YYPhase 3A@ . . .N. A12-15 YearsNAŠHr–pHsŪ Hr–pHr±ÜhHsulHsŪ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071484DV100714841007AŠFWHITE DVźDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1UEGOQ6Other Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B9DW" YYPhase 3A@ . . .N. A12-15 YearsNAŠHr–pHsŪ Hr–pHr±ÜhHsulHsŪ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071484DV100714841007AŠFWHITE DVźDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7BEOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BŖDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr–pHsŪ Hr–pHr±ÜhHsulHsŪ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071484DV100714841007AŠFWHITE DVźDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7BUOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BŖDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr–pHsŪ Hr–pHr±ÜhHsulHsŪ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071484DV100714841007AŠFWHITE DVźDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7C0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BŖDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr–pHsŪ Hr–pHr±ÜhHsulHsŪ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071484DV100714841007AŠFWHITE DVźDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEB7C6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BŖDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr–pHsŪ Hr–pHr±ÜhHsulHsŪ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071492DV100714921007AŠFWHITE DVźDVžPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z340H9Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13B¤DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr–s8Hr°ŗ|Hr–s8Hr°ŗ|..Placebo Placebo .DWŒYC4591001C4591001 1007 10071492DV100714921007AŠFWHITE DVźDVžPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSXJDXReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03B¹DW¢ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr–s8Hr°ŗ|Hr–s8Hr°ŗ|..Placebo Placebo .DWŒYC4591001C4591001 1007 10071496DV100714961007AąFASIAN DVėDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEB5K9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-02ADVė YYPhase 3A@ . . .N. A12-15 YearsNAąHr—Ā`Hs—QXHr—Ā`Hr±ŗ0Hs{¶Hs—QXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071496DV100714961007AąFASIAN DVėDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XEBGQPOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B®DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAąHr—Ā`Hs—QXHr—Ā`Hr±ŗ0Hs{¶Hs—QXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071496DV100714961007AąFASIAN DVėDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEBGQVOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B®DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAąHr—Ā`Hs—QXHr—Ā`Hr±ŗ0Hs{¶Hs—QXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071496DV100714961007AąFASIAN DVėDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEBGXZOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B®DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAąHr—Ā`Hs—QXHr—Ā`Hr±ŗ0Hs{¶Hs—QXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071496DV100714961007AąFASIAN DVėDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEBGY5Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B®DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAąHr—Ā`Hs—QXHr—Ā`Hr±ŗ0Hs{¶Hs—QXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071497DV100714971007AĄMASIAN DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YBCOEGVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08B½DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr—ÄøHr±øČHr—ÄøHr±øČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071499DV100714991007AąMWHITE DVģDV’Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X6ZYZRReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13B¢DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr™ģHr²ØHr™ģHr²Ø..Placebo Placebo .DWŒYC4591001C4591001 1007 10071499DV100714991007AąMWHITE DVģDV’Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z35AVMReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-04BøDW£ YYPhase 3A@ . . .N. A12-15 YearsNAąHr™ģHr²ØHr™ģHr²Ø..Placebo Placebo .DWŒYC4591001C4591001 1007 10071500DV100715001007AšFWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZQUFJ0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr™ØHr±Į8Hr™ØHr±Į8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071505DV100715051007AĄFWHITE DVšDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1O9K7TRAssessment of acute reaction for protocol specified timeframe after study intervention administration not performed at the vaccination visits. Procedures/Tests VACCINATION 1007V1_DAY1_VAX1_L NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .N. A12-15 YearsNAĄHrų`Hs£3ˆHrų`Hrŗ,Hs‡_<Hs£3ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071505DV100715051007AĄFWHITE DVšDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P947R2Other Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B9DW( YYPhase 3A@ . . .N. A12-15 YearsNAĄHrų`Hs£3ˆHrų`Hrŗ,Hs‡_<Hs£3ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071505DV100715051007AĄFWHITE DVšDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P947RIOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B9DW( YYPhase 3A@ . . .N. A12-15 YearsNAĄHrų`Hs£3ˆHrų`Hrŗ,Hs‡_<Hs£3ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071508DV100715081007AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P947S5Other Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-28B5DW$ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrž)ŌHr¹ŁHrž)ŌHr¹Ł..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071508DV100715081007AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P947SBOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-28B5DW$ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrž)ŌHr¹ŁHrž)ŌHr¹Ł..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071509DV100715091007AšFWHITE DVšDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PNQNFWVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-17BIDW8 YYPhase 3A@ . . .N. A12-15 YearsNAšHrž6øHsØ€Hrž6øHr¼OTHsv&¤HsØ€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071511DV100715111007AšMWHITE DVšDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGLXT8Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18B£DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHržTøHs7\HržTøHr¹»Hss€ Hs7\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071511DV100715111007AšMWHITE DVšDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGLXTEOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18B£DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHržTøHs7\HržTøHr¹»Hss€ Hs7\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071511DV100715111007AšMWHITE DVšDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXTKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18B£DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHržTøHs7\HržTøHr¹»Hss€ Hs7\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071511DV100715111007AšMWHITE DVšDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLXTQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18B£DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHržTøHs7\HržTøHr¹»Hss€ Hs7\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071515DV100715151007AĄMWHITE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1P947SUOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20B,DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŸCČHrŗųčHrŸCČHrŗųč..Placebo Placebo .DWŒYC4591001C4591001 1007 10071515DV100715151007AĄMWHITE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1P947T0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20B,DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŸCČHrŗųčHrŸCČHrŗųč..Placebo Placebo .DWŒYC4591001C4591001 1007 10071515DV100715151007AĄMWHITE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSXJE0Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14BžDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŸCČHrŗųčHrŸCČHrŗųč..Placebo Placebo .DWŒYC4591001C4591001 1007 10071515DV100715151007AĄMWHITE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YYPA1BReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-05B“DW¤ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŸCČHrŗųčHrŸCČHrŗųč..Placebo Placebo .DWŒYC4591001C4591001 1007 10071518DV100715181007AšMWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-201T7WVRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B2DW" YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŸXąHrŗšxHrŸXąHrŗšx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071519DV100715191007AšMWHITE DVńDWwPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UEHIZ7Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-03-31BrDWb YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸaČHsP)ōHrŸaČHr» Hs4LHHsP)ōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWaYC4591001C4591001 1007 10071521DV100715211007AŠMWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-201VBCZOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-06-17BĄDW° YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŸ|Hr»:LHrŸ|Hr»:L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071522DV100715221007AšFWHITE DVńDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XM5NTEOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BŖDWš YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ•XHsš `HrŸ•XHr»7|Hs~)0Hsš `Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071522DV100715221007AšFWHITE DVńDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XM5NTKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BŖDWš YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ•XHsš `HrŸ•XHr»7|Hs~)0Hsš `Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071522DV100715221007AšFWHITE DVńDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM5NTQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BŖDWš YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ•XHsš `HrŸ•XHr»7|Hs~)0Hsš `Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071522DV100715221007AšFWHITE DVńDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM5NTWOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BŖDWš YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ•XHsš `HrŸ•XHr»7|Hs~)0Hsš `Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071523DV100715231007AŠFWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YGGO8HIncorrect serology sample volume collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-06-22BÅDWµ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŸ“xHr» HrŸ“xHr» ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071524DV100715241007AšMWHITE DVńDWUPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P947TAOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-02-01B8DW( YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ§dHs#rœHrŸ§dHr» Hs±LHs#rœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW1YC4591001C4591001 1007 10071524DV100715241007AšMWHITE DVńDWUPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P947TGOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-02-01B8DW( YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ§dHs#rœHrŸ§dHr» Hs±LHs#rœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW1YC4591001C4591001 1007 10071524DV100715241007AšMWHITE DVńDWUPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1PDX794Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-03B:DW* YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ§dHs#rœHrŸ§dHr» Hs±LHs#rœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW1YC4591001C4591001 1007 10071524DV100715241007AšMWHITE DVńDWUPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YLJ7SARevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-02-25BPDW@ YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ§dHs#rœHrŸ§dHr» Hs±LHs#rœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW1YC4591001C4591001 1007 10071525DV100715251007AŠMWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PDX799Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-03B:DW* YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŸ„ĄHr» @HrŸ„ĄHr» @..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071528DV100715281007AąFWHITE DVņDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z35AVSReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BœDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr ’šHr¼yĄHr ’šHr¼yĄ..Placebo Placebo .DWŒYC4591001C4591001 1007 10071528DV100715281007AąFWHITE DVņDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z35B5LReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03B±DW¢ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ’šHr¼yĄHr ’šHr¼yĄ..Placebo Placebo .DWŒYC4591001C4591001 1007 10071529DV100715291007AąFMULTIPLE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OAL5G0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-09ADVņ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr ž0Hr¼LHHr ž0Hr¼LH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071529DV100715291007AąFMULTIPLE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YBCOEJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08B¶DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr ž0Hr¼LHHr ž0Hr¼LH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071530DV100715301007AĄFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XK3Y7FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-06-01BÆDW  YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr ”Hr»PHr ”Hr»P..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AąFWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1PNR0W3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-17BGDW8 YYPhase 3A@ . . .N. A12-15 YearsNAąHr ¢hHs”¤ÜHr ¢hHr»SŲHs|ßäHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AąFWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XM737SOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BØDW™ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ¢hHs”¤ÜHr ¢hHr»SŲHs|ßäHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AąFWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XM7388Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BØDW™ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ¢hHs”¤ÜHr ¢hHr»SŲHs|ßäHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AąFWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM738EOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BØDW™ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ¢hHs”¤ÜHr ¢hHr»SŲHs|ßäHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AąFWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM73FIOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BØDW™ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ¢hHs”¤ÜHr ¢hHr»SŲHs|ßäHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AąFWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XK3Y7IVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007COVID_B1 NO Non-Important2021-06-01BÆDW  YYPhase 3A@ . . .N. A12-15 YearsNAąHr ¢hHs”¤ÜHr ¢hHr»SŲHs|ßäHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AąFWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YV6XRQVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-06-22BÄDWµ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ¢hHs”¤ÜHr ¢hHr»SŲHs|ßäHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AąFWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA€1-1ZCDLPJVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1007V103_MONTH1 NO Non-Important2021-07-28BčDWŁ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ¢hHs”¤ÜHr ¢hHr»SŲHs|ßäHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071533DV100715331007AąMWHITE DVņDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBBEUOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26B©DWš YYPhase 3A@ . . .N. A12-15 YearsNAąHr °xHs™ŃäHr °xHr¼bPHs~$€Hs™ŃäPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071533DV100715331007AąMWHITE DVņDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XMBBFKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26B©DWš YYPhase 3A@ . . .N. A12-15 YearsNAąHr °xHs™ŃäHr °xHr¼bPHs~$€Hs™ŃäPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071533DV100715331007AąMWHITE DVņDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBGUOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26B©DWš YYPhase 3A@ . . .N. A12-15 YearsNAąHr °xHs™ŃäHr °xHr¼bPHs~$€Hs™ŃäPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071533DV100715331007AąMWHITE DVņDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBH0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26B©DWš YYPhase 3A@ . . .N. A12-15 YearsNAąHr °xHs™ŃäHr °xHr¼bPHs~$€Hs™ŃäPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071536DV100715361007AŠFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YBCOEMVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-09B·DWØ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr æHr»H˜Hr æHr»H˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071536DV100715361007AŠFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z6G6WBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-06-17BæDW° YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr æHr»H˜Hr æHr»H˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071537DV100715371007AŠMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTC5LJVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr Ņ°Hr¼”\Hr Ņ°Hr¼”\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071537DV100715371007AŠMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OT8120Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-29B4DW% YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr Ņ°Hr¼”\Hr Ņ°Hr¼”\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071539DV100715391007AšMWHITE DVņDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y5U9OORevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-02B°DW” YYPhase 3A@ . . .N. A12-15 YearsNAšHr ćTHs£<¬Hr ćTHr¼…Hs‡Œ“Hs£<¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071540DV100715401007AŠMWHITE DVņDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WYEJXDVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-05-12B›DWŒ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr äųHs£9(Hr äųHr¼…šHs‡¤Hs£9(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071540DV100715401007AŠMWHITE DVņDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YG8TD7Serology sample not collected Laboratory OPEN LABEL TREATMENT1007COVID_B1 NO Non-Important2021-06-02B°DW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHr äųHs£9(Hr äųHr¼…šHs‡¤Hs£9(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071540DV100715401007AŠMWHITE DVņDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YGE03FVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007COVID_B1 NO Non-Important2021-06-02B°DW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHr äųHs£9(Hr äųHr¼…šHs‡¤Hs£9(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071541DV100715411007AšMWHITE DVņDWEPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YHI2ITRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-02-09B?DW0 YYPhase 3A@ . . .N. A12-15 YearsNAšHr ÷øHsMøHr ÷øHr¼čHrņ£œHsMøPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW/YC4591001C4591001 1007 10071542DV100715421007AŠFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YBCOEZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08B¶DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr ūHr¼¢Hr ūHr¼¢..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071543DV100715431007AąMWHITE DVņDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X6ZYZUReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BœDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr ū<Hr¼€ČHr ū<Hr¼€Č..Placebo Placebo .DWYC4591001C4591001 1007 10071543DV100715431007AąMWHITE DVņDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y24OS3Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03B±DW¢ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ū<Hr¼€ČHr ū<Hr¼€Č..Placebo Placebo .DWYC4591001C4591001 1007 10071543DV100715431007AąMWHITE DVņDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YG8TDASerology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-06-23BÅDW¶ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ū<Hr¼€ČHr ū<Hr¼€Č..Placebo Placebo .DWYC4591001C4591001 1007 10071547DV100715471007AąMWHITE DVóDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XKP12AOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20B¢DW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr”öōHs‘é Hr”öōHr¼X<Hsvb¤Hs‘é Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071547DV100715471007AąMWHITE DVóDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XKP12QOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20B¢DW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr”öōHs‘é Hr”öōHr¼X<Hsvb¤Hs‘é Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071547DV100715471007AąMWHITE DVóDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XKP136Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20B¢DW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr”öōHs‘é Hr”öōHr¼X<Hsvb¤Hs‘é Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071547DV100715471007AąMWHITE DVóDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XKP13COther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20B¢DW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr”öōHs‘é Hr”öōHr¼X<Hsvb¤Hs‘é Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071547DV100715471007AąMWHITE DVóDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XKP13IOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20B¢DW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr”öōHs‘é Hr”öōHr¼X<Hsvb¤Hs‘é Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071551DV100715511007AŠMWHITE DVóDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1PP8P75Nasal swab not collected for the visit where it is required Laboratory VACCINATION 1007COVID_A NO Non-Important2020-12-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢1PHs—cÜHr¢1PHr»/ĄHs{¦ÄHs—cÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071551DV100715511007AŠMWHITE DVóDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1R2MXMQVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-03-02BSDWE YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢1PHs—cÜHr¢1PHr»/ĄHs{¦ÄHs—cÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071551DV100715511007AŠMWHITE DVóDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XKP15MOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B¦DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢1PHs—cÜHr¢1PHr»/ĄHs{¦ÄHs—cÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071551DV100715511007AŠMWHITE DVóDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XKP15SOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B¦DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢1PHs—cÜHr¢1PHr»/ĄHs{¦ÄHs—cÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071551DV100715511007AŠMWHITE DVóDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XKP168Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B¦DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢1PHs—cÜHr¢1PHr»/ĄHs{¦ÄHs—cÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071551DV100715511007AŠMWHITE DVóDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XKP16EOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B¦DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢1PHs—cÜHr¢1PHr»/ĄHs{¦ÄHs—cÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071551DV100715511007AŠMWHITE DVóDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XKP16KOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B¦DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢1PHs—cÜHr¢1PHr»/ĄHs{¦ÄHs—cÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071551DV100715511007AŠMWHITE DVóDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA€1-1YG8U0FVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007COVID_B1 NO Non-Important2021-06-22BĆDWµ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢1PHs—cÜHr¢1PHr»/ĄHs{¦ÄHs—cÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071552DV100715521007AšFWHITE DVóDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBBHQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BØDWš YYPhase 3A@ . . .N. A12-15 YearsNAšHr¢FąHsšHr¢FąHr»/„Hs~VlHsšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071552DV100715521007AšFWHITE DVóDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XMBBJAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BØDWš YYPhase 3A@ . . .N. A12-15 YearsNAšHr¢FąHsšHr¢FąHr»/„Hs~VlHsšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071552DV100715521007AšFWHITE DVóDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBJGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BØDWš YYPhase 3A@ . . .N. A12-15 YearsNAšHr¢FąHsšHr¢FąHr»/„Hs~VlHsšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071552DV100715521007AšFWHITE DVóDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBKQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BØDWš YYPhase 3A@ . . .N. A12-15 YearsNAšHr¢FąHsšHr¢FąHr»/„Hs~VlHsšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071554DV100715541007AąFWHITE DVóDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XD2IB4Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-22B¤DW– YYPhase 3A@ . . .N. A12-15 YearsNAąHr¢JdHr¼”<Hr¢JdHr¼”<..Placebo Placebo .DWŒYC4591001C4591001 1007 10071554DV100715541007AąFWHITE DVóDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z35B5OReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-17B¾DW° YYPhase 3A@ . . .N. A12-15 YearsNAąHr¢JdHr¼”<Hr¢JdHr¼”<..Placebo Placebo .DWŒYC4591001C4591001 1007 10071555DV100715551007AĄMWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XGK0G5Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-05-27B©DW› YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¢EšHr»G0Hr¢EšHr»G0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071555DV100715551007AĄMWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z4VSKLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-14B»DW­ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¢EšHr»G0Hr¢EšHr»G0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071557DV100715571007AšFWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YBEU83Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-10B³DW© YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§*čHrĀīHr§*čHrĀī..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071557DV100715571007AšFWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBB9L3Serology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-22BŻDWÓ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§*čHrĀīHr§*čHrĀī..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071557DV100715571007AšFWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZB3SZXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-22BŻDWÓ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§*čHrĀīHr§*čHrĀī..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071559DV100715591007AąFWHITE DV÷DW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PFSWJZOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21B'DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr§I`Hs›-šHr§I`HrĆ.ŒHs¶°Hs›-šPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AąFWHITE DV÷DW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PFSWK5Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21B'DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr§I`Hs›-šHr§I`HrĆ.ŒHs¶°Hs›-šPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AąFWHITE DV÷DW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBNSOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27B„DW› YYPhase 3A@ . . .N. A12-15 YearsNAąHr§I`Hs›-šHr§I`HrĆ.ŒHs¶°Hs›-šPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AąFWHITE DV÷DW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBNYOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27B„DW› YYPhase 3A@ . . .N. A12-15 YearsNAąHr§I`Hs›-šHr§I`HrĆ.ŒHs¶°Hs›-šPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AąFWHITE DV÷DW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XMBBO4Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27B„DW› YYPhase 3A@ . . .N. A12-15 YearsNAąHr§I`Hs›-šHr§I`HrĆ.ŒHs¶°Hs›-šPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AąFWHITE DV÷DW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XMBBOAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27B„DW› YYPhase 3A@ . . .N. A12-15 YearsNAąHr§I`Hs›-šHr§I`HrĆ.ŒHs¶°Hs›-šPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1UEHUXJRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-03-14B[DWQ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§lLHsŽ+Hr§lLHrÄ-ČHsr]¼HsŽ+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1UEHUXPRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-03-16B]DWS YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§lLHsŽ+Hr§lLHrÄ-ČHsr]¼HsŽ+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGL7AYOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§lLHsŽ+Hr§lLHrÄ-ČHsr]¼HsŽ+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGL7B4Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§lLHsŽ+Hr§lLHrÄ-ČHsr]¼HsŽ+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGL7BKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§lLHsŽ+Hr§lLHrÄ-ČHsr]¼HsŽ+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGL7BQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§lLHsŽ+Hr§lLHrÄ-ČHsr]¼HsŽ+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071562DV100715621007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGL7C6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§ŠˆHsŽŲHr§ŠˆHrĆB<HsrI”HsŽŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071562DV100715621007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGL7CCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§ŠˆHsŽŲHr§ŠˆHrĆB<HsrI”HsŽŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071562DV100715621007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGL7DCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§ŠˆHsŽŲHr§ŠˆHrĆB<HsrI”HsŽŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071562DV100715621007AĄFWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGL7DSOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§ŠˆHsŽŲHr§ŠˆHrĆB<HsrI”HsŽŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071563DV100715631007AĄMWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGL7DYOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§ˆlHsŽ Hr§ˆlHrĆ@˜HsrJ„HsŽ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071563DV100715631007AĄMWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGL7EEOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§ˆlHsŽ Hr§ˆlHrĆ@˜HsrJ„HsŽ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071563DV100715631007AĄMWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGL7EKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§ˆlHsŽ Hr§ˆlHrĆ@˜HsrJ„HsŽ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071563DV100715631007AĄMWHITE DV÷DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGL7EQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B›DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§ˆlHsŽ Hr§ˆlHrĆ@˜HsrJ„HsŽ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071564DV100715641007AąFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONNA3KOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§“čHrÅŠŲHr§“čHrÅŠŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071564DV100715641007AąFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONNA3QOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§“čHrÅŠŲHr§“čHrÅŠŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071564DV100715641007AąFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1OT812GVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§“čHrÅŠŲHr§“čHrÅŠŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071564DV100715641007AąFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1TE4I2PVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§“čHrÅŠŲHr§“čHrÅŠŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071564DV100715641007AąFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1PFF365Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-08B9DW/ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§“čHrÅŠŲHr§“čHrÅŠŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071565DV100715651007AąMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONN9JXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§–øHrÅŅ@Hr§–øHrÅŅ@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071565DV100715651007AąMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONN9K3Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§–øHrÅŅ@Hr§–øHrÅŅ@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071565DV100715651007AąMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1OT812JVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§–øHrÅŅ@Hr§–øHrÅŅ@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071566DV100715661007AšMWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1P2RFXFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-01B2DW( YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§”ŲHrĆ;4Hr§”ŲHrĆ;4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071566DV100715661007AšMWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z3S3BPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08B±DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§”ŲHrĆ;4Hr§”ŲHrĆ;4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071566DV100715661007AšMWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YYQVO9Serology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-07BĪDWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§”ŲHrĆ;4Hr§”ŲHrĆ;4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071566DV100715661007AšMWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZE8TVSSerology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-07BĪDWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§”ŲHrĆ;4Hr§”ŲHrĆ;4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071567DV100715671007AąMWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONN9K9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr؂HrÄ%XHr؂HrÄ%X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071567DV100715671007AąMWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONO00XOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr؂HrÄ%XHr؂HrÄ%X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071568DV100715681007AąMWHITE DVųDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSZQCJRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr؄`Hs”¤ÜHr؄`HrĆ`Hs…żHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1007 10071568DV100715681007AąMWHITE DVųDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSZQDTRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr؄`Hs”¤ÜHr؄`HrĆ`Hs…żHs”¤ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1007 10071569DV100715691007AĄFWHITE DVųDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO04POther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrؑHs£ŒHrؑHrÄf¼HsˆŗXHs£ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071569DV100715691007AĄFWHITE DVųDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO04VOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrؑHs£ŒHrؑHrÄf¼HsˆŗXHs£ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071570DV100715701007AšFWHITE DVųDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO051Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrؔPHs£0HrؔPHrÄeĢHsˆ»„Hs£0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071570DV100715701007AšFWHITE DVųDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO057Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrؔPHs£0HrؔPHrÄeĢHsˆ»„Hs£0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071571DV100715711007AąFWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONO05NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrص˜HrÅŻ€Hrص˜HrÅŻ€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071571DV100715711007AąFWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONO05TOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrص˜HrÅŻ€Hrص˜HrÅŻ€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071571DV100715711007AąFWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z3S3BTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK6 NO Non-Important2021-06-08B°DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrص˜HrÅŻ€Hrص˜HrÅŻ€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071572DV100715721007AĄFWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONO061Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrØä<Hrą4HrØä<Hrą4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071572DV100715721007AĄFWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONO08ZOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrØä<Hrą4HrØä<Hrą4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071573DV100715731007AĄMWHITE DVųDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSXJK7Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03B«DW¢ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrØęXHrĆ'üHrØęXHrĆ'ü..Placebo Placebo .DWŒYC4591001C4591001 1007 10071574DV100715741007AšMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1UEHV0TRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-03-13BXDWP YYPhase 3A@ . . .Y. A12-15 YearsNAšHr©Ņ HrŲŲHr©Ņ HrŲŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071574DV100715741007AšMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1VITA5CParticipant entered into asymptomatic swabbing part of study after they were unblinded Other REPEAT SCREENING 1 1007V201_SURVEIL_CONSENT NO Non-Important2021-03-17B\DWT YYPhase 3A@ . . .Y. A12-15 YearsNAšHr©Ņ HrŲŲHr©Ņ HrŲŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071574DV100715741007AšMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YBEU87Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-03BŖDW¢ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr©Ņ HrŲŲHr©Ņ HrŲŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071574DV100715741007AšMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z2PN6XVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-07-06BĖDWĆ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr©Ņ HrŲŲHr©Ņ HrŲŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071575DV100715751007AšMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONO0H7Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŖHrÅĒHrŖHrÅĒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071575DV100715751007AšMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONO0HDOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŖHrÅĒHrŖHrÅĒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071576DV100715761007AšFWHITE DVłDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSZQBDRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ“HsˆśHrŖ“HrÅÓØHslˆHsˆśPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW}YC4591001C4591001 1007 10071576DV100715761007AšFWHITE DVłDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSZQCDRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ“HsˆśHrŖ“HrÅÓØHslˆHsˆśPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW}YC4591001C4591001 1007 10071577DV100715771007AšMMULTIPLE DVłDW‹Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO0HJOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ<HsjO<HrŖ<HrÅÓäHsMP”HsjO<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWpYC4591001C4591001 1007 10071577DV100715771007AšMMULTIPLE DVłDW‹Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO0HPOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ<HsjO<HrŖ<HrÅÓäHsMP”HsjO<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWpYC4591001C4591001 1007 10071577DV100715771007AšMMULTIPLE DVłDW‹Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WZ7GVDOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-04-19B}DWu YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ<HsjO<HrŖ<HrÅÓäHsMP”HsjO<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWpYC4591001C4591001 1007 10071578DV100715781007AĄMMULTIPLE DVłDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO0IFOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŖ:ØHs—WpHrŖ:ØHrÅÕLHs{£øHs—WpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071578DV100715781007AĄMMULTIPLE DVłDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO0ILOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŖ:ØHs—WpHrŖ:ØHrÅÕLHs{£øHs—WpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071578DV100715781007AĄMMULTIPLE DVłDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XKVLC5Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŖ:ØHs—WpHrŖ:ØHrÅÕLHs{£øHs—WpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071578DV100715781007AĄMMULTIPLE DVłDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XKVLCBOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŖ:ØHs—WpHrŖ:ØHrÅÕLHs{£øHs—WpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071578DV100715781007AĄMMULTIPLE DVłDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XKVLD1Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŖ:ØHs—WpHrŖ:ØHrÅÕLHs{£øHs—WpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071578DV100715781007AĄMMULTIPLE DVłDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XKVLDHOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŖ:ØHs—WpHrŖ:ØHrÅÕLHs{£øHs—WpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071579DV100715791007AĄFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONO0IROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖ=HrÅĒHrŖ=HrÅĒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071579DV100715791007AĄFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONO0JROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖ=HrÅĒHrŖ=HrÅĒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071579DV100715791007AĄFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z4VSKOVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-16B·DWÆ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖ=HrÅĒHrŖ=HrÅĒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071580DV100715801007AąFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONO0JXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŖ>ąHrÅąŒHrŖ>ąHrÅąŒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071580DV100715801007AąFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONO0KXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŖ>ąHrÅąŒHrŖ>ąHrÅąŒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071581DV100715811007AšMWHITE DVśDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO0LDOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr«ulHs—3”Hr«ulHrĒ$ģHs{ŽdHs—3”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071581DV100715811007AšMWHITE DVśDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO0LJOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr«ulHs—3”Hr«ulHrĒ$ģHs{ŽdHs—3”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071581DV100715811007AšMWHITE DVśDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XKVLDNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BŸDW˜ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«ulHs—3”Hr«ulHrĒ$ģHs{ŽdHs—3”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071581DV100715811007AšMWHITE DVśDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XKVLENOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BŸDW˜ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«ulHs—3”Hr«ulHrĒ$ģHs{ŽdHs—3”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071581DV100715811007AšMWHITE DVśDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XKVLETOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BŸDW˜ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«ulHs—3”Hr«ulHrĒ$ģHs{ŽdHs—3”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071581DV100715811007AšMWHITE DVśDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XKVLEZOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BŸDW˜ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«ulHs—3”Hr«ulHrĒ$ģHs{ŽdHs—3”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071582DV100715821007AĄMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONO0M9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«wÄHrĒ#„Hr«wÄHrĒ#„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071582DV100715821007AĄMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONO0MFOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«wÄHrĒ#„Hr«wÄHrĒ#„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071582DV100715821007AĄMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XQ1WEJNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007COVID_A NO Non-Important2021-06-04BŖDW£ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«wÄHrĒ#„Hr«wÄHrĒ#„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071582DV100715821007AĄMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1YV6XRTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-14B“DW­ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«wÄHrĒ#„Hr«wÄHrĒ#„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071582DV100715821007AĄMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z3A98TSerology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-08BĢDWÅ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«wÄHrĒ#„Hr«wÄHrĒ#„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071583DV100715831007AšMWHITE DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO0MVOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr«œHsæxHr«œHrĒ&ĢHssŅ(HsæxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071583DV100715831007AšMWHITE DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONOEJLOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr«œHsæxHr«œHrĒ&ĢHssŅ(HsæxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071583DV100715831007AšMWHITE DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXUZOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18B™DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«œHsæxHr«œHrĒ&ĢHssŅ(HsæxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071583DV100715831007AšMWHITE DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLZ4ROther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18B™DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«œHsæxHr«œHrĒ&ĢHssŅ(HsæxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071583DV100715831007AšMWHITE DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGLZ4XOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18B™DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«œHsæxHr«œHrĒ&ĢHssŅ(HsæxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071583DV100715831007AšMWHITE DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGLZ53Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18B™DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«œHsæxHr«œHrĒ&ĢHssŅ(HsæxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071584DV100715841007AšMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONOEJROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr«}ÜHrĒ*PHr«}ÜHrĒ*P..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071584DV100715841007AšMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONOEKROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr«}ÜHrĒ*PHr«}ÜHrĒ*P..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071585DV100715851007AĄMWHITE DVśDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONOEKXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«~THslHr«~THrĒ'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071585DV100715851007AĄMWHITE DVśDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONOEUTOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«~THslHr«~THrĒ'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071585DV100715851007AĄMWHITE DVśDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXP0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B˜DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«~THslHr«~THrĒ'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071585DV100715851007AĄMWHITE DVśDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLXP6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B˜DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«~THslHr«~THrĒ'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071585DV100715851007AĄMWHITE DVśDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGLXPMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B˜DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«~THslHr«~THrĒ'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071585DV100715851007AĄMWHITE DVśDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGLXQCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B˜DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«~THslHr«~THrĒ'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071586DV100715861007AŠMWHITE DVśDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONOEYLOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr«ųHs”©ŒHr«ųHrĒ$°Hs…žHs”©ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071586DV100715861007AŠMWHITE DVśDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONOEYROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr«ųHs”©ŒHr«ųHrĒ$°Hs…žHs”©ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071587DV100715871007AąFASIAN DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONOF8EOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr«ƒHrĒ+@Hr«ƒHrĒ+@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071587DV100715871007AąFASIAN DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ONOF8KOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr«ƒHrĒ+@Hr«ƒHrĒ+@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071588DV100715881007AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS17WXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¹Ø”Hr×ķ@Hr¹Ø”Hr×ķ@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071588DV100715881007AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS17X3Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¹Ø”Hr×ķ@Hr¹Ø”Hr×ķ@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071588DV100715881007AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XTPZXZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07B¢DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¹Ø”Hr×ķ@Hr¹Ø”Hr×ķ@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071589DV100715891007AĄMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORAYSGOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹ø HsĆ°Hr¹ø HrÖ¢ČHssÉHsĆ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071589DV100715891007AĄMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ORAYUUOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹ø HsĆ°Hr¹ø HrÖ¢ČHssÉHsĆ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071589DV100715891007AĄMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLZ59Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŽDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹ø HsĆ°Hr¹ø HrÖ¢ČHssÉHsĆ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071589DV100715891007AĄMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLZ5FOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŽDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹ø HsĆ°Hr¹ø HrÖ¢ČHssÉHsĆ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071589DV100715891007AĄMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGLZ5LOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŽDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹ø HsĆ°Hr¹ø HrÖ¢ČHssÉHsĆ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071589DV100715891007AĄMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGLZ5ROther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŽDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹ø HsĆ°Hr¹ø HrÖ¢ČHssÉHsĆ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071591DV100715911007AŠMWHITE DWDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORAYW0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹Ķ`Hs¢ōōHr¹Ķ`Hr֛HHs‡b Hs¢ōōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071591DV100715911007AŠMWHITE DWDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZA1F4URevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-02BDW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹Ķ`Hs¢ōōHr¹Ķ`Hr֛HHs‡b Hs¢ōōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071592DV100715921007AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ORBV52Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¹ĖųHr֝ÜHr¹ĖųHr֝Ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071592DV100715921007AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ORBV58Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¹ĖųHr֝ÜHr¹ĖųHr֝Ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071592DV100715921007AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1QYQAN1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B;DW? YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¹ĖųHr֝ÜHr¹ĖųHr֝Ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071592DV100715921007AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1XTPZY3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07B¢DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¹ĖųHr֝ÜHr¹ĖųHr֝Ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071593DV100715931007AšMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QZCJI9Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsVACCINATION 1007V1_DAY1_VAX1_L YES-POP2,YES-POP3Important 2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ĶœHr¹ĶœHr¹ĶœHr¹Ķœ..Placebo .DW3YC4591001C4591001 1007 10071593DV100715931007AšMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1T5A5N5Blind broken outside of IRT when not permitted per protocol Procedures/Tests REPEAT SCREENING 1 1007V1_DAY1_VAX1_L NO Non-Important2021-02-12B/DW3 YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ĶœHr¹ĶœHr¹ĶœHr¹Ķœ..Placebo .DW3YC4591001C4591001 1007 10071594DV100715941007AąFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OROZM3Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-28ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¹įLHr×dHr¹įLHr×d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071594DV100715941007AąFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OROZMHOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-28ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¹įLHr×dHr¹įLHr×d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071594DV100715941007AąFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YV6XRWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-14B©DW­ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¹įLHr×dHr¹įLHr×d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071595DV100715951007AŠFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORBV5FOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹čHs‘ē|Hr¹čHrÖ±PHssš$Hs‘ē|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071595DV100715951007AŠFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ORBVGPOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹čHs‘ē|Hr¹čHrÖ±PHssš$Hs‘ē|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071595DV100715951007AŠFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGOXRROther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŽDW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹čHs‘ē|Hr¹čHrÖ±PHssš$Hs‘ē|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071595DV100715951007AŠFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGOXRXOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŽDW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹čHs‘ē|Hr¹čHrÖ±PHssš$Hs‘ē|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071595DV100715951007AŠFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGOXS3Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŽDW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹čHs‘ē|Hr¹čHrÖ±PHssš$Hs‘ē|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071595DV100715951007AŠFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGOXS9Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŽDW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹čHs‘ē|Hr¹čHrÖ±PHssš$Hs‘ē|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071596DV100715961007AŠMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OVTH5SOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹šˆHs—5tHr¹šˆHrŲDpHs{“ŌHs—5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071596DV100715961007AŠMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OVTH5YOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹šˆHs—5tHr¹šˆHrŲDpHs{“ŌHs—5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071596DV100715961007AŠMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM5FNNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B”DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹šˆHs—5tHr¹šˆHrŲDpHs{“ŌHs—5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071596DV100715961007AŠMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM5FNTOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B”DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹šˆHs—5tHr¹šˆHrŲDpHs{“ŌHs—5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071596DV100715961007AŠMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XM5FNZOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B”DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹šˆHs—5tHr¹šˆHrŲDpHs{“ŌHs—5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071596DV100715961007AŠMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XM737HOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24B”DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹šˆHs—5tHr¹šˆHrŲDpHs{“ŌHs—5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071597DV100715971007AąFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS17Z9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¹ņ¤HrÖūŲHr¹ņ¤HrÖūŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071597DV100715971007AąFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS17ZFOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¹ņ¤HrÖūŲHr¹ņ¤HrÖūŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071597DV100715971007AąFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YBEU8AVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK14 NO Non-Important2021-06-09B¤DWØ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¹ņ¤HrÖūŲHr¹ņ¤HrÖūŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071599DV100715991007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ORBVH1Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗąHrÖĀØHrŗąHrÖĀØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071599DV100715991007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ORBVHPOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗąHrÖĀØHrŗąHrÖĀØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071599DV100715991007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1XTPZY6Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-06B”DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗąHrÖĀØHrŗąHrÖĀØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071599DV100715991007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZIM294Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007SSWAB_WEEK16 NO Non-Important2021-07-09BĀDWĘ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗąHrÖĀØHrŗąHrÖĀØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071599DV100715991007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZHUT2GVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK18 NO Non-Important2021-07-13BĘDWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗąHrÖĀØHrŗąHrÖĀØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071600DV100716001007AĄFWHITE DWDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORBVHWOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŗŠHs¾Ć(HrŗŠHrÖĮøHs†lHs¾Ć(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071600DV100716001007AĄFWHITE DWDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ORC2NKOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŗŠHs¾Ć(HrŗŠHrÖĮøHs†lHs¾Ć(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071600DV100716001007AĄFWHITE DWDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YJ4OMAOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-26B–DWš YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŗŠHs¾Ć(HrŗŠHrÖĮøHs†lHs¾Ć(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071600DV100716001007AĄFWHITE DWDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YD7IBXSerology sample not collected Laboratory OPEN LABEL TREATMENT1007V101_VAX3 NO Non-Important2021-06-01BœDW  YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŗŠHs¾Ć(HrŗŠHrÖĮøHs†lHs¾Ć(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071600DV100716001007AĄFWHITE DWDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1Z6VL01Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-07-14BĒDWĖ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŗŠHs¾Ć(HrŗŠHrÖĮøHs†lHs¾Ć(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071601DV100716011007AšMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS17ZMOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗ(HrÖņ“Hrŗ(HrÖņ“..Placebo Placebo .DWŒYC4591001C4591001 1007 10071601DV100716011007AšMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OS17ZSOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗ(HrÖņ“Hrŗ(HrÖņ“..Placebo Placebo .DWŒYC4591001C4591001 1007 10071601DV100716011007AšMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Z4WZO6Serology sample not collected Laboratory FOLLOW-UP 1007V201_SURVEIL_CONSENT NO Non-Important2021-03-16BODWS YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗ(HrÖņ“Hrŗ(HrÖņ“..Placebo Placebo .DWŒYC4591001C4591001 1007 10071601DV100716011007AšMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1SMY9AMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-16BODWS YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗ(HrÖņ“Hrŗ(HrÖņ“..Placebo Placebo .DWŒYC4591001C4591001 1007 10071601DV100716011007AšMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YBYR3OReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13B‰DW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗ(HrÖņ“Hrŗ(HrÖņ“..Placebo Placebo .DWŒYC4591001C4591001 1007 10071601DV100716011007AšMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZCDLPNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-29BÖDWŚ YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗ(HrÖņ“Hrŗ(HrÖņ“..Placebo Placebo .DWŒYC4591001C4591001 1007 10071602DV100716021007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS189QOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗHr× HrŗHr× ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071602DV100716021007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS189XOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗHr× HrŗHr× ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071602DV100716021007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YBEU8NVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-08B£DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗHr× HrŗHr× ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071603DV100716031007AŠMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS1U2AOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŗ÷€Hr× Hrŗ÷€Hr× ..Placebo Placebo .DWYC4591001C4591001 1007 10071603DV100716031007AŠMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OS1U2GOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŗ÷€Hr× Hrŗ÷€Hr× ..Placebo Placebo .DWYC4591001C4591001 1007 10071603DV100716031007AŠMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSXJKAReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-05BŸDW¤ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŗ÷€Hr× Hrŗ÷€Hr× ..Placebo Placebo .DWYC4591001C4591001 1007 10071604DV100716041007AšFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OS1U2NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗššHr×,HrŗššHr×,..Placebo Placebo .DWŒYC4591001C4591001 1007 10071604DV100716041007AšFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1OS1U3DOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗššHr×,HrŗššHr×,..Placebo Placebo .DWŒYC4591001C4591001 1007 10071604DV100716041007AšFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z4VTMYReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BˆDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗššHr×,HrŗššHr×,..Placebo Placebo .DWŒYC4591001C4591001 1007 10071604DV100716041007AšFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z4VTN1Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-12B¦DW« YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗššHr×,HrŗššHr×,..Placebo Placebo .DWŒYC4591001C4591001 1007 10071605DV100716051007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ORC2O1Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŗż\HrÖ„\Hrŗż\HrÖ„\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071605DV100716051007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ORC2O7Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŗż\HrÖ„\Hrŗż\HrÖ„\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071605DV100716051007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YBEU8QVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-10B¤DW© YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŗż\HrÖ„\Hrŗż\HrÖ„\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071606DV100716061007AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS1U4OOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»DHrךHr»DHrך..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071606DV100716061007AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS1U4UOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»DHrךHr»DHrך..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071606DV100716061007AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1R24MVTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-04BBDWG YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»DHrךHr»DHrך..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071606DV100716061007AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YV6XRZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK10 NO Non-Important2021-06-14BØDW­ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»DHrךHr»DHrך..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071606DV100716061007AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1Z8JZKXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK14 NO Non-Important2021-07-18BŹDWĻ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»DHrךHr»DHrך..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071607DV100716071007AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS1U7JOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr»44Hs’øHr»44HrÖ’ Hss©ŲHs’øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071607DV100716071007AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS1U7POther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr»44Hs’øHr»44HrÖ’ Hss©ŲHs’øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071607DV100716071007AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1QYQPR7Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B:DW? YYPhase 3A@ . . .N. A12-15 YearsNAąHr»44Hs’øHr»44HrÖ’ Hss©ŲHs’øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071607DV100716071007AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7CCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr»44Hs’øHr»44HrÖ’ Hss©ŲHs’øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071607DV100716071007AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7CIOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr»44Hs’øHr»44HrÖ’ Hss©ŲHs’øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071607DV100716071007AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7DIOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr»44Hs’øHr»44HrÖ’ Hss©ŲHs’øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071607DV100716071007AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEB7E3Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr»44Hs’øHr»44HrÖ’ Hss©ŲHs’øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071607DV100716071007AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA€1-1YG8TEQVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007COVID_A1 NO Non-Important2021-06-21BÆDW“ YYPhase 3A@ . . .N. A12-15 YearsNAąHr»44Hs’øHr»44HrÖ’ Hss©ŲHs’øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071608DV100716081007AĄMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS1U7WOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr»2ĢHs’ŒHr»2ĢHrÖ’ŌHssŖŒHs’ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071608DV100716081007AĄMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS29Q4Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr»2ĢHs’ŒHr»2ĢHrÖ’ŌHssŖŒHs’ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071608DV100716081007AĄMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA€1-1QYQPRBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B:DW? YYPhase 3A@ . . .N. A12-15 YearsNAĄHr»2ĢHs’ŒHr»2ĢHrÖ’ŌHssŖŒHs’ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071608DV100716081007AĄMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1X75PELLab performed out of window Laboratory REPEAT SCREENING 1 1007COVID_A NO Non-Important2021-05-17BŒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr»2ĢHs’ŒHr»2ĢHrÖ’ŌHssŖŒHs’ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071608DV100716081007AĄMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7E9Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr»2ĢHs’ŒHr»2ĢHrÖ’ŌHssŖŒHs’ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071608DV100716081007AĄMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7EFOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr»2ĢHs’ŒHr»2ĢHrÖ’ŌHssŖŒHs’ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071608DV100716081007AĄMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7FAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr»2ĢHs’ŒHr»2ĢHrÖ’ŌHssŖŒHs’ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071608DV100716081007AĄMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEB7FGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr»2ĢHs’ŒHr»2ĢHrÖ’ŌHssŖŒHs’ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071609DV100716091007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS29UROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»9\Hr×HHr»9\Hr×H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071609DV100716091007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS29UXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»9\Hr×HHr»9\Hr×H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071609DV100716091007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WTN7R1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK10 NO Non-Important2021-04-28ByDW~ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»9\Hr×HHr»9\Hr×H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071609DV100716091007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1WTN7R4Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-04-28ByDW~ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»9\Hr×HHr»9\Hr×H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071609DV100716091007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1XTQ01LVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07B”DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»9\Hr×HHr»9\Hr×H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071610DV100716101007AšFAMERICAN INDIAN OR ALASKA NATIVE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OVTT3BOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr»=HrŁœ€Hr»=HrŁœ€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW}YC4591001C4591001 1007 10071610DV100716101007AšFAMERICAN INDIAN OR ALASKA NATIVE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OVTT3HOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr»=HrŁœ€Hr»=HrŁœ€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW}YC4591001C4591001 1007 10071612DV100716121007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS2K9AOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»;šHrÖüPHr»;šHrÖüP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071612DV100716121007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS2K9GOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»;šHrÖüPHr»;šHrÖüP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071612DV100716121007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1QZP5B3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-25B;DW@ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»;šHrÖüPHr»;šHrÖüP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071612DV100716121007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1U7XBCALab performed out of window Laboratory FOLLOW-UP 1007SSWAB_WEEK4 NO Non-Important2021-03-29B[DW` YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»;šHrÖüPHr»;šHrÖüP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071612DV100716121007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1YBEU8TVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-08B¢DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»;šHrÖüPHr»;šHrÖüP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071612DV100716121007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZIM297Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007SSWAB_WEEK16 NO Non-Important2021-07-10BĀDWĒ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»;šHrÖüPHr»;šHrÖüP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071612DV100716121007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1ZHUT51Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK18 NO Non-Important2021-07-13BÅDWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»;šHrÖüPHr»;šHrÖüP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071613DV100716131007AŠMWHITE DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS2KA7Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»M Hs˜lHr»M HrÖč(Hs|Ū4Hs˜lPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071613DV100716131007AŠMWHITE DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS2KADOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»M Hs˜lHr»M HrÖč(Hs|Ū4Hs˜lPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071613DV100716131007AŠMWHITE DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YCQC4YVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-03-31B]DWb YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»M Hs˜lHr»M HrÖč(Hs|Ū4Hs˜lPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071613DV100716131007AŠMWHITE DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7FMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25B”DW™ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»M Hs˜lHr»M HrÖč(Hs|Ū4Hs˜lPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071613DV100716131007AŠMWHITE DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7XBOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25B”DW™ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»M Hs˜lHr»M HrÖč(Hs|Ū4Hs˜lPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071613DV100716131007AŠMWHITE DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7XHOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25B”DW™ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»M Hs˜lHr»M HrÖč(Hs|Ū4Hs˜lPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071613DV100716131007AŠMWHITE DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEB7XNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25B”DW™ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»M Hs˜lHr»M HrÖč(Hs|Ū4Hs˜lPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071614DV100716141007AąMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORC1XTOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr»S`Hs©Ļ|Hr»S`HrÖ’˜Hsvq,Hs©Ļ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071614DV100716141007AąMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ORC1XZOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr»S`Hs©Ļ|Hr»S`HrÖ’˜Hsvq,Hs©Ļ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071614DV100716141007AąMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEBGKXOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr»S`Hs©Ļ|Hr»S`HrÖ’˜Hsvq,Hs©Ļ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071614DV100716141007AąMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEBGLNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr»S`Hs©Ļ|Hr»S`HrÖ’˜Hsvq,Hs©Ļ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071614DV100716141007AąMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEBGM3Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr»S`Hs©Ļ|Hr»S`HrÖ’˜Hsvq,Hs©Ļ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071614DV100716141007AąMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEBGMJOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr»S`Hs©Ļ|Hr»S`HrÖ’˜Hsvq,Hs©Ļ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071614DV100716141007AąMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YV6XS2Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-06-28B¶DW» YYPhase 3A@ . . .N. A12-15 YearsNAąHr»S`Hs©Ļ|Hr»S`HrÖ’˜Hsvq,Hs©Ļ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071615DV100716151007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS2KAKOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»LŠHr×xHr»LŠHr×x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071615DV100716151007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS2KEWOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»LŠHr×xHr»LŠHr×x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071615DV100716151007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XNE0EFVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-06-02BœDW” YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»LŠHr×xHr»LŠHr×x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071615DV100716151007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YBEU8WVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-11B„DWŖ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»LŠHr×xHr»LŠHr×x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071615DV100716151007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1Z499HLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK16 NO Non-Important2021-07-08BĄDWÅ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»LŠHr×xHr»LŠHr×x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071616DV100716161007AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS2KFDOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr»QDHrÖÜ4Hr»QDHrÖÜ4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071616DV100716161007AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS2KFJOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr»QDHrÖÜ4Hr»QDHrÖÜ4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071616DV100716161007AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YBEUAXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-03BDW¢ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr»QDHrÖÜ4Hr»QDHrÖÜ4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071616DV100716161007AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZCDLPQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-28BŌDWŁ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr»QDHrÖÜ4Hr»QDHrÖÜ4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071617DV100716171007AšFWHITE DWDWŠPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OVTT4IOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr»[XHsi^ÄHr»[XHrŲLhHsMGčHsi^ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWjYC4591001C4591001 1007 10071617DV100716171007AšFWHITE DWDWŠPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OVTT58Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr»[XHsi^ÄHr»[XHrŲLhHsMGčHsi^ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWjYC4591001C4591001 1007 10071618DV100716181007AŠMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ORC1Y6Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»[Hr֜°Hr»[Hr֜°..Placebo Placebo .DWŒYC4591001C4591001 1007 10071618DV100716181007AŠMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ORC1YCOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»[Hr֜°Hr»[Hr֜°..Placebo Placebo .DWŒYC4591001C4591001 1007 10071618DV100716181007AŠMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1QYQPREVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B:DW? YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»[Hr֜°Hr»[Hr֜°..Placebo Placebo .DWŒYC4591001C4591001 1007 10071618DV100716181007AŠMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSXJKGReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BˆDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»[Hr֜°Hr»[Hr֜°..Placebo Placebo .DWŒYC4591001C4591001 1007 10071618DV100716181007AŠMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XQC5GNNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007COVID_A NO Non-Important2021-06-01B›DW  YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»[Hr֜°Hr»[Hr֜°..Placebo Placebo .DWŒYC4591001C4591001 1007 10071618DV100716181007AŠMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSXJKDReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BDW¢ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»[Hr֜°Hr»[Hr֜°..Placebo Placebo .DWŒYC4591001C4591001 1007 10071619DV100716191007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS2KG0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼CœHrן¬Hr¼CœHrן¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071619DV100716191007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS2KG6Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼CœHrן¬Hr¼CœHrן¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071619DV100716191007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XTQ01OVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07B DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼CœHrן¬Hr¼CœHrן¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071620DV100716201007AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1QO6A4ISAE report delayed or not reported to Sponsor Safety Reporting VACCINATION 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-01B"DW( YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼M8HrŲRHr¼M8HrŲR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071620DV100716201007AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R1DOTBNasal swab not collected for the visit where it is required Laboratory VACCINATION 1007COVID_A NO Non-Important2021-02-05B&DW, YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼M8HrŲRHr¼M8HrŲR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071620DV100716201007AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZHW9RZVisit not done Visit Schedule VACCINATION 1007COVID_A1 NO Non-Important2021-02-05B&DW, YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼M8HrŲRHr¼M8HrŲR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071620DV100716201007AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1V8MALINasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1007COVID_B NO Non-Important2021-03-16BMDWS YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼M8HrŲRHr¼M8HrŲR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071620DV100716201007AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1TB4AGZSAE report delayed or not reported to Sponsor Safety Reporting FOLLOW-UP 1007Unplanned NO Non-Important2021-03-16BMDWS YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼M8HrŲRHr¼M8HrŲR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1007 10071621DV100716211007AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OVTTR7Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼Q¬HrŲR¼Hr¼Q¬HrŲR¼..Placebo Placebo .DW‘YC4591001C4591001 1007 10071621DV100716211007AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OVTTRDOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼Q¬HrŲR¼Hr¼Q¬HrŲR¼..Placebo Placebo .DW‘YC4591001C4591001 1007 10071622DV100716221007AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OVU6X8Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼PDHr¼PDHr¼PDHr¼PD..BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1007 10071622DV100716221007AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OVU6X6Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼PDHr¼PDHr¼PDHr¼PD..BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1007 10071622DV100716221007AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1PPEUWTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-18B3DW9 YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼PDHr¼PDHr¼PDHr¼PD..BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1007 10071623DV100716231007AŠMWHITE DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OROZMNOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼TōHs”ēlHr¼TōHrŁ¢ŌHs†LČHs”ēlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071623DV100716231007AŠMWHITE DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OROZMUOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼TōHs”ēlHr¼TōHrŁ¢ŌHs†LČHs”ēlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071623DV100716231007AŠMWHITE DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OVVC18Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼TōHs”ēlHr¼TōHrŁ¢ŌHs†LČHs”ēlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071623DV100716231007AŠMWHITE DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1OVVC3MOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼TōHs”ēlHr¼TōHrŁ¢ŌHs†LČHs”ēlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071623DV100716231007AŠMWHITE DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZE8TVVSerology sample not collected Laboratory OPEN LABEL TREATMENT1007V101_VAX3 NO Non-Important2021-06-01BšDW  YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼TōHs”ēlHr¼TōHrŁ¢ŌHs†LČHs”ēlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071624DV100716241007AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1OVVC8OVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼e HsŽ$4Hr¼e HrßßdHsuXHsŽ$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071624DV100716241007AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEBGN9Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼e HsŽ$4Hr¼e HrßßdHsuXHsŽ$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071624DV100716241007AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XEBGNPOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼e HsŽ$4Hr¼e HrßßdHsuXHsŽ$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071624DV100716241007AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEBGNVOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼e HsŽ$4Hr¼e HrßßdHsuXHsŽ$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071624DV100716241007AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEBGQJOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼e HsŽ$4Hr¼e HrßßdHsuXHsŽ$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OZPL4WOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼g<HsŽ"ĢHr¼g<HrߎtHsu¤HsŽ"ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OZPL52Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼g<HsŽ"ĢHr¼g<HrߎtHsu¤HsŽ"ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1OZPL53Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼g<HsŽ"ĢHr¼g<HrߎtHsu¤HsŽ"ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGOY0BOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼g<HsŽ"ĢHr¼g<HrߎtHsu¤HsŽ"ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGOY61Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼g<HsŽ"ĢHr¼g<HrߎtHsu¤HsŽ"ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGOY67Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼g<HsŽ"ĢHr¼g<HrߎtHsu¤HsŽ"ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGOY6DOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼g<HsŽ"ĢHr¼g<HrߎtHsu¤HsŽ"ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071626DV100716261007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS2KGPOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼€ŒHr×ļ˜Hr¼€ŒHr×ļ˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071626DV100716261007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OS2KGVOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼€ŒHr×ļ˜Hr¼€ŒHr×ļ˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071626DV100716261007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XTQ01RVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-03BœDW¢ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼€ŒHr×ļ˜Hr¼€ŒHr×ļ˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071627DV100716271007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OROZN8Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼‡Hr×čHr¼‡Hr×č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071627DV100716271007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OROZNMOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼‡Hr×čHr¼‡Hr×č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071627DV100716271007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XT1VKJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-06-08B”DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼‡Hr×čHr¼‡Hr×č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071627DV100716271007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1XTQ01UVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-08B”DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼‡Hr×čHr¼‡Hr×č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071628DV100716281007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OZPL49Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼ŲHrŲ0„Hr¼ŲHrŲ0„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071628DV100716281007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OZPL4NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼ŲHrŲ0„Hr¼ŲHrŲ0„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071628DV100716281007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1Z3S3BWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-22BÆDWµ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼ŲHrŲ0„Hr¼ŲHrŲ0„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071628DV100716281007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZIM22UNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007SSWAB_WEEK14 NO Non-Important2021-07-10BĮDWĒ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼ŲHrŲ0„Hr¼ŲHrŲ0„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071628DV100716281007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZIM291Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007SSWAB_WEEK16 NO Non-Important2021-07-28BÓDWŁ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼ŲHrŲ0„Hr¼ŲHrŲ0„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071628DV100716281007AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1ZCT7KBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-08-02BŲDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼ŲHrŲ0„Hr¼ŲHrŲ0„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071629DV100716291007AšFASIAN DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS2KJ9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼—üHs”Ļ„Hr¼—üHr×ķ@Hs†<œHs”Ļ„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071629DV100716291007AšFASIAN DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS2KJFOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼—üHs”Ļ„Hr¼—üHr×ķ@Hs†<œHs”Ļ„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071630DV100716301007AŠMASIAN DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS2KJWOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼–”Hs”Ń(Hr¼–”Hr×ģŒHs†>ōHs”Ń(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071630DV100716301007AŠMASIAN DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS2KKCOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼–”Hs”Ń(Hr¼–”Hr×ģŒHs†>ōHs”Ń(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071630DV100716301007AŠMASIAN DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM73FOOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-01BšDW  YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼–”Hs”Ń(Hr¼–”Hr×ģŒHs†>ōHs”Ń(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071630DV100716301007AŠMASIAN DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM73G4Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-01BšDW  YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼–”Hs”Ń(Hr¼–”Hr×ģŒHs†>ōHs”Ń(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071630DV100716301007AŠMASIAN DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XM73GAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-01BšDW  YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼–”Hs”Ń(Hr¼–”Hr×ģŒHs†>ōHs”Ń(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071630DV100716301007AŠMASIAN DWDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XM73GGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-01BšDW  YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼–”Hs”Ń(Hr¼–”Hr×ģŒHs†>ōHs”Ń(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071631DV100716311007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OZPL3HOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼”˜HrŁpHr¼”˜HrŁp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071631DV100716311007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OZPL3NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼”˜HrŁpHr¼”˜HrŁp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071632DV100716321007AŠFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OZPL2KOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼¦ Hs9Hr¼¦ HrŁ]ģHssŒPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071632DV100716321007AŠFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OZPL2QOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼¦ Hs9Hr¼¦ HrŁ]ģHssŒPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071632DV100716321007AŠFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGOXSFOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŒDW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼¦ Hs9Hr¼¦ HrŁ]ģHssŒPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071632DV100716321007AŠFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGOXZJOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŒDW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼¦ Hs9Hr¼¦ HrŁ]ģHssŒPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071632DV100716321007AŠFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGOXZPOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŒDW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼¦ Hs9Hr¼¦ HrŁ]ģHssŒPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071632DV100716321007AŠFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGOY05Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BŒDW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼¦ Hs9Hr¼¦ HrŁ]ģHssŒPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071633DV100716331007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OZPL27Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼„HrŁ |Hr¼„HrŁ |..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071633DV100716331007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OZPL2DOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼„HrŁ |Hr¼„HrŁ |..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071633DV100716331007AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XTQ01XVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07B DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼„HrŁ |Hr¼„HrŁ |..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071634DV100716341007AąMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OZPL1UOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĀę˜HrŽœlHrĀę˜HrŽœl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071634DV100716341007AąMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OZPL20Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĀę˜HrŽœlHrĀę˜HrŽœl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071635DV100716351007AŠMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OZPL1HOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĀą¼HrŽĒPHrĀą¼HrŽĒP..Placebo Placebo .DWŒYC4591001C4591001 1007 10071635DV100716351007AŠMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OZPL1NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĀą¼HrŽĒPHrĀą¼HrŽĒP..Placebo Placebo .DWŒYC4591001C4591001 1007 10071635DV100716351007AŠMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XD2IB7Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14BƒDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĀą¼HrŽĒPHrĀą¼HrŽĒP..Placebo Placebo .DWŒYC4591001C4591001 1007 10071636DV100716361007AĄFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XTQ020Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-03B—DW¢ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĀńœHrŽŽ HrĀńœHrŽŽ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071638DV100716381007AŠFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OZPDF2Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĀ÷<HrŽ‡HrĀ÷<HrŽ‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071638DV100716381007AŠFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OZPDFIOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĀ÷<HrŽ‡HrĀ÷<HrŽ‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071638DV100716381007AŠFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z4VZVTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-15B£DW® YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĀ÷<HrŽ‡HrĀ÷<HrŽ‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071638DV100716381007AŠFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z499HPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-07-08BŗDWÅ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĀ÷<HrŽ‡HrĀ÷<HrŽ‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071639DV100716391007AŠMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OZP63AOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĀżHrŽ“HrĀżHrŽ“..Placebo Placebo .DWYC4591001C4591001 1007 10071639DV100716391007AŠMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OZP63GOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĀżHrŽ“HrĀżHrŽ“..Placebo Placebo .DWYC4591001C4591001 1007 10071639DV100716391007AŠMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZIM22PNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-04-19BjDWu YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĀżHrŽ“HrĀżHrŽ“..Placebo Placebo .DWYC4591001C4591001 1007 10071639DV100716391007AŠMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZHUT54Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK8 NO Non-Important2021-04-28BsDW~ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĀżHrŽ“HrĀżHrŽ“..Placebo Placebo .DWYC4591001C4591001 1007 10071640DV100716401007AąFWHITE DW DWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R0CRESVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-02B:DWE YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆŲHs”ćčHrĆŲHrŽę@HsˆÖHs”ćčPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AŠFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OXAG96Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ(Hrą-čHrĆ(Hrą-č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AŠFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OXAG9COther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ(Hrą-čHrĆ(Hrą-č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AŠFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XD2IEMVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-05-24BDW˜ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ(Hrą-čHrĆ(Hrą-č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AŠFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1XTQ023Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07B›DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ(Hrą-čHrĆ(Hrą-č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AŠFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZB3T01Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK18 NO Non-Important2021-07-26BĢDW× YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ(Hrą-čHrĆ(Hrą-č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AŠFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1ZFDTHSVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_B1 NO Non-Important2021-08-09BŚDWå YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ(Hrą-čHrĆ(Hrą-č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071642DV100716421007AšMWHITE DW DW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OWKIN5Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĆ%,Hs§8HrĆ%,Hs§8..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071642DV100716421007AšMWHITE DW DW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OWKINBOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĆ%,Hs§8HrĆ%,Hs§8..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071642DV100716421007AšMWHITE DW DW›BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1QSQ8I6Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-22B2DW= YYPhase 3A@ . . .N. A12-15 YearsNAšHrĆ%,Hs§8HrĆ%,Hs§8..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071643DV100716431007AĄMWHITE DW DW·Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OWJJMQOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ#ÄHs¤`HrĆ#ÄHrŽŲlHs©Hs¤`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071643DV100716431007AĄMWHITE DW DW·Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OWJJOAOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ#ÄHs¤`HrĆ#ÄHrŽŲlHs©Hs¤`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071643DV100716431007AĄMWHITE DW DW·Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1QTCECTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-22B2DW= YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ#ÄHs¤`HrĆ#ÄHrŽŲlHs©Hs¤`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071643DV100716431007AĄMWHITE DW DW·Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBOGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW› YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ#ÄHs¤`HrĆ#ÄHrŽŲlHs©Hs¤`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071643DV100716431007AĄMWHITE DW DW·Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBOMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW› YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ#ÄHs¤`HrĆ#ÄHrŽŲlHs©Hs¤`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071643DV100716431007AĄMWHITE DW DW·Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XMBBOSOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW› YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ#ÄHs¤`HrĆ#ÄHrŽŲlHs©Hs¤`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071643DV100716431007AĄMWHITE DW DW·Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XMBBOYOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW› YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ#ÄHs¤`HrĆ#ÄHrŽŲlHs©Hs¤`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071644DV100716441007AŠMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OWJJM3Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ;pHrŽÜhHrĆ;pHrŽÜh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071644DV100716441007AŠMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OWJJMJOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ;pHrŽÜhHrĆ;pHrŽÜh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071644DV100716441007AŠMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XTQ026Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07B›DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ;pHrŽÜhHrĆ;pHrŽÜh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071645DV100716451007AąMWHITE DW DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OWJJKWOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ8(Hs™Č„HrĆ8(HrŽć4Hs~.Hs™Č„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071645DV100716451007AąMWHITE DW DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OWJJL2Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ8(Hs™Č„HrĆ8(HrŽć4Hs~.Hs™Č„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071645DV100716451007AąMWHITE DW DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBKWOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDWš YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ8(Hs™Č„HrĆ8(HrŽć4Hs~.Hs™Č„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071645DV100716451007AąMWHITE DW DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBN0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDWš YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ8(Hs™Č„HrĆ8(HrŽć4Hs~.Hs™Č„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071645DV100716451007AąMWHITE DW DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XMBBNGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDWš YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ8(Hs™Č„HrĆ8(HrŽć4Hs~.Hs™Č„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071645DV100716451007AąMWHITE DW DWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XMBBNMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDWš YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ8(Hs™Č„HrĆ8(HrŽć4Hs~.Hs™Č„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071646DV100716461007AĄMWHITE DW DWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OWJJI1Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆC,Hs”÷ŌHrĆC,HrŽįĢHsˆąPHs”÷ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071646DV100716461007AĄMWHITE DW DWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OWJJJ1Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆC,Hs”÷ŌHrĆC,HrŽįĢHsˆąPHs”÷ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071647DV100716471007AĄMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OWJJG2Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĆE„HrŽŲlHrĆE„HrŽŲl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071647DV100716471007AĄMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OWJJHUOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĆE„HrŽŲlHrĆE„HrŽŲl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071647DV100716471007AĄMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z3S3BZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08BœDW§ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĆE„HrŽŲlHrĆE„HrŽŲl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1007 10071648DV100716481007AšMASIAN DW DW‹Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ON6MQCOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ(dHsji@HrÄ(dHrßŅųHsNĀØHsji@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWuYC4591001C4591001 1007 10071648DV100716481007AšMASIAN DW DW‹Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ON6MQIOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ(dHsji@HrÄ(dHrßŅųHsNĀØHsji@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWuYC4591001C4591001 1007 10071649DV100716491007AąFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ON619EOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrÄ.ōHrą)ģHrÄ.ōHrą)ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071649DV100716491007AąFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ON6M4EOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrÄ.ōHrą)ģHrÄ.ōHrą)ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ON6MIHOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ON6MINOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1P1ZHV1Subject was vaccinated despite meeting temporary delay criterion #1 (current febrile illness or other acute illness within 48 hrs before study intervention administration. Includes current symptoms that could represent a potential COVID-19 illness.Investigational ProductVACCINATION 1007V1_DAY1_VAX1_L NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ON6MIOProcedure/Test not performed per protocol Procedures/Tests VACCINATION 1007V1_DAY1_VAX1_L NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA€1-1X3BCY0Lab performed out of window Laboratory FOLLOW-UP 1007V202_SURVEIL_SWAB|639570773683065NO Non-Important2021-04-26BpDW| YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTN7RRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK8 NO Non-Important2021-04-26BpDW| YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBP4Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW™ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBPAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW™ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XMBBPGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW™ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071650DV100716501007AŠMWHITE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XMBBPMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW™ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄ@LHs˜²HrÄ@LHrߣHs}šHs˜²Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071651DV100716511007AĄMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ON6MQZOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÄ=HrßźąHrÄ=Hrßźą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071651DV100716511007AĄMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ON6MR5Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÄ=HrßźąHrÄ=Hrßźą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071651DV100716511007AĄMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XTQ029Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BšDW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÄ=HrßźąHrÄ=Hrßźą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071652DV100716521007AĄFWHITE DW DW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1WTN7RUVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK8 NO Non-Important2021-04-20BjDWv YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄB,Hs l¬HrÄB,HrßŲ\Hs|ĒHHs l¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071652DV100716521007AĄFWHITE DW DW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1X3BCY3Lab performed out of window Laboratory FOLLOW-UP 1007V202_SURVEIL_SWAB|640689756662050NO Non-Important2021-04-26BpDW| YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄB,Hs l¬HrÄB,HrßŲ\Hs|ĒHHs l¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071652DV100716521007AĄFWHITE DW DW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XM5NRVOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW™ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄB,Hs l¬HrÄB,HrßŲ\Hs|ĒHHs l¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071652DV100716521007AĄFWHITE DW DW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XM5NSLOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW™ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄB,Hs l¬HrÄB,HrßŲ\Hs|ĒHHs l¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071652DV100716521007AĄFWHITE DW DW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM5NSROther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW™ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄB,Hs l¬HrÄB,HrßŲ\Hs|ĒHHs l¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071652DV100716521007AĄFWHITE DW DW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM5NSXOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW™ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄB,Hs l¬HrÄB,HrßŲ\Hs|ĒHHs l¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071652DV100716521007AĄFWHITE DW DW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YV6XSFVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-06-21BØDW“ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄB,Hs l¬HrÄB,HrßŲ\Hs|ĒHHs l¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071653DV100716531007AąMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XTQ02CVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BšDW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrÄn<Hrą!øHrÄn<Hrą!ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071654DV100716541007AĄFWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OV1ORANasal swab not collected for the visit where it is required Laboratory VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄkØHrą"äHrÄkØHrą"ä..Placebo Placebo .DWŒYC4591001C4591001 1007 10071654DV100716541007AĄFWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1QW05STSerology sample not collected Laboratory FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-23B2DW> YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄkØHrą"äHrÄkØHrą"ä..Placebo Placebo .DWŒYC4591001C4591001 1007 10071654DV100716541007AĄFWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSYJV7Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-17B…DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄkØHrą"äHrÄkØHrą"ä..Placebo Placebo .DWŒYC4591001C4591001 1007 10071654DV100716541007AĄFWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZCJ1HFSerology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-22BĒDWÓ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄkØHrą"äHrÄkØHrą"ä..Placebo Placebo .DWŒYC4591001C4591001 1007 10071655DV100716551007AąMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGLXQIOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅ{ÄHsŽ;hHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071655DV100716551007AąMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXQOOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅ{ÄHsŽ;hHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071655DV100716551007AąMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLXQUOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅ{ÄHsŽ;hHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071655DV100716551007AąMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGLXR0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅ{ÄHsŽ;hHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071655DV100716551007AąMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZE8TWISerology sample not collected Laboratory OPEN LABEL TREATMENT1007V101_VAX3 NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅ{ÄHsŽ;hHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071655DV100716551007AąMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z3A9BFSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsOPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-07-02B²DWæ YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅ{ÄHsŽ;hHrÅ{ÄHrį*ĢHsrƒ<HsŽ;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071656DV100716561007AąFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YBEUB2Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK10 NO Non-Important2021-06-08BšDW§ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrńčHrįv€HrńčHrįv€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071658DV100716581007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGLXR6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅęąHsŽ-ŠHrÅęąHrį9Hsr€lHsŽ-ŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071658DV100716581007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGLXRCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅęąHsŽ-ŠHrÅęąHrį9Hsr€lHsŽ-ŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071658DV100716581007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXSWOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅęąHsŽ-ŠHrÅęąHrį9Hsr€lHsŽ-ŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071658DV100716581007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLXT2Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅęąHsŽ-ŠHrÅęąHrį9Hsr€lHsŽ-ŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071658DV100716581007AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1YGUX98Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL TREATMENT1007COVID_A NO Non-Important2021-06-08BšDW§ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅęąHsŽ-ŠHrÅęąHrį9Hsr€lHsŽ-ŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1007 10071659DV100716591007AšFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1X3BCPSNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1007SSWAB_WEEK4 NO Non-Important2021-03-28BRDW_ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅć\Hrį„HrÅć\Hrį„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071659DV100716591007AšFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YEE5NZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-04-08B]DWj YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅć\Hrį„HrÅć\Hrį„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071659DV100716591007AšFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XTQ02FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07B™DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅć\Hrį„HrÅć\Hrį„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071660DV100716601007AĄMWHITE DWDW·Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X3BCXXNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1007SSWAB_WEEK4 NO Non-Important2021-03-28BRDW_ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÅālHs¤Ž¤HrÅālHrįƒÜHs‡q Hs¤Ž¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071660DV100716601007AĄMWHITE DWDW·Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YEE5O3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-04-08B]DWj YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÅālHs¤Ž¤HrÅālHrįƒÜHs‡q Hs¤Ž¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071661DV100716611007AŠFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XTQ02IVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07B˜DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĒ xHrāŲhHrĒ xHrāŲh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1007 10071662DV100716621007AšFWHITE DWDW$Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSYJVAReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-05B–DW¤ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒ)$Hrā|LHrĒ)$Hrā|L..Placebo Placebo .DWYC4591001C4591001 1007 10071662DV100716621007AšFWHITE DWDW$Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZH2UHGVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-08-12BŚDWč YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒ)$Hrā|LHrĒ)$Hrā|L..Placebo Placebo .DWYC4591001C4591001 1008 10081751DV100817511008AŠFWHITE DVźDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5EFIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B„DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr– Hs‰ņÄHr– Hr³0Hsn|°Hs‰ņÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081752DV100817521008AšMASIAN DVźDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WKF774Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK4 NO Non-Important2021-04-19BŒDWu YYPhase 3A@ . . .N. A12-15 YearsNAšHr–XHsŠ'Hr–XHr²PHslź€HsŠ'Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081752DV100817521008AšMASIAN DVźDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5EJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B¤DW YYPhase 3A@ . . .N. A12-15 YearsNAšHr–XHsŠ'Hr–XHr²PHslź€HsŠ'Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081753DV100817531008AąMASIAN DVźDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WKF777Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK4 NO Non-Important2021-04-19BŒDWu YYPhase 3A@ . . .Y. A12-15 YearsNAąHr–XDHr²œHr–XDHr²œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081756DV100817561008AšFWHITE DVėDWŒPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XDA5EMIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-22BŽDWx YYPhase 3A@ . . .N. A12-15 YearsNAšHr—›<HskęŠHr—›<Hr²0HsQŠ8HskęŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWwYC4591001C4591001 1008 10081756DV100817561008AšFWHITE DVėDWŒPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YL1U1ARevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-12B¢DWŒ YYPhase 3A@ . . .N. A12-15 YearsNAšHr—›<HskęŠHr—›<Hr²0HsQŠ8HskęŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWwYC4591001C4591001 1008 10081756DV100817561008AšFWHITE DVėDWŒPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YL1U48Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-12B¢DWŒ YYPhase 3A@ . . .N. A12-15 YearsNAšHr—›<HskęŠHr—›<Hr²0HsQŠ8HskęŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWwYC4591001C4591001 1008 10081757DV100817571008AĄMWHITE DVėDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5FJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17B§DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr—šˆHsśHr—šˆHr²|Hsrm4HsśPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081758DV100817581008AšFWHITE DVėDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WTN7S0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-29B•DW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr—¤œHr³ŌHr—¤œHr³Ō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081761DV100817611008AšFWHITE DVšDW}Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5FMIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-05BxDWg YYPhase 3A@ . . .N. A12-15 YearsNAšHrž:šHsX€Hrž:šHr¹ŖtHs;"˜HsX€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWgYC4591001C4591001 1008 10081763DV100817631008AąMWHITE DVšDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P9LCCZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-25B2DW! YYPhase 3A@ . . .N. A12-15 YearsNAąHržOHs¼äHržOHr¼r|Hsu$Hs¼äPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081763DV100817631008AąMWHITE DVšDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R5SPMOOther Informed Consent Informed Consent FOLLOW-UP 1008Consent NO Non-Important2021-03-12B`DWO YYPhase 3A@ . . .N. A12-15 YearsNAąHržOHs¼äHržOHr¼r|Hsu$Hs¼äPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081764DV100817641008AŠFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P9LCD3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-25B2DW! YYPhase 3A@ . . .Y. A12-15 YearsNAŠHržNdHr¼[HHržNdHr¼[H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081767DV100817671008AšMWHITE DVńDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5FPIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸ†”HsˆĻ¬HrŸ†”HrŗųčHsmO HsˆĻ¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081769DV100817691008AšMWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R7E1VZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-23BNDW> YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŸŽPHrŗžÄHrŸŽPHrŗžÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWvYC4591001C4591001 1008 10081773DV100817731008AŠMWHITE DVņDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5FSIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr Ó(HsŠhHr Ó(Hr» Hsn`HsŠhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081774DV100817741008AĄFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YM02Z7Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-17BæDW° YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr ŻšHr¹ĮØHr ŻšHr¹ĮØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081775DV100817751008AąMWHITE DVņDW±Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YNZMAZVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1008V102_VAX4 NO Non-Important2021-06-18BĄDW± YYPhase 3A@ . . .N. A12-15 YearsNAąHr Ż<Hsœ§HHr Ż<Hr¹ĄøHswø Hsœ§HPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081780DV100817801008AšFWHITE DVóDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5HJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BŸDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¢.DHsįhHr¢.DHrŗč¼Hsr4|HsįhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081788DV100817881008AŠFWHITE DV÷DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5HMIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B—DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr§3HsˆäLHr§3HrĀõ Hsl’ŌHsˆäLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081790DV100817901008AĄFWHITE DV÷DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5HPIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B—DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§lˆHsˆĶHr§lˆHrĀ÷xHsläąHsˆĶPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081793DV100817931008AąMWHITE DV÷DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5KAIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B—DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr§z\HsˆŁĄHr§z\HrĆLHsm*HsˆŁĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081794DV100817941008AĄFASIAN DV÷DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5KDIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B—DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§{ˆHsˆŁüHr§{ˆHrĆ˜Hsm1 HsˆŁüPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081796DV100817961008AšFWHITE DVųDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WNXXE5Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V202_SURVEIL_SWAB|641134295578050NO Non-Important2021-04-13BxDWo YYPhase 3A@ . . .N. A12-15 YearsNAšHrØŗ„Hsˆ³HrØŗ„HrÄu€HsnCDHsˆ³Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081796DV100817961008AšFWHITE DVųDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5KGIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B—DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrØŗ„Hsˆ³HrØŗ„HrÄu€HsnCDHsˆ³Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081798DV100817981008AŠFWHITE DVųDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5LNIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B—DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrØŹ°HsŠ)ŲHrØŹ°HrÄ}“Hsnb4HsŠ)ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081799DV100817991008AŠFWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OCN9STUrine pregnancy test not performed. Laboratory VACCINATION 1008V1_DAY1_VAX1_L NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrØĖÜHrÄ5HHrØĖÜHrÄ5H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081799DV100817991008AŠFWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2A4Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-04B¬DW£ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrØĖÜHrÄ5HHrØĖÜHrÄ5H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081799DV100817991008AŠFWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHUT58Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-15B·DW® YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrØĖÜHrÄ5HHrØĖÜHrÄ5H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081801DV100818011008AšFWHITE DVśDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZE8TWLSerology sample not collected Laboratory FOLLOW-UP 1008V201_SURVEIL_CONSENT NO Non-Important2021-03-22B`DWY YYPhase 3A@ . . .N. A12-15 YearsNAšHr«2(HsŽlHr«2(HrČHsrn`HsŽlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081801DV100818011008AšFWHITE DVśDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5LQIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17B˜DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHr«2(HsŽlHr«2(HrČHsrn`HsŽlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081803DV100818031008AšMBLACK OR AFRICAN AMERICAN DVśDWkPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5LTIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V102_VAX4 NO Non-Important2021-04-09BrDWk YYPhase 3A@ . . .N. A12-15 YearsNAšHr«^ģHs@SųHr«^ģHrĘģ4Hs$¦”Hs@SųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1008 10081804DV100818041008AąFASIAN DVśDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5OFIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B”DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr«eøHsˆŪÜHr«eøHrĒHsm1ĄHsˆŪÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081805DV100818051008AĄFASIAN DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHUT9RVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-07-01BÅDW¾ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«q¬HrĒ šHr«q¬HrĒ š..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081805DV100818051008AĄFASIAN DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YXHVRASerology sample not collected Laboratory REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-02BĘDWæ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«q¬HrĒ šHr«q¬HrĒ š..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081807DV100818071008AĄFWHITE DVūDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5OIIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B”DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬züHs‰ģ4Hr¬züHrČ?”HsnCųHs‰ģ4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081808DV100818081008AŠMASIAN DVūDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5OLIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17B—DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬~€HsāŠHr¬~€HrČ>¤Hsr3HsāŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081809DV100818091008AŠFASIAN DVūDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5OOIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B“DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬‹ Hsˆ½ÜHr¬‹ HrČI0HsmOĄHsˆ½ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081809DV100818091008AŠFASIAN DVūDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z6G6WHVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1008V103_MONTH1 NO Non-Important2021-07-14BŃDWĖ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬‹ Hsˆ½ÜHr¬‹ HrČI0HsmOĄHsˆ½ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081811DV100818111008AšFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OFAVJLOther Informed Consent Informed Consent VACCINATION 1008Consent NO Non-Important2020-12-18ADVū YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¬Ž¬HrČ6pHr¬Ž¬HrČ6p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081811DV100818111008AšFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1XPVX9KLab performed out of window Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK8 NO Non-Important2021-06-01B¦DW  YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¬Ž¬HrČ6pHr¬Ž¬HrČ6p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081811DV100818111008AšFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XSGB0VVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK8 NO Non-Important2021-06-01B¦DW  YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¬Ž¬HrČ6pHr¬Ž¬HrČ6p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081812DV100818121008AąMWHITE DVūDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5QZIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B“DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¬²Hs‰ķ$Hr¬²HrČfōHsmHōHs‰ķ$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081817DV100818171008AŠFASIAN DVūDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PLVAJEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-12B9DW3 YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬ÅHHsŠ ČHr¬ÅHHrÅĢ HsnfäHsŠ ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081817DV100818171008AŠFASIAN DVūDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5R2Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B”DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬ÅHHsŠ ČHr¬ÅHHrÅĢ HsnfäHsŠ ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081818DV100818181008AšMWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XT0RCTNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-25BŸDW™ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¬Ē(HrČcpHr¬Ē(HrČcp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081819DV100818191008AĄMWHITE DVžDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5R5Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18B•DW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr°lpHs/ Hr°lpHrĢ_¬Hss{čHs/ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081821DV100818211008AŠMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PF862JVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-08B2DW/ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°uHrĶ±¤Hr°uHrĶ±¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081822DV100818221008AŠFWHITE DVžDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5R8Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B‘DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°xÜHs‰ó“Hr°xÜHrĢb|HsncŲHs‰ó“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081825DV100818251008AĄFWHITE DVžDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5RBIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr°£„Hsˆ±4Hr°£„HrĢMdHsm&ųHsˆ±4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081826DV100818261008AąMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YD7IC0Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-05-04B‡DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr°¤ģHrĶ|Hr°¤ģHrĶ|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081828DV100818281008AąFWHITE DVžDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PDX79CVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1008V2_VAX2_L NO Non-Important2021-01-22B!DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr°ÆHsn¬Hr°ÆHrŚÜlHsnX\Hsn¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081828DV100818281008AąFWHITE DVžDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5REIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B‘DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHr°ÆHsn¬Hr°ÆHrŚÜlHsnX\Hsn¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081828DV100818281008AąFWHITE DVžDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Y1PBIBVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1008V102_VAX4 NO Non-Important2021-06-08BŖDW§ YYPhase 3A@ . . .N. A12-15 YearsNAąHr°ÆHsn¬Hr°ÆHrŚÜlHsnX\Hsn¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081831DV100818311008AšMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1VISO3TVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008COVID_A1 NO Non-Important2021-04-20BxDWv YYPhase 3A@ . . .Y. A12-15 YearsNAšHr±ÅčHrĶYĄHr±ÅčHrĶYĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081832DV100818321008AšFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIW26QVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-08-20BņDWš YYPhase 3A@ . . .Y. A12-15 YearsNAšHr±Ź˜HrĶ`ŒHr±Ź˜HrĶ`Œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‡YC4591001C4591001 1008 10081833DV100818331008AŠMWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5RRIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr±ÉlHs‰ō¤Hr±ÉlHrĶ`HsnoĢHs‰ō¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081836DV100818361008AąFWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QTCECWVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008COVID_A1 NO Non-Important2021-02-23B@DW> YYPhase 3A@ . . .N. A12-15 YearsNAąHr²4Hs‰śųHr²4HrĶ[(HsnKšHs‰śųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081836DV100818361008AąFWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5RUIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHr²4Hs‰śųHr²4HrĶ[(HsnKšHs‰śųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081837DV100818371008AĄMWHITE DV’DWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZMN4EIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr² ŠHs½ŌHr² ŠHrĶ·DHsuPHs½ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081838DV100818381008AšMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YBEUBBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr² ĄHrĶ¶THr² ĄHrĶ¶T..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081838DV100818381008AšMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YBEUBEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-05-21B—DW• YYPhase 3A@ . . .Y. A12-15 YearsNAšHr² ĄHrĶ¶THr² ĄHrĶ¶T..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081838DV100818381008AšMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YBEUBHVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-09BŖDWØ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr² ĄHrĶ¶THr² ĄHrĶ¶T..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081839DV100818391008AšFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XK42SNLab performed out of window Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-05-04B†DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr² (HrĶ©pHr² (HrĶ©p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081839DV100818391008AšFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YM02ZEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-05-04B†DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr² (HrĶ©pHr² (HrĶ©p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081839DV100818391008AšFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YM0301Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK8 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr² (HrĶ©pHr² (HrĶ©p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081839DV100818391008AšFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YM02ZBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-20BµDW³ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr² (HrĶ©pHr² (HrĶ©p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081840DV100818401008AšFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5RXIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHr³šHsŠ'€Hr³šHrĻ4Hsnˆ¤HsŠ'€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081842DV100818421008AĄFWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QW7RGHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-19B;DW: YYPhase 3A@ . . .N. A12-15 YearsNAĄHr³ ŠHs»ōHr³ ŠHrĶW¤Hsu Hs»ōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081843DV100818431008AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV6XSIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-06-30B¾DW½ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr³¼HrĻ$Hr³¼HrĻ$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081845DV100818451008AŠFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZE8TWOSerology sample not collected Laboratory FOLLOW-UP 1008V201_SURVEIL_CONSENT NO Non-Important2021-04-05BhDWg YYPhase 3A@ . . .N. A12-15 YearsNAŠHr³4Hs3œHr³4HrĢüHsrnŲHs3œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081845DV100818451008AŠFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5S0Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17B’DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr³4Hs3œHr³4HrĢüHsrnŲHs3œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081849DV100818491008AĄMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XDA5S3Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr³#\HsŠ ŒHr³#\HrŠ5xHsnz”HsŠ ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081849DV100818491008AĄMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YXG8IVSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsOPEN LABEL TREATMENT1008V102_VAX4 NO Non-Important2021-06-30B¾DW½ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr³#\HsŠ ŒHr³#\HrŠ5xHsnz”HsŠ ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081851DV100818511008AŠFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5S6Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18B“DW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr³2ŌHs-HHr³2ŌHrь Hss{4Hs-HPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081852DV100818521008AšMWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5S9Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18B“DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr³3ÄHs-ĄHr³3ÄHrэLHss{¬Hs-ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081854DV100818541008AšMASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z499HSVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-09BĀDWĘ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¹³\HrÕRtHr¹³\HrÕRt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081861DV100818611008AąMWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5SDIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BŒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrŗū|Hs‡†ŲHrŗū|HrÕrHsn‚Hs‡†ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081862DV100818621008AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHEE05Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-08-06BŻDWā YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»4Hr׳pHr»4Hr׳p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081863DV100818631008AŠFASIAN DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5SGIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BŒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr» PHsāXHr» PHrÕdųHsr3PHsāXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081864DV100818641008AĄFASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZH2CQMNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK18 NO Non-Important2021-07-24BŠDWÕ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr» |HrÕd€Hr» |HrÕd€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081866DV100818661008AŠMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5SJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B‰DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»8äHs‰īPHr»8äHrÕ{HsnEŲHs‰īPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081867DV100818671008AŠFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5VYIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B‰DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»9ŌHs‰īŒHr»9ŌHrÕ{“HsnFČHs‰īŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081868DV100818681008AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHUT9UVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-10B¤DW© YYPhase 3A@ . . .Y. A12-15 YearsNAšHr»;HrÖŚTHr»;HrÖŚT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081869DV100818691008AąFWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5W1Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B‰DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHr»>üHs‡c8Hr»>üHr֔ōHsnIŌHs‡c8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081870DV100818701008AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WTN7T0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-09BfDWk YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»C¬HrÕs€Hr»C¬HrÕs€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081870DV100818701008AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YV6XSLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-13BˆDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»C¬HrÕs€Hr»C¬HrÕs€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081870DV100818701008AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZF2K25Other lab deviation Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-03BDW¢ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»C¬HrÕs€Hr»C¬HrÕs€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081870DV100818701008AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YV6XT8Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-03BDW¢ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»C¬HrÕs€Hr»C¬HrÕs€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081870DV100818701008AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1Z499SPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-09BĮDWĘ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»C¬HrÕs€Hr»C¬HrÕs€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081871DV100818711008AąFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QW7RGLVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1008V2_VAX2_L NO Non-Important2021-02-16B1DW7 YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼P€HsˆĪDHr¼P€Hr¼P€Hsm2°HsˆĪDPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081871DV100818711008AąFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5W4Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B‡DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼P€HsˆĪDHr¼P€Hr¼P€Hsm2°HsˆĪDPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081872DV100818721008AšMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UIL7TCSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsOPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-09BeDWk YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼XHsYmŌHr¼XHrŚŁ$Hs@bDHsYmŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AšMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1UIL84USubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsOPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-09BeDWk YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼XHsYmŌHr¼XHrŚŁ$Hs@bDHsYmŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AšMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XK1TL9Nasal swab collected at a visit where it was not required Laboratory OPEN LABEL TREATMENT1008SSWAB_WEEK8 NO Non-Important2021-04-23BsDWy YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼XHsYmŌHr¼XHrŚŁ$Hs@bDHsYmŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AšMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XK2YZMNasal swab collected at a visit where it was not required Laboratory OPEN LABEL TREATMENT1008SSWAB_WEEK10 NO Non-Important2021-05-02B|DW‚ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼XHsYmŌHr¼XHrŚŁ$Hs@bDHsYmŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AšMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1WTN7SXVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1008SSWAB_WEEK6 NO Non-Important2021-05-02B|DW‚ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼XHsYmŌHr¼XHrŚŁ$Hs@bDHsYmŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AšMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XDAWC5Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-09BƒDW‰ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼XHsYmŌHr¼XHrŚŁ$Hs@bDHsYmŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AšMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XK2YZSNasal swab collected at a visit where it was not required Laboratory OPEN LABEL TREATMENT1008SSWAB_WEEK12 NO Non-Important2021-05-18BŒDW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼XHsYmŌHr¼XHrŚŁ$Hs@bDHsYmŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081873DV100818731008AŠFBLACK OR AFRICAN AMERICAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2A7Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-05-30B˜DWž YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¼XšHrÕJHr¼XšHrÕJ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081873DV100818731008AŠFBLACK OR AFRICAN AMERICAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHUT9XVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-15BØDW® YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¼XšHrÕJHr¼XšHrÕJ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081873DV100818731008AŠFBLACK OR AFRICAN AMERICAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZCDLQ3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-30BÕDWŪ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¼XšHrÕJHr¼XšHrÕJ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081874DV100818741008AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2ABNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-05-26B”DWš YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼_¼HrלŲHr¼_¼HrלŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081874DV100818741008AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XNE0EIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008COVID_B1 NO Non-Important2021-06-03BœDW¢ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼_¼HrלŲHr¼_¼HrלŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081874DV100818741008AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIM2EKNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-13B¦DW¬ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼_¼HrלŲHr¼_¼HrלŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081874DV100818741008AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZHUTBYVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-23B°DW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼_¼HrלŲHr¼_¼HrלŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081875DV100818751008AšFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWC8Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B‡DW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼`¬Hsˆ”$Hr¼`¬HrלœHslē8Hsˆ”$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081875DV100818751008AšFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XNE0FZVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1008COVID_B1 NO Non-Important2021-06-03BœDW¢ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼`¬Hsˆ”$Hr¼`¬HrלœHslē8Hsˆ”$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081876DV100818761008AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WH6QCHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK2 NO Non-Important2021-03-17BNDWT YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼„ˆHrŲ%DHr¼„ˆHrŲ%D..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081876DV100818761008AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1VIRO0XNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK4 NO Non-Important2021-03-27BXDW^ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼„ˆHrŲ%DHr¼„ˆHrŲ%D..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081877DV100818771008AąMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCBIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17B‹DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼‡ŠHsŽ$Hr¼‡ŠHrŲ6ŲHsrm4HsŽ$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081878DV100818781008AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2EZNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK20 NO Non-Important2021-07-11BĀDWČ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¼‰8HrŲ6$Hr¼‰8HrŲ6$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081879DV100818791008AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1V9SUKYNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-03-29BZDW` YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼ŠdHrŲąHr¼ŠdHrŲą..Placebo Placebo .DWŒYC4591001C4591001 1008 10081879DV100818791008AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XE4MVBNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK10 NO Non-Important2021-05-02B|DW‚ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼ŠdHrŲąHr¼ŠdHrŲą..Placebo Placebo .DWŒYC4591001C4591001 1008 10081879DV100818791008AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGCGK3Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1008V202_SURVEIL_SWAB|643544415756058YES-POP2,YES-POP3Important 2021-05-21BDW• YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼ŠdHrŲąHr¼ŠdHrŲą..Placebo Placebo .DWŒYC4591001C4591001 1008 10081879DV100818791008AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YBSBMIReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1008V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-12B„DW« YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼ŠdHrŲąHr¼ŠdHrŲą..Placebo Placebo .DWŒYC4591001C4591001 1008 10081880DV100818801008AąFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCEIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18BŒDW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼PHsu“Hr¼PHrÖėčHssĪąHsu“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081881DV100818811008AĄFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCHIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18BŒDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¼@HsušHr¼@HrÖķHssĻXHsušPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081882DV100818821008AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHEE09Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-08-16BåDWģ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr½¤XHrŁŽpHr½¤XHrŁŽp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081883DV100818831008AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z3S3C2Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK18 NO Non-Important2021-07-06B¼DWĆ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr½„„HrŁ¼Hr½„„HrŁ¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‹YC4591001C4591001 1008 10081884DV100818841008AšFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1QW7RGOVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1008V2_VAX2_L NO Non-Important2021-02-19B3DW: YYPhase 3A@ . . .N. A12-15 YearsNAšHr½­øHsˆĢÜHr½­øHr½­øHsmIØHsˆĢÜPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081884DV100818841008AšFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZE8TX1Serology sample not collected Laboratory FOLLOW-UP 1008V201_SURVEIL_CONSENT NO Non-Important2021-03-19BODWV YYPhase 3A@ . . .N. A12-15 YearsNAšHr½­øHsˆĢÜHr½­øHr½­øHsmIØHsˆĢÜPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081884DV100818841008AšFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCKIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B†DW YYPhase 3A@ . . .N. A12-15 YearsNAšHr½­øHsˆĢÜHr½­øHr½­øHsmIØHsˆĢÜPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081884DV100818841008AšFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Z499SSVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1008V103_MONTH1 NO Non-Important2021-07-09BæDWĘ YYPhase 3A@ . . .N. A12-15 YearsNAšHr½­øHsˆĢÜHr½­øHr½­øHsmIØHsˆĢÜPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081885DV100818851008AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WTN7T3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-06BaDWh YYPhase 3A@ . . .Y. A12-15 YearsNAąHr½²¤HrŁDœHr½²¤HrŁDœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081885DV100818851008AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZMN4ELVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-12B…DWŒ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr½²¤HrŁDœHr½²¤HrŁDœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081887DV100818871008AĄFWHITE DW DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCOIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B‚DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĀåäHsˆ“4HrĀåäHrŽĀÜHsmKˆHsˆ“4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081888DV100818881008AąMWHITE DW DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWLDIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B‚DW YYPhase 3A@ . . .N. A12-15 YearsNAąHrĀčHsˆŁ HrĀčHrŽÓDHsmJŌHsˆŁ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081891DV100818911008AąMWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWLGIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18B‡DW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĀóōHs&øHrĀóōHrŽ‚ąHss{4Hs&øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081892DV100818921008AąMAMERICAN INDIAN OR ALASKA NATIVE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WNXXE9Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V202_SURVEIL_SWAB|636898268190060NO Non-Important2021-03-03B;DWF YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ`Hs˜a8HrĆ`HrŽŅHs|“Hs˜a8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081892DV100818921008AąMAMERICAN INDIAN OR ALASKA NATIVE DW DW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WNXXECVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V202_SURVEIL_SWAB|638114927454060NO Non-Important2021-03-22BNDWY YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ`Hs˜a8HrĆ`HrŽŅHs|“Hs˜a8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081893DV100818931008AąFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHUTC1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK20 NO Non-Important2021-07-14BĄDWĖ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĆŒHrŽÉäHrĆŒHrŽÉä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081894DV100818941008AŠFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZE8TX4Serology sample not collected Laboratory FOLLOW-UP 1008V201_SURVEIL_CONSENT NO Non-Important2021-04-06B]DWh YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ)ÜHrį2ˆHrĆ)ÜHrį2ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081894DV100818941008AŠFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2ENNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK8 NO Non-Important2021-06-05B™DW¤ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ)ÜHrį2ˆHrĆ)ÜHrį2ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081894DV100818941008AŠFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHUTC4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V202_SURVEIL_SWAB|646226852049030NO Non-Important2021-06-20BØDW³ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ)ÜHrį2ˆHrĆ)ÜHrį2ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081894DV100818941008AŠFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z8JZL1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-07-17BĆDWĪ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ)ÜHrį2ˆHrĆ)ÜHrį2ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081896DV100818961008AšMWHITE DW DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWLJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BƒDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĆ+HsŠŲHrĆ+HrŽŠtHsn}ÜHsŠŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081897DV100818971008AŠFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2EQNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-11BžDWŖ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÄ<ČHrßß HrÄ<ČHrßß ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081897DV100818971008AŠFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHVGD3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-21BØDW“ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÄ<ČHrßß HrÄ<ČHrßß ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081898DV100818981008AĄFWHITE DW DW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTNENVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-13BcDWo YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄ?\Hs‡€ĄHrÄ?\HrŽˆųHslä¤Hs‡€ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081898DV100818981008AĄFWHITE DW DW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWQWIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄ?\Hs‡€ĄHrÄ?\HrŽˆųHslä¤Hs‡€ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081899DV100818991008AšFWHITE DW DW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTNENYVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 100813-Apr-21 NO Non-Important2021-04-13BcDWo YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ?ŌHs‡€„HrÄ?ŌHrŽ‰pHslåXHs‡€„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081899DV100818991008AšFWHITE DW DW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWQZIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ?ŌHs‡€„HrÄ?ŌHrŽ‰pHslåXHs‡€„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081900DV100819001008AŠFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHVGD6Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK20 NO Non-Important2021-07-18BĆDWĻ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÄr°Hrą# HrÄr°Hrą# ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081902DV100819021008AąMWHITE DW DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P19HPPAssessment of acute reaction for protocol specified timeframe after study intervention administration not performed at the vaccination visits. Procedures/Tests VACCINATION 1008V1_DAY1_VAX1_L NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAąHrÄvčHsˆå<HrÄvčHrąHsmHHsˆå<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081902DV100819021008AąMWHITE DW DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWR3Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHrÄvčHsˆå<HrÄvčHrąHsmHHsˆå<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081903DV100819031008AĄMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z6VL04Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-16BĮDWĶ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÄxHr߯HHrÄxHr߯H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081904DV100819041008AĄMWHITE DW DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWR6Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄ|LHsˆŚģHrÄ|LHrąąHsm>¤HsˆŚģPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081905DV100819051008AšFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2ETNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-13BŸDW¬ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrň0HräHrň0Hrä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081905DV100819051008AšFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHVGD9Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V202_SURVEIL_SWAB|646303539298030NO Non-Important2021-06-23B©DW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrň0HräHrň0Hrä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081905DV100819051008AšFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z6VL07Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK18 NO Non-Important2021-07-15BæDWĢ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrň0HräHrň0Hrä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081906DV100819061008AąFASIAN DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1VM3J5ZNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-18BgDWt YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŏ8Hrį9ĢHrŏ8Hrį9Ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081906DV100819061008AąFASIAN DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z499SVVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-07-02B²DWæ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŏ8Hrį9ĢHrŏ8Hrį9Ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081907DV100819071008AąFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWR9Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrŔŲHsŠ*ŒHrŔŲHrį6HHsn$HsŠ*ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081909DV100819091008AąMASIAN DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1TVW3JCNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK2 NO Non-Important2021-03-08B>DWK YYPhase 3A@ . . .N. A12-15 YearsNAąHrŖ@HsŽģHrŖ@HrįuHsu@HsŽģPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081909DV100819091008AąMASIAN DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YV6XTBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK8 NO Non-Important2021-05-05BxDW… YYPhase 3A@ . . .N. A12-15 YearsNAąHrŖ@HsŽģHrŖ@HrįuHsu@HsŽģPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081911DV100819111008AąMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWRCIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅĘHs‰ķœHrÅĘHrā¤HsnDčHs‰ķœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081912DV100819121008AĄMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZH2CTRNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK20 NO Non-Important2021-07-20BÄDWŃ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅĻ4HrāÉ,HrÅĻ4HrāÉ,..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081913DV100819131008AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWRPIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17B„DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅĢ HsŽ|HrÅĢ HrāÄ@Hsr4HsŽ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081914DV100819141008AąMWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QW7RL7Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1008V2_VAX2_L NO Non-Important2021-02-12B&DW3 YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅĖtHs‡”HrÅĖtHröZxHsm?”Hs‡”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081914DV100819141008AąMWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWRSIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B€DW YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅĖtHs‡”HrÅĖtHröZxHsm?”Hs‡”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081919DV100819191008AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OT9IF1Procedure not performed as part of vital signs. Procedures/Tests SCREENING 1008V2_VAX2_L NO Non-Important2020-11-01ĀCDVĢYNYPhase 3A@ . . .N. A12-15 YearsNAąHrĒ¼Hs’ <HrĒ¼HräTHsu¼Hs’ <Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081920DV100819201008AŠFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1XTRH45Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-05B–DW¤ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĒlHrāŗąHrĒlHrāŗą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081920DV100819201008AŠFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2EWNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-23BØDW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĒlHrāŗąHrĒlHrāŗą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081920DV100819201008AŠFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHVGDCVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-29B®DW¼ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĒlHrāŗąHrĒlHrāŗą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081921DV100819211008AšMWHITE DWDW‘Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XDAWRVIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-26BnDW| YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒ#HHsrw HrĒ#HHrä(HsVŗlHsrw Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWyYC4591001C4591001 1008 10081921DV100819211008AšMWHITE DWDW‘Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YLH3L5Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-17BƒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒ#HHsrw HrĒ#HHrä(HsVŗlHsrw Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWyYC4591001C4591001 1008 10081921DV100819211008AšMWHITE DWDW‘Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YLH3MPRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-17BƒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒ#HHsrw HrĒ#HHrä(HsVŗlHsrw Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWyYC4591001C4591001 1008 10081923DV100819231008AĄFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWRYIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B~DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ-Hsˆ·ÄHrČ-HrćĪųHsm($Hsˆ·ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081924DV100819241008AĄFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QZOQHUSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1008V2_VAX2_L NO Non-Important2021-02-11B#DW2 YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ0HsŠ ŲHrČ0HrćÓlHsnHØHsŠ ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081924DV100819241008AĄFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XDAWSBIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ0HsŠ ŲHrČ0HrćÓlHsnHØHsŠ ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081926DV100819261008AąFASIAN DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WOKKODNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-18BeDWt YYPhase 3A@ . . .N. A12-15 YearsNAąHrČmüHsŠ&THrČmüHräxHsnƒHsŠ&TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081926DV100819261008AąFASIAN DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZIZBL2Other Informed Consent Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrČmüHsŠ&THrČmüHräxHsnƒHsŠ&TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081926DV100819261008AąFASIAN DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XDAWSEIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrČmüHsŠ&THrČmüHräxHsnƒHsŠ&TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081930DV100819301008AĄFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWSHIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B{DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĢ"¼HsŠ PHrĢ"¼Hrēå8Hsm(ŲHsŠ PPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081933DV100819331008AĄMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWSUIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĢNĢHsŽ„HrĢNĢHréV˜HsruąHsŽ„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081934DV100819341008AŠFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z499SYVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK18 NO Non-Important2021-07-07B²DWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢW“Hrč ˆHrĢW“Hrč ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081935DV100819351008AšMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R0XVKGSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1008V2_VAX2_L NO Non-Important2021-02-25B.DW@ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢ^¼Hrź§(HrĢ^¼Hrź§(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWFYC4591001C4591001 1008 10081935DV100819351008AšMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZG7WSKVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-08-13B×DWé YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢ^¼Hrź§(HrĢ^¼Hrź§(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWFYC4591001C4591001 1008 10081936DV100819361008AąMWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWSXIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B|DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĢ`ŲHs‡OHrĢ`ŲHrč`HsnKHs‡OPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081937DV100819371008AŠFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV6XTEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-28B©DW» YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢeÄHrč \HrĢeÄHrč \..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081938DV100819381008AšFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWT0Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢgąHsłHrĢgąHréZHsr4|HsłPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081941DV100819411008AĄFASIAN DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWT3Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B{DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĶŖŲHsŠ(pHrĶŖŲHréX“Hsn{„HsŠ(pPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1008 10081942DV100819421008AšMASIAN DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWT6Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B{DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶ«HsŠ'ųHrĶ«HréY,Hsn{üHsŠ'ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1009 10091204DV100912041009AŠMWHITE DV»DWóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUC7Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BÓDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrXxHsó¼HrXxHrqnųHsŲšHsó¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW˜YC4591001C4591001 1009 10091205DV100912051009AšMWHITE DV»DVŃBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZMN4EOVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-18BŗDWt YYPhase 3A@ . . .Y. A12-15 YearsNAšHrX>ŲHruu HrX>ŲHruu ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW„YC4591001C4591001 1009 10091205DV100912051009AšMWHITE DV»DVŃBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YGSKODNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1009COVID_A NO Non-Important2021-05-10BŠDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrX>ŲHruu HrX>ŲHruu ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW„YC4591001C4591001 1009 10091209DV100912091009AŠFWHITE DV»DVĻBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUCAUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-19BŁDW“ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrXu°HrrĶ\HrXu°HrrĶ\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091212DV100912121009AŠFWHITE DV¼DW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1O05DG4Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-11-16B DVŪ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrYcHs’'<HrYcHr‚”“Hsw™lHs’'<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091213DV100912131009AšMWHITE DV¼DWSPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1RVVUQANasal swab collected at a visit where it was not required Laboratory VACCINATION 1009COVID_A NO Non-Important2020-12-02B0DVė YYPhase 3A@ . . .N. A12-15 YearsNAšHrYkŒHs l<HrYkŒHrr¾ HsÉ8Hs l<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW7YC4591001C4591001 1009 10091213DV100912131009AšMWHITE DV¼DWSPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OEKRU1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009V3_MONTH1_POSTVAX2_L NO Non-Important2020-12-16B>DVł YYPhase 3A@ . . .N. A12-15 YearsNAšHrYkŒHs l<HrYkŒHrr¾ HsÉ8Hs l<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW7YC4591001C4591001 1009 10091213DV100912131009AšMWHITE DV¼DWSPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1RVVF7LVisit conducted when not required per protocol Visit Schedule FOLLOW-UP 1009COVID_A1 NO Non-Important2021-01-04BQDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrYkŒHs l<HrYkŒHrr¾ HsÉ8Hs l<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW7YC4591001C4591001 1009 10091216DV100912161009AĄFWHITE DV¼DVŃBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUCDUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BŅDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrY‚HHru-HrY‚HHru-..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091218DV100912181009AŠFWHITE DV¼DVŃBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUCGUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BŅDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrYƒtHru.€HrYƒtHru.€..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091220DV100912201009AšMWHITE DVæDVŅPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTNEO1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK2 NO Non-Important2021-04-18B¶DWt YYPhase 3A@ . . .N. A12-15 YearsNAšHr]‘¼Hrvx€Hr]‘¼Hrvx€..Placebo Placebo .DWYC4591001C4591001 1009 10091221DV100912211009AąFWHITE DVæDVŅBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1NR3P0BUrine pregnancy test not performed. Laboratory VACCINATION 1009V1_DAY1_VAX1_L NO Non-Important2020-10-19ADVæ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr]’čHrvxHr]’čHrvx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091221DV100912211009AąFWHITE DVæDVŅBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WH6QCLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK2 NO Non-Important2021-04-18B¶DWt YYPhase 3A@ . . .Y. A12-15 YearsNAąHr]’čHrvxHr]’čHrvx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091223DV100912231009AąMWHITE DVæDVÕBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUD3Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BĻDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr]•ōHrz–ōHr]•ōHrz–ō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091229DV100912291009AĄFWHITE DVĄDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1O4AHO2Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-11-23B#DVā YYPhase 3A@ . . .N. A12-15 YearsNAĄHr_üHs“}0Hr_üHs#‚ŒHswŅŲHs“}0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091229DV100912291009AĄFWHITE DVĄDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZK3KGBSubject was vaccinated despite the site being instructed to discontinue further vaccination Investigational ProductFOLLOW-UP 1009Unplanned Vaccination NO Important 2021-03-18B–DWU YYPhase 3A@ . . .N. A12-15 YearsNAĄHr_üHs“}0Hr_üHs#‚ŒHswŅŲHs“}0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091231DV100912311009AšMASIAN DVĄDVŌBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUD6Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-14BĻDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr_ ąHry^Hr_ ąHry^..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1009 10091233DV100912331009AĄMWHITE DVĮDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUD9Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-18BŅDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr`čHs£XHr`čHr}eŒHs‡±ųHs£XPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1009 10091234DV100912341009AŠMWHITE DVĮDVÖBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XSGB0YVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK10 NO Non-Important2021-05-15BĻDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr`?ĄHr{åąHr`?ĄHr{åą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091237DV100912371009AąFWHITE DVĮDV×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUDCUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests FOLLOW-UP 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BĶDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr`OtHr}9ōHr`OtHr}9ō..Placebo Placebo .DWŽYC4591001C4591001 1009 10091240DV100912401009AŠMWHITE DVĮDVŌBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUDFUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BĶDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr`jhHryvpHr`jhHryvp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1009 10091246DV100912461009AŠMWHITE DVĀDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OCOVQRSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1009V2_VAX2_L NO Non-Important2020-12-07B/DVš YYPhase 3A@ . . .N. A12-15 YearsNAŠHra¤xHsˆ°Hra¤xHrzµäHssŚŌHsˆ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091246DV100912461009AŠMWHITE DVĀDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBKUDIUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BĢDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHra¤xHsˆ°Hra¤xHrzµäHssŚŌHsˆ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091272DV100912721009AĄMWHITE DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHWDGHVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009V4_MONTH6_L NO Non-Important2021-08-10BüDWę YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr— Hr±āDHr— Hr±āD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1009 10091274DV100912741009AĄMWHITE DVėDWŅPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS50NSVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr—ĖĄHsĒŌ,Hr—ĖĄHr¹—<HsÆhHsĒŌ,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW·YC4591001C4591001 1009 10091275DV100912751009AšMWHITE DVėDWŅPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS50NVVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr—ĖHHsĒŌhHr—ĖHHr¹–ÄHsƤHsĒŌhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW·YC4591001C4591001 1009 10091277DV100912771009AŠMWHITE DVģDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS50NYVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-12-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜śHs©Ń Hr˜śHr¼uÄHsĒ¬Hs©Ń Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091277DV100912771009AŠMWHITE DVģDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YM0304Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK2 NO Non-Important2021-05-07BœDW‡ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜śHs©Ń Hr˜śHr¼uÄHsĒ¬Hs©Ń Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091280DV100912801009AĄFWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUE5Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-06-21BÉDW“ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr™4tHr±ĮtHr™4tHr±Įt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1009 10091281DV100912811009AąMWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMN4LFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-05-04B™DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr™ĄHr±ĀdHr™ĄHr±Ād..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW±YC4591001C4591001 1009 10091283DV100912831009AŠFWHITE DVģDWĢPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZE8TX7Serology sample not collected Laboratory FOLLOW-UP 1009V201_SURVEIL_CONSENT NO Non-Important2021-03-30BvDWa YYPhase 3A@ . . .N. A12-15 YearsNAŠHr™pHsĄ`Hr™pHr³€Hs£|HsĄ`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1009 10091283DV100912831009AŠFWHITE DVģDWĢPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBKUE8Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-06-21BÉDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr™pHsĄ`Hr™pHr³€Hs£|HsĄ`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1009 10091284DV100912841009AšMWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUEBUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-06-21BÉDW“ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr™$Hr³ųHr™$Hr³ų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1009 10091296DV100912961009AąMWHITE DVšDWĶPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1SSS0N0Potential COVID-19 illness visit not done when required per protocol. Visit Schedule FOLLOW-UP 1009POT_COVID_ILL NO Non-Important2021-02-03B;DW* YYPhase 3A@ . . .N. A12-15 YearsNAąHrž6|HsĮ@äHrž6|Hr»,šHs¤•čHsĮ@äPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1009 10091304DV100913041009AŠMWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z03K9HVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009COVID_A1 NO Non-Important2021-06-28BĖDW» YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŸ¦tHr»XHrŸ¦tHr»X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1009 10091312DV100913121009AĄMWHITE DVņDWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YV6XU1Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-06-25BĒDWø YYPhase 3A@ . . .N. A12-15 YearsNAĄHr ęœHs„ŁXHr ęœHr»ģHs†3Hs„ŁXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1009 10091314DV100913141009AšMWHITE DVņDWŽPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZHEE0CVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-08-02BķDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHr ó¼Hs×Ä,Hr ó¼Hr¼Œ¼Hs“J`Hs×Ä,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¾YC4591001C4591001 1009 10091315DV100913151009AŠMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WTNEV2Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-26B‹DW| YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr”(Hr¹µ<Hr”(Hr¹µ<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1009 10091317DV100913171009AŠFWHITE DVóDWĢPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUEEUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-06-23BÄDW¶ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr”ü”HsĄHr”ü”Hr» „Hs„ÄHsĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1009 10091319DV100913191009AšMWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WTNEV5Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-26BŠDW| YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¢'“HrŗčHr¢'“Hrŗč..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1009 10091320DV100913201009AąMWHITE DVóDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PJ91L5Participant met exclusion criterion #01 (participant having other medical or psychiatric condition) Inclusion/Exclusion VACCINATION 1009V1_DAY1_VAX1_L YES-POP2,YES-POP3Important 2020-12-10ADVó YYPhase 3A@ . . .N. A12-15 YearsNAąHr¢)”Hs©®pHr¢)”Hr¼ˆHHs†\@Hs©®pPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1009 10091320DV100913201009AąMWHITE DVóDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YV6XU4Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-06-28BÉDW» YYPhase 3A@ . . .N. A12-15 YearsNAąHr¢)”Hs©®pHr¢)”Hr¼ˆHHs†\@Hs©®pPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1009 10091324DV100913241009AšFWHITE DVōDWīPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSGB11Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK8 NO Non-Important2021-05-19B DW“ YYPhase 3A@ . . .N. A12-15 YearsNAšHr£DšHsķ1@Hr£DšHr½˜(HsŅšÄHsķ1@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1009 10091326DV100913261009AĄFWHITE DVōDWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WTNEV8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-04BsDWf YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£H8Hs„ōÄHr£H8Hr¼HHs{ÜHs„ōÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091326DV100913261009AĄFWHITE DVōDWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1WTNEWFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-04-23B†DWy YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£H8Hs„ōÄHr£H8Hr¼HHs{ÜHs„ōÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091326DV100913261009AĄFWHITE DVōDWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XSGB14Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-05-17BžDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£H8Hs„ōÄHr£H8Hr¼HHs{ÜHs„ōÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091326DV100913261009AĄFWHITE DVōDWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-200C94RVisit not done Visit Schedule OPEN LABEL TREATMENT1009COVID_A1 NO Non-Important2021-06-09BµDWØ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£H8Hs„ōÄHr£H8Hr¼HHs{ÜHs„ōÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091326DV100913261009AĄFWHITE DVōDWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YV6XU7Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-06-25BÅDWø YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£H8Hs„ōÄHr£H8Hr¼HHs{ÜHs„ōÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091326DV100913261009AĄFWHITE DVōDWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZJTC3XRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL FOLLOW-UP1009Consent NO Non-Important2021-08-10BóDWę YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£H8Hs„ōÄHr£H8Hr¼HHs{ÜHs„ōÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091326DV100913261009AĄFWHITE DVōDWøPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZJTC4DRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL FOLLOW-UP1009Consent NO Non-Important2021-08-10BóDWę YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£H8Hs„ōÄHr£H8Hr¼HHs{ÜHs„ōÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091330DV100913301009AŠFWHITE DVōDWŁPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z63DGCSerology sample not collected Laboratory FOLLOW-UP 1009V201_SURVEIL_CONSENT NO Non-Important2021-03-25BiDW\ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£näHsŃ+ųHr£näHr¼ZXHsµxøHsŃ+ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1009 10091330DV100913301009AŠFWHITE DVōDWŁPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YY0VDTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK12 NO Non-Important2021-06-26BĘDW¹ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£näHsŃ+ųHr£näHr¼ZXHsµxøHsŃ+ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1009 10091330DV100913301009AŠFWHITE DVōDWŁPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBKUF1Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-07-06BŠDWĆ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£näHsŃ+ųHr£näHr¼ZXHsµxøHsŃ+ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1009 10091331DV100913311009AŠFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Y55S32Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-06-04B°DW£ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr£€šHr¼cHr£€šHr¼c..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091335DV100913351009AšFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XDAH01Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-02-22BJDW= YYPhase 3A@ . . .Y. A12-15 YearsNAšHr£­Hr½£ąHr£­Hr½£ą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW=YC4591001C4591001 1009 10091336DV100913361009AŠMWHITE DVōDWįPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSGB17Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-05-31B¬DWŸ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£­xHsÜHr£­xHr½¤XHsĮ;DHsÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWæYC4591001C4591001 1009 10091338DV100913381009AšFWHITE DV÷DWęPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTC0L3Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-18B$DW YYPhase 3A@ . . .N. A12-15 YearsNAšHr§f¬HsāI$Hr§f¬Hr§f¬HsʦˆHsāI$Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWµYC4591001C4591001 1009 10091339DV100913391009AąFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PDX7EPVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-18B$DW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr§g$HrÕa8Hr§g$HrÕa8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWµYC4591001C4591001 1009 10091340DV100913401009AšFWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV6XUAVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK14 NO Non-Important2021-06-28BÅDW» YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§Œ,HrĆ6„Hr§Œ,HrĆ6„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1009 10091344DV100913441009AšMWHITE DVųDWZPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBJNERNasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1009COVID_B NO Non-Important2021-07-30BäDWŪ YYPhase 3A@ . . .N. A12-15 YearsNAšHrاÄHs*ˆHrاÄHrĀü(Hs tHs*ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW?YC4591001C4591001 1009 10091347DV100913471009AŠFWHITE DVųDWįPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZH2UNXVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-08-05BźDWį YYPhase 3A@ . . .N. A12-15 YearsNAŠHrØĪ4HsÜ|HrØĪ4HrŒHsø-ÄHsÜ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWæYC4591001C4591001 1009 10091350DV100913501009AąFWHITE DVłDWąPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZALCUNOther Informed Consent Informed Consent FOLLOW-UP 1009Consent NO Non-Important2021-07-06BĖDWĆ YYPhase 3A@ . . .N. A12-15 YearsNAąHr©ß|HsŚŗ$Hr©ß|HrĘš0HsæTHsŚŗ$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĘYC4591001C4591001 1009 10091351DV100913511009AĄFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZE8U0XSerology sample not collected Laboratory FOLLOW-UP 1009V201_SURVEIL_CONSENT NO Non-Important2021-03-22BaDWY YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr©ūŲHrÅø“Hr©ūŲHrÅø“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¾YC4591001C4591001 1009 10091355DV100913551009AĄMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZD1VOFNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1009SSWAB_WEEK16 NO Non-Important2021-07-08BĶDWÅ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖ0HrČxÄHrŖ0HrČxÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĖYC4591001C4591001 1009 10091356DV100913561009AŠFWHITE DVłDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PKDRMGVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-10B9DW1 YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŖ;\HsŠÄHrŖ;\HrĆG Hsr‹¬HsŠÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1009 10091358DV100913581009AąFWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV6XUXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK10 NO Non-Important2021-06-24B¾DW· YYPhase 3A@ . . .Y. A12-15 YearsNAąHr«,LHrÅvŲHr«,LHrÅvŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1009 10091360DV100913601009AšFWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YBEUBNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-06-07B­DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr«NüHrÅĮœHr«NüHrÅĮœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1009 10091361DV100913611009AŠFWHITE DVśDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z7HG8PVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1009V103_MONTH1 NO Non-Important2021-07-19B×DWŠ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr«^ģHsŽHr«^ģHrēųHsrœŒHsŽPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091362DV100913621009AĄMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PAQ0TFVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«|ģHrĢiĄHr«|ģHrĢiĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1009 10091363DV100913631009AąMWHITE DVśDW÷Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS1Q5BLab performed out of window Laboratory VACCINATION 1009COVID_A NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr«|tHsłpHr«|tHr«|tHsÓÕHsłpPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŃYC4591001C4591001 1009 10091363DV100913631009AąMWHITE DVśDW÷Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1PDX7ESVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-11BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr«|tHsłpHr«|tHr«|tHsÓÕHsłpPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŃYC4591001C4591001 1009 10091363DV100913631009AąMWHITE DVśDW÷Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1PDYN65Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009COVID_A1 NO Non-Important2021-02-09B7DW0 YYPhase 3A@ . . .N. A12-15 YearsNAąHr«|tHsłpHr«|tHr«|tHsÓÕHsłpPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŃYC4591001C4591001 1009 10091363DV100913631009AąMWHITE DVśDW÷Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZD1VOINasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1009SSWAB_WEEK12 NO Non-Important2021-07-12BŠDWÉ YYPhase 3A@ . . .N. A12-15 YearsNAąHr«|tHsłpHr«|tHr«|tHsÓÕHsłpPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŃYC4591001C4591001 1009 10091363DV100913631009AąMWHITE DVśDW÷Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZMN4LIVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-08-27BžDW÷ YYPhase 3A@ . . .N. A12-15 YearsNAąHr«|tHsłpHr«|tHr«|tHsÓÕHsłpPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŃYC4591001C4591001 1009 10091364DV100913641009AĄFWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OVT3GIVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-19B"DW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«ƒHrÖš Hr«ƒHrÖš ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÓYC4591001C4591001 1009 10091364DV100913641009AĄFWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z6VL0AVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK14 NO Non-Important2021-07-12BŠDWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«ƒHrÖš Hr«ƒHrÖš ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÓYC4591001C4591001 1009 10091365DV100913651009AĄMWHITE DVśDWļPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OVT3GMVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-19B"DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«ƒøHsīvĢHr«ƒøHrÖš˜HsĘĪ$HsīvĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW˜YC4591001C4591001 1009 10091365DV100913651009AĄMWHITE DVśDWļPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZB90CKOther Informed Consent Informed Consent REPEAT SCREENING 1 1009Consent NO Non-Important2021-07-06BŹDWĆ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«ƒøHsīvĢHr«ƒøHrÖš˜HsĘĪ$HsīvĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW˜YC4591001C4591001 1009 10091365DV100913651009AĄMWHITE DVśDWļPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZJNOUTVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-08-19BöDWļ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«ƒøHsīvĢHr«ƒøHrÖš˜HsĘĪ$HsīvĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW˜YC4591001C4591001 1009 10091366DV100913661009AąFWHITE DVśDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1QZSYN3Urine pregnancy test not performed. Laboratory VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr«‡<Hsü“°Hr«‡<Hs ČHsā9¬Hsü“°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWįYC4591001C4591001 1009 10091366DV100913661009AąFWHITE DVśDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZK3KGFSubject was vaccinated despite the site being instructed to discontinue further vaccination Investigational ProductFOLLOW-UP 1009Unplanned Vaccination NO Important 2021-02-26BHDWA YYPhase 3A@ . . .N. A12-15 YearsNAąHr«‡<Hsü“°Hr«‡<Hs ČHsā9¬Hsü“°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWįYC4591001C4591001 1009 10091366DV100913661009AąFWHITE DVśDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1RVXPUNUrine pregnancy test not performed. Laboratory FOLLOW-UP 1009Unplanned Vaccination NO Non-Important2021-03-04BNDWG YYPhase 3A@ . . .N. A12-15 YearsNAąHr«‡<Hsü“°Hr«‡<Hs ČHsā9¬Hsü“°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWįYC4591001C4591001 1009 10091366DV100913661009AąFWHITE DVśDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XSGB1AVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK10 NO Non-Important2021-05-22BDW– YYPhase 3A@ . . .N. A12-15 YearsNAąHr«‡<Hsü“°Hr«‡<Hs ČHsā9¬Hsü“°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWįYC4591001C4591001 1009 10091366DV100913661009AąFWHITE DVśDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZJ22XRNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1009SSWAB_WEEK20 NO Non-Important2021-07-28BąDWŁ YYPhase 3A@ . . .N. A12-15 YearsNAąHr«‡<Hsü“°Hr«‡<Hs ČHsā9¬Hsü“°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWįYC4591001C4591001 1009 10091366DV100913661009AąFWHITE DVśDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZNNH4TRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1009Consent NO Non-Important2021-08-10BķDWę YYPhase 3A@ . . .N. A12-15 YearsNAąHr«‡<Hsü“°Hr«‡<Hs ČHsā9¬Hsü“°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWįYC4591001C4591001 1009 10091380DV100913801009AąMWHITE DWDWÉPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZIUMM3Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1009V103_MONTH1 NO Non-Important2021-08-18BéDWī YYPhase 3A@ . . .N. A12-15 YearsNAąHr»QDHs¼3$Hr»QDHrÖö8Hs£+THs¼3$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1009 10091382DV100913821009AąFWHITE DW DW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZNKP23Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1009COVID_B NO Non-Important2021-07-08BŗDWÅ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ:Hs‡LøHrĆ:HrŽę|Hsn5pHs‡LøPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091387DV100913871009AĄMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R1RFRNVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-05B;DWH YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrż°HrāåLHrż°HrāåL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1009 10091390DV100913901009AąFWHITE DWDWóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCT7KEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK16 NO Non-Important2021-07-27BŹDWŲ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘżČHsóŹdHrĘżČHrār8Hs××(HsóŹdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1009 10091394DV100913941009AšMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WTNEWIVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-27BoDW} YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĒ$8HrįiœHrĒ$8Hrįiœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091394DV100913941009AšMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZMN4LLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-05-04BvDW„ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĒ$8HrįiœHrĒ$8Hrįiœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091395DV100913951009AŠMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTNEWLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-27BoDW} YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĒ#„Hs—-ōHrĒ#„HrįjHs~S$Hs—-ōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091395DV100913951009AŠMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZKZNV1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-05-04BvDW„ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĒ#„Hs—-ōHrĒ#„HrįjHs~S$Hs—-ōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1009 10091396DV100913961009AšMWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZH2UO0Potential COVID-19 illness visit not done when required per protocol. Visit Schedule REPEAT SCREENING 1 1009V4_MONTH6_L NO Non-Important2021-08-11BŁDWē YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĒ.ˆHrą4HrĒ.ˆHrą4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWvYC4591001C4591001 1009 10091399DV100913991009AĄFWHITE DWDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZB3T04Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK14 NO Non-Important2021-07-20BĀDWŃ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ@ĄHsļĻHrČ@ĄHrćč„HsÓēŠHsļĻPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŚYC4591001C4591001 1009 10091400DV100914001009AĄMWHITE DWDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1QZ3TPRVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-02-12B$DW3 YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČU`HsżčHrČU`HröG@HsżčHsżčPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWēYC4591001C4591001 1009 10091400DV100914001009AĄMWHITE DWDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YWWQWWLab performed out of window Laboratory FOLLOW-UP 1009COVID_B NO Non-Important2021-06-18B¢DW± YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČU`HsżčHrČU`HröG@HsżčHsżčPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWēYC4591001C4591001 1009 10091400DV100914001009AĄMWHITE DWDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZMN4LOLab performed out of window Laboratory FOLLOW-UP 1009SSWAB_WEEK14 NO Non-Important2021-07-28BŹDWŁ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČU`HsżčHrČU`HröG@HsżčHsżčPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWēYC4591001C4591001 1009 10091404DV100914041009AĄFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZB3T07Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK10 NO Non-Important2021-07-12BŗDWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrȄ|HrćĶĢHrȄ|HrćĶĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1009 10091406DV100914061009AšMWHITE DWDWļPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1SSS10VPotential COVID-19 illness visit not done when required per protocol. Visit Schedule VACCINATION 1009POT_COVID_ILL NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAšHrȘhHsīzPHrȘhHrćÉŠHsĻżdHsīzPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1009 10091407DV100914071009AŠFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHVLXGVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK2 NO Non-Important2021-05-03BqDWƒ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢB$HrēēTHrĢB$HrēēT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1009 10091407DV100914071009AŠFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z499TBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK6 NO Non-Important2021-06-23B¤DW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢB$HrēēTHrĢB$HrēēT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1009 10091407DV100914071009AŠFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZD1VPFNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-07-12B·DWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢB$HrēēTHrĢB$HrēēT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1009 10091407DV100914071009AŠFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZD1VPINasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1009SSWAB_WEEK10 NO Non-Important2021-07-31BŹDWÜ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢB$HrēēTHrĢB$HrēēT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1009 10091407DV100914071009AŠFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZHWDGKVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-08-03BĶDWß YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢB$HrēēTHrĢB$HrēēT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1009 10091408DV100914081009AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YK0FBJNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1009COVID_A NO Non-Important2021-06-24B„DW· YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢ„xHréƒŌHrĢ„xHréƒŌ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWēYC4591001C4591001 1009 10091408DV100914081009AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZB3T0AVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK10 NO Non-Important2021-07-20BæDWŃ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢ„xHréƒŌHrĢ„xHréƒŌ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWēYC4591001C4591001 1009 10091409DV100914091009AąFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZB3T0DVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK10 NO Non-Important2021-07-20BæDWŃ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĢ„Hréƒ\HrĢ„Hréƒ\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWēYC4591001C4591001 1009 10091410DV100914101009AĄFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PAG7MTVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1009V2_VAX2_L NO Non-Important2021-02-01BDW( YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĶgŠHrč&ŲHrĶgŠHrč&Ų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091410DV100914101009AĄFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YBECDLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-06-04BDW£ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĶgŠHrč&ŲHrĶgŠHrč&Ų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091412DV100914121009AšMWHITE DWDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1T8K11VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-15B?DWR YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶ·¼Hsļ¼HrĶ·¼HrēĀLHsŌØHsļ¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1009 10091412DV100914121009AšMWHITE DWDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZE8U10Serology sample not collected Laboratory FOLLOW-UP 1009V201_SURVEIL_CONSENT NO Non-Important2021-03-29BMDW` YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶ·¼Hsļ¼HrĶ·¼HrēĀLHsŌØHsļ¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1009 10091412DV100914121009AšMWHITE DWDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YY0VDWVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK10 NO Non-Important2021-07-02B¬DWæ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶ·¼Hsļ¼HrĶ·¼HrēĀLHsŌØHsļ¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1009 10091413DV100914131009AŠFWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z9VPFJNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1009COVID_A NO Non-Important2021-07-27BÅDWŲ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ¼ØHrźÄ°HrĶ¼ØHrźÄ°..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131821DV101318211013AąMBLACK OR AFRICAN AMERICAN DVéDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P02XECICD signed by unauthorized site personnel Informed Consent FOLLOW-UP 1013Consent NO Non-Important2021-01-27B;DW# YYPhase 3A@ . . .Y. A12-15 YearsNAąHr”źąHr°ŗ|Hr”źąHr°ŗ|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131823DV101318231013AšFBLACK OR AFRICAN AMERICAN DVźDWŹPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA125453201IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1013Vax 1 NO Non-Important2020-12-01ADVź YYPhase 3A@ . . .N. A12-15 YearsNAšHr–6üHs½²XHr–6üHr±ž Hs¢ū„Hs½²XPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131823DV101318231013AšFBLACK OR AFRICAN AMERICAN DVźDWŹPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZJQFESSite staff training missing/incomplete Other OPEN LABEL FOLLOW-UP1013V103_MONTH1 NO Non-Important2021-08-12B’DWč YYPhase 3A@ . . .N. A12-15 YearsNAšHr–6üHs½²XHr–6üHr±ž Hs¢ū„Hs½²XPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131824DV101318241013AąFBLACK OR AFRICAN AMERICAN DVźDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTC3LSSerology sample not collected Laboratory FOLLOW-UP 1013V201_SURVEIL_CONSENT NO Non-Important2021-01-19B2DW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr–7°Hr±’Hr–7°Hr±’..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131828DV101318281013AąMWHITE DVėDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OI3QA0Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—d Hr¼ČHr—d Hr¼Č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131828DV101318281013AąMWHITE DVėDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Y55S3FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-06-09B¾DWØ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—d Hr¼ČHr—d Hr¼Č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131830DV101318301013AąFWHITE DVėDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTC5ONVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-23BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr—fųHr³W Hr—fųHr³W ..Placebo Placebo ..YC4591001C4591001 1013 10131830DV101318301013AąFWHITE DVėDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OT48B1Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-18B0DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr—fųHr³W Hr—fųHr³W ..Placebo Placebo ..YC4591001C4591001 1013 10131830DV101318301013AąFWHITE DVėDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1PDYT7DVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-18B0DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr—fųHr³W Hr—fųHr³W ..Placebo Placebo ..YC4591001C4591001 1013 10131830DV101318301013AąFWHITE DVėDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PO9518Serology sample not collected Laboratory FOLLOW-UP 1013V201_SURVEIL_CONSENT NO Non-Important2021-01-28B:DW$ YYPhase 3A@ . . .N. A12-15 YearsNAąHr—fųHr³W Hr—fųHr³W ..Placebo Placebo ..YC4591001C4591001 1013 10131830DV101318301013AąFWHITE DVėDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZMNWARVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-22BŽDWx YYPhase 3A@ . . .N. A12-15 YearsNAąHr—fųHr³W Hr—fųHr³W ..Placebo Placebo ..YC4591001C4591001 1013 10131835DV101318351013AąFBLACK OR AFRICAN AMERICAN DVėDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTBW9SVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr—‚ Hs˜­(Hr—‚ Hr±öäHs~rŒHs˜­(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1013 10131839DV101318391013AąFWHITE DVėDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P6MT44Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-19B1DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr—ŠŌHr³P Hr—ŠŌHr³P ..Placebo Placebo .DW¾YC4591001C4591001 1013 10131839DV101318391013AąFWHITE DVėDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZA0E4VReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1013V2_VAX2_L YES-POP2,YES-POP3Important 2021-07-02BÕDWæ YYPhase 3A@ . . .N. A12-15 YearsNAąHr—ŠŌHr³P Hr—ŠŌHr³P ..Placebo Placebo .DW¾YC4591001C4591001 1013 10131839DV101318391013AąFWHITE DVėDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z6W3C1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-07-14BįDWĖ YYPhase 3A@ . . .N. A12-15 YearsNAąHr—ŠŌHr³P Hr—ŠŌHr³P ..Placebo Placebo .DW¾YC4591001C4591001 1013 10131841DV101318411013AŠFBLACK OR AFRICAN AMERICAN DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZCEMEProcedure/Test not performed per protocol Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr—½8Hr²“Hr—½8Hr²“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1013 10131841DV101318411013AŠFBLACK OR AFRICAN AMERICAN DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OTBW9VVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr—½8Hr²“Hr—½8Hr²“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1013 10131842DV101318421013AšFBLACK OR AFRICAN AMERICAN DVėDWŃPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTBW9YVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr—½°HsĘź€Hr—½°Hr²LHs›g˜HsĘź€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1013 10131842DV101318421013AšFBLACK OR AFRICAN AMERICAN DVėDWŃPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTC5OZVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr—½°HsĘź€Hr—½°Hr²LHs›g˜HsĘź€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1013 10131842DV101318421013AšFBLACK OR AFRICAN AMERICAN DVėDWŃPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WTQAQPVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-05B}DWg YYPhase 3A@ . . .N. A12-15 YearsNAšHr—½°HsĘź€Hr—½°Hr²LHs›g˜HsĘź€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1013 10131842DV101318421013AšFBLACK OR AFRICAN AMERICAN DVėDWŃPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YM00WRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK12 NO Non-Important2021-04-14B†DWp YYPhase 3A@ . . .N. A12-15 YearsNAšHr—½°HsĘź€Hr—½°Hr²LHs›g˜HsĘź€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1013 10131842DV101318421013AšFBLACK OR AFRICAN AMERICAN DVėDWŃPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZB3T13Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1013V102_VAX4 NO Non-Important2021-07-20BēDWŃ YYPhase 3A@ . . .N. A12-15 YearsNAšHr—½°HsĘź€Hr—½°Hr²LHs›g˜HsĘź€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1013 10131843DV101318431013AąMBLACK OR AFRICAN AMERICAN DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1PDYT7GVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-27B9DW# YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—ĄHr²¬Hr—ĄHr²¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131843DV101318431013AąMBLACK OR AFRICAN AMERICAN DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YNZMB5Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-14B†DWp YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—ĄHr²¬Hr—ĄHr²¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131843DV101318431013AąMBLACK OR AFRICAN AMERICAN DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1YNZMB8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK14 NO Non-Important2021-05-06BœDW† YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—ĄHr²¬Hr—ĄHr²¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131843DV101318431013AąMBLACK OR AFRICAN AMERICAN DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZF2K28Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1013SSWAB_WEEK18 NO Non-Important2021-06-02B·DW” YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—ĄHr²¬Hr—ĄHr²¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131843DV101318431013AąMBLACK OR AFRICAN AMERICAN DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZF2K6RNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1013SSWAB_WEEK20 NO Non-Important2021-06-16BÅDWÆ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—ĄHr²¬Hr—ĄHr²¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131843DV101318431013AąMBLACK OR AFRICAN AMERICAN DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1Z6W3C4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-07-15BāDWĢ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—ĄHr²¬Hr—ĄHr²¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131844DV101318441013AŠMBLACK OR AFRICAN AMERICAN DVėDWĢPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PDYTCTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-27B9DW# YYPhase 3A@ . . .N. A12-15 YearsNAŠHr—æHsĄ\ŲHr—æHr²`Hs¤®„HsĄ\ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131844DV101318441013AŠMBLACK OR AFRICAN AMERICAN DVėDWĢPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YV6XV0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK14 NO Non-Important2021-05-06BœDW† YYPhase 3A@ . . .N. A12-15 YearsNAŠHr—æHsĄ\ŲHr—æHr²`Hs¤®„HsĄ\ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131844DV101318441013AŠMBLACK OR AFRICAN AMERICAN DVėDWĢPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YV6XV3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK16 NO Non-Important2021-05-14B¤DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr—æHsĄ\ŲHr—æHr²`Hs¤®„HsĄ\ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131845DV101318451013AĄFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OTBWA1Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜® Hr³HdHr˜® Hr³Hd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131845DV101318451013AĄFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZCEMIProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-21B2DW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜® Hr³HdHr˜® Hr³Hd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131845DV101318451013AĄFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WTQAQSVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-03-22BnDWY YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜® Hr³HdHr˜® Hr³Hd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131845DV101318451013AĄFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZMNWAUVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK12 NO Non-Important2021-04-29B”DW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜® Hr³HdHr˜® Hr³Hd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131850DV101318501013AšFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTC5P5Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr˜ŁüHr³XĢHr˜ŁüHr³XĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1013 10131850DV101318501013AšFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WNXXF8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V202_SURVEIL_SWAB|637164238669060NO Non-Important2021-02-23BSDW> YYPhase 3A@ . . .Y. A12-15 YearsNAšHr˜ŁüHr³XĢHr˜ŁüHr³XĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1013 10131850DV101318501013AšFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YNZMBBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-05-04B™DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr˜ŁüHr³XĢHr˜ŁüHr³XĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1013 10131851DV101318511013AšFMULTIPLE DVšDW×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZH10SYVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1013V102_VAX4 NO Non-Important2021-07-26BčDW× YYPhase 3A@ . . .N. A12-15 YearsNAšHrž4HsĪ¼ˆHrž4Hr¹ßäHs —ĢHsĪ¼ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131851DV101318511013AšFMULTIPLE DVšDW×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZSWS68Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1013V103_MONTH1 NO Non-Important2021-08-31CĄDWū YYPhase 3A@ . . .N. A12-15 YearsNAšHrž4HsĪ¼ˆHrž4Hr¹ßäHs —ĢHsĪ¼ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1013 10131856DV101318561013AšMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PLVATBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-08B>DW/ YYPhase 3A@ . . .N. A12-15 YearsNAšHr æHr¼›Hr æHr¼›..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1013 10131858DV101318581013AŠFWHITE DVņDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTQAQVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-03-31BqDWb YYPhase 3A@ . . .N. A12-15 YearsNAŠHr ½˜Hs˜¼ Hr ½˜Hr»4pHssŁØHs˜¼ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131858DV101318581013AŠFWHITE DVņDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z6G6WZVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1013V102_VAX4 NO Non-Important2021-06-15B½DW® YYPhase 3A@ . . .N. A12-15 YearsNAŠHr ½˜Hs˜¼ Hr ½˜Hr»4pHssŁØHs˜¼ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131859DV101318591013AšMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2F2Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-04-03BtDWe YYPhase 3A@ . . .Y. A12-15 YearsNAšHr ¼0Hr½‘˜Hr ¼0Hr½‘˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1013 10131859DV101318591013AšMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIM2G9Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-21B†DWw YYPhase 3A@ . . .Y. A12-15 YearsNAšHr ¼0Hr½‘˜Hr ¼0Hr½‘˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1013 10131859DV101318591013AšMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZIM2GCNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK12 NO Non-Important2021-05-09B˜DW‰ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr ¼0Hr½‘˜Hr ¼0Hr½‘˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1013 10131859DV101318591013AšMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-201SLGJVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK14 NO Non-Important2021-05-13BœDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr ¼0Hr½‘˜Hr ¼0Hr½‘˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1013 10131861DV101318611013AĄMBLACK OR AFRICAN AMERICAN DVóDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS50V9Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1013V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr”ņųHrĆ8Hr”ņųHrĆ8..Placebo Placebo .DWõYC4591001C4591001 1013 10131861DV101318611013AĄMBLACK OR AFRICAN AMERICAN DVóDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZNJA6OVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-08-25C0DWõ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr”ņųHrĆ8Hr”ņųHrĆ8..Placebo Placebo .DWõYC4591001C4591001 1013 10131865DV101318651013AŠMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2GFNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-04-11BwDWm YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr§=äHrÅÕHr§=äHrÅÕ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1013 10131865DV101318651013AŠMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHVRQTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-28BˆDW~ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr§=äHrÅÕHr§=äHrÅÕ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1013 10131866DV101318661013AšMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2GSNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-04-11BwDWm YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§=0HrÅŌ˜Hr§=0HrÅŌ˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1013 10131866DV101318661013AšMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHVRQXVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-28BˆDW~ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§=0HrÅŌ˜Hr§=0HrÅŌ˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1013 10131867DV101318671013AĄMBLACK OR AFRICAN AMERICAN DVśDW½Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTBWA7Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«G@Hs¬”Hr«G@HrĂ Hs†;čHs¬”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131867DV101318671013AĄMBLACK OR AFRICAN AMERICAN DVśDW½Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WNXXFLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V202_SURVEIL_SWAB|637152332007060NO Non-Important2021-03-10BTDWM YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«G@Hs¬”Hr«G@HrĂ Hs†;čHs¬”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131867DV101318671013AĄMBLACK OR AFRICAN AMERICAN DVśDW½Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1V8LW61Lab performed out of window Laboratory FOLLOW-UP 1013COVID_A NO Non-Important2021-03-16BZDWS YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«G@Hs¬”Hr«G@HrĂ Hs†;čHs¬”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131867DV101318671013AĄMBLACK OR AFRICAN AMERICAN DVśDW½Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Z3S3C8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-05-05BŒDW… YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«G@Hs¬”Hr«G@HrĂ Hs†;čHs¬”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131867DV101318671013AĄMBLACK OR AFRICAN AMERICAN DVśDW½Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1YY0VE2Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1013V102_VAX4 NO Non-Important2021-06-30BÄDW½ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«G@Hs¬”Hr«G@HrĂ Hs†;čHs¬”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131868DV101318681013AŠFMULTIPLE DVžDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126429301IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1013Vax 1 NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°x HrĶÆÄHr°x HrĶÆÄ..Placebo Placebo ..YC4591001C4591001 1013 10131869DV101318691013AąMWHITE DVžDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PG5YQ1Participant randomized into incorrect age stratum in Impala Randomization VACCINATION 1013V1_DAY1_VAX1 NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAąHr°†ģHrĻDHr°†ģHrĻD..Placebo Placebo .DW”YC4591001C4591001 1013 10131870DV101318701013AšMWHITE DVžDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126429501IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1013Vax 1 NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr°‡ HrĻHr°‡ HrĻ..Placebo Placebo ..YC4591001C4591001 1013 10131872DV101318721013AĄMMULTIPLE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA126429401IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1013Vax 1 NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°™¬HrĢlTHr°™¬HrĢlT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1013 10131872DV101318721013AĄMMULTIPLE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1SST1U8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013COVID_A1 NO Non-Important2021-03-17BWDWT YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°™¬HrĢlTHr°™¬HrĢlT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1013 10131873DV101318731013AŠFASIAN DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1PF862OVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-03B,DW* YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±åČHrĪöHr±åČHrĪö..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1013 10131873DV101318731013AŠFASIAN DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZF2K6UNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK22 NO Non-Important2021-07-16BĻDWĶ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±åČHrĪöHr±åČHrĪö..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1013 10131873DV101318731013AŠFASIAN DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHJ099Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK24 NO Non-Important2021-07-18BŃDWĻ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±åČHrĪöHr±åČHrĪö..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1013 10131874DV101318741013AĄMASIAN DV’DWēPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PF862RVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-03B,DW* YYPhase 3A@ . . .N. A12-15 YearsNAĄHr±ŚˆHsćĪ4Hr±ŚˆHrĪō`HsĘåŠHsćĪ4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŃYC4591001C4591001 1013 10131874DV101318741013AĄMASIAN DV’DWēPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZMNWCLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK14 NO Non-Important2021-05-19B•DW“ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr±ŚˆHsćĪ4Hr±ŚˆHrĪō`HsĘåŠHsćĪ4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŃYC4591001C4591001 1013 10131877DV101318771013AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA126525801IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1013Vax 2 NO Non-Important2021-01-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr³ HHrĻœHr³ HHrĻœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131877DV101318771013AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1R163EXVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-01BEDWD YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr³ HHrĻœHr³ HHrĻœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131877DV101318771013AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZF2K6XNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1013SSWAB_WEEK18 NO Non-Important2021-07-05BĆDWĀ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr³ HHrĻœHr³ HHrĻœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131878DV101318781013AĄMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZMNWCOVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-04-22ByDWx YYPhase 3A@ . . .N. A12-15 YearsNAĄHr³PHrĻ(Hr³PHrĻ(..Placebo Placebo .DW‘YC4591001C4591001 1013 10131878DV101318781013AĄMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XE9KW3Potential COVID-19 illness visit not done when required per protocol. Visit Schedule REPEAT SCREENING 1 1013Potential COVID illness visit NO Non-Important2021-05-19B”DW“ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr³PHrĻ(Hr³PHrĻ(..Placebo Placebo .DW‘YC4591001C4591001 1013 10131880DV101318801013AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WNXXFOVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK4 NO Non-Important2021-03-03BGDWF YYPhase 3A@ . . .Y. A12-15 YearsNAąHr³DHrĢr0Hr³DHrĢr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131880DV101318801013AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WTQAQYVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK6 NO Non-Important2021-03-22BZDWY YYPhase 3A@ . . .Y. A12-15 YearsNAąHr³DHrĢr0Hr³DHrĢr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131880DV101318801013AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZAYZKBNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1013SSWAB_WEEK16 NO Non-Important2021-05-31B DWŸ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr³DHrĢr0Hr³DHrĢr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131880DV101318801013AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YNZMBEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013SSWAB_WEEK18 NO Non-Important2021-06-14B®DW­ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr³DHrĢr0Hr³DHrĢr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131882DV101318821013AšMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WNXXFRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V202_SURVEIL_SWAB|637066170801060NO Non-Important2021-02-23B8DW> YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼THsŽ>tHr¼THrÖģŲHsr|pHsŽ>tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131882DV101318821013AšMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTQARLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK6 NO Non-Important2021-03-03B@DWF YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼THsŽ>tHr¼THrÖģŲHsr|pHsŽ>tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131883DV101318831013AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZKZNV5Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK6 NO Non-Important2021-04-21BpDWw YYPhase 3A@ . . .N. A12-15 YearsNAąHr½¦°Hs’0$Hr½¦°HrŁ¤xHsvˆŲHs’0$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131883DV101318831013AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XA31YTUrine pregnancy test not performed. Laboratory OPEN LABEL TREATMENT1013V101_VAX3 NO Non-Important2021-05-20BDW” YYPhase 3A@ . . .N. A12-15 YearsNAąHr½¦°Hs’0$Hr½¦°HrŁ¤xHsvˆŲHs’0$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131884DV101318841013AąFASIAN DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIUMM7Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-08-18BąDWī YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĘŌLHrā߬HrĘŌLHrā߬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1013 10131885DV101318851013AąFWHITE DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA127000101IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1013Vax 2 NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘÕxHs˜®HrĘÕxHrą3ˆHs¢Hs˜®Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1016 10161307DV101613071016AŠFBLACK OR AFRICAN AMERICAN DV»DW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WNXXFXVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016V202_SURVEIL_SWAB|635942664602060NO Non-Important2021-02-25B†DW@ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrX5xHs‘č0HrX5xHrrxüHstęHs‘č0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161307DV101613071016AŠFBLACK OR AFRICAN AMERICAN DV»DW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUF7Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BÓDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrX5xHs‘č0HrX5xHrrxüHstęHs‘č0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161308DV101613081016AŠMWHITE DV»DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUGYUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BÓDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrX6ąHs—ŠHrX6ąHrqLHs~ĄHs—ŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161310DV101613101016AŠMWHITE DV»DVĻBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUH1Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BÓDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrX]Hrrj°HrX]Hrrj°..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161311DV101613111016AšMWHITE DV»DVĪBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WZ8A6TVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016COVID_B1 NO Non-Important2021-05-11BŃDW‹ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrXbšHrq_HrXbšHrq_..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW@YC4591001C4591001 1016 10161314DV101613141016AŠFWHITE DV¼DVŠBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WH6QX9Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK2 NO Non-Important2021-02-24B„DW? YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrYw¼HrsÄ(HrYw¼HrsÄ(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1016 10161314DV101613141016AŠFWHITE DV¼DVŠBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUH4Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-26BßDWš YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrYw¼HrsÄ(HrYw¼HrsÄ(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1016 10161315DV101613151016AąFWHITE DV¼DWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PFGQHRLab performed out of window Laboratory FOLLOW-UP 1016V202_SURVEIL_SWAB|634578737276080NO Non-Important2021-02-09BuDW0 YYPhase 3A@ . . .N. A12-15 YearsNAąHrY­,HsŚØHrY­,HruTHsvl@HsŚØPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161315DV101613151016AąFWHITE DV¼DWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WH6QXMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK2 NO Non-Important2021-02-09BuDW0 YYPhase 3A@ . . .N. A12-15 YearsNAąHrY­,HsŚØHrY­,HruTHsvl@HsŚØPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161315DV101613151016AąFWHITE DV¼DWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBKUI1Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-17BÖDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrY­,HsŚØHrY­,HruTHsvl@HsŚØPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161316DV101613161016AšMWHITE DV¼DWSPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1O4N1URVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1016V2_VAX2_L NO Non-Important2020-11-13BDVŲ YYPhase 3A@ . . .N. A12-15 YearsNAšHrYÆHHs ¹HrYÆHHrYÆHHsÆlHs ¹Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1016 10161318DV101613181016AąMWHITE DV¼DW¼Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUI4Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BŅDW YYPhase 3A@ . . .N. A12-15 YearsNAąHrY¶Hs«*ŌHrY¶Hrr¶ Hs’#øHs«*ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161319DV101613191016AĄFWHITE DV¼DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUI7Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-18B×DW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrY¹\Hs—i|HrY¹\Hrr“üHs}$Hs—i|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1016 10161320DV101613201016AąMWHITE DVĮDVŌBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUIAUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-17BŃDW‘ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr` ŌHry €Hr` ŌHry €..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161322DV101613221016AąFWHITE DVæDVŌBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUIXUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BĻDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr]u`HryøHr]u`Hryø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161323DV101613231016AŠFBLACK OR AFRICAN AMERICAN DVæDVŌBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUJ0Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BĻDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr]”PHry"ˆHr]”PHry"ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161324DV101613241016AšFBLACK OR AFRICAN AMERICAN DVæDW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUJ3Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BĻDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr]“ŲHs›QĢHr]“ŲHry#Hs«pHs›QĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161325DV101613251016AąFWHITE DVæDVÕBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUJGUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BĻDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr] ųHrzÆHr] ųHrzÆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161326DV101613261016AąMWHITE DVĄDVÕBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKUJJUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BĪDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr^©XHrzg`Hr^©XHrzg`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161327DV101613271016AĄMWHITE DVĄDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKPG3Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BĪDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr^©XHs”£8Hr^©XHrzg$Hs†FtHs”£8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161329DV101613291016AąMWHITE DVĄDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKPG7Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-17BŅDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr^ŖüHsŪ\Hr^ŖüHrz¶ Hsu!HsŪ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161330DV101613301016AŠFWHITE DVĄDVÖBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKPGAUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BĪDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr^ņ“Hr|¤Hr^ņ“Hr|¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161331DV101613311016AĄFWHITE DVĄDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBKPNBUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-18BÓDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr^ńˆHs—;PHr^ńˆHr|<Hs~jXHs—;PPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1016 10161331DV101613311016AĄFWHITE DVĄDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZHW9QZNasal swab collected at a visit where it was not required Laboratory OPEN LABEL FOLLOW-UP1016COVID_B NO Non-Important2021-08-09C`DWå YYPhase 3A@ . . .N. A12-15 YearsNAĄHr^ńˆHs—;PHr^ńˆHr|<Hs~jXHs—;PPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1016 10161332DV101613321016AąMBLACK OR AFRICAN AMERICAN DVĮDVŌBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKPNEUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BĶDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr`>”Hry!ŌHr`>”Hry!Ō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161334DV101613341016AąFWHITE DVĮDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKPNHUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-17BŃDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr`D4Hs˜l“Hr`D4Hr|\Hsæ\Hs˜l“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161335DV101613351016AŠFWHITE DVĮDVÖBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WTQARUVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK6 NO Non-Important2021-04-14B°DWp YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr`^tHr{“0Hr`^tHr{“0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161335DV101613351016AŠFWHITE DVĮDVÖBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKPNKUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-17BŃDW‘ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr`^tHr{“0Hr`^tHr{“0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161336DV101613361016AšFWHITE DVĮDW×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WTQARXVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK6 NO Non-Important2021-04-14B°DWp YYPhase 3A@ . . .N. A12-15 YearsNAšHr`^ģHsĪ™ŲHr`^ģHr{“ØHs“1LHsĪ™ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161336DV101613361016AšFWHITE DVĮDW×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBL5IHUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-17BŃDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHr`^ģHsĪ™ŲHr`^ģHr{“ØHs“1LHsĪ™ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161336DV101613361016AšFWHITE DVĮDW×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBAIRMOther Informed Consent Informed Consent REPEAT SCREENING 1 1016Consent NO Non-Important2021-07-05C DWĀ YYPhase 3A@ . . .N. A12-15 YearsNAšHr`^ģHsĪ™ŲHr`^ģHr{“ØHs“1LHsĪ™ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161338DV101613381016AĄMBLACK OR AFRICAN AMERICAN DVĀDVÕBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OESW8DIncorrect serology sample volume collected Laboratory VACCINATION 1016V1_DAY1_VAX1_L NO Non-Important2020-10-22ADVĀ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHraQųHrzk˜HraQųHrzk˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161338DV101613381016AĄMBLACK OR AFRICAN AMERICAN DVĀDVÕBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1OSSM9YVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016V3_MONTH1_POSTVAX2_L NO Non-Important2020-12-28BDDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHraQųHrzk˜HraQųHrzk˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161338DV101613381016AĄMBLACK OR AFRICAN AMERICAN DVĀDVÕBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZBL5IKUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-14BĶDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHraQųHrzk˜HraQųHrzk˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161339DV101613391016AŠMWHITE DVĀDVÕBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBL5INUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-14BĶDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHra^(Hrz_ąHra^(Hrz_ą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161340DV101613401016AĄMWHITE DVĀDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBL5JAUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-14BĶDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHra^dHs˜kÄHra^dHrz_¤Hs~üHs˜kÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161343DV101613431016AąMWHITE DVĀDVŲBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBL5JDUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-14BĶDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAąHra­$Hr~ŠĄHra­$Hr~ŠĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161344DV101613441016AšFWHITE DVĀDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBL5JGUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-17BŠDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHra®PHsŽ>°Hra®PHr{üœHstŲ0HsŽ>°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161350DV101613501016AąMWHITE DVéDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YBECDPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK18 NO Non-Important2021-06-14BÅDW­ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr”Į(Hr°}ŒHr”Į(Hr°}Œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161351DV101613511016AąFWHITE DVéDWÉPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z6G6X2Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1016V102_VAX4 NO Non-Important2021-07-12BįDWÉ YYPhase 3A@ . . .N. A12-15 YearsNAąHr”æ„Hs¼ Hr”æ„Hr°iÜHs—"Hs¼ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161356DV101613561016AŠMWHITE DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMNWCRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK12 NO Non-Important2021-05-12B¢DWŒ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr—kØHr±½šHr—kØHr±½š..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161357DV101613571016AĄMWHITE DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WTQAS0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK10 NO Non-Important2021-04-14B†DWp YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr—r°Hr±ĆĢHr—r°Hr±ĆĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161361DV101613611016AŠMWHITE DVķDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTQAS3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK6 NO Non-Important2021-03-12BcDWO YYPhase 3A@ . . .N. A12-15 YearsNAŠHršģHsŽ) HršģHr³ HsrjÜHsŽ) Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161362DV101613621016AĄMBLACK OR AFRICAN AMERICAN DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS8YWUVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1016V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHršOXHr¹åHHršOXHr¹åH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161362DV101613621016AĄMBLACK OR AFRICAN AMERICAN DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZMNWCUVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK16 NO Non-Important2021-05-27BÆDW› YYPhase 3A@ . . .Y. A12-15 YearsNAĄHršOXHr¹åHHršOXHr¹åH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161363DV101613631016AšFWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1SXW32MPotential COVID-19 illness visit not done when required per protocol. Visit Schedule VACCINATION 1016POT_COVID_ILL NO Non-Important2021-01-08B DW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŸœ$Hr¹ķōHrŸœ$Hr¹ķō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161363DV101613631016AšFWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WH6QXPVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK2 NO Non-Important2021-02-23BNDW> YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŸœ$Hr¹ķōHrŸœ$Hr¹ķō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161364DV101613641016AšFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WTQAS6Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK6 NO Non-Important2021-03-26BlDW] YYPhase 3A@ . . .Y. A12-15 YearsNAšHr åčHr½©Hr åčHr½©..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1016 10161364DV101613641016AšFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WTQAS9Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK8 NO Non-Important2021-04-20B…DWv YYPhase 3A@ . . .Y. A12-15 YearsNAšHr åčHr½©Hr åčHr½©..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1016 10161364DV101613641016AšFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YV6XVGVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK10 NO Non-Important2021-05-28B«DWœ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr åčHr½©Hr åčHr½©..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1016 10161364DV101613641016AšFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YV6XVJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK12 NO Non-Important2021-06-28BŹDW» YYPhase 3A@ . . .Y. A12-15 YearsNAšHr åčHr½©Hr åčHr½©..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1016 10161366DV101613661016AĄMWHITE DVųDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QTCH4NVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-17BADW8 YYPhase 3A@ . . .N. A12-15 YearsNAĄHrØĻŲHsµæ€HrØĻŲHrĒ1ŠHsu3˜Hsµæ€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161366DV101613661016AĄMWHITE DVųDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1UCOGAQVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016COVID_A1 NO Non-Important2021-04-06BqDWh YYPhase 3A@ . . .N. A12-15 YearsNAĄHrØĻŲHsµæ€HrØĻŲHrĒ1ŠHsu3˜Hsµæ€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161366DV101613661016AĄMWHITE DVųDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBAISZOther Informed Consent Informed Consent OPEN LABEL TREATMENT1016Consent NO Non-Important2021-07-06BĢDWĆ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrØĻŲHsµæ€HrØĻŲHrĒ1ŠHsu3˜Hsµæ€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161366DV101613661016AĄMWHITE DVųDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Z3S3CBVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1016V102_VAX4 NO Non-Important2021-07-07BĶDWÄ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrØĻŲHsµæ€HrØĻŲHrĒ1ŠHsu3˜Hsµæ€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161369DV101613691016AĄFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PI38GEVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1016V2_VAX2_L NO Non-Important2021-01-27BDW# YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼ŸøHrį…ųHr¼ŸøHrį…ų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1016 10161370DV101613701016AšMMULTIPLE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OQLI4ASubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1016Consent NO Non-Important2021-01-04ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĀõ\HrŽźxHrĀõ\HrŽźx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1016 10161370DV101613701016AšMMULTIPLE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OQLI4GSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1016Consent NO Non-Important2021-01-04ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĀõ\HrŽźxHrĀõ\HrŽźx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1016 10161370DV101613701016AšMMULTIPLE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WTQASCVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK8 NO Non-Important2021-04-06B]DWh YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĀõ\HrŽźxHrĀõ\HrŽźx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1016 10161370DV101613701016AšMMULTIPLE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z6W3CHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK12 NO Non-Important2021-05-17B†DW‘ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĀõ\HrŽźxHrĀõ\HrŽźx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1016 10161370DV101613701016AšMMULTIPLE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1Z6W3CKVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK16 NO Non-Important2021-07-13BæDWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĀõ\HrŽźxHrĀõ\HrŽźx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1016 10161376DV101613761016AšFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YM00WVVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK24 NO Non-Important2021-06-23BØDW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĘš0HrßōøHrĘš0Hrßōø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWƒYC4591001C4591001 1016 10161376DV101613761016AšFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z6W3CNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK26 NO Non-Important2021-07-15B¾DWĢ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĘš0HrßōøHrĘš0Hrßōø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWƒYC4591001C4591001 1016 10161377DV101613771016AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YM00WYVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK24 NO Non-Important2021-06-23BØDW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĘšlHrßõ0HrĘšlHrßõ0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161377DV101613771016AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z6W3CQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK26 NO Non-Important2021-07-15B¾DWĢ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĘšlHrßõ0HrĘšlHrßõ0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161378DV101613781016AĄMWHITE DWDWõPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCJKLIUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-07-26BÉDW× YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĒ(čHsöf\HrĒ(čHrą;DHsŚøDHsöf\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW×YC4591001C4591001 1016 10161379DV101613791016AŠMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PDYTCWVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1016V2_VAX2_L NO Non-Important2021-02-05BDW, YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĒ2üHs©œ(HrĒ2üHrĒ2üHs†¼Hs©œ(Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161379DV101613791016AŠMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YP0QZZVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1016V102_VAX4 NO Non-Important2021-06-28B­DW» YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĒ2üHs©œ(HrĒ2üHrĒ2üHs†¼Hs©œ(Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161379DV101613791016AŠMWHITE DWDW»Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YV6XVMVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1016V102_VAX4 NO Non-Important2021-06-28B­DW» YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĒ2üHs©œ(HrĒ2üHrĒ2üHs†¼Hs©œ(Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1016 10161381DV101613811016AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHW9ODVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK26 NO Non-Important2021-08-04BŃDWą YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČ.Hrā•œHrČ.Hrā•œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161382DV101613821016AĄMASIAN DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z8JZN5Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK24 NO Non-Important2021-07-19BĮDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČ2tHrāŃ$HrČ2tHrāŃ$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161384DV101613841016AŠFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WH6QXSVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1016SSWAB_WEEK2 NO Non-Important2021-02-17B)DW8 YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrČ8HrįHrČ8Hrį..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161384DV101613841016AŠFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YV6XVZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK14 NO Non-Important2021-05-12B}DWŒ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrČ8HrįHrČ8Hrį..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161384DV101613841016AŠFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YV6XW2Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016SSWAB_WEEK16 NO Non-Important2021-06-28B¬DW» YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrČ8HrįHrČ8Hrį..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391250DV103912501039AąFWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z3S3JIVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1039V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr™śHr¹ŽHr™śHr¹Ž..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391250DV103912501039AąFWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YXOAEWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1039V4_MONTH6_L NO Non-Important2021-07-06B×DWĆ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr™śHr¹ŽHr™śHr¹Ž..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391251DV103912511039AšFASIAN DVšDW@Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTLH1DVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1039V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŪHsLĄHrŪHrĀĆčHréHsLĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW)YC4591001C4591001 1039 10391252DV103912521039AšMWHITE DVšDWqPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1V9RO1QAssessment of acute reaction for protocol specified timeframe after study intervention administration not performed at the vaccination visits. Procedures/Tests OPEN LABEL TREATMENT1039V102_VAX4 NO Non-Important2021-04-15B‚DWq YYPhase 3A@ . . .N. A12-15 YearsNAšHrąHsH<¼HrąHr¹µ<Hs,ŽąHsH<¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWVYC4591001C4591001 1039 10391255DV103912551039AĄMWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z4EZ0HVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1039V4_MONTH6_L NO Non-Important2021-07-12BŚDWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrž°Hr» Hrž°Hr» ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391256DV103912561039AĄMWHITE DVšDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131632401IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13BžDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrž<HsˆĀČHrž<Hr» Hsm|HsˆĀČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391256DV103912561039AĄMWHITE DVšDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 131647801Other IP deviation Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13BžDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrž<HsˆĀČHrž<Hr» Hsm|HsˆĀČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391256DV103912561039AĄMWHITE DVšDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XK8VV6Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13BžDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrž<HsˆĀČHrž<Hr» Hsm|HsˆĀČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391258DV103912581039AŠFWHITE DVšDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131633601IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13BžDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž Hs†8Hrž Hr¹É(Hsm$Hs†8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391258DV103912581039AŠFWHITE DVšDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XO2U2GIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13BžDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž Hs†8Hrž Hr¹É(Hsm$Hs†8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391258DV103912581039AŠFWHITE DVšDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 131862401IP administered prior to Almac authorizing it for use Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-06-01B±DW  YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž Hs†8Hrž Hr¹É(Hsm$Hs†8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391259DV103912591039AŠMWHITE DVšDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131737001IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-14BŸDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž'ōHsŠäHrž'ōHr¹¼Hsnx<HsŠäPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391259DV103912591039AŠMWHITE DVšDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 131739301Other IP deviation Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-14BŸDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž'ōHsŠäHrž'ōHr¹¼Hsnx<HsŠäPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391259DV103912591039AŠMWHITE DVšDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XO2U2OIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14BŸDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž'ōHsŠäHrž'ōHr¹¼Hsnx<HsŠäPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391260DV103912601039AąMWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZE7IL5Other Informed Consent Informed Consent REPEAT SCREENING 1 1039Consent NO Non-Important2021-07-29BėDWŚ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrž1ĢHr¹ÜŲHrž1ĢHr¹ÜŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391264DV103912641039AĄFASIAN DVńDW˜Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1R0TGKPVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1039V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-01BTDWD YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŸaHs{ØhHrŸaHr» Hs{ØhHs{ØhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391264DV103912641039AĄFASIAN DVńDW˜Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131862301IP administered prior to Almac authorizing it for use Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-24BØDW˜ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŸaHs{ØhHrŸaHr» Hs{ØhHs{ØhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391264DV103912641039AĄFASIAN DVńDW˜Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U2RIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-24BØDW˜ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŸaHs{ØhHrŸaHr» Hs{ØhHs{ØhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391264DV103912641039AĄFASIAN DVńDW˜Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XA0FOFAssessment of acute reaction for protocol specified timeframe after study intervention administration not performed at the vaccination visits. Procedures/Tests OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-24BØDW˜ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŸaHs{ØhHrŸaHr» Hs{ØhHs{ØhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391265DV103912651039AĄMASIAN DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R0TGKSVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1039V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-01BTDWD YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŸd˜Hr»ŲHrŸd˜Hr»Ų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391266DV103912661039AĄMWHITE DVńDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U2UIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14BžDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŸtHsˆŲŠHrŸtHr»XHsn|°HsˆŲŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391268DV103912681039AŠFWHITE DVńDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131632501IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŸwXHsŠlHrŸwXHr¹‡ˆHslņxHsŠlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391268DV103912681039AŠFWHITE DVńDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U2XIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŸwXHsŠlHrŸwXHr¹‡ˆHslņxHsŠlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391270DV103912701039AŠFWHITE DVņDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131632601IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13BœDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr ¬ōHsˆŽ„Hr ¬ōHr¹£äHslŽŒHsˆŽ„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391270DV103912701039AŠFWHITE DVņDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U30Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13BœDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr ¬ōHsˆŽ„Hr ¬ōHr¹£äHslŽŒHsˆŽ„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391271DV103912711039AąFWHITE DVņDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131633301IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13BœDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr ĪšHsˆæHr ĪšHr¹Ń˜Hsl’ŌHsˆæPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391271DV103912711039AąFWHITE DVņDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U33Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13BœDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr ĪšHsˆæHr ĪšHr¹Ń˜Hsl’ŌHsˆæPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391273DV103912731039AĄFWHITE DVņDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131633401IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13BœDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr ĻhHsˆæHr ĻhHr¹Ń\Hsl’˜HsˆæPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391273DV103912731039AĄFWHITE DVņDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U36Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13BœDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr ĻhHsˆæHr ĻhHr¹Ń\Hsl’˜HsˆæPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391274DV103912741039AŠMWHITE DVłDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U39Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B–DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr©ĮHs‰ÖhHr©ĮHrĀĀDHsnOtHs‰ÖhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391277DV103912771039AąFBLACK OR AFRICAN AMERICAN DVłDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131632701IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13B•DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr©ŻœHsŠHHr©ŻœHrŘ\Hslć<HsŠHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391277DV103912771039AąFBLACK OR AFRICAN AMERICAN DVłDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U3CIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13B•DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr©ŻœHsŠHHr©ŻœHrŘ\Hslć<HsŠHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391279DV103912791039AąFWHITE DVłDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U3FIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-17B™DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr©ōŠHsļ<Hr©ōŠHrŶŌHsrGšHsļ<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391279DV103912791039AąFWHITE DVłDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X4R37JAssessment of acute reaction for protocol specified timeframe after study intervention administration not performed at the vaccination visits. Procedures/Tests OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-17B™DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr©ōŠHsļ<Hr©ōŠHrŶŌHsrGšHsļ<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391280DV103912801039AŠFWHITE DVśDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U3IIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B•DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr«äHsŠ,äHr«äHrĘŁģHsn0ĄHsŠ,äPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391281DV103912811039AšFWHITE DVśDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z9VPFMNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1039COVID_A NO Non-Important2021-07-23BŪDWŌ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr«ZxHrÄohHr«ZxHrÄoh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW0YC4591001C4591001 1039 10391283DV103912831039AšMWHITE DVūDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U3LIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13B“DW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¬k HsˆĻ4Hr¬k HrĘ³Hsl֔HsˆĻ4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391285DV103912851039AŠFWHITE DVūDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131675401IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-14B”DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬täHs‰ŲĄHr¬täHrČtHsn-“Hs‰ŲĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391285DV103912851039AŠFWHITE DVūDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U3OIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B”DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬täHs‰ŲĄHr¬täHrČtHsn-“Hs‰ŲĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391285DV103912851039AŠFWHITE DVūDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z4H7FBVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1039V103_MONTH1 NO Non-Important2021-07-12BĻDWÉ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬täHs‰ŲĄHr¬täHrČtHsn-“Hs‰ŲĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391286DV103912861039AŠFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2GVNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1039SSWAB_WEEK8 NO Non-Important2021-05-24BžDW˜ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬w“HrČ8Hr¬w“HrČ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391286DV103912861039AŠFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIM2GYNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1039SSWAB_WEEK10 NO Non-Important2021-06-11B°DWŖ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬w“HrČ8Hr¬w“HrČ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391286DV103912861039AŠFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZIM2HBNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1039SSWAB_WEEK12 NO Non-Important2021-06-29BĀDW¼ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬w“HrČ8Hr¬w“HrČ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391286DV103912861039AŠFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZIM2HENasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1039SSWAB_WEEK14 NO Non-Important2021-07-16BÓDWĶ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬w“HrČ8Hr¬w“HrČ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391287DV103912871039AąFWHITE DVūDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131632301IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13B“DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¬ČHsˆ™ˆHr¬ČHrČHHsm˜Hsˆ™ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391287DV103912871039AąFWHITE DVūDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U3RIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13B“DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¬ČHsˆ™ˆHr¬ČHrČHHsm˜Hsˆ™ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391292DV103912921039AŠFWHITE DVūDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U48Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B”DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬©(Hs‰ŪTHr¬©(HrČGPHsn0 Hs‰ŪTPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391294DV103912941039AŠMASIAN DVžDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131675301IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-14B‘DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ŌHs‰ń˜Hr°ŌHrĪ0Hsn+˜Hs‰ń˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391294DV103912941039AŠMASIAN DVžDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U4BIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B‘DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ŌHs‰ń˜Hr°ŌHrĪ0Hsn+˜Hs‰ń˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391296DV103912961039AŠMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131675801Other IP deviation Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-14B‰DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŗėPHs‰ļ@HrŗėPHr֊¤HsnAÜHs‰ļ@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391296DV103912961039AŠMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U4EIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B‰DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŗėPHs‰ļ@HrŗėPHr֊¤HsnAÜHs‰ļ@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391296DV103912961039AŠMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Y76TP1Assessment of acute reaction for protocol specified timeframe after study intervention administration not performed at the vaccination visits. Procedures/Tests OPEN LABEL TREATMENT1039V102_VAX4 NO Non-Important2021-06-04BžDW£ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŗėPHs‰ļ@HrŗėPHr֊¤HsnAÜHs‰ļ@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391297DV103912971039AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OUFGFZVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1039V2_VAX2_L NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŗšxHrփœHrŗšxHrփœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391297DV103912971039AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QW05QOSerology sample not collected Laboratory FOLLOW-UP 1039V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-22B8DW= YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŗšxHrփœHrŗšxHrփœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391299DV103912991039AšMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U4HIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B‰DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrŗöĢHs‰óšHrŗöĢHr։šHsn@ģHs‰óšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391300DV103913001039AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QT350LVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1039COVID_A1 NO Non-Important2021-02-22B8DW= YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr»(HrŁ.ŠHr»(HrŁ.Š..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391301DV103913011039AąMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131633501IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-13BˆDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr»tHsŠ"Hr»tHrŁ/ Hsm ōHsŠ"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391301DV103913011039AąMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U4KIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13BˆDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr»tHsŠ"Hr»tHrŁ/ Hsm ōHsŠ"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391301DV103913011039AąMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z4WZJQVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1039V103_MONTH1 NO Non-Important2021-07-13BÅDWŹ YYPhase 3A@ . . .N. A12-15 YearsNAąHr»tHsŠ"Hr»tHrŁ/ Hsm ōHsŠ"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1039 10391303DV103913031039AŠMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U4NIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13BˆDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»(ōHs‰ÖąHr»(ōHrŁ'HsmģHs‰ÖąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391304DV103913041039AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZ3TQBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1039V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B:DW? YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»+ÄHrÖĄČHr»+ÄHrÖĄČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391305DV103913051039AŠMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U4QIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŲ$HsŠ\HrŲ$HrŽu„Hsn–HsŠ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391305DV103913051039AŠMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z4EZ0NVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1039V103_MONTH1 NO Non-Important2021-07-12B¼DWÉ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŲ$HsŠ\HrŲ$HrŽu„Hsn–HsŠ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391307DV103913071039AšFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131737101IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÅ»ĄHs‰ū4HrÅ»ĄHrįY4Hsnu0Hs‰ū4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391307DV103913071039AšFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U4TIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÅ»ĄHs‰ū4HrÅ»ĄHrįY4Hsnu0Hs‰ū4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391308DV103913081039AŠFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OT9E0ZUrine pregnancy test not performed. Laboratory VACCINATION 1039V1_DAY1_VAX1_L NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÅ»üHrįYpHrÅ»üHrįYp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391309DV103913091039AąMASIAN DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131737501IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-17BƒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘ¹XHsc0HrĘ¹XHrįkøHsr.dHsc0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391309DV103913091039AąMASIAN DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U4WIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-17BƒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘ¹XHsc0HrĘ¹XHrįkøHsr.dHsc0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391309DV103913091039AąMASIAN DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z8JZNBVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1039V103_MONTH1 NO Non-Important2021-07-20BĆDWŃ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘ¹XHsc0HrĘ¹XHrįkøHsr.dHsc0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391310DV103913101039AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131737201IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-14B€DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĘĮŒHsńXHrĘĮŒHrßĻ8Hsny¤HsńXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391310DV103913101039AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U4ZIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B€DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĘĮŒHsńXHrĘĮŒHrßĻ8Hsny¤HsńXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391310DV103913101039AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Y1PBIFVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1039V102_VAX4 NO Non-Important2021-06-07B˜DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĘĮŒHsńXHrĘĮŒHrßĻ8Hsny¤HsńXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391311DV103913111039AšMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z9VJW9Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1039V4_MONTH6_L NO Non-Important2021-07-21BÄDWŅ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĘŲHHrćĢdHrĘŲHHrćĢd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391312DV103913121039AŠMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZGKJ9SVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1039V4_MONTH6_L NO Non-Important2021-08-10BŲDWę YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĘÕxHrāu¼HrĘÕxHrāu¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391313DV103913131039AąMWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131675701IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-14B€DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘēüHsˆ§ŌHrĘēüHrāŠ\Hsng Hsˆ§ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391313DV103913131039AąMWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U52Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B€DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘēüHsˆ§ŌHrĘēüHrāŠ\Hsng Hsˆ§ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391314DV103913141039AąFASIAN DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131737401IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-17BƒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘīŒHsŹčHrĘīŒHrā©LHsrˆHsŹčPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391314DV103913141039AąFASIAN DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U55Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-17BƒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘīŒHsŹčHrĘīŒHrā©LHsrˆHsŹčPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391317DV103913171039AĄMASIAN DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1R2N24TVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1039COVID_A1 NO Non-Important2021-02-26B3DWA YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĒ $Hsˆ…œHrĒ $Hrā“PHsnŠüHsˆ…œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391317DV103913171039AĄMASIAN DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1S02Y4LNasal swab collected at a visit where it was not required Laboratory FOLLOW-UP 1039COVID_A NO Non-Important2021-03-02B7DWE YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĒ $Hsˆ…œHrĒ $Hrā“PHsnŠüHsˆ…œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391317DV103913171039AĄMASIAN DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U58Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B€DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĒ $Hsˆ…œHrĒ $Hrā“PHsnŠüHsˆ…œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391318DV103913181039AšFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZEM9G4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1039V4_MONTH6_L NO Non-Important2021-08-09B×DWå YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĒHrä čHrĒHrä č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‹YC4591001C4591001 1039 10391318DV103913181039AšFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZNKOP9Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1039COVID_A NO Non-Important2021-08-23BåDWó YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĒHrä čHrĒHrä č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‹YC4591001C4591001 1039 10391319DV103913191039AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131861901IP administered prior to Almac authorizing it for use Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-20B…DW” YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ 0Hs“eĄHrČ 0HrćēHsvcHs“eĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391319DV103913191039AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 131873801IP administered prior to Almac authorizing it for use Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-20B…DW” YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ 0Hs“eĄHrČ 0HrćēHsvcHs“eĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391319DV103913191039AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XO2U7JIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-20B…DW” YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ 0Hs“eĄHrČ 0HrćēHsvcHs“eĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391320DV103913201039AĄFWHITE DWDW%Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X6ZZ00Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1039V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-17B‚DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ)Hr棄HrČ)Hr棄..Placebo Placebo .DWŒYC4591001C4591001 1039 10391320DV103913201039AĄFWHITE DWDW%Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z7FGYKReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1039V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-13BDW¬ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ)Hr棄HrČ)Hr棄..Placebo Placebo .DWŒYC4591001C4591001 1039 10391320DV103913201039AĄFWHITE DWDW%Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZJE4GTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1039V4_MONTH6_L NO Non-Important2021-08-23BäDWó YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ)Hr棄HrČ)Hr棄..Placebo Placebo .DWŒYC4591001C4591001 1039 10391321DV103913211039AĄFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P93YSNUrine pregnancy test not performed. Laboratory VACCINATION 1039V2_VAX2_L NO Non-Important2021-01-08ADW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ$ HsmHrČ$ Hrć“øHsrHsmPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391321DV103913211039AĄFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U7MIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-17B‚DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ$ HsmHrČ$ Hrć“øHsrHsmPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391325DV103913251039AŠFASIAN DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XO2U7PIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-13B{DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢA4Hsˆ‹xHrĢA4Hrē²\HslńHsˆ‹xPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391327DV103913271039AšMWHITE DWDW(Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X70YRLReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1039V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-15B}DW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢE0Hrē¶ŠHrĢE0Hrē¶Š..Placebo Placebo .DWYC4591001C4591001 1039 10391327DV103913271039AšMWHITE DWDW(Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y24OS7Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1039V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-05B’DW¤ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢE0Hrē¶ŠHrĢE0Hrē¶Š..Placebo Placebo .DWYC4591001C4591001 1039 10391328DV103913281039AąFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131675601IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-14B|DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĢFŌHsŠ|HrĢFŌHrčłPHsndPHsŠ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391328DV103913281039AąFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XO2U7SIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B|DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĢFŌHsŠ|HrĢFŌHrčłPHsndPHsŠ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391329DV103913291039AŠMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131862001IP administered prior to Almac authorizing it for use Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-20B‚DW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢ`ŲHs’ HrĢ`ŲHrēµ¤HsvcXHs’ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391329DV103913291039AŠMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 131874101IP administered prior to Almac authorizing it for use Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-20B‚DW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢ`ŲHs’ HrĢ`ŲHrēµ¤HsvcXHs’ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391329DV103913291039AŠMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XOLIALIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-20B‚DW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢ`ŲHs’ HrĢ`ŲHrēµ¤HsvcXHs’ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391330DV103913301039AšMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZH29RPPotential COVID-19 illness visit not done when required per protocol. Visit Schedule REPEAT SCREENING 1 1039Potential COVID Illness Visit NO Non-Important2021-06-29BŖDW¼ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢ_4HréLHHrĢ_4HréLH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWqYC4591001C4591001 1039 10391333DV103913331039AšMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131951301IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-21B‚DW• YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶeHs“ftHrĶeHré°HswµČHs“ftPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391333DV103913331039AšMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 131862101IP administered prior to Almac authorizing it for use Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-21B‚DW• YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶeHs“ftHrĶeHré°HswµČHs“ftPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391333DV103913331039AšMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XOLIAOIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-21B‚DW• YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶeHs“ftHrĶeHré°HswµČHs“ftPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391334DV103913341039AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131862201IP administered prior to Almac authorizing it for use Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-21B‚DW• YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĶešHs“f8HrĶešHrétHsw¶Hs“f8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391334DV103913341039AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XOLIARIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-21B‚DW• YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĶešHs“f8HrĶešHrétHsw¶Hs“f8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391337DV103913371039AšMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XOLIAUIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-14B{DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶˆÜHsŠHrĶˆÜHrźMdHsnUČHsŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391339DV103913391039AĄFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131737701IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1039Vax 3 NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĶÆHsĖœHrĶÆHrźWHssyHsĖœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1039 10391339DV103913391039AĄFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XOLIAXIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1039V101_VAX3 NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĶÆHsĖœHrĶÆHrźWHssyHsĖœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441251DV104412511044AąFWHITE DVéDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2HHNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1044SSWAB_WEEK4 NO Non-Important2021-05-31B·DWŸ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr•4Hr±ÕœHr•4Hr±Õœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441251DV104412511044AąFWHITE DVéDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHVRR0Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044SSWAB_WEEK6 NO Non-Important2021-06-07B¾DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr•4Hr±ÕœHr•4Hr±Õœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441252DV104412521044AŠMWHITE DVéDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XI77XOIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17B©DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr•ČHsö€Hr•ČHr°Š4Hsr@čHsö€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441253DV104412531044AŠMWHITE DVéDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YRZ2LMSurveillance for asymptomatic SARS-CoV-2 infection is performed after Visit-4 Other REPEAT SCREENING 1 1044SSWAB_WEEK8 NO Non-Important2021-06-29BŌDW¼ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr•&hHr°„XHr•&hHr°„X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441255DV104412551044AĄMWHITE DVźDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OEJ3JOOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-01ADVź YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr–!ØHr° “Hr–!ØHr° “..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441256DV104412561044AąMWHITE DVźDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OEJNTGOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-01ADVź YYPhase 3A@ . . .N. A12-15 YearsNAąHr–!äHs“,Hr–!äHr° šHsre“Hs“,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441256DV104412561044AąMWHITE DVźDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XF78UQIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17BØDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr–!äHs“,Hr–!äHr° šHsre“Hs“,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441257DV104412571044AąFWHITE DVźDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PF8637Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1044V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-19B2DW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr–WTHr³a“Hr–WTHr³a“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441260DV104412601044AšMWHITE DVźDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X4317RIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14B„DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHr–x$Hsˆō“Hr–x$Hr±ü„Hsn“äHsˆō“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441261DV104412611044AąFWHITE DVźDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS3076Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1044V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-18B1DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr–xŲHsŠI|Hr–xŲHr²@HsnwHsŠI|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441261DV104412611044AąFWHITE DVźDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XIEIZLIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14B„DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHr–xŲHsŠI|Hr–xŲHr²@HsnwHsŠI|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441264DV104412641044AąFWHITE DVšDWóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZGMKN9Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1044Potential ReVax Initial Contact NO Non-Important2021-07-08BÖDWÅ YYPhase 3A@ . . .N. A12-15 YearsNAąHržUäHsórDHržUäHr¹¶¤HsĪÉäHsórDPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÅYC4591001C4591001 1044 10441264DV104412641044AąFWHITE DVšDWóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZJNOUXVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1044V102_VAX4 NO Non-Important2021-08-23C@DWó YYPhase 3A@ . . .N. A12-15 YearsNAąHržUäHsórDHržUäHr¹¶¤HsĪÉäHsórDPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÅYC4591001C4591001 1044 10441265DV104412651044AąMWHITE DVšDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XF78UNIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-19B¤DW“ YYPhase 3A@ . . .N. A12-15 YearsNAąHrž^HsĆ°Hrž^Hr¹µšHsuųHsĆ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441266DV104412661044AąFWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YG8TBELab performed out of window Laboratory REPEAT SCREENING 1 1044SSWAB_WEEK4 NO Non-Important2021-06-01B°DW  YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŸ\(Hr¹ŅÄHrŸ\(Hr¹ŅÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1044 10441267DV104412671044AąMWHITE DVńDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XF78UKIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-19B£DW“ YYPhase 3A@ . . .N. A12-15 YearsNAąHrŸc0Hs©čHrŸc0Hr¹ØXHstķHHs©čPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441270DV104412701044AŠFNOT REPORTED DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4J85ROther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-08ADVń YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŸ’ˆHr½¬ŒHrŸ’ˆHr½¬Œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441270DV104412701044AŠFNOT REPORTED DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1X4410VRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1044Consent NO Non-Important2021-04-21B‡DWw YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŸ’ˆHr½¬ŒHrŸ’ˆHr½¬Œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441270DV104412701044AŠFNOT REPORTED DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1X44111Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1044Consent NO Non-Important2021-04-21B‡DWw YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŸ’ˆHr½¬ŒHrŸ’ˆHr½¬Œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441271DV104412711044AšFWHITE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1P4JVCXOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-08ADVń YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸøųHr¹šLHrŸøųHr¹šL..Placebo Placebo .DWYC4591001C4591001 1044 10441271DV104412711044AšFWHITE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z64ZDTReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1044V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-24BØDW˜ YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸøųHr¹šLHrŸøųHr¹šL..Placebo Placebo .DWYC4591001C4591001 1044 10441271DV104412711044AšFWHITE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z4VTNYReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1044V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-14B½DW­ YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸøųHr¹šLHrŸøųHr¹šL..Placebo Placebo .DWYC4591001C4591001 1044 10441275DV104412751044AĄFWHITE DVņDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XF78UHIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17B DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr ”“Hs‹pHr ”“Hr»pHsr`ČHs‹pPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441276DV104412761044AąMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PF863AVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1044V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-25B0DW! YYPhase 3A@ . . .Y. A12-15 YearsNAąHr µdHr»`Hr µdHr»`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441277DV104412771044AšFWHITE DVņDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XF6VNYIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17B DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHr ŃüHs0Hr ŃüHrŗžˆHsr•üHs0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1044 10441278DV104412781044AŠFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YS04S1Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1044Consent NO Non-Important2021-04-21B†DWw YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr ŃHHr»H Hr ŃHHr»H ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441278DV104412781044AŠFWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YS04S7Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1044Consent NO Non-Important2021-04-21B†DWw YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr ŃHHr»H Hr ŃHHr»H ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441280DV104412801044AšMWHITE DVņDW8Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PFEZ97Other Informed Consent Informed Consent SCREENING 1044Consent NO Non-Important2020-10-29Ā)DVÉYNYPhase 3A@ . . .N. A12-15 YearsNAšHr”ØHrż!Hr”ØHrŗüäHrā…4Hrż!Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW"YC4591001C4591001 1044 10441281DV104412811044AšMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4JVE2Other Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-09ADVņ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr”Hr»pHr”Hr»p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441284DV104412841044AšMWHITE DVóDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X4I040Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-13B›DW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¢3lHsˆäLHr¢3lHr»4čHsm:lHsˆäLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWƒYC4591001C4591001 1044 10441285DV104412851044AšFWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4JVENOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-10ADVó YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¢@ČHr¼LüHr¢@ČHr¼Lü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1044 10441285DV104412851044AšFWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P9A3XZOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¢@ČHr¼LüHr¢@ČHr¼Lü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1044 10441286DV104412861044AšFWHITE DVōDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X5SA8QOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr£HģHs’ąHr£HģHr¼ ØHsrO¬Hs’ąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441286DV104412861044AšFWHITE DVōDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X5U5HWIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17BžDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHr£HģHs’ąHr£HģHr¼ ØHsrO¬Hs’ąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441288DV104412881044AĄFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YIQUTKVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044V4_MONTH6_L NO Non-Important2021-06-17BøDW° YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr©ęüHrÅøšHr©ęüHrÅøš..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441289DV104412891006AŠFWHITE DVłDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTLH1HVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1044V2_VAX2_L NO Non-Important2021-01-11BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŖ hHrĢ^€HrŖ hHrĢ^€..Placebo Placebo ..YC4591001C4591001 1044 10441292DV104412921044AšMWHITE DVśDWcPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA129890401IP documentation error – IP preparation form errors Investigational ProductOPEN LABEL TREATMENT1044Vax 4 NO Non-Important2021-04-01BjDWc YYPhase 3A@ . . .N. A12-15 YearsNAšHr«eHs5¼Hr«eHrÄI¬HsŲČHs5¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1044 10441293DV104412931044AĄMWHITE DVśDWŽPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X5U65HOther Informed Consent Informed Consent OPEN LABEL TREATMENT1044Consent NO Non-Important2021-05-14B•DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«štHsnœHr«štHrē€HsnœHsnœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441293DV104412931044AĄMWHITE DVśDWŽPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XI77XHIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14B•DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«štHsnœHr«štHrē€HsnœHsnœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441293DV104412931044AĄMWHITE DVśDWŽPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YBSBOMReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsOPEN LABEL TREATMENT1044V101_VAX3 YES-POP2,YES-POP3Important 2021-06-04BŖDW£ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«štHsnœHr«štHrē€HsnœHsnœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441293DV104412931044AĄMWHITE DVśDWŽPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YSDS0RVisit not done Visit Schedule OPEN LABEL TREATMENT1044V102_Vax4 NO Non-Important2021-06-07B­DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«štHsnœHr«štHrē€HsnœHsnœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441294DV104412941044AąMWHITE DVśDWŽPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X5U66MOther Informed Consent Informed Consent OPEN LABEL TREATMENT1044Consent NO Non-Important2021-05-14B•DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHr«š°HsnœTHr«š°HrēDHsnœTHsnœTPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441294DV104412941044AąMWHITE DVśDWŽPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XF6VNVIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14B•DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHr«š°HsnœTHr«š°HrēDHsnœTHsnœTPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441294DV104412941044AąMWHITE DVśDWŽPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YXG8J2Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsOPEN LABEL TREATMENT1044V101_VAX3 YES-POP2,YES-POP3Important 2021-06-04BŖDW£ YYPhase 3A@ . . .N. A12-15 YearsNAąHr«š°HsnœTHr«š°HrēDHsnœTHsnœTPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441294DV104412941044AąMWHITE DVśDWŽPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YSDS0VVisit not done Visit Schedule OPEN LABEL TREATMENT1044V102_VAX4 NO Non-Important2021-06-07B­DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAąHr«š°HsnœTHr«š°HrēDHsnœTHsnœTPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441295DV104412951044AĄMWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHJ07RNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1044SSWAB_WEEK10 NO Non-Important2021-07-11BĪDWČ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¬q`HrČ'¬Hr¬q`HrČ'¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441295DV104412951044AĄMWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZBK2CTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044V4_MONTH6_L NO Non-Important2021-07-26BŻDW× YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¬q`HrČ'¬Hr¬q`HrČ'¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441301DV104413011044AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZC5VQSSubject/LAR did not sign the ICD but gave verbal consent Informed Consent REPEAT SCREENING 1 1044Consent NO Non-Important2021-07-12BÄDWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr»;xHrÕilHr»;xHrÕil..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1044 10441302DV104413021044AąFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XF6VNRIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17BŒDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr»VäHsė@Hr»VäHr× øHsr‹čHsė@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441303DV104413031044AšMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P6MY0JOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-29ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHr»W\Hslõ„Hr»W\Hr× |HsN­ĢHslõ„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWrYC4591001C4591001 1044 10441303DV104413031044AšMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P6MY2NOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2020-12-29ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHr»W\Hslõ„Hr»W\Hr× |HsN­ĢHslõ„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWrYC4591001C4591001 1044 10441308DV104413081044AĄMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEWESTIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17B‹DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¼hąHsæxHr¼hąHrŲD¬Hsrp|HsæxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441309DV104413091044AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XSWW3XOther Informed Consent Informed Consent FOLLOW-UP 1044Consent NO Non-Important2021-04-29ByDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼t\HrՉLHr¼t\HrՉL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1044 10441312DV104413121044AąMWHITE DW DW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEWESQIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14BƒDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĀź”Hs‡bHHrĀź”HrąÄHsnv Hs‡bHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441315DV104413151044AąFWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XIIUESIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17B†DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆ(Hs8HrĆ(HrŽŻ”Hsrš4Hs8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441317DV104413171044AŠFWHITE DW DWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEWESNIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-19BˆDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĆ4¤Hs“8HrĆ4¤Hrį~šHsu“Hs“8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1044 10441318DV104413181044AąFBLACK OR AFRICAN AMERICAN DW DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEWESJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14B‚DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrÄ;`HsŠ0ąHrÄ;`HrŽ• Hsn_ÜHsŠ0ąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441319DV104413191044AĄMBLACK OR AFRICAN AMERICAN DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHJ07VNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1044SSWAB_WEEK14 NO Non-Important2021-08-01BŃDWŻ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÄ;œHrŽ•ÜHrÄ;œHrŽ•Ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441320DV104413201044AšMWHITE DW DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3HOIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14B‚DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄY`HsŠ(¬HrÄY`Hrß’Hsn}dHsŠ(¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441322DV104413221044AąMASIAN DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YBPIORSerology sample not collected Laboratory FOLLOW-UP 1044V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-02B9DWE YYPhase 3A@ . . .N. A12-15 YearsNAąHrÄ}“HrįŽ¤HrÄ}“HrįŽ¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWNYC4591001C4591001 1044 10441323DV104413231044AšMWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XIMI20Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17B…DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĖŒHs8LHrĖŒHrāøLHsršpHs8LPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441324DV104413241044AšFWHITE DW DW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3HLIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14B‚DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ©ÄHsˆ„HrÄ©ÄHrŽ”HsnŠHHsˆ„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441326DV104413261044AŠFWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3H8Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-19B†DW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrňäHsĮHrňäHrŽµ¼HsuäHsĮPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1044 10441327DV104413271044AšFWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3H5Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-19B†DW“ YYPhase 3A@ . . .N. A12-15 YearsNAšHrʼn HsĮXHrʼn HrŽµųHsuØHsĮXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1044 10441328DV104413281044AšFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHW9OHVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044SSWAB_WEEK12 NO Non-Important2021-08-03BŅDWß YYPhase 3A@ . . .Y. A12-15 YearsNAšHrśąHrßäPHrśąHrßäP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441329DV104413291044AĄFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZH2UOPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044V4_MONTH6_L NO Non-Important2021-08-10BŁDWę YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅøxHrį…HrÅøxHrį…..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441330DV104413301044AąFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3H2Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-19B†DW“ YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅĪDHsvhHrÅĪDHrįvHsuœHsvhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1044 10441331DV104413311044AĄMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4HDGOOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅķčHrįHrÅķčHrį..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441332DV104413321044AšMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4H28YOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-06ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrÅī$HsŠHČHrÅī$HrįXHsn~HsŠHČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441332DV104413321044AšMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XA5OHXIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÅī$HsŠHČHrÅī$HrįXHsn~HsŠHČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441333DV104413331044AŠMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZDT2QOther Informed Consent Informed Consent FOLLOW-UP 1044Consent NO Non-Important2021-02-26B4DWA YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÅż`Hrįq”HrÅż`Hrįq”..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441334DV104413341044AĄFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R25YIQVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1044V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-05B:DWH YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĘŲĄHrßįųHrĘŲĄHrßįų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441335DV104413351044AšFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4HS1AOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-07ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒ <HsŽ?(HrĒ <Hrä HssåœHsŽ?(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441335DV104413351044AšFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XEW3DXIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-18B„DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒ <HsŽ?(HrĒ <Hrä HssåœHsŽ?(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441335DV104413351044AšFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z39HM9Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1044COVID_A NO Non-Important2021-07-08B·DWÅ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒ <HsŽ?(HrĒ <Hrä HssåœHsŽ?(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441336DV104413361044AĄFASIAN DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHJ07YNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1044SSWAB_WEEK12 NO Non-Important2021-07-26BÉDW× YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĒ/“HrāŚ„HrĒ/“HrāŚ„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441337DV104413371044AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3DUIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-19B„DW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČ($Hs’hHrČ($HrćŪ(Hstā¼Hs’hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441338DV104413381044AŠFWHITE DWDW%Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4HS7ZOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-08ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČ($Hrćé°HrČ($Hrćé°..Placebo Placebo ..YC4591001C4591001 1044 10441339DV104413391044AšFASIAN DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4IE6BOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-08ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČyxHrä%tHrČyxHrä%t..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441340DV104413401044AŠMWHITE DWDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P9A429Other Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-08ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČzhHs†,HrČzhHrä&ÜHsmAtHs†,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441340DV104413401044AŠMWHITE DWDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X4I0PAIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-13B~DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČzhHs†,HrČzhHrä&ÜHsmAtHs†,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441341DV104413411044AąMWHITE DWDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XA5OC7Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-13B~DW YYPhase 3A@ . . .N. A12-15 YearsNAąHrČz¤Hs†hHrČz¤Hrä'THsmAtHs†hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441344DV104413441044AšMASIAN DWDWSPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1SSQJNGVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1044V102_VAX4 NO Non-Important2021-03-16BCDWS YYPhase 3A@ . . .N. A12-15 YearsNAšHrÉ{„Hs HrÉ{„Hrä LHr’ŖLHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW1YC4591001C4591001 1044 10441345DV104413451044AĄFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3DRIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17BDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrɌdHsģ0HrɌdHrāŌ0HsrC|Hsģ0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441346DV104413461044AĄMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4J31POther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-09ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrɋģHrā…¬HrɋģHrā…¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441348DV104413481044AŠMWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3DOIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17BDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrɖHsŠĢHrɖHrāĒÄHsr…ŠHsŠĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441350DV104413501044AšFASIAN DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4J39AOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-09ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrɝ€HrćųtHrɝ€Hrćųt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWuYC4591001C4591001 1044 10441350DV104413501044AšFASIAN DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1PG6OK3Participant randomized into incorrect age stratum in Impala Randomization VACCINATION 1044V1_DAY1_VAX1 NO Non-Important2021-01-09ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrɝ€HrćųtHrɝ€Hrćųt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWuYC4591001C4591001 1044 10441351DV104413511044AšMWHITE DWDWóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4J39WOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-10ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŹÉ¼Hsó» HrŹÉ¼HrčHsŁcōHsó» Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŚYC4591001C4591001 1044 10441351DV104413511044AšMWHITE DWDWóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZCT7M4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044SSWAB_WEEK10 NO Non-Important2021-07-29BÉDWŚ YYPhase 3A@ . . .N. A12-15 YearsNAšHrŹÉ¼Hsó» HrŹÉ¼HrčHsŁcōHsó» Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŚYC4591001C4591001 1044 10441353DV104413531044AŠFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBRT3RICD signed by subject/LAR had not received IRB/IEC approval Informed Consent REPEAT SCREENING 1 1044Consent NO Non-Important2021-07-29BÉDWŚ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŹĢHrč¬HrŹĢHrč¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441354DV104413541044AŠFWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3DLIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-19B‚DW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŹŻlHs‹čHrŹŻlHrćł HstāHs‹čPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441355DV104413551044AąFASIAN DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZAED6SOther Informed Consent Informed Consent REPEAT SCREENING 1 1044Consent NO Non-Important2021-07-28BČDWŁ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŹŻØHrćśHrŹŻØHrćś..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441356DV104413561044AĄMWHITE DWDW)Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZDSNTUReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1044V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14B}DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŹŽ˜Hré‚lHrŹŽ˜Hré‚l..Placebo Placebo ..YC4591001C4591001 1044 10441356DV104413561044AĄMWHITE DWDW)Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZDSNTRReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1044V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-04B’DW£ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŹŽ˜Hré‚lHrŹŽ˜Hré‚l..Placebo Placebo ..YC4591001C4591001 1044 10441356DV104413561044AĄMWHITE DWDW)Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZBRTAHICD signed by subject/LAR had not received IRB/IEC approval Informed Consent REPEAT SCREENING 1 1044Consent NO Non-Important2021-07-29BÉDWŚ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŹŽ˜Hré‚lHrŹŽ˜Hré‚l..Placebo Placebo ..YC4591001C4591001 1044 10441357DV104413571044AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P9NP45Other Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-10ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŹėøHsŽ?dHrŹėøHrääHssåŲHsŽ?dPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441357DV104413571044AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XEW3DIIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-18BDW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŹėøHsŽ?dHrŹėøHrääHssåŲHsŽ?dPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441358DV104413581044AąMASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4KWCQOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-10ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŹėHrēų¬HrŹėHrēų¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441358DV104413581044AąMASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WZ7WX7Other Informed Consent Informed Consent FOLLOW-UP 1044Consent NO Non-Important2021-03-05B7DWH YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŹėHrēų¬HrŹėHrēų¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441359DV104413591044AšFWHITE DWDW@BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1QZSEWUUrine pregnancy test not performed. Laboratory VACCINATION 1044V2_VAX2_L NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢLHsĶäHrĢLHsĶä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1044 10441359DV104413591044AšFWHITE DWDW@BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1QZ3TQEVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1044V2_VAX2_L NO Non-Important2021-02-25B.DW@ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢLHsĶäHrĢLHsĶä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1044 10441359DV104413591044AšFWHITE DWDW@BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZAED7OOther Informed Consent Informed Consent REPEAT SCREENING 1 1044Consent NO Non-Important2021-07-28BĒDWŁ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢLHsĶäHrĢLHsĶä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1044 10441360DV104413601044AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QZ3TQHVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1044V2_VAX2_L NO Non-Important2021-02-25B.DW@ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢHsŽCŲHrĢHsĪ HsrA$HsŽCŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441360DV104413601044AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3DFIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17BDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢHsŽCŲHrĢHsĪ HsrA$HsŽCŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441361DV104413611044AšMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMOHA4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044SSWAB_WEEK8 NO Non-Important2021-07-12B·DWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢ?THrź•HrĢ?THrź•..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441362DV104413621044AąMWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XIEISIIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-13B{DW YYPhase 3A@ . . .N. A12-15 YearsNAąHrĢODHsŠ5HrĢODHrźwXHsmKHsŠ5Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441363DV104413631044AŠFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4LJ88Other Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢ[tHsŠA„HrĢ[tHrčXHsnpHsŠA„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441363DV104413631044AŠFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XA5OC4Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-14B|DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢ[tHsŠA„HrĢ[tHrčXHsnpHsŠA„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441365DV104413651044AšFWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4LJC3Other Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢiHHs‡UÜHrĢiHHrée\Hsm&ųHs‡UÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441365DV104413651044AšFWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P4LJCJOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢiHHs‡UÜHrĢiHHrée\Hsm&ųHs‡UÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441365DV104413651044AšFWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XIIUEXIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-13B{DW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢiHHs‡UÜHrĢiHHrée\Hsm&ųHs‡UÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441366DV104413661044AšMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4LJCPOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢhŠHrée HrĢhŠHrée ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441366DV104413661044AšMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P4M1FPOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢhŠHrée HrĢhŠHrée ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441367DV104413671044AĄMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4M1FVOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĢz Hrź‡„HrĢz Hrź‡„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441367DV104413671044AĄMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P4M1H6Other Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĢz Hrź‡„HrĢz Hrź‡„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441368DV104413681044AšFWHITE DWDWaPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA130185201IP documentation error – IP preparation form errors Investigational ProductOPEN LABEL TREATMENT1044Vax 4 NO Non-Important2021-03-30BODWa YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢ‚ Hs39ŌHrĢ‚ Hrź¢“Hs`Hs39ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1044 10441369DV104413691044AĄMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4MDN4Other Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĢ†Hré{(HrĢ†Hré{(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441369DV104413691044AĄMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P4MDNAOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĢ†Hré{(HrĢ†Hré{(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441369DV104413691044AĄMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZB3T7EVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044SSWAB_WEEK12 NO Non-Important2021-07-15BŗDWĢ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĢ†Hré{(HrĢ†Hré{(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441369DV104413691044AĄMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZHW9OKVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044SSWAB_WEEK14 NO Non-Important2021-08-03BĶDWß YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĢ†Hré{(HrĢ†Hré{(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441370DV104413701044AšMWHITE DWDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4MDQ0Other Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢ…ąHs m$HrĢ…ąHrézģHs†@\Hs m$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441370DV104413701044AšMWHITE DWDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P4MDRAOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢ…ąHs m$HrĢ…ąHrézģHs†@\Hs m$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441372DV104413721044AŠMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4NM1COther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢ“HréTHrĢ“HréT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441373DV104413731044AąFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3D2Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17B~DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĶr\Hs1¼HrĶr\Hrė¾Hsr@4Hs1¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441374DV104413741044AšMWHITE DWDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4ME7UOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶ HsļˆPHrĶ Hré"ĢHsļˆPHsļˆPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1044 10441375DV104413751044AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBRTCCICD signed by subject/LAR had not received IRB/IEC approval Informed Consent REPEAT SCREENING 1 1044Consent NO Non-Important2021-07-29BĒDWŚ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ˜Hré/8HrĶ˜Hré/8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441376DV104413761044AšMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P4N756Other Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŌHré.üHrĶŌHré.ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1044 10441376DV104413761044AšMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1P4N75WOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŌHré.üHrĶŌHré.ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1044 10441376DV104413761044AšMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBRTE2ICD signed by subject/LAR had not received IRB/IEC approval Informed Consent REPEAT SCREENING 1 1044Consent NO Non-Important2021-07-29BĒDWŚ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŌHré.üHrĶŌHré.ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1044 10441377DV104413771044AĄFWHITE DW(DW=BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1QVZNTNVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1044V2_VAX2_L NO Non-Important2021-02-22BDW= YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrēłœHsĒŠHrēłœHsĒŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441377DV104413771044AĄFWHITE DW(DW=BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2HKNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1044SSWAB_WEEK10 NO Non-Important2021-07-04BšDWĮ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrēłœHsĒŠHrēłœHsĒŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441377DV104413771044AĄFWHITE DW(DW=BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z6W3DNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1044SSWAB_WEEK8 NO Non-Important2021-07-14B¤DWĖ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrēłœHsĒŠHrēłœHsĒŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441378DV104413781044AĄFWHITE DWDW+BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4MZWXOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĶŖ$HrģĢHrĶŖ$HrģĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441378DV104413781044AĄFWHITE DWDW+BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P4MZXNOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĶŖ$HrģĢHrĶŖ$HrģĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441380DV104413801044AŠMWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4MZYOOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĶĀ„Hsˆń0HrĶĀ„HrźŹŒHsm'pHsˆń0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441380DV104413801044AŠMWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XEW3CZIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-13BzDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĶĀ„Hsˆń0HrĶĀ„HrźŹŒHsm'pHsˆń0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441381DV104413811044AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4NLRNOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĶĆ°Hs“pˆHrĶĆ°HrēįxHsr“,Hs“pˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441381DV104413811044AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XIEIS9Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-17B~DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĶĆ°Hs“pˆHrĶĆ°HrēįxHsr“,Hs“pˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441381DV104413811044AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Y55S3IVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1044V102_VAX4 NO Non-Important2021-06-11B—DWŖ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĶĆ°Hs“pˆHrĶĆ°HrēįxHsr“,Hs“pˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1044 10441382DV104413821044AŠFWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P4NLVPOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĶ×ŲHs‡HrĶ×ŲHrźµ8HsmMhHs‡Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441382DV104413821044AŠFWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P4NLWFOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĶ×ŲHs‡HrĶ×ŲHrźµ8HsmMhHs‡Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441382DV104413821044AŠFWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XI77XLIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-13BzDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĶ×ŲHs‡HrĶ×ŲHrźµ8HsmMhHs‡Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441383DV104413831044AąMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P4NLWLOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĶלHrź“üHrĶלHrź“ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441383DV104413831044AąMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P4NLXVOther Informed Consent Informed Consent VACCINATION 1044Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĶלHrź“üHrĶלHrź“ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441383DV104413831044AąMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZCT7MRVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 104429-Jul-21 NO Non-Important2021-07-29BĒDWŚ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĶלHrź“üHrĶלHrź“ü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1044 10441384DV104413841044AŠMWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEW3CVIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1044V101_VAX3 NO Non-Important2021-05-20BDW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĶŲČHs‡ HrĶŲČHrģģHsvvĢHs‡ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571376DV105713761057AŠMWHITE DVšDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OJOITMOther Informed Consent Informed Consent VACCINATION 1057Consent NO Non-Important2021-01-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrżÄHrĆ<HrżÄHrĆ<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571376DV105713761057AŠMWHITE DVšDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OTLT2ZVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrżÄHrĆ<HrżÄHrĆ<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571379DV105713791057AąFASIAN DVšDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z3S3JRVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1057SSWAB_WEEK12 NO Non-Important2021-07-06BŌDWĆ YYPhase 3A@ . . .N. A12-15 YearsNAąHržP¼HsŠdHržP¼Hr¼ŖDHsmHøHsŠdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571380DV105713801057AŠFWHITE DVńDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTLT32Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŸDHrĀŠHrŸDHrĀŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571382DV105713821057AŠFBLACK OR AFRICAN AMERICAN DVńDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTLT35Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŸ¢HrÄ6tHrŸ¢HrÄ6t..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571383DV105713831057AąFWHITE DVńDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y55S3LVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057V102_VAX4 NO Non-Important2021-06-11BŗDWŖ YYPhase 3A@ . . .N. A12-15 YearsNAąHrŸ™Hs“GĄHrŸ™Hr¼`HsrHs“GĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571388DV105713881057AąMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PFBCGFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-03B9DW* YYPhase 3A@ . . .Y. A12-15 YearsNAąHr ÕHr¹±|Hr ÕHr¹±|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571388DV105713881057AąMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z3S3JUVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057SSWAB_WEEK12 NO Non-Important2021-07-07BÓDWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr ÕHr¹±|Hr ÕHr¹±|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571388DV105713881057AąMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z7HZD4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-07-12BŲDWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr ÕHr¹±|Hr ÕHr¹±|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571389DV105713891057AĄFWHITE DVņDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OTLT38Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr Ö4HrĆ<ŲHr Ö4HrĆ<Ų..Placebo Placebo .DWYC4591001C4591001 1057 10571389DV105713891057AĄFWHITE DVņDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z7FGZ7Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1057V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-23B¦DW— YYPhase 3A@ . . .N. A12-15 YearsNAĄHr Ö4HrĆ<ŲHr Ö4HrĆ<Ų..Placebo Placebo .DWYC4591001C4591001 1057 10571389DV105713891057AĄFWHITE DVņDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z7FGZAReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1057V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-12BŗDW« YYPhase 3A@ . . .N. A12-15 YearsNAĄHr Ö4HrĆ<ŲHr Ö4HrĆ<Ų..Placebo Placebo .DWYC4591001C4591001 1057 10571391DV105713911057AšMWHITE DVņDWTPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QYIC26Procedure/Test not performed per protocol Procedures/Tests OPEN LABEL TREATMENT1057V101_VAX3 NO Non-Important2021-02-24BNDW? YYPhase 3A@ . . .N. A12-15 YearsNAšHr Ū˜Hs"@Hr Ū˜Hr¹čĢHsgˆHs"@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1057 10571391DV105713911057AšMWHITE DVņDWTPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1UCOGATVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057COVID_A1 NO Non-Important2021-04-07BxDWi YYPhase 3A@ . . .N. A12-15 YearsNAšHr Ū˜Hs"@Hr Ū˜Hr¹čĢHsgˆHs"@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1057 10571394DV105713941057AšFWHITE DVņDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XIHFPAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1057Consent NO Non-Important2021-05-17B DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAšHr óDHs‰ÜHr óDHr».XHsr‡8Hs‰ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571395DV105713951057AŠFBLACK OR AFRICAN AMERICAN DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1OTC13WVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-14B%DW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr õ$HrŠeĄHr õ$HrŠeĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571395DV105713951057AŠFBLACK OR AFRICAN AMERICAN DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1OS3079Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-14B%DW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr õ$HrŠeĄHr õ$HrŠeĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571395DV105713951057AŠFBLACK OR AFRICAN AMERICAN DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QYVAY5Other Informed Consent Informed Consent FOLLOW-UP 1057Consent NO Non-Important2021-02-17BGDW8 YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr õ$HrŠeĄHr õ$HrŠeĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571395DV105713951057AŠFBLACK OR AFRICAN AMERICAN DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIMKN3Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK18 NO Non-Important2021-07-04BŠDWĮ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr õ$HrŠeĄHr õ$HrŠeĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571396DV105713961057AŠMBLACK OR AFRICAN AMERICAN DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OTMNKTVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¢+8Hr¹ŻŒHr¢+8Hr¹ŻŒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571396DV105713961057AŠMBLACK OR AFRICAN AMERICAN DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1PPEUYFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057COVID_A1 NO Non-Important2021-02-11B@DW2 YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¢+8Hr¹ŻŒHr¢+8Hr¹ŻŒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571396DV105713961057AŠMBLACK OR AFRICAN AMERICAN DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z7WAR7Nasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK14 NO Non-Important2021-07-06BŃDWĆ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¢+8Hr¹ŻŒHr¢+8Hr¹ŻŒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571396DV105713961057AŠMBLACK OR AFRICAN AMERICAN DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z3S3JXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057SSWAB_WEEK14 NO Non-Important2021-07-06BŃDWĆ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¢+8Hr¹ŻŒHr¢+8Hr¹ŻŒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571398DV105713981057AąMWHITE DVóDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSGB35Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057V102_VAX4 NO Non-Important2021-06-03B°DW¢ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¢A|Hsˆ×hHr¢A|Hr¼{(HsrjÜHsˆ×hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571399DV105713991057AĄMWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R1TIWJNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1057COVID_A NO Non-Important2021-02-08B=DW/ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¢E“Hr»>HHr¢E“Hr»>H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571400DV105714001057AŠMBLACK OR AFRICAN AMERICAN DVōDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QAG8QGNasal swab not collected for the visit where it is required Laboratory VACCINATION 1057COVID_A NO Non-Important2021-01-19B(DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£G„HsŽ/ģHr£G„Hr¼5ČHsrn`HsŽ/ģPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571400DV105714001057AŠMBLACK OR AFRICAN AMERICAN DVōDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZJNOV0Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1057V103_MONTH1 NO Non-Important2021-08-04BķDWą YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£G„HsŽ/ģHr£G„Hr¼5ČHsrn`HsŽ/ģPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571401DV105714011057AŠFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OJNEENOther Informed Consent Informed Consent VACCINATION 1057Consent NO Non-Important2020-12-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr£ZHr¼~čHr£ZHr¼~č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571401DV105714011057AŠFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YY0VE6Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-06-14BŗDW­ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr£ZHr¼~čHr£ZHr¼~č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571402DV105714021057AšFWHITE DV÷DW[Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R0XBYWProcedure/Test not performed per protocol Procedures/Tests OPEN LABEL TREATMENT1057V101_VAX3 NO Non-Important2021-03-03BPDWF YYPhase 3A@ . . .N. A12-15 YearsNAšHr§†PHs+XĢHr§†PHrÅÅ HsÆdHs+XĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1057 10571404DV105714041057AŠFWHITE DVłDWŅPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OTBWAQVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr©åXHsČ&čHr©åXHrĆ'ĄHs©ŻHsČ&čPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1057 10571404DV105714041057AŠFWHITE DVłDWŅPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1POJ18UProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1057V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-16B?DW7 YYPhase 3A@ . . .N. A12-15 YearsNAŠHr©åXHsČ&čHr©åXHrĆ'ĄHs©ŻHsČ&čPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1057 10571404DV105714041057AŠFWHITE DVłDWŅPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1QW7RLAVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-16B?DW7 YYPhase 3A@ . . .N. A12-15 YearsNAŠHr©åXHsČ&čHr©åXHrĆ'ĄHs©ŻHsČ&čPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1057 10571404DV105714041057AŠFWHITE DVłDWŅPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZIM2M3Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1057SSWAB_WEEK6 NO Non-Important2021-04-13BwDWo YYPhase 3A@ . . .N. A12-15 YearsNAŠHr©åXHsČ&čHr©åXHrĆ'ĄHs©ŻHsČ&čPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1057 10571408DV105714081057AąMWHITE DVśDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XIHFRVOther Informed Consent Informed Consent OPEN LABEL TREATMENT1057Consent NO Non-Important2021-05-25B DW™ YYPhase 3A@ . . .N. A12-15 YearsNAąHr«dČHsšhHr«dČHrăHs}ĄHsšhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571408DV105714081057AąMWHITE DVśDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 132107401IP documentation error – IP preparation form errors Investigational ProductOPEN LABEL TREATMENT1057Vax 3 NO Non-Important2021-05-25B DW™ YYPhase 3A@ . . .N. A12-15 YearsNAąHr«dČHsšhHr«dČHrăHs}ĄHsšhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571409DV105714091057AĄMWHITE DVśDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2M6Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK12 NO Non-Important2021-06-13B³DW¬ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«]üHrĄHr«]üHrĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571411DV105714111057AšFWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV7391Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-06-25BæDWø YYPhase 3A@ . . .Y. A12-15 YearsNAšHr«ŲHrÅĄHr«ŲHrÅĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571412DV105714121057AŠMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1XSGB38Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057SSWAB_WEEK2 NO Non-Important2021-04-29B†DW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr«‚HrÅüHr«‚HrÅü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571412DV105714121057AŠMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XSHVNPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057SSWAB_WEEK4 NO Non-Important2021-05-28B£DWœ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr«‚HrÅüHr«‚HrÅü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571412DV105714121057AŠMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIM2M9Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK6 NO Non-Important2021-06-15BµDW® YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr«‚HrÅüHr«‚HrÅü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571412DV105714121057AŠMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZB3T7UVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-07-21BŁDWŅ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr«‚HrÅüHr«‚HrÅü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571413DV105714131057AŠMWHITE ..BNT162b2 Phase 2/3 (30 mcg)B2_P23_30Not Treated NOTTRT BNT162b2 Phase 2/3 (30 mcg) A€.12-15 YearsAA1-1QYDAN9Randomization done out of sequence Randomization SCREENING 1057V1_DAY1_VAX1_L NO Non-Important2020-12-21ADVž NYPhase 3A@ . . .N. A12-15 YearsNAŠ...... ..NC4591001C4591001 1057 10571414DV105714141057AšFMULTIPLE DVžDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1TVTP2UVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057COVID_A1 NO Non-Important2021-03-26B`DW] YYPhase 3A@ . . .N. A12-15 YearsNAšHr°“ HrĶŗPHr°“ HrĶŗP..Placebo Placebo ..YC4591001C4591001 1057 10571415DV105714151057AąFWHITE DVžDWĘPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OQ3W62Subject/LAR signed consent but did not date it Informed Consent VACCINATION 1057Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAąHr°µHsø1 Hr°µHrŠ]PHsˆŲXHsø1 Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571415DV105714151057AąFWHITE DVžDWĘPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS307CVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr°µHsø1 Hr°µHrŠ]PHsˆŲXHsø1 Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571415DV105714151057AąFWHITE DVžDWĘPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ROCW9BVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-12BRDWO YYPhase 3A@ . . .N. A12-15 YearsNAąHr°µHsø1 Hr°µHrŠ]PHsˆŲXHsø1 Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571415DV105714151057AąFWHITE DVžDWĘPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Z7HZD8Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057V102_VAX4 NO Non-Important2021-07-09BÉDWĘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr°µHsø1 Hr°µHrŠ]PHsˆŲXHsø1 Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571416DV105714161057AąMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1U10WZ0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-19BYDWV YYPhase 3A@ . . .Y. A12-15 YearsNAąHr°¶ųHrĻ(Hr°¶ųHrĻ(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571416DV105714161057AąMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1TB0ZMOVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-21B[DWX YYPhase 3A@ . . .Y. A12-15 YearsNAąHr°¶ųHrĻ(Hr°¶ųHrĻ(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571417DV105714171057AąFWHITE DVžDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QW7RLDVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-16B:DW7 YYPhase 3A@ . . .N. A12-15 YearsNAąHr°øŲHs—aĄHr°øŲHrĢiüHsrxģHs—aĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571417DV105714171057AąFWHITE DVžDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1V9SP86Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1057COVID_A NO Non-Important2021-04-08BmDWj YYPhase 3A@ . . .N. A12-15 YearsNAąHr°øŲHs—aĄHr°øŲHrĢiüHsrxģHs—aĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571417DV105714171057AąFWHITE DVžDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X5VTP1Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057COVID_A1 NO Non-Important2021-05-17B”DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAąHr°øŲHs—aĄHr°øŲHrĢiüHsrxģHs—aĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571417DV105714171057AąFWHITE DVžDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YV7395Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057V102_VAX4 NO Non-Important2021-06-14B°DW­ YYPhase 3A@ . . .N. A12-15 YearsNAąHr°øŲHs—aĄHr°øŲHrĢiüHsrxģHs—aĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571418DV105714181057AąFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OSO0CPVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr²ÄHrĢWxHr²ÄHrĢWx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571419DV105714191057AąMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QW99BDVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-16B9DW7 YYPhase 3A@ . . .Y. A12-15 YearsNAąHr² ¤HrĢ3œHr² ¤HrĢ3œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571420DV105714201057AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTC5PEVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2020-12-23ADW YYPhase 3A@ . . .N. A12-15 YearsNAąHr³¼HrĢ24Hr³¼HrĢ24..Placebo Placebo ..YC4591001C4591001 1057 10571422DV105714221057AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OSE3Z2Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr³^ØHrĻ Hr³^ØHrĻ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571422DV105714221057AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZCK4QProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1057V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-10B2DW1 YYPhase 3A@ . . .Y. A12-15 YearsNAąHr³^ØHrĻ Hr³^ØHrĻ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571423DV105714231057AšMBLACK OR AFRICAN AMERICAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YGVR68Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1057COVID_A NO Non-Important2021-04-28B~DW~ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr“[HrŃ`ÄHr“[HrŃ`Ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571426DV105714261057AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1T4K572Nasal swab not collected for the visit where it is required Laboratory VACCINATION 1057COVID_A NO Non-Important2021-01-04AĄDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr“phHrŁ¢ Hr“phHrŁ¢ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571426DV105714261057AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1PFBCGJVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr“phHrŁ¢ Hr“phHrŁ¢ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571426DV105714261057AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1R0XW3CSerology sample not collected Laboratory FOLLOW-UP 1057V201_SURVEIL_CONSENT NO Non-Important2021-03-03BFDWF YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr“phHrŁ¢ Hr“phHrŁ¢ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571427DV105714271057AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R1TIWMNasal swab not collected for the visit where it is required Laboratory VACCINATION 1057COVID_A NO Non-Important2021-01-04AĄDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr“qŠHrŁ |Hr“qŠHrŁ |..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571427DV105714271057AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1P99Q83Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr“qŠHrŁ |Hr“qŠHrŁ |..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571427DV105714271057AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIMKLANasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK10 NO Non-Important2021-05-17B‘DW‘ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr“qŠHrŁ |Hr“qŠHrŁ |..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571427DV105714271057AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZHFDYBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-08-02BŽDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr“qŠHrŁ |Hr“qŠHrŁ |..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571428DV105714281057AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PFBUHTVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr“uHrŁ¢ Hr“uHrŁ¢ ..Placebo Placebo .DWYC4591001C4591001 1057 10571428DV105714281057AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P85LUEVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1057COVID_A1 NO Non-Important2021-02-03B*DW* YYPhase 3A@ . . .N. A12-15 YearsNAąHr“uHrŁ¢ Hr“uHrŁ¢ ..Placebo Placebo .DWYC4591001C4591001 1057 10571428DV105714281057AąMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZHW9ONVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-08-02BŽDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHr“uHrŁ¢ Hr“uHrŁ¢ ..Placebo Placebo .DWYC4591001C4591001 1057 10571429DV105714291057AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1PFBUHWVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr“v€HrŁ Hr“v€HrŁ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571429DV105714291057AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKLDNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK10 NO Non-Important2021-05-17B‘DW‘ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr“v€HrŁ Hr“v€HrŁ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571429DV105714291057AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHFDYFVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-08-02BŽDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr“v€HrŁ Hr“v€HrŁ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571431DV105714311057AŠMWHITE DWDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YY0VE9Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057V102_VAX4 NO Non-Important2021-06-21B®DW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼…<Hs „ÜHr¼…<HrՊ“Hsµ„Hs „ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571432DV105714321057AĄFWHITE DWDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PG5AYAVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1057COVID_A1 NO Non-Important2021-02-11B,DW2 YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¼ˆ„Hs†N0Hr¼ˆ„HrÕØxHsm7œHs†N0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571434DV105714341057AŠMMULTIPLE DWDW¼Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PPEV1AVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057COVID_A1 NO Non-Important2021-02-18B2DW9 YYPhase 3A@ . . .N. A12-15 YearsNAŠHr½Ŗ4Hs«¤Hr½Ŗ4HrŁ–ąHs‘ńHs«¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571434DV105714341057AŠMMULTIPLE DWDW¼Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YGVRK7Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057COVID_B NO Non-Important2021-05-13B†DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr½Ŗ4Hs«¤Hr½Ŗ4HrŁ–ąHs‘ńHs«¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571436DV105714361057AąFBLACK OR AFRICAN AMERICAN DW DWķPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZU7VTAOther Informed Consent Informed Consent REPEAT SCREENING 1 1057Consent NO Non-Important2021-07-21BĒDWŅ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆČHsėŃģHrĆČHrŽ‹PHsÉ>ĄHsėŃģPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWµYC4591001C4591001 1057 10571436DV105714361057AąFBLACK OR AFRICAN AMERICAN DW DWķPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 133628501IP documentation error – IP preparation form errors Investigational ProductOPEN LABEL TREATMENT1057Vax 3 NO Non-Important2021-07-22BČDWÓ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆČHsėŃģHrĆČHrŽ‹PHsÉ>ĄHsėŃģPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWµYC4591001C4591001 1057 10571436DV105714361057AąFBLACK OR AFRICAN AMERICAN DW DWķPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZHW9OQVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057V102_VAX4 NO Non-Important2021-08-17BāDWķ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆČHsėŃģHrĆČHrŽ‹PHsÉ>ĄHsėŃģPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWµYC4591001C4591001 1057 10571437DV105714371057AšMWHITE DW DWęPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZU6STVOther Informed Consent Informed Consent REPEAT SCREENING 1 1057Consent NO Non-Important2021-07-19BÅDWŠ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĆ6„HsāRHHrĆ6„HrŽŽüHsĘŻ$HsāRHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1057 10571438DV105714381057AŠFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WNXXHAVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057SSWAB_WEEK2 NO Non-Important2021-04-06B]DWh YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ9HrŽŽ HrĆ9HrŽŽ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1057 10571438DV105714381057AŠFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKLGNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1057SSWAB_WEEK6 NO Non-Important2021-05-10BDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ9HrŽŽ HrĆ9HrŽŽ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1057 10571440DV105714401057AĄMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z8JZNEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-07-19BĆDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅ×hHrįqHrÅ×hHrįq..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571441DV105714411057AŠMASIAN DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P9Y0UZVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-27BDW# YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅŚģHsēŒHrÅŚģHrį~xHsu.čHsēŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571441DV105714411057AŠMASIAN DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X5XE3DVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057COVID_A1 NO Non-Important2021-05-19B†DW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅŚģHsēŒHrÅŚģHrį~xHsu.čHsēŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571442DV105714421057AŠMBLACK OR AFRICAN AMERICAN DWDWÓPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P9Y0X2Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2021-01-29BDW% YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĘē„HsÉ:HrĘē„Hrćģ€Hs€ĆüHsÉ:Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571442DV105714421057AŠMBLACK OR AFRICAN AMERICAN DWDWÓPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA133628701IP documentation error – IP preparation form errors Investigational ProductOPEN LABEL TREATMENT1057Vax 4 NO Non-Important2021-07-22BÅDWÓ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĘē„HsÉ:HrĘē„Hrćģ€Hs€ĆüHsÉ:Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571442DV105714421057AŠMBLACK OR AFRICAN AMERICAN DWDWÓPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZCT7NUVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1057V102_VAX4 NO Non-Important2021-07-22BÅDWÓ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĘē„HsÉ:HrĘē„Hrćģ€Hs€ĆüHsÉ:Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571443DV105714431057AĄFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKMONasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK12 NO Non-Important2021-06-06B–DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČ7œHrāĆČHrČ7œHrāĆČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571443DV105714431057AĄFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHW9OTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-08-11BŲDWē YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČ7œHrāĆČHrČ7œHrāĆČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571444DV105714441057AąFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKMRNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK12 NO Non-Important2021-06-06B–DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrČ9@HrāĘ\HrČ9@HrāĘ\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571444DV105714441057AąFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHW9OWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057V4_MONTH6_L NO Non-Important2021-08-11BŲDWē YYPhase 3A@ . . .Y. A12-15 YearsNAąHrČ9@HrāĘ\HrČ9@HrāĘ\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571445DV105714451057AšMWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKMUNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK6 NO Non-Important2021-05-04BrDW„ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢ(ŌHrēäüHrĢ(ŌHrēäü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW|YC4591001C4591001 1057 10571446DV105714461057AŠFWHITE DWDW(Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PAG7MWVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2021-02-01BDW( YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢVˆHrčLHrĢVˆHrčL..Placebo Placebo ..YC4591001C4591001 1057 10571447DV105714471057AšMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PAGL3FVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2021-02-01BDW( YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢuxHsÖ HrĢuxHrčlHssŁØHsÖ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571447DV105714471057AšMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZMOHIDVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057SSWAB_WEEK8 NO Non-Important2021-05-10BxDWŠ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢuxHsÖ HrĢuxHrčlHssŁØHsÖ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571448DV105714481057AŠFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1PAGL3IVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1057V2_VAX2_L NO Non-Important2021-02-01BDW( YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢw”HrčØHrĢw”HrčØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571448DV105714481057AŠFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YV739LVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1057SSWAB_WEEK8 NO Non-Important2021-05-10BxDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢw”HrčØHrĢw”HrčØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571448DV105714481057AŠFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YV7398Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057SSWAB_WEEK12 NO Non-Important2021-06-14B›DW­ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢw”HrčØHrĢw”HrčØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571448DV105714481057AŠFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKN6Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK14 NO Non-Important2021-07-02B­DWæ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢw”HrčØHrĢw”HrčØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571451DV105714511057AĄFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YGVRKANasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057COVID_A NO Non-Important2021-05-14B{DWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĶ©4HréTHrĶ©4HréT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571451DV105714511057AĄFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YY0VECVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057SSWAB_WEEK10 NO Non-Important2021-06-14BšDW­ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĶ©4HréTHrĶ©4HréT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571451DV105714511057AĄFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z9VJWFVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1057SSWAB_WEEK12 NO Non-Important2021-07-15B¹DWĢ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĶ©4HréTHrĶ©4HréT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571452DV105714521057AĄFWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKMXNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK12 NO Non-Important2021-06-15B›DW® YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĶŖ`Hrź“HHrĶŖ`Hrź“H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571453DV105714531057AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P9Y0NXNasal swab not collected for the visit where it is required Laboratory VACCINATION 1057V2_VAX2_L NO Non-Important2021-02-01BDW( YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĶæHsŽøHrĶæHrč ŌHsr‰HsŽøPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1057 10571454DV105714541057AŠFWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA127406501IP documentation error - Confirmation of blind error Investigational ProductVACCINATION 1057Vax 2 NO Non-Important2021-02-03BDW* YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ¾ˆHrź®lHrĶ¾ˆHrź®l..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1057 10571454DV105714541057AŠFWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIMKN0Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1057SSWAB_WEEK12 NO Non-Important2021-06-11B—DWŖ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ¾ˆHrź®lHrĶ¾ˆHrź®l..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1066 10661394DV106613941066AąMWHITE DVņDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OCQ6GOVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1066V1_DAY1_VAX1_L NO Non-Important2020-12-09ADVņ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ©4Hs˜£Hr ©4Hr¼]dHssq\Hs˜£Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661394DV106613941066AąMWHITE DVņDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UCYA9VOther Informed Consent Informed Consent VACCINATION 1066Consent NO Non-Important2020-12-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr ©4Hs˜£Hr ©4Hr¼]dHssq\Hs˜£Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661394DV106613941066AąMWHITE DVņDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZKZNV8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066SSWAB_WEEK14 NO Non-Important2021-05-16BŸDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr ©4Hs˜£Hr ©4Hr¼]dHssq\Hs˜£Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661394DV106613941066AąMWHITE DVņDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X6A31BOther Informed Consent Informed Consent OPEN LABEL TREATMENT1066Consent NO Non-Important2021-05-18B”DW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr ©4Hs˜£Hr ©4Hr¼]dHssq\Hs˜£Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661394DV106613941066AąMWHITE DVņDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1YBECEPVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1066V102_VAX4 NO Non-Important2021-06-15B½DW® YYPhase 3A@ . . .N. A12-15 YearsNAąHr ©4Hs˜£Hr ©4Hr¼]dHssq\Hs˜£Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661395DV106613951066AĄMWHITE DVźDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YM0M5HVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066SSWAB_WEEK12 NO Non-Important2021-05-13B¤DW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr–LČHr° Hr–LČHr° ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661395DV106613951066AĄMWHITE DVźDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YM0M5KVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1066SSWAB_WEEK16 NO Non-Important2021-06-15BÅDW® YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr–LČHr° Hr–LČHr° ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661397DV106613971066AąMWHITE DVźDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS307ZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-18B1DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr–tdHs¢ąHr–tdHr²¼HstČHs¢ąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661401DV106614011066AąMWHITE DVėDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OJPYDLOther Informed Consent Informed Consent VACCINATION 1066Consent NO Non-Important2020-12-21BDVž YYPhase 3A@ . . .N. A12-15 YearsNAąHr—£pHsŃxHr—£pHr°«øHsu)üHsŃxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661401DV106614011066AąMWHITE DVėDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1R2N1FBOther Informed Consent Informed Consent FOLLOW-UP 1066Consent NO Non-Important2021-03-03B\DWF YYPhase 3A@ . . .N. A12-15 YearsNAąHr—£pHsŃxHr—£pHr°«øHsu)üHsŃxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661401DV106614011066AąMWHITE DVėDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1R2N12MLab performed out of window Laboratory FOLLOW-UP 1066SSWAB_WEEK2 NO Non-Important2021-03-10BcDWM YYPhase 3A@ . . .N. A12-15 YearsNAąHr—£pHsŃxHr—£pHr°«øHsu)üHsŃxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661401DV106614011066AąMWHITE DVėDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WNXXHDVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066V202_SURVEIL_SWAB|637091580454060NO Non-Important2021-03-31BxDWb YYPhase 3A@ . . .N. A12-15 YearsNAąHr—£pHsŃxHr—£pHr°«øHsu)üHsŃxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661402DV106614021066AąFWHITE DVėDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R069XLOther Informed Consent Informed Consent FOLLOW-UP 1066Consent NO Non-Important2021-03-02B[DWE YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—Æ(Hr°»ØHr—Æ(Hr°»Ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661403DV106614031066AąMWHITE DVģDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P17VXSVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-28B9DW$ YYPhase 3A@ . . .N. A12-15 YearsNAąHr˜ĘLHs€äHr˜ĘLHr³<Hss©`Hs€äPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661403DV106614031066AąMWHITE DVģDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X6A31MOther Informed Consent Informed Consent OPEN LABEL TREATMENT1066Consent NO Non-Important2021-05-18B§DW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr˜ĘLHs€äHr˜ĘLHr³<Hss©`Hs€äPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661404DV106614041066AĄFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P2Q1X6Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-28B9DW$ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜ĘHr³xHr˜ĘHr³x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661404DV106614041066AĄFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R2N1BTOther Informed Consent Informed Consent FOLLOW-UP 1066Consent NO Non-Important2021-03-04B\DWG YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜ĘHr³xHr˜ĘHr³x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661407DV106614071066AšFWHITE DVķDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OJPYE0Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1066V2_VAX2_L NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrš ŲHr±ÆhHrš ŲHr±Æh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661409DV106614091066AĄMWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P2QYJIOther Informed Consent Informed Consent VACCINATION 1066Consent NO Non-Important2020-12-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŸ¢“Hr¹ŚDHrŸ¢“Hr¹ŚD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661410DV106614101066AŠFWHITE DVņDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P2QYVSOther Informed Consent Informed Consent VACCINATION 1066Consent NO Non-Important2020-12-29BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr ĶˆHsX,Hr ĶˆHr»CčHss°¤HsX,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661411DV106614111066AšMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OJPYEPOther Informed Consent Informed Consent VACCINATION 1066Consent NO Non-Important2020-12-29BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr ÷Hr»)lHr ÷Hr»)l..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW2YC4591001C4591001 1066 10661412DV106614121066AąFWHITE DVņDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z7JCRFVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1066V103_MONTH1 NO Non-Important2021-07-20BąDWŃ YYPhase 3A@ . . .N. A12-15 YearsNAąHr öŒHsĆtHr öŒHr»)0Hssi(HsĆtPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661412DV106614121066AąFWHITE DVņDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z8JZNRVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1066V103_MONTH1 NO Non-Important2021-07-20BąDWŃ YYPhase 3A@ . . .N. A12-15 YearsNAąHr öŒHsĆtHr öŒHr»)0Hssi(HsĆtPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661414DV106614141066AšMWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZMOHJNVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066SSWAB_WEEK10 NO Non-Important2021-05-24B¢DW˜ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§(HrĀū°Hr§(HrĀū°..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1066 10661415DV106614151066AąFWHITE DV÷DW×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1RU8TTOOther Informed Consent Informed Consent FOLLOW-UP 1066Consent NO Non-Important2021-03-08BUDWK YYPhase 3A@ . . .N. A12-15 YearsNAąHr§HHsĪˆHr§HHrĀūtHs²ŌPHsĪˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1066 10661415DV106614151066AąFWHITE DV÷DW×Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZMOHJQVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066SSWAB_WEEK10 NO Non-Important2021-05-26B¤DWš YYPhase 3A@ . . .N. A12-15 YearsNAąHr§HHsĪˆHr§HHrĀūtHs²ŌPHsĪˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1066 10661417DV106614171066AĄMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHU0P6Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1066V4_MONTH6_L NO Non-Important2021-08-18BöDWī YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖDHrÅĢ HrŖDHrÅĢ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661418DV106614181066AąMWHITE DVłDW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YLIKXXVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1066V102_VAX4 NO Non-Important2021-06-17BøDW° YYPhase 3A@ . . .N. A12-15 YearsNAąHrŖlHs› \HrŖlHrÄ{ HsvgHs› \Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661419DV106614191066AąFMULTIPLE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z7HZDBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1066V4_MONTH6_L NO Non-Important2021-07-19BŲDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŖ&€HrÅ·ˆHrŖ&€HrÅ·ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661421DV106614211066AąMWHITE DV’DW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z6GSJBVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1066V102_VAX4 NO Non-Important2021-06-17B²DW° YYPhase 3A@ . . .N. A12-15 YearsNAąHr±ĆTHs›œHr±ĆTHrĪ½Hstõ@Hs›œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661423DV106614231066AąMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P17W3SVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1066V2_VAX2_L NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼/°Hs—BHr¼/°HrßĪHHsu!PHs—BPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1066 10661423DV106614231066AąMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YBECESVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1066V102_VAX4 NO Non-Important2021-06-14B§DW­ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼/°Hs—BHr¼/°HrßĪHHsu!PHs—BPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1066 10661425DV106614251066AąFWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R2N1HFOther Informed Consent Informed Consent FOLLOW-UP 1066Consent NO Non-Important2021-03-02B9DWE YYPhase 3A@ . . .N. A12-15 YearsNAąHrĄ¼Hs?THrĄ¼Hrą"äHsv“Hs?TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661425DV106614251066AąFWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZMOHJTVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1066SSWAB_WEEK14 NO Non-Important2021-05-20BˆDW” YYPhase 3A@ . . .N. A12-15 YearsNAąHrĄ¼Hs?THrĄ¼Hrą"äHsv“Hs?TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661425DV106614251066AąFWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZH29XAPotential COVID-19 illness visit not done when required per protocol. Visit Schedule OPEN LABEL FOLLOW-UP1066Potential COVID Illness Visit NO Non-Important2021-07-20BÅDWŃ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĄ¼Hs?THrĄ¼Hrą"äHsv“Hs?TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661427DV106614271066AšMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKNUNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1066SSWAB_WEEK14 NO Non-Important2021-06-13BŸDW¬ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrőHrį6ĄHrőHrį6Ą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661427DV106614271066AšMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHVRW3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1066SSWAB_WEEK16 NO Non-Important2021-06-24BŖDW· YYPhase 3A@ . . .Y. A12-15 YearsNAšHrőHrį6ĄHrőHrį6Ą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661430DV106614301066AŠMWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YNLIHVNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1066SSWAB_WEEK10 NO Non-Important2021-05-16B‚DW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĘ·Hrßŗ HrĘ·Hrßŗ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661430DV106614301066AŠMWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YDS916Lab performed out of window Laboratory REPEAT SCREENING 1 1066SSWAB_WEEK12 NO Non-Important2021-06-22B§DWµ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĘ·Hrßŗ HrĘ·Hrßŗ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661430DV106614301066AŠMWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHW9OZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1066SSWAB_WEEK12 NO Non-Important2021-06-22B§DWµ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĘ·Hrßŗ HrĘ·Hrßŗ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661431DV106614311066AšFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z6W3DQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1066SSWAB_WEEK20 NO Non-Important2021-07-15B¾DWĢ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĘšlHrįLHrĘšlHrįL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661432DV106614321066AąFWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R06A0NOther Informed Consent Informed Consent FOLLOW-UP 1066Consent NO Non-Important2021-03-03B8DWF YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘóšHs·¼HrĘóšHrą$Hss’,Hs·¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661432DV106614321066AąFWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1R06A0PVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-03B8DWF YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘóšHs·¼HrĘóšHrą$Hss’,Hs·¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661432DV106614321066AąFWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZMP80PVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1066SSWAB_WEEK14 NO Non-Important2021-05-18B„DW’ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĘóšHs·¼HrĘóšHrą$Hss’,Hs·¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661433DV106614331066AĄFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WKGILOVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066SSWAB_WEEK2 NO Non-Important2021-04-05BYDWg YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĒ'€HsŽ°HrĒ'€Hrą'XHst՜HsŽ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661433DV106614331066AĄFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WNXXHGVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1066V202_SURVEIL_SWAB|639314209930065NO Non-Important2021-04-13BaDWo YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĒ'€HsŽ°HrĒ'€Hrą'XHst՜HsŽ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661434DV106614341066AšMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z7WBFSNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1066SSWAB_WEEK16 NO Non-Important2021-07-03B­DWĄ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŒœHré. HrĶŒœHré. ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661434DV106614341066AšMWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHVRW6Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1066SSWAB_WEEK18 NO Non-Important2021-07-14BøDWĖ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŒœHré. HrĶŒœHré. ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661435DV106614351066AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z7X8NWNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1066SSWAB_WEEK16 NO Non-Important2021-07-03B­DWĄ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶŒ`Hré.HHrĶŒ`Hré.H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1066 10661435DV106614351066AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHVRW9Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1066SSWAB_WEEK18 NO Non-Important2021-07-14BøDWĖ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶŒ`Hré.HHrĶŒ`Hré.H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1077 10771275DV107712751077AŠMWHITE DVģDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTC5PKVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1077V2_VAX2_L NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜õ¤HsŽHr˜õ¤Hr²XHsrqäHsŽPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1077 10771277DV107712771077AŠMWHITE DVķDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YWMHO1Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1077Consent NO Non-Important2020-12-23BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr™żHs™āÄHr™żHr³€Hs{Hs™āÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1077 10771277DV107712771077AŠMWHITE DVķDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTC5Q0Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1077V2_VAX2_L NO Non-Important2020-12-23BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr™żHs™āÄHr™żHr³€Hs{Hs™āÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1077 10771278DV107712781077AŠMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTC5Q3Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1077V2_VAX2_L NO Non-Important2020-12-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™üœHr³¼Hr™üœHr³¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1077 10771282DV107712821077AąMWHITE DV÷DW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X70YTBReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1077V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-15B™DW YYPhase 3A@ . . .N. A12-15 YearsNAąHr§“pHrČ<Hr§“pHrČ<..Placebo Placebo .DWYC4591001C4591001 1077 10771284DV107712841077AšMWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV739OVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1077V4_MONTH6_L NO Non-Important2021-06-28BÄDW» YYPhase 3A@ . . .Y. A12-15 YearsNAšHrØvPHrÅg$HrØvPHrÅg$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWAYC4591001C4591001 1077 10771287DV107712871077AšMWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZ3TQKVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1077V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-15B?DW6 YYPhase 3A@ . . .Y. A12-15 YearsNAšHrؾ¼HrÅ Hrؾ¼HrÅ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1077 10771288DV107712881077AšMBLACK OR AFRICAN AMERICAN DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTBWD0Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1077V1_DAY1_VAX1_L NO Non-Important2020-12-16ADVł YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŖxHrŌ¤HrŖxHrŌ¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1077 10771288DV107712881077AšMBLACK OR AFRICAN AMERICAN DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OTC5Q6Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1077V2_VAX2_L NO Non-Important2020-12-16ADVł YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŖxHrŌ¤HrŖxHrŌ¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1077 10771289DV107712891077AąFWHITE DVūDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XND6C8Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1077V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14B”DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¬¼œHrČePHr¬¼œHrČeP..Placebo Placebo .DWYC4591001C4591001 1077 10771290DV107712901077AąFWHITE DVūDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XND6CBReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1077V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14B”DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¬¼ŲHrČeČHr¬¼ŲHrČeČ..Placebo Placebo .DWŽYC4591001C4591001 1077 10771292DV107712921077AąMWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTBWD3Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1077V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¬ĢHrŤČHr¬ĢHrŤČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‹YC4591001C4591001 1077 10771294DV107712941077AąMWHITE DWDW±Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y7HCTIOther Informed Consent Informed Consent FOLLOW-UP 1077Consent NO Non-Important2021-02-22B9DW= YYPhase 3A@ . . .N. A12-15 YearsNAąHr¹Õ”Hsœ øHr¹Õ”HrŲ%Hs{“ Hsœ øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1077 10771294DV107712941077AąMWHITE DWDW±Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YNZMC0Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1077V102_VAX4 NO Non-Important2021-06-18B­DW± YYPhase 3A@ . . .N. A12-15 YearsNAąHr¹Õ”Hsœ øHr¹Õ”HrŲ%Hs{“ Hsœ øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1077 10771295DV107712951077AšMWHITE DWDWTPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YXAU31Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1077Consent NO Non-Important2021-02-25B<DW@ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ŽHs"ˆHr¹ŽHrŲ/XHsæŌHs"ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW=YC4591001C4591001 1077 10771296DV107712961077AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z3S3LKVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1077V4_MONTH6_L NO Non-Important2021-07-07BæDWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»ĄHrŲHr»ĄHrŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841543DV108415431084AĄMWHITE DVūDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZHVRWCVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1084SSWAB_WEEK12 NO Non-Important2021-04-30B†DW€ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬ŠÄHsŽ4`Hr¬ŠÄHrČxLHsrŽ|HsŽ4`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841543DV108415431084AĄMWHITE DVūDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA132057201Other IP deviation Investigational ProductOPEN LABEL TREATMENT1084Vax 4 YES-POP2,YES-POP3Important 2021-06-07B¬DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬ŠÄHsŽ4`Hr¬ŠÄHrČxLHsrŽ|HsŽ4`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841545DV108415451084AĄFWHITE DVūDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126305601IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1084Vax 1 NO Non-Important2020-12-21A@DVž YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬ŻlHs{€Hr¬ŻlHrÅŻ¼HssāĢHs{€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841545DV108415451084AĄFWHITE DVūDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WTQAUFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1084SSWAB_WEEK6 NO Non-Important2021-03-17BZDWT YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬ŻlHs{€Hr¬ŻlHrÅŻ¼HssāĢHs{€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841545DV108415451084AĄFWHITE DVūDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZBAKVGPotential COVID-19 illness visit not done when required per protocol. Visit Schedule OPEN LABEL TREATMENT1084COVID_A NO Non-Important2021-05-26B DWš YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬ŻlHs{€Hr¬ŻlHrÅŻ¼HssāĢHs{€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841545DV108415451084AĄFWHITE DVūDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YGW4W6Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL TREATMENT1084COVID_B NO Non-Important2021-06-01B¦DW  YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬ŻlHs{€Hr¬ŻlHrÅŻ¼HssāĢHs{€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841545DV108415451084AĄFWHITE DVūDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1Z499THVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1084V103_MONTH1 NO Non-Important2021-07-06BÉDWĆ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬ŻlHs{€Hr¬ŻlHrÅŻ¼HssāĢHs{€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841548DV108415481084AŠFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YVJHODNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084COVID_A NO Non-Important2021-06-28B¾DW» YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°ŖPHrĻTHr°ŖPHrĻT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841550DV108415501084AšMWHITE DVžDWõPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126305501IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1084Vax 1 NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr°«|Hsö,Hr°«|HrĻ Hs×ń¤Hsö,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841551DV108415511084AŠMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1V8MAM9Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1084COVID_A NO Non-Important2021-04-08BmDWj YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¬äHrĻ XHr°¬äHrĻ X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1084 10841551DV108415511084AŠMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZHW9S5Visit not done Visit Schedule FOLLOW-UP 1084COVID_A1 NO Non-Important2021-04-08BmDWj YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¬äHrĻ XHr°¬äHrĻ X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1084 10841551DV108415511084AŠMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIMKO7Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084SSWAB_WEEK20 NO Non-Important2021-07-20BŌDWŃ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¬äHrĻ XHr°¬äHrĻ X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1084 10841551DV108415511084AŠMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZIMKOANasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084SSWAB_WEEK24 NO Non-Important2021-08-02BįDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¬äHrĻ XHr°¬äHrĻ X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1084 10841551DV108415511084AŠMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZHFDYIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1084V4_MONTH6_L NO Non-Important2021-08-02BįDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¬äHrĻ XHr°¬äHrĻ X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1084 10841552DV108415521084AŠMWHITE DVžDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131731301IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductREPEAT SCREENING 1 1084Vax 3 NO Non-Important2021-05-21B˜DW• YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°®LHs“Z¼Hr°®LHrĢpŒHs{ĻČHs“Z¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841552DV108415521084AŠMWHITE DVžDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YBECEYVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1084V102_VAX4 NO Non-Important2021-06-11B­DWŖ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°®LHs“Z¼Hr°®LHrĢpŒHs{ĻČHs“Z¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841555DV108415551084AŠMWHITE DVžDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZIMKODNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1084SSWAB_WEEK22 NO Non-Important2021-07-16BŠDWĶ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ÅHsļ{0Hr°ÅHrĢb|HsŌ”Hsļ{0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW×YC4591001C4591001 1084 10841555DV108415551084AŠMWHITE DVžDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZIMKOGNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084SSWAB_WEEK24 NO Non-Important2021-07-26BŚDW× YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ÅHsļ{0Hr°ÅHrĢb|HsŌ”Hsļ{0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW×YC4591001C4591001 1084 10841556DV108415561084AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1SKY4UJRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1084Consent NO Non-Important2021-02-22B9DW= YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¹“ˆHrÕH`Hr¹“ˆHrÕH`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841560DV108415601084AšMWHITE DWDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1PFCI2HVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1084V2_VAX2_L NO Non-Important2021-01-22BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ĖųHs nČHr¹ĖųHrŚūŌHs€ś˜Hs nČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1084 10841560DV108415601084AšMWHITE DWDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1VIR1CSOther Informed Consent Informed Consent FOLLOW-UP 1084Consent NO Non-Important2021-02-25B<DW@ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ĖųHs nČHr¹ĖųHrŚūŌHs€ś˜Hs nČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1084 10841560DV108415601084AšMWHITE DWDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1VIRPIFOther Informed Consent Informed Consent FOLLOW-UP 1084Consent NO Non-Important2021-02-25B<DW@ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ĖųHs nČHr¹ĖųHrŚūŌHs€ś˜Hs nČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1084 10841560DV108415601084AšMWHITE DWDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA0132130401IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1084Vax 3 NO Non-Important2021-05-28B˜DWœ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ĖųHs nČHr¹ĖųHrŚūŌHs€ś˜Hs nČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1084 10841560DV108415601084AšMWHITE DWDW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1YV739RVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1084V102_VAX4 NO Non-Important2021-06-21B°DW“ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ĖųHs nČHr¹ĖųHrŚūŌHs€ś˜Hs nČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1084 10841561DV108415611084AšFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBJNEVNasal swab not collected for the visit where it is required Laboratory OPEN LABEL TREATMENT1084COVID_A NO Non-Important2021-06-07B¢DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹Ś€HsŽüHr¹Ś€HrÕ[˜HsrØHsŽüPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841562DV108415621084AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YNZMC3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1084SSWAB_WEEK16 NO Non-Important2021-06-20BÆDW³ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¹ų€HrÕ_XHr¹ų€HrÕ_X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1084 10841562DV108415621084AĄMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YV739UVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1084SSWAB_WEEK18 NO Non-Important2021-06-28B·DW» YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¹ų€HrÕ_XHr¹ų€HrÕ_X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1084 10841563DV108415631084AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKNXNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084SSWAB_WEEK12 NO Non-Important2021-05-21BDW• YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¼V˜HrÕgHr¼V˜HrÕg..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1084 10841563DV108415631084AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHW3RXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1084SSWAB_WEEK16 NO Non-Important2021-06-14B§DW­ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¼V˜HrÕgHr¼V˜HrÕg..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1084 10841564DV108415641084AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YJ08MCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1084Consent NO Non-Important2021-05-21BDW• YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¼WLHs“lŒHr¼WLHrÕcTHsw²¼Hs“lŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1084 10841564DV108415641084AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZHFDZZVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1084V103_MONTH1 NO Non-Important2021-08-05BŪDWį YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¼WLHs“lŒHr¼WLHrÕcTHsw²¼Hs“lŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1084 10841565DV108415651084AąFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z49RQKVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1084V103_MONTH1 NO Non-Important2021-07-07B¾DWÄ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼eŌHs“m@Hr¼eŌHrŲPÜHswp,Hs“m@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1084 10841566DV108415661084AšMASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1OTBWD6Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1084V1_DAY1_VAX1_L NO Non-Important2020-12-30ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¼zģHrÕ]xHr¼zģHrÕ]x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841566DV108415661084AšMASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1OTTUDRVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1084V2_VAX2_L NO Non-Important2021-01-18BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¼zģHrÕ]xHr¼zģHrÕ]x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841566DV108415661084AšMASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1Z49RQNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1084SSWAB_WEEK20 NO Non-Important2021-07-04B»DWĮ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¼zģHrÕ]xHr¼zģHrÕ]x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841566DV108415661084AšMASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKY5Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084SSWAB_WEEK22 NO Non-Important2021-07-22BĶDWÓ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¼zģHrÕ]xHr¼zģHrÕ]x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841566DV108415661084AšMASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIMKY8Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084SSWAB_WEEK24 NO Non-Important2021-07-26BŃDW× YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¼zģHrÕ]xHr¼zģHrÕ]x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841567DV108415671084AąFASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZKYT1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1084V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B9DW? YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼ƒŌHrÕ¢`Hr¼ƒŌHrÕ¢`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841567DV108415671084AąFASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHW3S0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1084SSWAB_WEEK10 NO Non-Important2021-05-06B€DW† YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¼ƒŌHrÕ¢`Hr¼ƒŌHrÕ¢`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841568DV108415681084AšMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R6YX5XVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1084V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-08BEDWK YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼’\HrÕ`HHr¼’\HrÕ`H..Placebo Placebo .DW YC4591001C4591001 1084 10841569DV108415691084AąFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z3UG3SOther Informed Consent Informed Consent VACCINATION 1084Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼£<Hs“:ÜHr¼£<HrŚ÷`HswŚXHs“:ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841569DV108415691084AąFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z49RQQVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1084V103_MONTH1 NO Non-Important2021-07-07B¾DWÄ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼£<Hs“:ÜHr¼£<HrŚ÷`HswŚXHs“:ÜPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841570DV108415701084AŠMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z49RRXVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1084V103_MONTH1 NO Non-Important2021-07-07B¾DWÄ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼£šHs“;THr¼£šHrŚö¬HswŚŠHs“;TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841571DV108415711084AšFASIAN DWDWąPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZJPZBOSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsFOLLOW-UP 1084V101_VAX3 NO Non-Important2021-05-07BDW‡ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼„”HsŚĘHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841571DV108415711084AšFASIAN DWDWąPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZGPU9HVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1084V102_VAX4 NO Non-Important2021-08-04BŚDWą YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼„”HsŚĘHr¼„”HrŲ?„Hsw½ĄHsŚĘPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841572DV108415721084AŠFWHITE DW DW±Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PG6OT7Participant randomized into incorrect age stratum in Impala Randomization VACCINATION 1084V1_DAY1_VAX1 NO Non-Important2021-01-04ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĀįpHsœ¦”HrĀįpHrŽč Hs ÄHsœ¦”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1084 10841572DV108415721084AŠFWHITE DW DW±Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA132130601IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1084Vax 3 NO Non-Important2021-05-28B‘DWœ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĀįpHsœ¦”HrĀįpHrŽč Hs ÄHsœ¦”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1084 10841575DV108415751084AšMASIAN DW DW‡Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YV73A7Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1084V103_MONTH1 NO Non-Important2021-06-30B²DW½ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĆ@\Hse`lHrĆ@\Hrįš HsI¶ŒHse`lPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWqYC4591001C4591001 1084 10841578DV108415781084AŠMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKOJNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084SSWAB_WEEK20 NO Non-Important2021-07-18BĀDWĻ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÅŖ,Hrį‡`HrÅŖ,Hrį‡`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841578DV108415781084AŠMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIMKY2Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084SSWAB_WEEK22 NO Non-Important2021-07-28BĢDWŁ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÅŖ,Hrį‡`HrÅŖ,Hrį‡`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841579DV108415791084AŠFWHITE DWDW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XD2IBCReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1084V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŽÜHrį”¼HrŽÜHrį”¼..Placebo Placebo .DWYC4591001C4591001 1084 10841582DV108415821084AĄMASIAN DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHW3S3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1084SSWAB_WEEK18 NO Non-Important2021-07-02B²DWæ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅŌ˜Hrį™ØHrÅŌ˜Hrį™Ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1084 10841586DV108415861084AšMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZIMKO0Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1084SSWAB_WEEK6 NO Non-Important2021-04-12B_DWn YYPhase 3A@ . . .N. A12-15 YearsNAšHrČD€Hs“4HrČD€Hrćę¤HsvnŌHs“4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841586DV108415861084AšMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZHW3U4Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1084SSWAB_WEEK8 NO Non-Important2021-04-22BiDWx YYPhase 3A@ . . .N. A12-15 YearsNAšHrČD€Hs“4HrČD€Hrćę¤HsvnŌHs“4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841586DV108415861084AšMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z49RS0Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1084V103_MONTH1 NO Non-Important2021-07-07BµDWÄ YYPhase 3A@ . . .N. A12-15 YearsNAšHrČD€Hs“4HrČD€Hrćę¤HsvnŌHs“4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841588DV108415881084AąFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA131731501IP Documentation Error - Confirmation of Treatment - Received Form errors Investigational ProductOPEN LABEL TREATMENT1084Vax 3 NO Non-Important2021-05-21B†DW• YYPhase 3A@ . . .N. A12-15 YearsNAąHrČXØHs“5“HrČXØHrįw¬HswŁ¤Hs“5“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1084 10841588DV108415881084AąFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z49XQDVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1084V103_MONTH1 NO Non-Important2021-07-07BµDWÄ YYPhase 3A@ . . .N. A12-15 YearsNAąHrČXØHs“5“HrČXØHrįw¬HswŁ¤Hs“5“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1084 10841591DV108415911084AĄFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OT3RASUrine pregnancy test not performed. Laboratory VACCINATION 1084V1_DAY1_VAX1_L NO Non-Important2021-01-11A@DW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČjHrćŌ\HrČjHrćŌ\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1084 10841593DV108415931084AĄMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIMKO3Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1084SSWAB_WEEK8 NO Non-Important2021-04-27BnDW} YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČq¼Hrćķ¬HrČq¼Hrćķ¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841593DV108415931084AĄMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WOTDBDVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1084COVID_A1 NO Non-Important2021-05-05BvDW… YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČq¼Hrćķ¬HrČq¼Hrćķ¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841593DV108415931084AĄMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZHW3U7Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1084SSWAB_WEEK10 NO Non-Important2021-05-07BxDW‡ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČq¼Hrćķ¬HrČq¼Hrćķ¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841593DV108415931084AĄMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z8R4YLOther Informed Consent Informed Consent REPEAT SCREENING 1 1084Consent NO Non-Important2021-07-23BÅDWŌ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČq¼Hrćķ¬HrČq¼Hrćķ¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1084 10841594DV108415941084AĄMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z8R4P4Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1084SSWAB_WEEK16 NO Non-Important2021-06-30B®DW½ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČ}ģHrćšōHrČ}ģHrćšō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1084 10841594DV108415941084AĄMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZJO3SBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1084SSWAB_WEEK16 NO Non-Important2021-06-30B®DW½ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČ}ģHrćšōHrČ}ģHrćšō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1084 10841594DV108415941084AĄMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZE57WTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1084SSWAB_WEEK18 NO Non-Important2021-07-03B±DWĄ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrČ}ģHrćšōHrČ}ģHrćšō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1091 10911394DV109113941091AšFWHITE DVėDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OU3MTLParticipant randomized into incorrect age stratum in Impala Randomization VACCINATION 1091V1_DAY1_VAX1_L NO Non-Important2021-01-12B*DW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr—ŽHr°Hr—ŽHr°..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW;YC4591001C4591001 1091 10911396DV109113961091AšFWHITE DVėDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTC5QCVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1091V2_VAX2_L NO Non-Important2020-12-21BDVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr—“ČHs† (Hr—“ČHr°·4Hsk–äHs† (Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW†YC4591001C4591001 1091 10911396DV109113961091AšFWHITE DVėDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YXHKDGSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsOPEN LABEL TREATMENT1091V102_VAX4 NO Non-Important2021-06-25BĪDWø YYPhase 3A@ . . .N. A12-15 YearsNAšHr—“ČHs† (Hr—“ČHr°·4Hsk–äHs† (Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW†YC4591001C4591001 1091 10911399DV109113991091AąMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTOAG7Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1091V2_VAX2_L NO Non-Important2021-01-07B#DW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrš HrĒ.ˆHrš HrĒ.ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911399DV109113991091AąMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZB3TC5Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1091V4_MONTH6_L NO Non-Important2021-07-21BęDWŅ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrš HrĒ.ˆHrš HrĒ.ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911400DV109114001091AąFWHITE DVķDWĆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126403201IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1091Vax 2 NO Non-Important2020-12-29BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHršHHs“mÄHršHHr»EPHs†B<Hs“mÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW™YC4591001C4591001 1091 10911400DV109114001091AąFWHITE DVķDWĆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTOAGBVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1091V2_VAX2_L NO Non-Important2020-12-29BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHršHHs“mÄHršHHr»EPHs†B<Hs“mÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW™YC4591001C4591001 1091 10911400DV109114001091AąFWHITE DVķDWĆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z2PN7QVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1091V102_VAX4 NO Non-Important2021-07-06B×DWĆ YYPhase 3A@ . . .N. A12-15 YearsNAąHršHHs“mÄHršHHr»EPHs†B<Hs“mÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW™YC4591001C4591001 1091 10911400DV109114001091AąFWHITE DVķDWĆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZL0455Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1091V103_MONTH1 NO Non-Important2021-08-24C€DWō YYPhase 3A@ . . .N. A12-15 YearsNAąHršHHs“mÄHršHHr»EPHs†B<Hs“mÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW™YC4591001C4591001 1091 10911403DV109114031091AšMBLACK OR AFRICAN AMERICAN DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YGWXYANasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1091COVID_A NO Non-Important2021-04-21BˆDWw YYPhase 3A@ . . .Y. A12-15 YearsNAšHrž ŌHrŗé4Hrž ŌHrŗé4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911403DV109114031091AšMBLACK OR AFRICAN AMERICAN DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZMQLYDVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1091SSWAB_WEEK4 NO Non-Important2021-05-05B–DW… YYPhase 3A@ . . .Y. A12-15 YearsNAšHrž ŌHrŗé4Hrž ŌHrŗé4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911404DV109114041091AŠFWHITE DVšDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PLVATHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1091V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-09BADW0 YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž'ōHr¹ĄHrž'ōHr¹Ą..Placebo Placebo .DWĆYC4591001C4591001 1091 10911404DV109114041091AŠFWHITE DVšDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z65R7FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1091V4_MONTH6_L NO Non-Important2021-07-14BÜDWĖ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž'ōHr¹ĄHrž'ōHr¹Ą..Placebo Placebo .DWĆYC4591001C4591001 1091 10911406DV109114061091AąMWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YBFWRQVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1091V4_MONTH6_L NO Non-Important2021-06-14B¾DW­ YYPhase 3A@ . . .Y. A12-15 YearsNAąHržQ¬Hr¹¹ģHržQ¬Hr¹¹ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1091 10911406DV109114061091AąMWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZGN0A6Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1091Potential ReVax Initial Contact NO Non-Important2021-06-15BæDW® YYPhase 3A@ . . .Y. A12-15 YearsNAąHržQ¬Hr¹¹ģHržQ¬Hr¹¹ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1091 10911412DV109114121091AšFMULTIPLE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YNZMC6Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1091V4_MONTH6_L NO Non-Important2021-06-22BÄDWµ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr ļüHr¼˜tHr ļüHr¼˜t..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1091 10911412DV109114121091AšFMULTIPLE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZGN0A9Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1091Potential ReVax Initial Contact NO Non-Important2021-06-23BÅDW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr ļüHr¼˜tHr ļüHr¼˜t..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1091 10911413DV109114131091AĄMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTOAIZVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1091V2_VAX2_L NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr ļ HrĒHr ļ HrĒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW˜YC4591001C4591001 1091 10911414DV109114141091AąMWHITE DVņDW™BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OTOAJ2Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1091V2_VAX2_L NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr ļ„Hs}*lHr ļ„Hs}*l..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW˜YC4591001C4591001 1091 10911414DV109114141091AąMWHITE DVņDW™BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZCK4UProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1091V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-09B?DW0 YYPhase 3A@ . . .N. A12-15 YearsNAąHr ļ„Hs}*lHr ļ„Hs}*l..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW˜YC4591001C4591001 1091 10911415DV109114151091AšFASIAN DVóDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126403401IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1091Vax 2 NO Non-Important2020-12-29BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr”÷äHs”ūŠHr”÷äHr»F@Hs†VÜHs”ūŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1091 10911415DV109114151091AšFASIAN DVóDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTBWDCVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1091V2_VAX2_L NO Non-Important2020-12-29BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr”÷äHs”ūŠHr”÷äHr»F@Hs†VÜHs”ūŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1091 10911416DV109114161091AšMWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTBWDFVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1091V2_VAX2_L NO Non-Important2020-12-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¢€Hr¼pHr¢€Hr¼p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW}YC4591001C4591001 1091 10911417DV109114171091AŠFWHITE DVóDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OTBWDIVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1091V2_VAX2_L NO Non-Important2020-12-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢¼HsæšHr¢¼Hr¼Œ¼HssuŠHsæšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1091 10911417DV109114171091AŠFWHITE DVóDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X70Z4SLab performed out of window Laboratory REPEAT SCREENING 1 1091V101_VAX3 NO Non-Important2021-05-17BŸDW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢¼HsæšHr¢¼Hr¼Œ¼HssuŠHsæšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1091 10911417DV109114171091AŠFWHITE DVóDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X7QZHCUrine pregnancy test not performed. Laboratory OPEN LABEL TREATMENT1091V101_VAX3 NO Non-Important2021-05-18B DW’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢¼HsæšHr¢¼Hr¼Œ¼HssuŠHsæšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1091 10911417DV109114171091AŠFWHITE DVóDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZHFE02Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1091V103_MONTH1 NO Non-Important2021-08-04BīDWą YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¢¼HsæšHr¢¼Hr¼Œ¼HssuŠHsæšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1091 10911423DV109114231091AąFBLACK OR AFRICAN AMERICAN DV÷DWŅPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XN7T8VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1091SSWAB_WEEK8 NO Non-Important2021-05-26B¤DWš YYPhase 3A@ . . .N. A12-15 YearsNAąHr§6 HsČ7ČHr§6 HrŇ|Hs¬{(HsČ7ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW·YC4591001C4591001 1091 10911424DV109114241091AąMWHITE DVųDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126403501IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1091Vax 1 NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .N. A12-15 YearsNAąHrؕ|HsĶ|Hrؕ|HrĀįčHstʜHsĶ|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911426DV109114261091AŠFWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Y77ZLBNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1091COVID_A NO Non-Important2021-05-04BŒDW„ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖąHrĒ øHrŖąHrĒ ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1091 10911427DV109114271091AĄMWHITE DVłDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1SSSYKILab performed out of window Laboratory FOLLOW-UP 1091COVID_A NO Non-Important2021-03-12BWDWO YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŖ„Hrś¤HrŖ„Hrś¤..Placebo Placebo .DW’YC4591001C4591001 1091 10911429DV109114291091AšMWHITE DVłDW}Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WKGQ2XVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1091V102_VAX4 NO Non-Important2021-04-27B…DW} YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖˆHsX3ÄHrŖˆHrÅhHs5š€HsX3ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWbYC4591001C4591001 1091 10911430DV109114301091AŠFWHITE DVłDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XA0G0ZUrine pregnancy test not performed. Laboratory OPEN LABEL TREATMENT1091V101_VAX3 NO Non-Important2021-05-20BœDW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŖ&DHsŽ\HrŖ&DHrĆĢHsv› HsŽ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1091 10911430DV109114301091AŠFWHITE DVłDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y1PBIIVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1091V102_VAX4 NO Non-Important2021-06-07B®DW¦ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŖ&DHsŽ\HrŖ&DHrĆĢHsv› HsŽ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1091 10911431DV109114311091AŠMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTOAJ5Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1091V2_VAX2_L NO Non-Important2021-01-12BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr«*lHrĶOpHr«*lHrĶOp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911431DV109114311091AŠMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YY0VEFVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1091V4_MONTH6_L NO Non-Important2021-07-01BÅDW¾ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr«*lHrĶOpHr«*lHrĶOp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911432DV109114321091AĄFWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PFCI2KVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1091V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-02B0DW) YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«)ōHrżģHr«)ōHrżģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1091 10911432DV109114321091AĄFWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Y55S3XVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1091V4_MONTH6_L NO Non-Important2021-06-10B°DW© YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«)ōHrżģHr«)ōHrżģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1091 10911437DV109114371091AŠMWHITE DVśDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126619801IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1091Vax 1 NO Non-Important2020-12-17ADVś YYPhase 3A@ . . .N. A12-15 YearsNAŠHr«„ØHs˜ČHr«„ØHrÅ}hHs~m(Hs˜ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1091 10911439DV109114391091AąMWHITE DVūDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTC113Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1091V2_VAX2_L NO Non-Important2021-01-08BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¬pHs£=œHr¬pHrČ0Hs‡Š Hs£=œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911443DV109114431091AĄMASIAN DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS3082Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1091V2_VAX2_L NO Non-Important2021-01-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°³8HrŃR<Hr°³8HrŃR<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1091 10911443DV109114431091AĄMASIAN DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHFE05Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1091V4_MONTH6_L NO Non-Important2021-08-12BėDWč YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°³8HrŃR<Hr°³8HrŃR<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1091 10911445DV109114451091AŠMASIAN DVžDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QZ5JVJVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1091V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-22B@DW= YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°³°Hs—iHr°³°HrĢTlHsv„¬Hs—iPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1091 10911445DV109114451091AŠMASIAN DVžDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YBFWRTVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1091V102_VAX4 NO Non-Important2021-06-14B°DW­ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°³°Hs—iHr°³°HrĢTlHsv„¬Hs—iPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1091 10911447DV109114471091AšMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R1U4A4Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1091COVID_A NO Non-Important2021-02-16B9DW7 YYPhase 3A@ . . .Y. A12-15 YearsNAšHr±Ä¼HrŠ!ŒHr±Ä¼HrŠ!Œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWTYC4591001C4591001 1091 10911447DV109114471091AšMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1U6JECJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1091COVID_A1 NO Non-Important2021-04-01BeDWc YYPhase 3A@ . . .Y. A12-15 YearsNAšHr±Ä¼HrŠ!ŒHr±Ä¼HrŠ!Œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWTYC4591001C4591001 1091 10911450DV109114501091AŠMMULTIPLE DV’DWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126619901IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1091Vax 1 NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr²˜Hs|čHr²˜HrĻžÜHswuTHs|čPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911451DV109114511091AšMWHITE ..BNT162b2 Phase 2/3 (30 mcg)B2_P23_30Not Treated NOTTRT BNT162b2 Phase 2/3 (30 mcg) A€.12-15 YearsAA127396801IP documentation error – IP preparation form errors Investigational ProductSCREENING 1091Vax 1 NO Non-Important2020-12-22ADV’ NYPhase 3A@ . . .N. A12-15 YearsNAš...... ..NC4591001C4591001 1091 10911451DV109114511091AšMWHITE ..BNT162b2 Phase 2/3 (30 mcg)B2_P23_30Not Treated NOTTRT BNT162b2 Phase 2/3 (30 mcg) A€.12-15 YearsAA 1-1OLFHVMRandomization done out of sequence Randomization SCREENING 1091V1_DAY1_VAX1_L NO Non-Important2020-12-22ADV’ NYPhase 3A@ . . .N. A12-15 YearsNAš...... ..NC4591001C4591001 1091 10911452DV109114521091AąFWHITE DV’DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126620101IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1091Vax 1 NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr²Hs—A¤Hr²HrĪØčHsvšlHs—A¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911452DV109114521091AąFWHITE DV’DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YBFWSGVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1091V102_VAX4 NO Non-Important2021-06-14BÆDW­ YYPhase 3A@ . . .N. A12-15 YearsNAąHr²Hs—A¤Hr²HrĪØčHsvšlHs—A¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911453DV109114531091AšFASIAN DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QW99BHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1091V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-17B:DW8 YYPhase 3A@ . . .Y. A12-15 YearsNAšHr²ŒHrĶnŲHr²ŒHrĶnŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW=YC4591001C4591001 1091 10911455DV109114551091AĄFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1QZ5JVNVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1091V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-26B<DWA YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŗžˆHr֚HrŗžˆHr֚..Placebo Placebo .DWYC4591001C4591001 1091 10911455DV109114551091AĄFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZHXSRRReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1091V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BˆDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŗžˆHr֚HrŗžˆHr֚..Placebo Placebo .DWYC4591001C4591001 1091 10911455DV109114551091AĄFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZHXSRUReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1091V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BDW¢ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŗžˆHr֚HrŗžˆHr֚..Placebo Placebo .DWYC4591001C4591001 1091 10911456DV109114561091AŠFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z65DBCReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1091V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BˆDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»V0HrՔHr»V0HrՔ..Placebo Placebo .DWYC4591001C4591001 1091 10911456DV109114561091AŠFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z65DB9Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1091V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BDW¢ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr»V0HrՔHr»V0HrՔ..Placebo Placebo .DWYC4591001C4591001 1091 10911459DV109114591091AąMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QWNWLZSerology sample not labeled properly and had to discarded Laboratory FOLLOW-UP 1091V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-18B4DW9 YYPhase 3A@ . . .N. A12-15 YearsNAąHr»U|Hs‘ą°Hr»U|HrÖÄÄHsvˆœHs‘ą°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1091 10911461DV109114611091AąFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA0126701301IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1091Vax 2 NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼gHrÖįŌHr¼gHrÖįŌ..Placebo Placebo .DWYC4591001C4591001 1091 10911461DV109114611091AąFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z4WHQLReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1091V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼gHrÖįŌHr¼gHrÖįŌ..Placebo Placebo .DWYC4591001C4591001 1091 10911461DV109114611091AąFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZC6C32Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1091V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-09B¢DWØ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼gHrÖįŌHr¼gHrÖįŌ..Placebo Placebo .DWYC4591001C4591001 1091 10911464DV109114641091AŠFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZMQLYGVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1091SSWAB_WEEK6 NO Non-Important2021-06-09BDWØ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ;¬Hrį HrĆ;¬Hrį ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1091 10911464DV109114641091AŠFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z66YV6Procedure/Test performed out of window Procedures/Tests REPEAT SCREENING 1 1091V202_SURVEIL_SWAB|645370543089030NO Non-Important2021-07-09B»DWĘ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ;¬Hrį HrĆ;¬Hrį ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1091 10911466DV109114661091AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZB3TC8Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1091V103_MONTH1 NO Non-Important2021-07-20BæDWŃ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĢcäHsŽ4ŲHrĢcäHréuˆHssė<HsŽ4ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1123 11231422DV112314221123AšMWHITE DVźDVžPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126573301IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1123Vax 2 NO Non-Important2020-12-21BDVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr–ąHr°eąHr–ąHr°eą..Placebo Placebo .DW‘YC4591001C4591001 1123 11231422DV112314221123AšMWHITE DVźDVžPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WKGQ3PVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK2 NO Non-Important2021-04-12B…DWn YYPhase 3A@ . . .N. A12-15 YearsNAšHr–ąHr°eąHr–ąHr°eą..Placebo Placebo .DW‘YC4591001C4591001 1123 11231425DV112314251123AąFWHITE DVėDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OAE2C8Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1123V1_DAY1_VAX1_L NO Non-Important2020-12-02ADVė YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—WųHr°_ŒHr—WųHr°_Œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231425DV112314251123AąFWHITE DVėDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z0DRESSurveillance for asymptomatic SARS-CoV-2 infection is performed after Visit-4 Other REPEAT SCREENING 1 1123SSWAB_WEEK16 NO Non-Important2021-06-28BŃDW» YYPhase 3A@ . . .Y. A12-15 YearsNAąHr—WųHr°_ŒHr—WųHr°_Œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231431DV112314311123AŠMWHITE DVķDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126573401IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1123Vax 2 NO Non-Important2020-12-23BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr™ū¬HsęHr™ū¬Hr³(„HssäpHsęPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1123 11231431DV112314311123AŠMWHITE DVķDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X5V207Incorrect serology sample volume collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-03-08B_DWK YYPhase 3A@ . . .N. A12-15 YearsNAŠHr™ū¬HsęHr™ū¬Hr³(„HssäpHsęPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1123 11231434DV112314341123AĄFWHITE DVšDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126573601IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1123Vax 2 NO Non-Important2020-12-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrų$Hr¹šHHrų$Hr¹šH..Placebo Placebo .DWYC4591001C4591001 1123 11231438DV112314381123AąFAMERICAN INDIAN OR ALASKA NATIVE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126573701IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1123Vax 2 NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHrŸMÜHrрHrŸMÜHrр..Placebo Placebo .DW“YC4591001C4591001 1123 11231438DV112314381123AąFAMERICAN INDIAN OR ALASKA NATIVE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTP359Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1123V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHrŸMÜHrрHrŸMÜHrр..Placebo Placebo .DW“YC4591001C4591001 1123 11231438DV112314381123AąFAMERICAN INDIAN OR ALASKA NATIVE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XSHVP7Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK8 NO Non-Important2021-05-15BŸDW YYPhase 3A@ . . .N. A12-15 YearsNAąHrŸMÜHrрHrŸMÜHrр..Placebo Placebo .DW“YC4591001C4591001 1123 11231438DV112314381123AąFAMERICAN INDIAN OR ALASKA NATIVE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Z49XQIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK10 NO Non-Important2021-06-08B·DW§ YYPhase 3A@ . . .N. A12-15 YearsNAąHrŸMÜHrрHrŸMÜHrр..Placebo Placebo .DW“YC4591001C4591001 1123 11231439DV112314391123AĄFAMERICAN INDIAN OR ALASKA NATIVE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTP35CVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1123V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŸMdHrŇHrŸMdHrŇ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231439DV112314391123AĄFAMERICAN INDIAN OR ALASKA NATIVE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1XSHVPAVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK8 NO Non-Important2021-05-04B”DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŸMdHrŇHrŸMdHrŇ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231439DV112314391123AĄFAMERICAN INDIAN OR ALASKA NATIVE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YV73AJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK12 NO Non-Important2021-06-09BøDWØ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŸMdHrŇHrŸMdHrŇ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231440DV112314401123AŠMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z7WBEWNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1123SSWAB_WEEK16 NO Non-Important2021-06-28BŹDW» YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr ’xHr¹™ŠHr ’xHr¹™Š..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231441DV112314411123AąMBLACK OR AFRICAN AMERICAN DVņDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126574301IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1123Vax 2 NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr ³HHrĆ°Hr ³HHrĆ°..Placebo Placebo ..YC4591001C4591001 1123 11231441DV112314411123AąMBLACK OR AFRICAN AMERICAN DVņDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTP35FVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1123V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr ³HHrĆ°Hr ³HHrĆ°..Placebo Placebo ..YC4591001C4591001 1123 11231442DV112314421123AĄMWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126574501IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1123Vax 2 NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr »|Hs”ā€Hr »|HrĆHs~YšHs”ā€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1123 11231442DV112314421123AĄMWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTP35IVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1123V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr »|Hs”ā€Hr »|HrĆHs~YšHs”ā€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1123 11231442DV112314421123AĄMWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YO3CTDVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1123V102_VAX4 NO Non-Important2021-06-22BÄDWµ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr »|Hs”ā€Hr »|HrĆHs~YšHs”ā€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1123 11231442DV112314421123AĄMWHITE DVņDWµPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YY0VN4Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1123SSWAB_WEEK12 NO Non-Important2021-06-24BĘDW· YYPhase 3A@ . . .N. A12-15 YearsNAĄHr »|Hs”ā€Hr »|HrĆHs~YšHs”ā€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1123 11231443DV112314431123AąFWHITE DVņDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTP35VVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1123V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr »HrĆÄHr »HrĆÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231445DV112314451123AĄFWHITE DVņDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126574601IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1123Vax 2 NO Non-Important2020-12-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr ŲHr¼”xHr ŲHr¼”x..Placebo Placebo .DW’YC4591001C4591001 1123 11231446DV112314461123AąMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XK2B4FUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1123Potential ReVax Initial Contact NO Non-Important2021-02-15BEDW6 YYPhase 3A@ . . .Y. A12-15 YearsNAąHr ÜÄHr¼”šHr ÜÄHr¼”š..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1123 11231447DV112314471123AŠMWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YY0VN7Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK14 NO Non-Important2021-06-21BĀDW“ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¢2|Hrŗ’“Hr¢2|Hrŗ’“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231448DV112314481123AŠMBLACK OR AFRICAN AMERICAN DVōDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126574701IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1123Vax 2 NO Non-Important2020-12-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£-¼Hr¼>°Hr£-¼Hr¼>°..Placebo Placebo ..YC4591001C4591001 1123 11231448DV112314481123AŠMBLACK OR AFRICAN AMERICAN DVōDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1VKCCUVPotential COVID-19 illness visit not done when required per protocol. Visit Schedule FOLLOW-UP 1123POT_COVID_ILL NO Non-Important2021-04-15B~DWq YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£-¼Hr¼>°Hr£-¼Hr¼>°..Placebo Placebo ..YC4591001C4591001 1123 11231449DV112314491123AšFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YBFWTIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK8 NO Non-Important2021-05-30B«DWž YYPhase 3A@ . . .Y. A12-15 YearsNAšHr£=čHr¼ äHr£=čHr¼ ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231449DV112314491123AšFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZNKOPCNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1123COVID_A NO Non-Important2021-08-27C@DW÷ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr£=čHr¼ äHr£=čHr¼ ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231450DV112314501123AšMBLACK OR AFRICAN AMERICAN DVōDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126575001IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1123Vax 2 NO Non-Important2020-12-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr£D“Hs™¹üHr£D“Hr¼$Hs~d|Hs™¹üPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1123 11231450DV112314501123AšMBLACK OR AFRICAN AMERICAN DVōDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WKGQ3SVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK2 NO Non-Important2021-03-27BkDW^ YYPhase 3A@ . . .N. A12-15 YearsNAšHr£D“Hs™¹üHr£D“Hr¼$Hs~d|Hs™¹üPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1123 11231450DV112314501123AšMBLACK OR AFRICAN AMERICAN DVōDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YO3CTGVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK6 NO Non-Important2021-04-28B‹DW~ YYPhase 3A@ . . .N. A12-15 YearsNAšHr£D“Hs™¹üHr£D“Hr¼$Hs~d|Hs™¹üPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWšYC4591001C4591001 1123 11231453DV112314531123AĄMWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV73AMVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK14 NO Non-Important2021-06-21B½DW“ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrØÉüHrĒˆHrØÉüHrĒˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231453DV112314531123AĄMWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZCT7OCVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK16 NO Non-Important2021-07-12BŅDWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrØÉüHrĒˆHrØÉüHrĒˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231456DV112314561123AŠFWHITE DVłDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X5V21RIncorrect serology sample volume collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-03-17B\DWT YYPhase 3A@ . . .N. A12-15 YearsNAŠHr©Š|Hs)ˆHr©Š|HrĆHss€ŌHs)ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231457DV112314571123AšFWHITE DVłDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X5V201Incorrect serology sample volume collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-03-16B[DWS YYPhase 3A@ . . .N. A12-15 YearsNAšHr©ū`Hs‰īŒHr©ū`HrĀćHsnL,Hs‰īŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231458DV112314581123AĄFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WNXXJDVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123V202_SURVEIL_SWAB|638374719052060NO Non-Important2021-04-13BwDWo YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖüHrĆ3<HrŖüHrĆ3<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231458DV112314581123AĄFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZCT7OPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123V4_MONTH6_L NO Non-Important2021-08-02BęDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŖüHrĆ3<HrŖüHrĆ3<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231462DV112314621123AĄMWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIH3YNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK14 NO Non-Important2021-06-17B·DW° YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«n(HrČqHr«n(HrČq..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231463DV112314631123AąFWHITE DVūDW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YDATG7Other Informed Consent Informed Consent FOLLOW-UP 1123Consent NO Non-Important2021-03-16BYDWS YYPhase 3A@ . . .N. A12-15 YearsNAąHr¬pHs›+ Hr¬pHrĘĖ Hs~S$Hs›+ Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231466DV112314661123AŠFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WNYMPBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123V202_SURVEIL_SWAB|637577843450060NO Non-Important2021-04-08BpDWj YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬ĮHrÅĀČHr¬ĮHrÅĀČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231466DV112314661123AŠFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YV73BJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK10 NO Non-Important2021-06-03BØDW¢ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¬ĮHrÅĀČHr¬ĮHrÅĀČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231467DV112314671123AŠMWHITE DVžDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X5UAEJIncorrect serology sample volume collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-03-08BNDWK YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°_ČHs‡BhHr°_ČHrĢHsnOtHs‡BhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231467DV112314671123AŠMWHITE DVžDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z63DG8Nasal swab collected at a visit where it was not required Laboratory OPEN LABEL TREATMENT1123SSWAB_WEEK10 NO Non-Important2021-05-17B”DW‘ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°_ČHs‡BhHr°_ČHrĢHsnOtHs‡BhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231467DV112314671123AŠMWHITE DVžDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z7FGGPNasal swab collected at a visit where it was not required Laboratory OPEN LABEL TREATMENT1123SSWAB_WEEK12 NO Non-Important2021-05-31B¢DWŸ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°_ČHs‡BhHr°_ČHrĢHsnOtHs‡BhPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231468DV112314681123AšFWHITE DVžDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1V8CKLHNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1123SSWAB_WEEK4 NO Non-Important2021-03-30BdDWa YYPhase 3A@ . . .N. A12-15 YearsNAšHr°`|Hs¢ü°Hr°`|HrĢųHs‰ņˆHs¢ü°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231468DV112314681123AšFWHITE DVžDW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZNKP1XNasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1123COVID_B NO Non-Important2021-08-13BģDWé YYPhase 3A@ . . .N. A12-15 YearsNAšHr°`|Hs¢ü°Hr°`|HrĢųHs‰ņˆHs¢ü°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231469DV112314691123AąFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBPCS9Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK10 NO Non-Important2021-07-02BĀDWæ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr°~|HrĶp|Hr°~|HrĶp|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231472DV112314721123AšFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YY0VNAVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK14 NO Non-Important2021-07-01BĮDW¾ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr°‘<HrĶc Hr°‘<HrĶc ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231473DV112314731123AšFWHITE DVžDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X5V22SIncorrect serology sample volume collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-03-16BVDWS YYPhase 3A@ . . .N. A12-15 YearsNAšHr°’,HsTØHr°’,HrĶÆLHssé\HsTØPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231474DV112314741123AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z4VF88Other Informed Consent Informed Consent REPEAT SCREENING 1 1123Consent NO Non-Important2021-07-12BĢDWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°°¤HrĢ ØHr°°¤HrĢ Ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231474DV112314741123AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZD1SFNNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1123SSWAB_WEEK18 NO Non-Important2021-07-18BŅDWĻ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°°¤HrĢ ØHr°°¤HrĢ Ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231475DV112314751123AąMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZD1SFRNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1123SSWAB_WEEK18 NO Non-Important2021-07-18BŅDWĻ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr°°,HrĢ 0Hr°°,HrĢ 0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231476DV112314761123AŠFWHITE DVžDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X5UAEMIncorrect serology sample volume collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-03-08BNDWK YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ø$Hs‡l˜Hr°ø$HrĢNHsnaDHs‡l˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231476DV112314761123AŠFWHITE DVžDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XSHW3JVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK2 NO Non-Important2021-03-30BdDWa YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ø$Hs‡l˜Hr°ø$HrĢNHsnaDHs‡l˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231476DV112314761123AŠFWHITE DVžDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XSHW3MVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK4 NO Non-Important2021-04-20ByDWv YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ø$Hs‡l˜Hr°ø$HrĢNHsnaDHs‡l˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231476DV112314761123AŠFWHITE DVžDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XSHW3PVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1123SSWAB_WEEK6 NO Non-Important2021-05-21B˜DW• YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ø$Hs‡l˜Hr°ø$HrĢNHsnaDHs‡l˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231476DV112314761123AŠFWHITE DVžDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMG4CWRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1123Consent NO Non-Important2021-06-02B¤DW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ø$Hs‡l˜Hr°ø$HrĢNHsnaDHs‡l˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231476DV112314761123AŠFWHITE DVžDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XMG4FCRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1123Consent NO Non-Important2021-06-02B¤DW” YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ø$Hs‡l˜Hr°ø$HrĢNHsnaDHs‡l˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231477DV112314771123AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1XT0RDGSerology samples processed incorrectly Laboratory FOLLOW-UP 1123V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-08B2DW/ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°Å¼HrĢ'ØHr°Å¼HrĢ'Ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231477DV112314771123AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XE4MVINasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1123SSWAB_WEEK10 NO Non-Important2021-05-05BˆDW… YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°Å¼HrĢ'ØHr°Å¼HrĢ'Ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231477DV112314771123AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z5ZOC3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK10 NO Non-Important2021-06-24BŗDW· YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°Å¼HrĢ'ØHr°Å¼HrĢ'Ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231477DV112314771123AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZCT7OSVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK12 NO Non-Important2021-07-15BĻDWĢ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°Å¼HrĢ'ØHr°Å¼HrĢ'Ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231481DV112314811123AšFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZL0458Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK16 NO Non-Important2021-07-30BŽDWŪ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr°ĢˆHrĶČHr°ĢˆHrĶČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231481DV112314811123AšFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHFE08Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123V4_MONTH6_L NO Non-Important2021-08-03BāDWß YYPhase 3A@ . . .Y. A12-15 YearsNAšHr°ĢˆHrĶČHr°ĢˆHrĶČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231482DV112314821123AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XSHW42Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK6 NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±±ĄHrĢbøHr±±ĄHrĢbø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231482DV112314821123AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z6W3DTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK12 NO Non-Important2021-06-30BæDW½ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±±ĄHrĢbøHr±±ĄHrĢbø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231484DV112314841123AąFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YY0VNNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK14 NO Non-Important2021-06-28B½DW» YYPhase 3A@ . . .Y. A12-15 YearsNAąHr±æXHrĶdÄHr±æXHrĶdÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231485DV112314851123AŠFWHITE DV’DW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSVK3KVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK2 NO Non-Important2021-05-05B‡DW… YYPhase 3A@ . . .N. A12-15 YearsNAŠHr±Ķ¤Hs£HdHr±Ķ¤HrĶb0Hs‡L|Hs£HdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231485DV112314851123AŠFWHITE DV’DW¶Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YJNEMNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1123Consent NO Non-Important2021-06-23BøDW¶ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr±Ķ¤Hs£HdHr±Ķ¤HrĶb0Hs‡L|Hs£HdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231486DV112314861123AąFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XSHW45Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK6 NO Non-Important2021-05-11BDW‹ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr±ÓDHrĢRŒHr±ÓDHrĢRŒ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231488DV112314881123AĄFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1SSTSU2Other Informed Consent Informed Consent FOLLOW-UP 1123Consent NO Non-Important2021-03-05BJDWH YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr±ž HrĪŅdHr±ž HrĪŅd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231488DV112314881123AĄFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YY0VNQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK14 NO Non-Important2021-06-21B¶DW“ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr±ž HrĪŅdHr±ž HrĪŅd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231489DV112314891123AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZNH9IPVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK6 NO Non-Important2021-05-03B…DWƒ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr²˜HrĢ8ˆHr²˜HrĢ8ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231489DV112314891123AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZD1SFVNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1123SSWAB_WEEK16 NO Non-Important2021-07-09BČDWĘ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr²˜HrĢ8ˆHr²˜HrĢ8ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231489DV112314891123AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZMUK1JNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1123SSWAB_WEEK18 NO Non-Important2021-07-25BŲDWÖ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr²˜HrĢ8ˆHr²˜HrĢ8ˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231491DV112314911123AąMWHITE DV’DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WKGQ3VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK2 NO Non-Important2021-03-26B_DW] YYPhase 3A@ . . .N. A12-15 YearsNAąHr²ųHrĢ1ųHr²ųHrĢ1ų..Placebo Placebo .DW‘YC4591001C4591001 1123 11231491DV112314911123AąMWHITE DV’DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSHW48Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK8 NO Non-Important2021-05-12BŽDWŒ YYPhase 3A@ . . .N. A12-15 YearsNAąHr²ųHrĢ1ųHr²ųHrĢ1ų..Placebo Placebo .DW‘YC4591001C4591001 1123 11231492DV112314921123AšMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X5V21OIncorrect serology sample volume collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-03-19BWDWV YYPhase 3A@ . . .N. A12-15 YearsNAšHr³¬HsŽlHr³¬HrĪ¬lHssćHsŽlPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1123 11231493DV112314931123AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV73BMVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK10 NO Non-Important2021-06-09B©DWØ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr³”HrќÄHr³”HrќÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231493DV112314931123AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YY0VNTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK12 NO Non-Important2021-06-28B¼DW» YYPhase 3A@ . . .Y. A12-15 YearsNAąHr³”HrќÄHr³”HrќÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231494DV112314941123AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YV73BPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK10 NO Non-Important2021-06-10BŖDW© YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr³!@HrŠ\`Hr³!@HrŠ\`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231494DV112314941123AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIMKYBNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1123SSWAB_WEEK12 NO Non-Important2021-06-28B¼DW» YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr³!@HrŠ\`Hr³!@HrŠ\`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231494DV112314941123AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIMKYENasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1123SSWAB_WEEK14 NO Non-Important2021-07-12BŹDWÉ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr³!@HrŠ\`Hr³!@HrŠ\`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231497DV112314971123AŠMWHITE DWDW±Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PFGS6PVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1123V2_VAX2_L NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr³5,Hsœ ōHr³5,Hr×ī0Hs Hsœ ōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231499DV112314991123AĄMWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X5V204Incorrect serology sample volume collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-04-06BdDWh YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹§,Hs‡KČHr¹§,HrÕSÜHsnBĢHs‡KČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231501DV112315011123AĄFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QVZNTQVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1123V2_VAX2_L NO Non-Important2021-02-18B5DW9 YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹Ē„Hs“_ØHr¹Ē„Hrž~ˆHswĢĄHs“_ØPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231501DV112315011123AĄFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1R7E22GVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1123V2_VAX2_L NO Non-Important2021-02-18B5DW9 YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹Ē„Hs“_ØHr¹Ē„Hrž~ˆHswĢĄHs“_ØPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231501DV112315011123AĄFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZEO98JSerology sample not collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-03-22BUDWY YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¹Ē„Hs“_ØHr¹Ē„Hrž~ˆHswĢĄHs“_ØPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231504DV112315041123AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z3T77VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK2 NO Non-Important2021-04-14BlDWp YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¹ńxHrÕMÄHr¹ńxHrÕMÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231504DV112315041123AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YBFWVTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK6 NO Non-Important2021-05-28B˜DWœ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¹ńxHrÕMÄHr¹ńxHrÕMÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231504DV112315041123AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YY0VNWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK8 NO Non-Important2021-06-18B­DW± YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¹ńxHrÕMÄHr¹ńxHrÕMÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231504DV112315041123AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZD1SGINasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1123SSWAB_WEEK12 NO Non-Important2021-07-19BĢDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¹ńxHrÕMÄHr¹ńxHrÕMÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231506DV112315061123AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XSHW4BVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK6 NO Non-Important2021-05-21B‘DW• YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¹ų¼HrÕf`Hr¹ų¼HrÕf`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231506DV112315061123AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YY1KH9Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK8 NO Non-Important2021-06-17B¬DW° YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¹ų¼HrÕf`Hr¹ų¼HrÕf`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231507DV112315071123AąFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XTRH4LVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK2 NO Non-Important2021-05-08B„DWˆ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗ°HrÕmhHrŗ°HrÕmh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1123 11231508DV112315081123AŠFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R27M2XOther Informed Consent Informed Consent FOLLOW-UP 1123Consent NO Non-Important2021-02-19B6DW: YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŗģHr×ķøHrŗģHr×ķø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231509DV112315091123AĄFWHITE DWDW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YGWY06Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1123COVID_B NO Non-Important2021-05-12B‡DWŒ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr»°Hs›ZHr»°HrŁ†Hs~küHs›ZPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231513DV112315131123AĄMWHITE DWDW½Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YBR2OOSerology sample not collected Laboratory OPEN LABEL TREATMENT1123V101_VAX3 NO Non-Important2021-06-11B¤DWŖ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¼P€Hs¬:<Hr¼P€HrŲ1°Hs“98Hs¬:<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231514DV112315141123AšMWHITE DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZL045BVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1123SSWAB_WEEK4 NO Non-Important2021-04-28BxDW~ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¼øHs˜~HHr¼øHrՍ Hs|ՔHs˜~HPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231518DV112315181123AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIH3YRVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK14 NO Non-Important2021-07-06B½DWĆ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr¼Ÿ|HrŲ;Hr¼Ÿ|HrŲ;..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231519DV112315191123AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z49XQLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK12 NO Non-Important2021-06-30B·DW½ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼ØÜHrŲ4Hr¼ØÜHrŲ4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1123 11231520DV112315201123AĄMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UGA2G4Potential COVID-19 illness visit not done when required per protocol. Visit Schedule FOLLOW-UP 1123POT_COVID_ILL NO Non-Important2021-03-22BSDWY YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¼¬ŲHs“(XHr¼¬ŲHrÕzLHswĻĢHs“(XPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1123 11231521DV112315211123AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1OTBORWUrine pregnancy test not performed. Laboratory VACCINATION 1123V1_DAY1_VAX1_L NO Non-Important2021-01-04A`DW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼¬ŲHrÕzÄHr¼¬ŲHrÕzÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231521DV112315211123AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XT0RDJSerology samples processed incorrectly Laboratory FOLLOW-UP 1123V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-15B0DW6 YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼¬ŲHrÕzÄHr¼¬ŲHrÕzÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1123 11231522DV112315221123AšMWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X8NVUROther Informed Consent Informed Consent OPEN LABEL TREATMENT1123Consent NO Non-Important2021-05-18B†DW’ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄh$Hsj8HrÄh$Hrą/Hss£ĄHsj8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1123 11231523DV112315231123AĄMWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X5V21UIncorrect serology sample volume collected Laboratory FOLLOW-UP 1123V201_SURVEIL_CONSENT NO Non-Important2021-03-10BADWM YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄh$HsjtHrÄh$Hrą/PHss¤ģHsjtPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1123 11231523DV112315231123AĄMWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X8NVVCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1123Consent NO Non-Important2021-05-18B†DW’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄh$HsjtHrÄh$Hrą/PHss¤ģHsjtPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1123 11231524DV112315241123AąMWHITE DW DW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P9Y0WDVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1123V2_VAX2_L NO Non-Important2021-01-29BDW% YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĀĄHrāŁŠHrĀĄHrāŁŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231524DV112315241123AąMWHITE DW DW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZCKCPProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1123V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-25B4DW@ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĀĄHrāŁŠHrĀĄHrāŁŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231524DV112315241123AąMWHITE DW DW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z4A0XOVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK10 NO Non-Important2021-07-07BøDWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĀĄHrāŁŠHrĀĄHrāŁŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1123 11231525DV112315251123AąFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P9Y0X5Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1123V2_VAX2_L NO Non-Important2021-01-29BDW% YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĒ/xHrä!“HrĒ/xHrä!“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231525DV112315251123AąFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YBFWVWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK6 NO Non-Important2021-05-26BŒDWš YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĒ/xHrä!“HrĒ/xHrä!“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231525DV112315251123AąFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z4A0XRVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK10 NO Non-Important2021-07-01B°DW¾ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĒ/xHrä!“HrĒ/xHrä!“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231525DV112315251123AąFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZL045EVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1123SSWAB_WEEK12 NO Non-Important2021-07-28BĖDWŁ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĒ/xHrä!“HrĒ/xHrä!“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231526DV112315261123AąFWHITE DWDW™Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P9Y0X8Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1123V2_VAX2_L NO Non-Important2021-01-29BDW% YYPhase 3A@ . . .N. A12-15 YearsNAąHrČLHs} HrČLHrćÉXHs} Hs} Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1123 11231526DV112315261123AąFWHITE DWDW™Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZMUK3KVisit not done Visit Schedule FOLLOW-UP 1123COVID_A1 NO Non-Important2021-05-10B{DWŠ YYPhase 3A@ . . .N. A12-15 YearsNAąHrČLHs} HrČLHrćÉXHs} Hs} Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1124 11241236DV112412361124AŠFASIAN DV÷DW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OHE227Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1124Consent NO Non-Important2020-12-14ADV÷ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr§A,HrĀźXHr§A,HrĀźX..Placebo Placebo .DWYC4591001C4591001 1124 11241236DV112412361124AŠFASIAN DV÷DW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1R1QHLDProcedure/Test not performed per protocol Procedures/Tests VACCINATION 1124V1_DAY1_VAX1_L NO Non-Important2020-12-14ADV÷ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr§A,HrĀźXHr§A,HrĀźX..Placebo Placebo .DWYC4591001C4591001 1124 11241236DV112412361124AŠFASIAN DV÷DW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WXMUSWSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1124Consent NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr§A,HrĀźXHr§A,HrĀźX..Placebo Placebo .DWYC4591001C4591001 1124 11241236DV112412361124AŠFASIAN DV÷DW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XRQ1J5Subject/LAR signed a superseded/outdated version of the ICD Informed Consent FOLLOW-UP 1124Consent NO Non-Important2021-03-10BWDWM YYPhase 3A@ . . .N. A12-15 YearsNAŠHr§A,HrĀźXHr§A,HrĀźX..Placebo Placebo .DWYC4591001C4591001 1124 11241238DV112412381124AŠMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R1QHLGProcedure/Test not performed per protocol Procedures/Tests VACCINATION 1124V1_DAY1_VAX1_L NO Non-Important2020-12-14ADV÷ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr§y0HrÅÓ0Hr§y0HrÅÓ0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1124 11241239DV112412391124AĄMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XRMY2DRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1124Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr§z\HrÅŚģHr§z\HrÅŚģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1124 11241239DV112412391124AĄMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1XROYO3Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1124Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr§z\HrÅŚģHr§z\HrÅŚģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1124 11241242DV112412421124AąMWHITE DV÷DW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XRQ1Z8Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1124Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr§’DHrÄsÜHr§’DHrÄsÜ..Placebo Placebo .DWŽYC4591001C4591001 1124 11241242DV112412421124AąMWHITE DV÷DW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XRQPY7Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1124Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr§’DHrÄsÜHr§’DHrÄsÜ..Placebo Placebo .DWŽYC4591001C4591001 1124 11241243DV112412431124AŠMWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTBWDOVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1124V2_VAX2_L NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrسōHrč¤HrسōHrč¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1124 11241245DV112412451124AąFWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZ5JZ9Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1124V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-11B;DW2 YYPhase 3A@ . . .Y. A12-15 YearsNAąHrØåąHrÅšøHrØåąHrÅšø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1124 11241246DV112412461124AĄFWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PLTDO9Serology sample not collected Laboratory FOLLOW-UP 1124V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-11B;DW2 YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrØåhHrÅń0HrØåhHrÅń0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1124 11241246DV112412461124AĄFWHITE DVųDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1QZ5JZCVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1124V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-11B;DW2 YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrØåhHrÅń0HrØåhHrÅń0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1124 11241247DV112412471124AŠMWHITE DVłDWÓPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PJVT0SVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1124V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-10B9DW1 YYPhase 3A@ . . .N. A12-15 YearsNAŠHr©ĶpHsɑōHr©ĶpHrÄgpHs«H HsɑōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1124 11241249DV112412491124AąMWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z91JB5Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1124V4_MONTH6_L NO Non-Important2021-07-21BŚDWŅ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŖHrĆ4¤HrŖHrĆ4¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1124 11241253DV112412531124AĄFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z9VJX1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1124V4_MONTH6_L NO Non-Important2021-07-23BŚDWŌ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¬ŗ€HrČ?Hr¬ŗ€HrČ?..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1124 11241254DV112412541124AąMWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZCDVUEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1124V4_MONTH6_L NO Non-Important2021-07-30BįDWŪ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¬¹ĢHrČ>¤Hr¬¹ĢHrČ>¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1124 11241255DV112412551124AŠFWHITE DVūDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORZGE4Subject/LAR did not sign the ICD but gave verbal consent Informed Consent VACCINATION 1124Consent NO Non-Important2020-12-18ADVū YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬Õ°HsÕDHr¬Õ°HrÅß$Hsu*°HsÕDPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1124 11241255DV112412551124AŠFWHITE DVūDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PLU8K6Subject/LAR signed and dated ICD after screen/enroll date Informed Consent VACCINATION 1124Consent NO Non-Important2021-01-22B$DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬Õ°HsÕDHr¬Õ°HrÅß$Hsu*°HsÕDPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1124 11241258DV112412581124AąFWHITE DWDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QZSEOZVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1124V2_VAX2_L NO Non-Important2021-01-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr³'”Hs‡üHr³'”HrŠb<Hsr‰Hs‡üPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1124 11241262DV112412621124AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTC116Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1124V2_VAX2_L NO Non-Important2021-01-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr³NøHrĢvąHr³NøHrĢvą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1124 11241262DV112412621124AšFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1QZ5JZFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1124V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-17B9DW8 YYPhase 3A@ . . .Y. A12-15 YearsNAšHr³NøHrĢvąHr³NøHrĢvą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1124 11241265DV112412651124AąFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OTBWDRVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1124V2_VAX2_L NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr»`HrÕQ„Hr»`HrÕQ„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1124 11241268DV112412681124AąFWHITE DW DW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P9Y0VCVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1124V2_VAX2_L NO Non-Important2021-01-27BDW# YYPhase 3A@ . . .N. A12-15 YearsNAąHrĆšHs„<HrĆšHrįb”HssĢHs„<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1124 11241271DV112412711124AĄMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P2SC9WVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1124V2_VAX2_L NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĐģHrą9dHrĐģHrą9d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1124 11241272DV112412721124AĄMWHITE DW DWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P9Y0VFVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1124V2_VAX2_L NO Non-Important2021-01-27BDW# YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĔčHsĪxHrĔčHrįd°HssęHsĪxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1124 11241275DV112412751124AŠMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P9Y0VIVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1124V2_VAX2_L NO Non-Important2021-01-27BDW# YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrČo(HrįŽąHrČo(HrįŽą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1124 11241275DV112412751124AŠMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZH2W41Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1124V4_MONTH6_L NO Non-Important2021-08-11BŲDWē YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrČo(HrįŽąHrČo(HrįŽą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1125 11251246DV112512461125AŠFWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OCMPICOther Informed Consent Informed Consent VACCINATION 1125Consent NO Non-Important2020-12-10ADVó YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr”ėxHr¼mĢHr”ėxHr¼mĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1125 11251246DV112512461125AŠFWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1OTC3JVVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1125V2_VAX2_L NO Non-Important2020-12-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr”ėxHr¼mĢHr”ėxHr¼mĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1125 11251246DV112512461125AŠFWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1PNNGCRProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1125V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-27B1DW# YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr”ėxHr¼mĢHr”ėxHr¼mĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1125 11251249DV112512491125AąFWHITE DVōDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OCMPJROther Informed Consent Informed Consent VACCINATION 1125Consent NO Non-Important2020-12-11ADVō YYPhase 3A@ . . .N. A12-15 YearsNAąHr£‚Hs|€Hr£‚Hr¼£xHsr£XHs|€Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1125 11251252DV112512521125AŠMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PFGS6VVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1125V2_VAX2_L NO Non-Important2021-01-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ(HrĪ©`HrŖ(HrĪ©`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1125 11251253DV112512531125AĄMWHITE DVłDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XII77OOther Informed Consent Informed Consent FOLLOW-UP 1125Consent NO Non-Important2021-05-09B‘DW‰ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŖ'čHs˜epHrŖ'čHrĘhHs|ÉÜHs˜epPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1125 11251253DV112512531125AĄMWHITE DVłDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XIJLDOOther Informed Consent Informed Consent FOLLOW-UP 1125Consent NO Non-Important2021-05-09B‘DW‰ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrŖ'čHs˜epHrŖ'čHrĘhHs|ÉÜHs˜epPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1126 11261230DV112612301013AŠMWHITE DVéDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHJ09CNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1013SSWAB_WEEK14 NO Non-Important2021-06-21BĢDW“ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr•ŲHr°Ø4Hr•ŲHr°Ø4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261230DV112612301013AŠMWHITE DVéDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZNJADQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-08-26CąDWö YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr•ŲHr°Ø4Hr•ŲHr°Ø4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261239DV112612391126AšFWHITE DVėDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTQAVEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126SSWAB_WEEK4 NO Non-Important2021-04-18BŠDWt YYPhase 3A@ . . .N. A12-15 YearsNAšHr—] Hså(Hr—] Hr°X„HsrS0Hså(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261239DV112612391126AšFWHITE DVėDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZNH9ITVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126SSWAB_WEEK6 NO Non-Important2021-05-10B DWŠ YYPhase 3A@ . . .N. A12-15 YearsNAšHr—] Hså(Hr—] Hr°X„HsrS0Hså(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261240DV112612401126AšMWHITE DVėDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTQAVHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126SSWAB_WEEK4 NO Non-Important2021-04-18BŠDWt YYPhase 3A@ . . .N. A12-15 YearsNAšHr—]\Hs’@Hr—]\Hr°XHHsw³čHs’@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261240DV112612401126AšMWHITE DVėDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZL04FHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126SSWAB_WEEK6 NO Non-Important2021-05-10B DWŠ YYPhase 3A@ . . .N. A12-15 YearsNAšHr—]\Hs’@Hr—]\Hr°XHHsw³čHs’@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261246DV112612461126AŠMWHITE DVėDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZNH9IWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126SSWAB_WEEK8 NO Non-Important2021-05-24B®DW˜ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr—§äHr³Hr—§äHr³..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261250DV112612501126AĄMWHITE DVėDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z6HTNEVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1126V102_VAX4 NO Non-Important2021-06-15BÄDW® YYPhase 3A@ . . .N. A12-15 YearsNAĄHr—Ė„Hs˜ČXHr—Ė„Hr±÷˜HstöäHs˜ČXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261255DV112612551126AšMWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128934701IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr˜’øHr³ŲHr˜’øHr³Ų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWµYC4591001C4591001 1126 11261255DV112612551126AšMWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 128934801IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2020-12-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr˜’øHr³ŲHr˜’øHr³Ų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWµYC4591001C4591001 1126 11261258DV112612581126AŠFMULTIPLE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128934001IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™œHr±¶pHr™œHr±¶p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¼YC4591001C4591001 1126 11261258DV112612581126AŠFMULTIPLE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 128934101IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™œHr±¶pHr™œHr±¶p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¼YC4591001C4591001 1126 11261262DV112612621126AšFWHITE DVķDWFPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128933401IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .N. A12-15 YearsNAšHršVœHswœHršVœHr³=œHróėųHswœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW0YC4591001C4591001 1126 11261262DV112612621126AšFWHITE DVķDWFPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 128933501IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2020-12-23BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHršVœHswœHršVœHr³=œHróėųHswœPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW0YC4591001C4591001 1126 11261263DV112612631126AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128933601IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrš`tHr³\Hrš`tHr³\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW·YC4591001C4591001 1126 11261263DV112612631126AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 128933701IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2020-12-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrš`tHr³\Hrš`tHr³\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW·YC4591001C4591001 1126 11261264DV112612641126AŠFWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128933801IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHršn„Hr³JHršn„Hr³J..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261264DV112612641126AŠFWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 128933901IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2020-12-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHršn„Hr³JHršn„Hr³J..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261265DV112612651126AąMWHITE DV÷DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128935501IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr§”¼Hs—=ØHr§”¼HrĀŅčHsu€Hs—=ØPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261265DV112612651126AąMWHITE DV÷DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z6HTPZVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1126V102_VAX4 NO Non-Important2021-06-14B·DW­ YYPhase 3A@ . . .N. A12-15 YearsNAąHr§”¼Hs—=ØHr§”¼HrĀŅčHsu€Hs—=ØPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261266DV112612661126AĄFWHITE DV÷DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTBWDXVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1126V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§)Hs—> Hr§)HrĀÓ`Hsu€Hs—> Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261266DV112612661126AĄFWHITE DV÷DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z6HTQ2Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1126V102_VAX4 NO Non-Important2021-06-14B·DW­ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§)Hs—> Hr§)HrĀÓ`Hsu€Hs—> Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261267DV112612671126AŠMWHITE DV÷DWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128935601IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr§3XHs“'ąHr§3XHrĆ7°HswĶģHs“'ąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1126 11261268DV112612681126AŠFWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128935701IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-14ADV÷ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr§?Hrą¬Hr§?Hrą¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261268DV112612681126AŠFWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 128935801IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr§?Hrą¬Hr§?Hrą¬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261269DV112612691126AšFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128935901IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-14ADV÷ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§Z@HrřLHr§Z@HrřL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261269DV112612691126AšFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 128936001IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§Z@HrřLHr§Z@HrřL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261269DV112612691126AšFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YV73CPVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126SSWAB_WEEK6 NO Non-Important2021-05-12B–DWŒ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§Z@HrřLHr§Z@HrřL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261269DV112612691126AšFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YV73CSVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126SSWAB_WEEK8 NO Non-Important2021-06-17BŗDW° YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§Z@HrřLHr§Z@HrřL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261269DV112612691126AšFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZNISRVVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126SSWAB_WEEK10 NO Non-Important2021-07-21BÜDWŅ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§Z@HrřLHr§Z@HrřL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261270DV112612701126AšMWHITE DV÷DW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128936101IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr§r Hs‘ŲōHr§r HrŝüHsv€ąHs‘ŲōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1126 11261270DV112612701126AšMWHITE DV÷DW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WZ8AA7Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126COVID_A1 NO Non-Important2021-05-12B–DWŒ YYPhase 3A@ . . .N. A12-15 YearsNAšHr§r Hs‘ŲōHr§r HrŝüHsv€ąHs‘ŲōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1126 11261271DV112612711126AšMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128935101IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-14ADV÷ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§‡@HrŽdHr§‡@HrŽd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261271DV112612711126AšMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 128935001IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§‡@HrŽdHr§‡@HrŽd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261271DV112612711126AšMWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z7HZGCVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126V4_MONTH6_L NO Non-Important2021-07-16B×DWĶ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§‡@HrŽdHr§‡@HrŽd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261273DV112612731126AŠFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128935201IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-14ADV÷ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr§ž8HrÅāØHr§ž8HrÅāØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261273DV112612731126AŠFWHITE DV÷DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 128935301IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 2 NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr§ž8HrÅāØHr§ž8HrÅāØ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261274DV112612741126AšFWHITE DVųDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128935401IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1126Vax 1 NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .N. A12-15 YearsNAšHr؞ÜHs’aŌHr؞ÜHrĀķdHsv„ Hs’aŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1126 11261275DV112612751126AšFWHITE DVųDWFPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZL0IAZNasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1126COVID_A NO Non-Important2021-08-26B’DWö YYPhase 3A@ . . .N. A12-15 YearsNAšHrØŚÜHs…4HrØŚÜHrÅę¤HrńW€Hs…4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW+YC4591001C4591001 1126 11261277DV112612771126AšFWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZNISRYVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126SSWAB_WEEK8 NO Non-Important2021-05-19BœDW“ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrØćˆHrÄq HrØćˆHrÄq ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW€YC4591001C4591001 1126 11261278DV112612781126AšFWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZNISS1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126SSWAB_WEEK8 NO Non-Important2021-05-19BœDW“ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrØļ|HrÄq„HrØļ|HrÄq„..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW€YC4591001C4591001 1126 11261281DV112612811126AĄMASIAN DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZKYVMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-12B;DW3 YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr©źDHrĒ,äHr©źDHrĒ,ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261282DV112612821126AŠFASIAN DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YO3CTJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126SSWAB_WEEK12 NO Non-Important2021-06-21B¼DW“ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr©š˜HrŕPHr©š˜HrŕP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261286DV112612861126AŠMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS3088Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1126V2_VAX2_L NO Non-Important2021-01-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ5ųHrĪģąHrŖ5ųHrĪģą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261286DV112612861126AŠMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1PE33HVVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1126V2_VAX2_L NO Non-Important2021-01-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ5ųHrĪģąHrŖ5ųHrĪģą..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261287DV112612871126AšMWHITE DVłDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OSQUCWProcedure not performed as part of vital signs. Procedures/Tests VACCINATION 1126V2_VAX2_L NO Non-Important2021-01-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ6pHs‘ī„HrŖ6pHrŖ6pHsvEXHs‘ī„Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261287DV112612871126AšMWHITE DVłDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OS308BVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1126V2_VAX2_L NO Non-Important2021-01-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ6pHs‘ī„HrŖ6pHrŖ6pHsvEXHs‘ī„Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261287DV112612871126AšMWHITE DVłDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1R1DW8BVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1126V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-10B9DW1 YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖ6pHs‘ī„HrŖ6pHrŖ6pHsvEXHs‘ī„Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261288DV112612881126AŠMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PAGL8XSerology sample not collected Laboratory FOLLOW-UP 1126V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-04B3DW+ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ:lHrś,HrŖ:lHrś,..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261288DV112612881126AŠMWHITE DVłDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z3A98WSerology sample not collected Laboratory REPEAT SCREENING 1 1126V4_MONTH6_L NO Non-Important2021-07-06BĖDWĆ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ:lHrś,HrŖ:lHrś,..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261289DV112612891126AąFWHITE DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R29WY3Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1126COVID_A NO Non-Important2021-03-03BMDWF YYPhase 3A@ . . .N. A12-15 YearsNAąHr«RDHsĢ\Hr«RDHrÅĀPHsry HsĢ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261289DV112612891126AąFWHITE DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1R054QWVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126COVID_A1 NO Non-Important2021-03-03BMDWF YYPhase 3A@ . . .N. A12-15 YearsNAąHr«RDHsĢ\Hr«RDHrÅĀPHsry HsĢ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261290DV112612901126AĄMNOT REPORTED DVśDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z8JZNXVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1126V103_MONTH1 NO Non-Important2021-07-16BŌDWĶ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«zŠHsĀĄHr«zŠHrÄs(HssŌųHsĀĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261293DV112612931126AąFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZGP8WQNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1126SSWAB_WEEK18 NO Non-Important2021-07-17BŌDWĪ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¬hšHrȈHr¬hšHrȈ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261295DV112612951126AąMASIAN DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZNIT6KVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126SSWAB_WEEK10 NO Non-Important2021-06-10BÆDW© YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¬©ÜHrČs$Hr¬©ÜHrČs$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261302DV112613021126AąMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R7E22JVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1126V2_VAX2_L NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr³@äHs“d”Hr³@äHrŁ‰„HswÓHs“d”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261304DV112613041126AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1V9T0HYNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1126COVID_A NO Non-Important2021-04-02B_DWd YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»œHrÕŖŠHr»œHrÕŖŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1126 11261304DV112613041126AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZEA8WWSerology sample not collected Laboratory FOLLOW-UP 1126V201_SURVEIL_CONSENT NO Non-Important2021-04-02B_DWd YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»œHrÕŖŠHr»œHrÕŖŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1126 11261304DV112613041126AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZF0ONPSerology sample not collected Laboratory FOLLOW-UP 1126V201_SURVEIL_CONSENT NO Non-Important2021-04-02B_DWd YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»œHrÕŖŠHr»œHrÕŖŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1126 11261304DV112613041126AŠMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1VS0QE2Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126COVID_A1 NO Non-Important2021-04-02B_DWd YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»œHrÕŖŠHr»œHrÕŖŠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1126 11261307DV112613071126AąFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WPLKQJNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1126COVID_A NO Non-Important2021-03-29BUDW` YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĆ9HrŽÖČHrĆ9HrŽÖČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261307DV112613071126AąFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YV73CVVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126SSWAB_WEEK10 NO Non-Important2021-06-17B„DW° YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĆ9HrŽÖČHrĆ9HrŽÖČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261308DV112613081126AĄMWHITE DW DWĘPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1V8MVSJNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1126COVID_A NO Non-Important2021-04-13BdDWo YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ:DHsøA°HrĆ:DHrŽÖČHsœbŲHsøA°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261308DV112613081126AĄMWHITE DW DWĘPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTQAVKVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126SSWAB_WEEK4 NO Non-Important2021-04-27BrDW} YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ:DHsøA°HrĆ:DHrŽÖČHsœbŲHsøA°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261308DV112613081126AĄMWHITE DW DWĘPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YO3CTMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126SSWAB_WEEK6 NO Non-Important2021-05-06B{DW† YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĆ:DHsøA°HrĆ:DHrŽÖČHsœbŲHsøA°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261309DV112613091126AĄMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YV73D8Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1126SSWAB_WEEK10 NO Non-Important2021-06-17B„DW° YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĆ:ųHrŽ×|HrĆ:ųHrŽ×|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261311DV112613111126AŠMWHITE DW DW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z9VPG2Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1126COVID_A NO Non-Important2021-07-22BĒDWÓ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÄyHs U“HrÄyHrįi`Hs‡¦øHs U“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1126 11261312DV112613121126AąFWHITE DW DWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZL04FKVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126SSWAB_WEEK6 NO Non-Important2021-05-10B~DWŠ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĀ„HsƒšHrĀ„HrŽÕŲHssÆxHsƒšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1126 11261314DV112613141126AŠMWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1U6JP1UVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1126COVID_A1 NO Non-Important2021-03-03B9DWF YYPhase 3A@ . . .N. A12-15 YearsNAŠHržHsŽ“Hr³,DHrš>“Hr³,D..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1139 11391151DV113911511139AąMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 125912101IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrš>“Hr³,DHrš>“Hr³,D..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1139 11391152DV113911521139AšFWHITE DVķDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA125900701IP documentation error - Confirmation of blind error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .N. A12-15 YearsNAšHršhlHsˆŌ\HršhlHr¹ńxHsm$(HsˆŌ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391152DV113911521139AšFWHITE DVķDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 125912201IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .N. A12-15 YearsNAšHršhlHsˆŌ\HršhlHr¹ńxHsm$(HsˆŌ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391152DV113911521139AšFWHITE DVķDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1PI2W6VVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1139V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHršhlHsˆŌ\HršhlHr¹ńxHsm$(HsˆŌ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391152DV113911521139AšFWHITE DVķDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X45HFSIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1139V101_VAX3 NO Non-Important2021-05-13B”DW YYPhase 3A@ . . .N. A12-15 YearsNAšHršhlHsˆŌ\HršhlHr¹ńxHsm$(HsˆŌ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391154DV113911541139AĄFWHITE DVķDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA125930001IP documentation error - Confirmation of blind error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .N. A12-15 YearsNAĄHršjˆHsˆų°HršjˆHr¹÷THsm|Hsˆų°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391154DV113911541139AĄFWHITE DVķDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 125912401IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .N. A12-15 YearsNAĄHršjˆHsˆų°HršjˆHr¹÷THsm|Hsˆų°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391154DV113911541139AĄFWHITE DVķDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1PI2W85Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1139V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHršjˆHsˆų°HršjˆHr¹÷THsm|Hsˆų°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391154DV113911541139AĄFWHITE DVķDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X45HFPIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1139V101_VAX3 NO Non-Important2021-05-13B”DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHršjˆHsˆų°HršjˆHr¹÷THsm|Hsˆų°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391155DV113911551139AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA0125930101IP documentation error - Confirmation of blind error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrškxHr¹šLHrškxHr¹šL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1139 11391155DV113911551139AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@125912501IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrškxHr¹šLHrškxHr¹šL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1139 11391155DV113911551139AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P1VYB3Other Informed Consent Informed Consent VACCINATION 1139Consent NO Non-Important2021-01-26B6DW" YYPhase 3A@ . . .Y. A12-15 YearsNAšHrškxHr¹šLHrškxHr¹šL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1139 11391155DV113911551139AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1TT1O1DOther Informed Consent Informed Consent VACCINATION 1139Consent NO Non-Important2021-01-26B6DW" YYPhase 3A@ . . .Y. A12-15 YearsNAšHrškxHr¹šLHrškxHr¹šL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1139 11391155DV113911551139AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1WTQB5DVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1139SSWAB_WEEK4 NO Non-Important2021-03-02BYDWE YYPhase 3A@ . . .Y. A12-15 YearsNAšHrškxHr¹šLHrškxHr¹šL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1139 11391155DV113911551139AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZJ0QB6Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1139SSWAB_WEEK18 NO Non-Important2021-06-08B»DW§ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrškxHr¹šLHrškxHr¹šL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1139 11391155DV113911551139AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1YVJHOWNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1139COVID_A NO Non-Important2021-06-17BÄDW° YYPhase 3A@ . . .Y. A12-15 YearsNAšHrškxHr¹šLHrškxHr¹šL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1139 11391155DV113911551139AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA€1-1ZHW9SPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1139SSWAB_WEEK20 NO Non-Important2021-06-28BĻDW» YYPhase 3A@ . . .Y. A12-15 YearsNAšHrškxHr¹šLHrškxHr¹šL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1139 11391155DV113911551139AšMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z6WJCVVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1139V4_MONTH6_L NO Non-Important2021-07-08BŁDWÅ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrškxHr¹šLHrškxHr¹šL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW:YC4591001C4591001 1139 11391156DV113911561139AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA125930301IP documentation error - Confirmation of blind error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .Y. A12-15 YearsNAąHrždHr»BųHrždHr»Bų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391156DV113911561139AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 125912601IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .Y. A12-15 YearsNAąHrždHr»BųHrždHr»Bų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391156DV113911561139AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZJ0QB9Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1139SSWAB_WEEK8 NO Non-Important2021-04-05BxDWg YYPhase 3A@ . . .Y. A12-15 YearsNAąHrždHr»BųHrždHr»Bų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391156DV113911561139AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1ZHW9SSVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1139SSWAB_WEEK10 NO Non-Important2021-04-13B€DWo YYPhase 3A@ . . .Y. A12-15 YearsNAąHrždHr»BųHrždHr»Bų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391156DV113911561139AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZJ0QBCNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1139SSWAB_WEEK12 NO Non-Important2021-05-01B’DW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrždHr»BųHrždHr»Bų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391156DV113911561139AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZJ0QBGNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1139SSWAB_WEEK14 NO Non-Important2021-05-19B¤DW“ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrždHr»BųHrždHr»Bų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391156DV113911561139AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1ZHW9T5Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1139SSWAB_WEEK16 NO Non-Important2021-05-24B©DW˜ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrždHr»BųHrždHr»Bų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1139 11391157DV113911571139AšMMULTIPLE DVńDWhPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA125930401IP documentation error - Confirmation of blind error Investigational ProductVACCINATION 1139Vax 1 NO Non-Important2020-12-08ADVń YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸZ HsDWK YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅx|Hrāu¼HrÅx|Hrāu¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401391DV114013911140AĄFMULTIPLE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YY1KIAVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1140SSWAB_WEEK6 NO Non-Important2021-04-15BdDWq YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅx|Hrāu¼HrÅx|Hrāu¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401391DV114013911140AĄFMULTIPLE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YY1KI4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK10 NO Non-Important2021-05-26BDWš YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅx|Hrāu¼HrÅx|Hrāu¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401391DV114013911140AĄFMULTIPLE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1YY1KI7Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK12 NO Non-Important2021-06-16B¢DWÆ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅx|Hrāu¼HrÅx|Hrāu¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401391DV114013911140AĄFMULTIPLE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1Z6WJLMVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK14 NO Non-Important2021-07-13B½DWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅx|Hrāu¼HrÅx|Hrāu¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401392DV114013921140AšMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WNYMXAVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1140V202_SURVEIL_SWAB|639480041999065NO Non-Important2021-04-05BZDWg YYPhase 3A@ . . .N. A12-15 YearsNAšHrņPHs»|HrņPHrįcüHstöäHs»|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401392DV114013921140AšMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WNYMXXVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1140V202_SURVEIL_SWAB|639480041999065NO Non-Important2021-04-28BqDW~ YYPhase 3A@ . . .N. A12-15 YearsNAšHrņPHs»|HrņPHrįcüHstöäHs»|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401392DV114013921140AšMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YY1KINVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1140V103_MONTH1 NO Non-Important2021-07-01B±DW¾ YYPhase 3A@ . . .N. A12-15 YearsNAšHrņPHs»|HrņPHrįcüHstöäHs»|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401393DV114013931140AąMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA126675201IP administered prior to Almac authorizing it for use Investigational ProductVACCINATION 1140Vax 1 NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrÅĄ4HrįošHrÅĄ4Hrįoš..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401393DV114013931140AąMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1V8MALFLab performed out of window Laboratory FOLLOW-UP 1140COVID_A NO Non-Important2021-04-12BaDWn YYPhase 3A@ . . .Y. A12-15 YearsNAąHrÅĄ4HrįošHrÅĄ4Hrįoš..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401393DV114013931140AąMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z6WJLPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK16 NO Non-Important2021-07-14B¾DWĖ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrÅĄ4HrįošHrÅĄ4Hrįoš..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401394DV114013941140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA126675301IP administered prior to Almac authorizing it for use Investigational ProductVACCINATION 1140Vax 1 NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅŅ@HrāæĢHrÅŅ@HrāæĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401394DV114013941140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1P9Y0WTVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1140V2_VAX2_L NO Non-Important2021-01-28BDW$ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅŅ@HrāæĢHrÅŅ@HrāæĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401394DV114013941140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YY1KITVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1140SSWAB_WEEK6 NO Non-Important2021-05-04BwDW„ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅŅ@HrāæĢHrÅŅ@HrāæĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401394DV114013941140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1YY1KIQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK10 NO Non-Important2021-06-12BžDW« YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅŅ@HrāæĢHrÅŅ@HrāæĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401394DV114013941140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1Z6WZXKVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK12 NO Non-Important2021-07-07B·DWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅŅ@HrāæĢHrÅŅ@HrāæĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401394DV114013941140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIML0INasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1140SSWAB_WEEK14 NO Non-Important2021-07-25BÉDWÖ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅŅ@HrāæĢHrÅŅ@HrāæĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401394DV114013941140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1ZHGLIYVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140V4_MONTH6_L NO Non-Important2021-08-06BÕDWā YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅŅ@HrāæĢHrÅŅ@HrāæĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401395DV114013951140AĄFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1R2N265Nasal swab not collected for the visit where it is required Laboratory VACCINATION 1140COVID_A NO Non-Important2021-02-25B2DW@ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĘ÷ģHs“)ĄHrĘ÷ģHrā–ČHsv!ōHs“)ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401395DV114013951140AĄFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R0ME2XOther Informed Consent Informed Consent FOLLOW-UP 1140Consent NO Non-Important2021-03-01B6DWD YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĘ÷ģHs“)ĄHrĘ÷ģHrā–ČHsv!ōHs“)ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401395DV114013951140AĄFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1RUGYW5Other Informed Consent Informed Consent FOLLOW-UP 1140Consent NO Non-Important2021-03-12BADWO YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĘ÷ģHs“)ĄHrĘ÷ģHrā–ČHsv!ōHs“)ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401397DV114013971140AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P9Y0WWVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1140V2_VAX2_L NO Non-Important2021-01-28BDW$ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČ'čHsŽ:<HrČ'čHrāŗąHsr‡tHsŽ:<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401397DV114013971140AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1R290ICVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1140V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-01B5DWD YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČ'čHsŽ:<HrČ'čHrāŗąHsr‡tHsŽ:<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401397DV114013971140AŠFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1RVJD5QOther Informed Consent Informed Consent FOLLOW-UP 1140Consent NO Non-Important2021-03-09B=DWL YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČ'čHsŽ:<HrČ'čHrāŗąHsr‡tHsŽ:<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401398DV114013981140AąMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA126678501IP administered prior to Almac authorizing it for use Investigational ProductVACCINATION 1140Vax 1 NO Non-Important2021-01-08ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrČP°Hrā®ģHrČP°Hrā®ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401398DV114013981140AąMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YCOMCRVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK10 NO Non-Important2021-06-06B–DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrČP°Hrā®ģHrČP°Hrā®ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401398DV114013981140AąMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z6WZXNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK14 NO Non-Important2021-07-09B·DWĘ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrČP°Hrā®ģHrČP°Hrā®ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401398DV114013981140AąMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZHW9POVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK16 NO Non-Important2021-08-03BŠDWß YYPhase 3A@ . . .Y. A12-15 YearsNAąHrČP°Hrā®ģHrČP°Hrā®ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401399DV114013991140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA126678601IP administered prior to Almac authorizing it for use Investigational ProductVACCINATION 1140Vax 1 NO Non-Important2021-01-08ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČQdHrāÆ HrČQdHrāÆ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401399DV114013991140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YY1KIWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK10 NO Non-Important2021-06-19B£DW² YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČQdHrāÆ HrČQdHrāÆ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401399DV114013991140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z6WZXQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK12 NO Non-Important2021-07-09B·DWĘ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČQdHrāÆ HrČQdHrāÆ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401399DV114013991140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIML8NNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1140SSWAB_WEEK14 NO Non-Important2021-07-27BÉDWŲ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČQdHrāÆ HrČQdHrāÆ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401400DV114014001140AŠMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X97ZMBNasal swab not collected by site staff prior to vaccination. Laboratory OPEN LABEL TREATMENT1140V101_VAX3 NO Non-Important2021-05-19B„DW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČY˜Hs“y4HrČY˜HrāÅØHsu#0Hs“y4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401400DV114014001140AŠMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X97ZMESerology sample collected after vaccination at vaccination visits. Laboratory OPEN LABEL TREATMENT1140V101_VAX3 NO Non-Important2021-05-19B„DW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČY˜Hs“y4HrČY˜HrāÅØHsu#0Hs“y4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401400DV114014001140AŠMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZHGLJ1Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1140V103_MONTH1 NO Non-Important2021-08-04BŃDWą YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČY˜Hs“y4HrČY˜HrāÅØHsu#0Hs“y4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1140 11401401DV114014011140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P1RA7ZProcedure not performed as part of vital signs. Procedures/Tests SCREENING 1140V2_VAX2_L NO Non-Important2021-01-05Į0DW YNYPhase 3A@ . . .Y. A12-15 YearsNAšHrČWHrā¶lHrČWHrā¶l..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401401DV114014011140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA126677201IP administered prior to Almac authorizing it for use Investigational ProductVACCINATION 1140Vax 1 NO Non-Important2021-01-08ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČWHrā¶lHrČWHrā¶l..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401401DV114014011140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1R2GD38Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1140V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-05B9DWH YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČWHrā¶lHrČWHrā¶l..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401401DV114014011140AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z7HZODVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1140SSWAB_WEEK18 NO Non-Important2021-07-14B¼DWĖ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČWHrā¶lHrČWHrā¶l..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401402DV114014021140AĄFWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R0ME67Other Informed Consent Informed Consent FOLLOW-UP 1140Consent NO Non-Important2021-02-26B2DWA YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ|üHs LHrČ|üHrā”ĢHswÅHs LPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1140 11401403DV114014031140AĄFWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R0MEBJOther Informed Consent Informed Consent FOLLOW-UP 1140Consent NO Non-Important2021-02-26B2DWA YYPhase 3A@ . . .N. A12-15 YearsNAĄHrČ}ģHs ÄHrČ}ģHrā¢€HswÅ|Hs ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421319DV114213191142AĄFWHITE DVźDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZCKEFEUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-16BĘDWÆ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr–>Hr°”,Hr–>Hr°”,..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1142 11421321DV114213211142AĄMBLACK OR AFRICAN AMERICAN DVėDVžBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QWANCJOther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-02B?DW) YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr—bHHr°a0Hr—bHHr°a0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1142 11421323DV114213231142AŠMWHITE DVģDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTUAC8Serology sample not collected Laboratory FOLLOW-UP 1142V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-22B3DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜æ€Hsļ}ÄHr˜æ€Hr² (HsŃqHsļ}ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1142 11421323DV114213231142AŠMWHITE DVģDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1U6IAIVOther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-10BFDW1 YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜æ€Hsļ}ÄHr˜æ€Hr² (HsŃqHsļ}ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1142 11421323DV114213231142AŠMWHITE DVģDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1PG66KJSerology sample not collected Laboratory FOLLOW-UP 1142V201_SURVEIL_CONSENT NO Non-Important2021-02-10BFDW1 YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜æ€Hsļ}ÄHr˜æ€Hr² (HsŃqHsļ}ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1142 11421323DV114213231142AŠMWHITE DVģDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZCKEG4Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-17BÅDW° YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜æ€Hsļ}ÄHr˜æ€Hr² (HsŃqHsļ}ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1142 11421324DV114213241142AĄMWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XNJQX5Other Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-05-10BŸDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜½ÜHr² HHr˜½ÜHr² H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1142 11421324DV114213241142AĄMWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZCKEG7Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-17BÅDW° YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜½ÜHr² HHr˜½ÜHr² H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW°YC4591001C4591001 1142 11421325DV114213251142AŠFWHITE DVģDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XNJRCWOther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-01B=DW( YYPhase 3A@ . . .N. A12-15 YearsNAŠHr™0Hs—O“Hr™0Hr±·`Hs{„˜Hs—O“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421325DV114213251142AŠFWHITE DVģDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1UCOSTTNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK6 NO Non-Important2021-03-20BlDWW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr™0Hs—O“Hr™0Hr±·`Hs{„˜Hs—O“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421325DV114213251142AŠFWHITE DVģDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WXBDJSVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK6 NO Non-Important2021-03-25BqDW\ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr™0Hs—O“Hr™0Hr±·`Hs{„˜Hs—O“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421326DV114213261142AĄFWHITE DVģDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XBUONKOther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-01B=DW( YYPhase 3A@ . . .N. A12-15 YearsNAĄHr˜’@Hs—OHr˜’@Hr±øPHs{¤äHs—OPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421326DV114213261142AĄFWHITE DVģDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1UI3ZQXNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK6 NO Non-Important2021-03-21BmDWX YYPhase 3A@ . . .N. A12-15 YearsNAĄHr˜’@Hs—OHr˜’@Hr±øPHs{¤äHs—OPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421326DV114213261142AĄFWHITE DVģDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WXBDJVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK6 NO Non-Important2021-03-25BqDW\ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr˜’@Hs—OHr˜’@Hr±øPHs{¤äHs—OPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421326DV114213261142AĄFWHITE DVģDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XNKCEVRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1142Consent NO Non-Important2021-05-24B­DW˜ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr˜’@Hs—OHr˜’@Hr±øPHs{¤äHs—OPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421327DV114213271142AĄMWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WZH1GGVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142COVID_A1 NO Non-Important2021-05-10BŸDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜ī$Hr²Hr˜ī$Hr²..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW·YC4591001C4591001 1142 11421327DV114213271142AĄMWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZCKEGAUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-24BĢDW· YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜ī$Hr²Hr˜ī$Hr²..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW·YC4591001C4591001 1142 11421329DV114213291142AąFWHITE DVķDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WXBDLBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK8 NO Non-Important2021-04-12B‚DWn YYPhase 3A@ . . .N. A12-15 YearsNAąHršdHs‰ö HršdHr³ØHsn<<Hs‰ö Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421329DV114213291142AąFWHITE DVķDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WXBDL8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK10 NO Non-Important2021-04-19B‰DWu YYPhase 3A@ . . .N. A12-15 YearsNAąHršdHs‰ö HršdHr³ØHsn<<Hs‰ö Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421329DV114213291142AąFWHITE DVķDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZHW8Z1Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1142V103_MONTH1 NO Non-Important2021-08-10BśDWę YYPhase 3A@ . . .N. A12-15 YearsNAąHršdHs‰ö HršdHr³ØHsn<<Hs‰ö Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421330DV114213301142AŠMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WXBDLHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK8 NO Non-Important2021-04-12B‚DWn YYPhase 3A@ . . .Y. A12-15 YearsNAŠHršHr³ÄHršHr³Ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421330DV114213301142AŠMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WXBDLEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK10 NO Non-Important2021-04-19B‰DWu YYPhase 3A@ . . .Y. A12-15 YearsNAŠHršHr³ÄHršHr³Ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421330DV114213301142AŠMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZGPHW4Nasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK18 NO Non-Important2021-07-21BęDWŅ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHršHr³ÄHršHr³Ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421330DV114213301142AŠMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z91JBBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142SSWAB_WEEK18 NO Non-Important2021-07-21BęDWŅ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHršHr³ÄHršHr³Ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421333DV114213331142AŠMNOT REPORTED DVūDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OE55I5Nasal swab not collected for the visit where it is required Laboratory SCREENING 1142V1_DAY1_VAX1_L NO Non-Important2020-12-04ĮąDVķYNYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬s@HrĒÜHr¬s@HrĒÜ..Placebo Placebo .DWÓYC4591001C4591001 1142 11421333DV114213331142AŠMNOT REPORTED DVūDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1OE55I2Serology sample not collected Laboratory SCREENING 1142V1_DAY1_VAX1_L NO Non-Important2020-12-04ĮąDVķYNYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬s@HrĒÜHr¬s@HrĒÜ..Placebo Placebo .DWÓYC4591001C4591001 1142 11421333DV114213331142AŠMNOT REPORTED DVūDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZA0V12Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK22 NO Non-Important2021-07-12BĻDWÉ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬s@HrĒÜHr¬s@HrĒÜ..Placebo Placebo .DWÓYC4591001C4591001 1142 11421333DV114213331142AŠMNOT REPORTED DVūDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZG93FXNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK24 NO Non-Important2021-07-26BŻDW× YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬s@HrĒÜHr¬s@HrĒÜ..Placebo Placebo .DWÓYC4591001C4591001 1142 11421335DV114213351142AŠFWHITE DVķDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XN7TBBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK14 NO Non-Important2021-05-16B¤DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrš?hHsļ˜øHrš?hHr³EXHsÓ¾THsļ˜øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWøYC4591001C4591001 1142 11421335DV114213351142AŠFWHITE DVķDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X92JEMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142COVID_B1 NO Non-Important2021-05-21B©DW• YYPhase 3A@ . . .N. A12-15 YearsNAŠHrš?hHsļ˜øHrš?hHr³EXHsÓ¾THsļ˜øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWøYC4591001C4591001 1142 11421335DV114213351142AŠFWHITE DVķDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCKEMNUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-25BĢDWø YYPhase 3A@ . . .N. A12-15 YearsNAŠHrš?hHsļ˜øHrš?hHr³EXHsÓ¾THsļ˜øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWøYC4591001C4591001 1142 11421340DV114213401142AŠFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WHGZ9IVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK2 NO Non-Important2021-02-22BNDW= YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr’hHr¹›8Hr’hHr¹›8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1142 11421340DV114213401142AŠFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZCKEMQUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-07-06BŌDWĆ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr’hHr¹›8Hr’hHr¹›8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1142 11421341DV114213411142AąMWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WHGZ9VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK2 NO Non-Important2021-02-22BNDW= YYPhase 3A@ . . .Y. A12-15 YearsNAąHr’¤Hr¹œ Hr’¤Hr¹œ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421341DV114213411142AąMWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WNYMY3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142V202_SURVEIL_SWAB|637507613037060NO Non-Important2021-03-01BUDWD YYPhase 3A@ . . .Y. A12-15 YearsNAąHr’¤Hr¹œ Hr’¤Hr¹œ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421342DV114213421142AšMWHITE DVšDW}Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1U6KP1SOther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-03B;DW* YYPhase 3A@ . . .N. A12-15 YearsNAšHrž0HsX'XHrž0Hr¼ŸøHs<{˜HsX'XPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWcYC4591001C4591001 1142 11421342DV114213421142AšMWHITE DVšDW}Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WNYMYQVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142V202_SURVEIL_SWAB|636912809185060NO Non-Important2021-02-22BNDW= YYPhase 3A@ . . .N. A12-15 YearsNAšHrž0HsX'XHrž0Hr¼ŸøHs<{˜HsX'XPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWcYC4591001C4591001 1142 11421342DV114213421142AšMWHITE DVšDW}Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WKEYNFRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-12B`DWO YYPhase 3A@ . . .N. A12-15 YearsNAšHrž0HsX'XHrž0Hr¼ŸøHs<{˜HsX'XPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWcYC4591001C4591001 1142 11421342DV114213421142AšMWHITE DVšDW}Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YERU6CRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-12B`DWO YYPhase 3A@ . . .N. A12-15 YearsNAšHrž0HsX'XHrž0Hr¼ŸøHs<{˜HsX'XPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWcYC4591001C4591001 1142 11421342DV114213421142AšMWHITE DVšDW}Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZBK2DCVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1142V103_MONTH1 NO Non-Important2021-06-11B»DWŖ YYPhase 3A@ . . .N. A12-15 YearsNAšHrž0HsX'XHrž0Hr¼ŸøHs<{˜HsX'XPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWcYC4591001C4591001 1142 11421344DV114213441142AŠFNOT REPORTED DVńDWóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OPSIQ0Other Informed Consent Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-08ADVń YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŸrØHsó®ųHrŸrØHr¹¬ĢHsó®ųHsó®ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1142 11421344DV114213441142AŠFNOT REPORTED DVńDWóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QWB8DAOther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-01B8DW( YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŸrØHsó®ųHrŸrØHr¹¬ĢHsó®ųHsó®ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1142 11421344DV114213441142AŠFNOT REPORTED DVńDWóPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YVHD29Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142SSWAB_WEEK22 NO Non-Important2021-06-28BĖDW» YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŸrØHsó®ųHrŸrØHr¹¬ĢHsó®ųHsó®ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1142 11421345DV114213451142AšFNOT REPORTED DVńDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QWB8H2Other Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-01B8DW( YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸtHsž'HHrŸtHr¹«dHsž'HHsž'HPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1142 11421345DV114213451142AšFNOT REPORTED DVńDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YVHD2NVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142SSWAB_WEEK22 NO Non-Important2021-06-28BĖDW» YYPhase 3A@ . . .N. A12-15 YearsNAšHrŸtHsž'HHrŸtHr¹«dHsž'HHsž'HPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1142 11421346DV114213461142AŠFWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZCKEMTUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-25BĘDWø YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr”ō$Hrŗū|Hr”ō$Hrŗū|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWøYC4591001C4591001 1142 11421348DV114213481142AĄMWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QWB8P1Other Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-02B7DW) YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr”óčHr½µtHr”óčHr½µt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1142 11421349DV114213491142AšMWHITE DVóDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCKEMZUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-30BĖDW½ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¢“HsļŗxHr¢“Hr¼ŲHsŅmˆHsļŗxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1142 11421351DV114213511142AšFWHITE DVōDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCKEPKUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-28BČDW» YYPhase 3A@ . . .N. A12-15 YearsNAšHr£DHsļ‰ōHr£DHr¼a`HsŃHsļ‰ōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW»YC4591001C4591001 1142 11421352DV114213521142AŠMWHITE DVōDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OTQ4MPVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1142V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£‚XHsļ” Hr£‚XHrĆ,čHsļ” Hsļ” Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÉYC4591001C4591001 1142 11421352DV114213521142AŠMWHITE DVōDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WHGZ9YVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK2 NO Non-Important2021-02-20BHDW; YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£‚XHsļ” Hr£‚XHrĆ,čHsļ” Hsļ” Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÉYC4591001C4591001 1142 11421352DV114213521142AŠMWHITE DVōDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZNJADUVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK6 NO Non-Important2021-03-31BoDWb YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£‚XHsļ” Hr£‚XHrĆ,čHsļ” Hsļ” Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÉYC4591001C4591001 1142 11421352DV114213521142AŠMWHITE DVōDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WKF7DENasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK8 NO Non-Important2021-04-14B}DWp YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£‚XHsļ” Hr£‚XHrĆ,čHsļ” Hsļ” Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÉYC4591001C4591001 1142 11421352DV114213521142AŠMWHITE DVōDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1YVHD2QVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK10 NO Non-Important2021-04-22B…DWx YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£‚XHsļ” Hr£‚XHrĆ,čHsļ” Hsļ” Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÉYC4591001C4591001 1142 11421352DV114213521142AŠMWHITE DVōDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZCKEPNUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-07-12BÖDWÉ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr£‚XHsļ” Hr£‚XHrĆ,čHsļ” Hsļ” Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÉYC4591001C4591001 1142 11421353DV114213531142AąMWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WOKL36Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK12 NO Non-Important2021-04-23B†DWy YYPhase 3A@ . . .Y. A12-15 YearsNAąHr£ƒHHr½““Hr£ƒHHr½““..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1142 11421353DV114213531142AąMWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YBHJHWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142SSWAB_WEEK20 NO Non-Important2021-06-04B°DW£ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr£ƒHHr½““Hr£ƒHHr½““..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1142 11421354DV114213541142AąFBLACK OR AFRICAN AMERICAN DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1T3QF3GNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK4 NO Non-Important2021-03-11B[DWN YYPhase 3A@ . . .Y. A12-15 YearsNAąHr£„8Hr¼žHr£„8Hr¼ž..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1142 11421354DV114213541142AąFBLACK OR AFRICAN AMERICAN DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YCOMCUVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142SSWAB_WEEK14 NO Non-Important2021-06-07B³DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr£„8Hr¼žHr£„8Hr¼ž..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1142 11421355DV114213551142AĄMMULTIPLE DV÷DWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCKEPQUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-30BĒDW½ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr§9¬HsźeHr§9¬HrĀäøHsŠ`HsźePlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1142 11421356DV114213561142AąFBLACK OR AFRICAN AMERICAN DV÷DWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCKEPTUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-30BĒDW½ YYPhase 3A@ . . .N. A12-15 YearsNAąHr§=0HsźexHr§=0HrĀćŒHsŠ0HsźexPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1142 11421358DV114213581142AŠFBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WLITERSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr،ŠHrĐ8Hr،ŠHrĐ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421358DV114213581142AŠFBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WLITFRSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr،ŠHrĐ8Hr،ŠHrĐ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421358DV114213581142AŠFBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1OTC3JMVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1142V1_DAY1_VAX1_L NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr،ŠHrĐ8Hr،ŠHrĐ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421358DV114213581142AŠFBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QWCRSGOther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-04B4DW+ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr،ŠHrĐ8Hr،ŠHrĐ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421358DV114213581142AŠFBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1WXBDLKVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK4 NO Non-Important2021-03-09BUDWL YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr،ŠHrĐ8Hr،ŠHrĐ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421358DV114213581142AŠFBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1XK2Z5SNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK14 NO Non-Important2021-05-17BšDW‘ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr،ŠHrĐ8Hr،ŠHrĐ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421358DV114213581142AŠFBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA€1-1ZHW9PIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142V4_MONTH6_L NO Non-Important2021-07-14BŌDWĖ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr،ŠHrĐ8Hr،ŠHrĐ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421358DV114213581142AŠFBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z8RQKMLab performed out of window Laboratory REPEAT SCREENING 1 1142V4_MONTH6_L NO Non-Important2021-07-19BŁDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr،ŠHrĐ8Hr،ŠHrĐ8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421359DV114213591142AšMMULTIPLE DVųDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WLITFXSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .N. A12-15 YearsNAšHrØ“ØHsĪšHrØ“ØHrĆØHs{¶<HsĪšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421359DV114213591142AšMMULTIPLE DVųDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WLITG3Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .N. A12-15 YearsNAšHrØ“ØHsĪšHrØ“ØHrĆØHs{¶<HsĪšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421359DV114213591142AšMMULTIPLE DVųDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WHGZA1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK2 NO Non-Important2021-02-22BFDW= YYPhase 3A@ . . .N. A12-15 YearsNAšHrØ“ØHsĪšHrØ“ØHrĆØHs{¶<HsĪšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421359DV114213591142AšMMULTIPLE DVųDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1RHZC29Serology sample not collected Laboratory FOLLOW-UP 1142SSWAB_WEEK4 NO Non-Important2021-03-08BTDWK YYPhase 3A@ . . .N. A12-15 YearsNAšHrØ“ØHsĪšHrØ“ØHrĆØHs{¶<HsĪšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421359DV114213591142AšMMULTIPLE DVųDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-201SLGMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK6 NO Non-Important2021-03-16B\DWS YYPhase 3A@ . . .N. A12-15 YearsNAšHrØ“ØHsĪšHrØ“ØHrĆØHs{¶<HsĪšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421359DV114213591142AšMMULTIPLE DVųDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1Y55SB3Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1142V102_VAX4 NO Non-Important2021-06-09B±DWØ YYPhase 3A@ . . .N. A12-15 YearsNAšHrØ“ØHsĪšHrØ“ØHrĆØHs{¶<HsĪšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421360DV114213601142AŠMBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WLITGJSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrسHrĆLHrسHrĆL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421360DV114213601142AŠMBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WLITGPSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrسHrĆLHrسHrĆL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421360DV114213601142AŠMBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1WHGZA4Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK2 NO Non-Important2021-02-22BFDW= YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrسHrĆLHrسHrĆL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421360DV114213601142AŠMBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1RHZC2CSerology sample not collected Laboratory FOLLOW-UP 1142SSWAB_WEEK4 NO Non-Important2021-03-08BTDWK YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrسHrĆLHrسHrĆL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421360DV114213601142AŠMBLACK OR AFRICAN AMERICAN DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZHW9PLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142V4_MONTH6_L NO Non-Important2021-08-13BņDWé YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrسHrĆLHrسHrĆL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421361DV114213611142AĄMWHITE DVłDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WLITGVSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-16ADVł YYPhase 3A@ . . .N. A12-15 YearsNAĄHr©Õ,Hsļ¹ÄHr©Õ,HrĀÜHHsŅnšHsļ¹ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1142 11421361DV114213611142AĄMWHITE DVłDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WLITH1Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-16ADVł YYPhase 3A@ . . .N. A12-15 YearsNAĄHr©Õ,Hsļ¹ÄHr©Õ,HrĀÜHHsŅnšHsļ¹ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1142 11421361DV114213611142AĄMWHITE DVłDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1U7T8IOOther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-01B0DW( YYPhase 3A@ . . .N. A12-15 YearsNAĄHr©Õ,Hsļ¹ÄHr©Õ,HrĀÜHHsŅnšHsļ¹ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1142 11421361DV114213611142AĄMWHITE DVłDWšPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZCKEPWUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-06-30BÅDW½ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr©Õ,Hsļ¹ÄHr©Õ,HrĀÜHHsŅnšHsļ¹ÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW½YC4591001C4591001 1142 11421362DV114213621142AŠFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WLITI1Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-16ADVł YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr©Ų°HrĆ0Hr©Ų°HrĆ0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421362DV114213621142AŠFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WLITIHSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-16ADVł YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr©Ų°HrĆ0Hr©Ų°HrĆ0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421362DV114213621142AŠFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1SL24ETLab performed out of window Laboratory FOLLOW-UP 1142SSWAB_WEEK2 NO Non-Important2021-02-23BFDW> YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr©Ų°HrĆ0Hr©Ų°HrĆ0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421362DV114213621142AŠFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YCOMD7Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142SSWAB_WEEK18 NO Non-Important2021-05-27B£DW› YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr©Ų°HrĆ0Hr©Ų°HrĆ0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421362DV114213621142AŠFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1YVHD2TVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142SSWAB_WEEK20 NO Non-Important2021-06-18B¹DW± YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr©Ų°HrĆ0Hr©Ų°HrĆ0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421363DV114213631142AŠMWHITE DVłDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WLITINSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-16ADVł YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ ČHrźaHrŖ ČHrźa..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1142 11421363DV114213631142AŠMWHITE DVłDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WLITJDSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-16ADVł YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ ČHrźaHrŖ ČHrźa..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1142 11421363DV114213631142AŠMWHITE DVłDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1PFE8L2Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1142V2_VAX2_L NO Non-Important2021-02-03B2DW* YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ ČHrźaHrŖ ČHrźa..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1142 11421363DV114213631142AŠMWHITE DVłDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1QWB4OQVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1142V2_VAX2_L NO Non-Important2021-02-03B2DW* YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ ČHrźaHrŖ ČHrźa..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1142 11421363DV114213631142AŠMWHITE DVłDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZQ7GX7Serology sample not collected Laboratory REPEAT SCREENING 1 1142V4_MONTH6_L NO Non-Important2021-08-30C DWś YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ ČHrźaHrŖ ČHrźa..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1142 11421363DV114213631142AŠMWHITE DVłDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1ZQSKQSVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142V4_MONTH6_L NO Non-Important2021-08-30C DWś YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖ ČHrźaHrŖ ČHrźa..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1142 11421364DV114213641142AĄFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WLITJJSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-18ADVū YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¬ ōHrČzhHr¬ ōHrČzh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421364DV114213641142AĄFWHITE DVūDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WLITJPSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-18ADVū YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¬ ōHrČzhHr¬ ōHrČzh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421365DV114213651142AĄMWHITE DVūDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WLITK5Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-18ADVū YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬¾|HsµgŲHr¬¾|HrĒ$8Hsœ¶ĄHsµgŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1142 11421365DV114213651142AĄMWHITE DVūDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WLITKBSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-18ADVū YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬¾|HsµgŲHr¬¾|HrĒ$8Hsœ¶ĄHsµgŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1142 11421365DV114213651142AĄMWHITE DVūDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1R3H3R3Site staff training missing/incomplete Other FOLLOW-UP 1142V202_SURVEIL_SWAB|636548569914060NO Non-Important2021-03-03BLDWF YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬¾|HsµgŲHr¬¾|HrĒ$8Hsœ¶ĄHsµgŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1142 11421365DV114213651142AĄMWHITE DVūDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1WXBDLNVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK4 NO Non-Important2021-03-03BLDWF YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬¾|HsµgŲHr¬¾|HrĒ$8Hsœ¶ĄHsµgŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1142 11421365DV114213651142AĄMWHITE DVūDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZHW9SEVisit not done Visit Schedule FOLLOW-UP 1142COVID_A1 NO Non-Important2021-05-03B‰DWƒ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬¾|HsµgŲHr¬¾|HrĒ$8Hsœ¶ĄHsµgŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1142 11421365DV114213651142AĄMWHITE DVūDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZBK2DFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK14 NO Non-Important2021-05-07BDW‡ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬¾|HsµgŲHr¬¾|HrĒ$8Hsœ¶ĄHsµgŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1142 11421365DV114213651142AĄMWHITE DVūDWÄPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1ZNJN1AVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK16 NO Non-Important2021-05-16B–DW YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¬¾|HsµgŲHr¬¾|HrĒ$8Hsœ¶ĄHsµgŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÆYC4591001C4591001 1142 11421366DV114213661142AšMWHITE DVžDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZK004JRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr°zHsź~ČHr°zHrĢ_čHsŠšHsź~ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421366DV114213661142AšMWHITE DVžDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZK008VRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr°zHsź~ČHr°zHrĢ_čHsŠšHsź~ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421366DV114213661142AšMWHITE DVžDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZK009BRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr°zHsź~ČHr°zHrĢ_čHsŠšHsź~ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421366DV114213661142AšMWHITE DVžDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZK009HRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr°zHsź~ČHr°zHrĢ_čHsŠšHsź~ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421366DV114213661142AšMWHITE DVžDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1WM8MITSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr°zHsź~ČHr°zHrĢ_čHsŠšHsź~ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421366DV114213661142AšMWHITE DVžDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1WM8MKNSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr°zHsź~ČHr°zHrĢ_čHsŠšHsź~ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421366DV114213661142AšMWHITE DVžDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1ZCKEPZUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-07-13BĶDWŹ YYPhase 3A@ . . .N. A12-15 YearsNAšHr°zHsź~ČHr°zHrĢ_čHsŠšHsź~ČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421367DV114213671142AĄMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WM8MKUSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°{4HrĢaČHr°{4HrĢaČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421367DV114213671142AĄMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WM8ML0Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°{4HrĢaČHr°{4HrĢaČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421367DV114213671142AĄMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZCKEQ2Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1142Potential ReVax Initial Contact NO Non-Important2021-07-13BĶDWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°{4HrĢaČHr°{4HrĢaČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŹYC4591001C4591001 1142 11421368DV114213681142AĄMWHITE DVžDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZK07XDRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAĄHr°tąHs¹œHr°tąHrĶ›`Hsu-DHs¹œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421368DV114213681142AĄMWHITE DVžDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZK07XJRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAĄHr°tąHs¹œHr°tąHrĶ›`Hsu-DHs¹œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421368DV114213681142AĄMWHITE DVžDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WM8MMKSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAĄHr°tąHs¹œHr°tąHrĶ›`Hsu-DHs¹œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421368DV114213681142AĄMWHITE DVžDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1WM8MMQSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAĄHr°tąHs¹œHr°tąHrĶ›`Hsu-DHs¹œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421368DV114213681142AĄMWHITE DVžDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZK07X1Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAĄHr°tąHs¹œHr°tąHrĶ›`Hsu-DHs¹œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421368DV114213681142AĄMWHITE DVžDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1ZK07X7Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAĄHr°tąHs¹œHr°tąHrĶ›`Hsu-DHs¹œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421368DV114213681142AĄMWHITE DVžDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XQ8VY1Other Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-05-10BDWŠ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr°tąHs¹œHr°tąHrĶ›`Hsu-DHs¹œPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421369DV114213691142AŠFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WM8MO0Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¢ŠHrѦŲHr°¢ŠHrѦŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421369DV114213691142AŠFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WM8MO6Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¢ŠHrѦŲHr°¢ŠHrѦŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421369DV114213691142AŠFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1OTQ4MSVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1142V2_VAX2_L NO Non-Important2021-01-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¢ŠHrѦŲHr°¢ŠHrѦŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421369DV114213691142AŠFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XQ9ZB7Other Informed Consent Informed Consent REPEAT SCREENING 1 1142Consent NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¢ŠHrѦŲHr°¢ŠHrѦŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421369DV114213691142AŠFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZDSO7MNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK18 NO Non-Important2021-07-22BÖDWÓ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¢ŠHrѦŲHr°¢ŠHrѦŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421370DV114213701142AŠFWHITE DVžDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WM8MOMSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°¤8HsüūHHr°¤8HrĢH“Hsį$¤HsüūHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1142 11421370DV114213701142AŠFWHITE DVžDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WMOAN5Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°¤8HsüūHHr°¤8HrĢH“Hsį$¤HsüūHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1142 11421370DV114213701142AŠFWHITE DVžDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1U7TT47Other Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-08B2DW/ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°¤8HsüūHHr°¤8HrĢH“Hsį$¤HsüūHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1142 11421370DV114213701142AŠFWHITE DVžDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1SK9U7ZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142COVID_A1 NO Non-Important2021-03-17BWDWT YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°¤8HsüūHHr°¤8HrĢH“Hsį$¤HsüūHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1142 11421370DV114213701142AŠFWHITE DVžDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XK2Z5VNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK12 NO Non-Important2021-05-06B‰DW† YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°¤8HsüūHHr°¤8HrĢH“Hsį$¤HsüūHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1142 11421370DV114213701142AŠFWHITE DVžDWśPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZNJN1EVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK14 NO Non-Important2021-05-27BžDW› YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°¤8HsüūHHr°¤8HrĢH“Hsį$¤HsüūHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĆYC4591001C4591001 1142 11421371DV114213711142AŠMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WMOAU1Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¤tHrĢg¤Hr°¤tHrĢg¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421371DV114213711142AŠMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WMOAURSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¤tHrĢg¤Hr°¤tHrĢg¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421371DV114213711142AŠMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z8PSBGIncorrect serology sample volume collected Laboratory REPEAT SCREENING 1 1142V4_MONTH6_L NO Non-Important2021-07-13BĶDWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr°¤tHrĢg¤Hr°¤tHrĢg¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421372DV114213721142AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WMOAUXSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±Ā HrĢ\dHr±Ā HrĢ\d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421372DV114213721142AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WMOAVDSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±Ā HrĢ\dHr±Ā HrĢ\d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421372DV114213721142AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1R3H3RCSite staff training missing/incomplete Other FOLLOW-UP 1142V202_SURVEIL_SWAB|636456040862060NO Non-Important2021-03-02BGDWE YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±Ā HrĢ\dHr±Ā HrĢ\d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421372DV114213721142AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1WXBDM0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK4 NO Non-Important2021-03-02BGDWE YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±Ā HrĢ\dHr±Ā HrĢ\d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421372DV114213721142AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1ZNJN1HVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK12 NO Non-Important2021-04-19BwDWu YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±Ā HrĢ\dHr±Ā HrĢ\d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421372DV114213721142AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YYTKPXNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK18 NO Non-Important2021-05-31B”DWŸ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±Ā HrĢ\dHr±Ā HrĢ\d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421372DV114213721142AŠMWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z94BDKSerology sample not collected Laboratory REPEAT SCREENING 1 1142V4_MONTH6_L NO Non-Important2021-07-13BĢDWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr±Ā HrĢ\dHr±Ā HrĢ\d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421373DV114213731142AšMBLACK OR AFRICAN AMERICAN DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WMOAVJSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr±Ä€HsŠ8Hr±Ä€HrĶ½ Hsn“ØHsŠ8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421373DV114213731142AšMBLACK OR AFRICAN AMERICAN DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WMOAVPSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .N. A12-15 YearsNAšHr±Ä€HsŠ8Hr±Ä€HrĶ½ Hsn“ØHsŠ8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421373DV114213731142AšMBLACK OR AFRICAN AMERICAN DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZH2CRUVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1142V103_MONTH1 NO Non-Important2021-07-13BĢDWŹ YYPhase 3A@ . . .N. A12-15 YearsNAšHr±Ä€HsŠ8Hr±Ä€HrĶ½ Hsn“ØHsŠ8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421374DV114213741142AąFBLACK OR AFRICAN AMERICAN DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WMOAVVSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr±Å¬HrĶ¾Hr±Å¬HrĶ¾..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421374DV114213741142AąFBLACK OR AFRICAN AMERICAN DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WMOAW1Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr±Å¬HrĶ¾Hr±Å¬HrĶ¾..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421374DV114213741142AąFBLACK OR AFRICAN AMERICAN DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YYTKQ0Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK18 NO Non-Important2021-06-15B°DW® YYPhase 3A@ . . .Y. A12-15 YearsNAąHr±Å¬HrĶ¾Hr±Å¬HrĶ¾..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421374DV114213741142AąFBLACK OR AFRICAN AMERICAN DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZGPI5ENasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK22 NO Non-Important2021-07-13BĢDWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr±Å¬HrĶ¾Hr±Å¬HrĶ¾..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421375DV114213751142AĄMWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WN0SR7Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr±ėąHsŠ(¬Hr±ėąHrĢd\HsnxšHsŠ(¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421375DV114213751142AĄMWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WN0T93Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr±ėąHsŠ(¬Hr±ėąHrĢd\HsnxšHsŠ(¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421375DV114213751142AĄMWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YYSSUWProcedure/Test not performed per protocol Procedures/Tests VACCINATION 1142V1_DAY1_VAX1_L NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr±ėąHsŠ(¬Hr±ėąHrĢd\HsnxšHsŠ(¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421375DV114213751142AĄMWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X66W73Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK8 NO Non-Important2021-04-04BhDWf YYPhase 3A@ . . .N. A12-15 YearsNAĄHr±ėąHsŠ(¬Hr±ėąHrĢd\HsnxšHsŠ(¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421375DV114213751142AĄMWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZNJN3SVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK12 NO Non-Important2021-05-11BDW‹ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr±ėąHsŠ(¬Hr±ėąHrĢd\HsnxšHsŠ(¬Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421376DV114213761142AĄFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WN0T99Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr±éÄHrŠ\œHr±éÄHrŠ\œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421376DV114213761142AĄFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WN0T9FSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr±éÄHrŠ\œHr±éÄHrŠ\œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421376DV114213761142AĄFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1UGC9J6Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142COVID_A1 NO Non-Important2021-04-08BlDWj YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr±éÄHrŠ\œHr±éÄHrŠ\œ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421377DV114213771142AąFWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WN1MDZSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr±ė¤HsŠ<˜Hr±ė¤HrĪµHsn”ŌHsŠ<˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421377DV114213771142AąFWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WN1MEPSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .N. A12-15 YearsNAąHr±ė¤HsŠ<˜Hr±ė¤HrĪµHsn”ŌHsŠ<˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421377DV114213771142AąFWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XRNUCBOther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-11B4DW2 YYPhase 3A@ . . .N. A12-15 YearsNAąHr±ė¤HsŠ<˜Hr±ė¤HrĪµHsn”ŌHsŠ<˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421377DV114213771142AąFWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XN7TBEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK6 NO Non-Important2021-03-19BXDWV YYPhase 3A@ . . .N. A12-15 YearsNAąHr±ė¤HsŠ<˜Hr±ė¤HrĪµHsn”ŌHsŠ<˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421377DV114213771142AąFWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1U1RKVSVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142COVID_A1 NO Non-Important2021-03-31BdDWb YYPhase 3A@ . . .N. A12-15 YearsNAąHr±ė¤HsŠ<˜Hr±ė¤HrĪµHsn”ŌHsŠ<˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421377DV114213771142AąFWHITE DV’DW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZBK2DIVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1142V103_MONTH1 NO Non-Important2021-07-11BŹDWČ YYPhase 3A@ . . .N. A12-15 YearsNAąHr±ė¤HsŠ<˜Hr±ė¤HrĪµHsn”ŌHsŠ<˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421379DV114213791142AŠMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WN1MEVSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-28ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹©HHs“r,Hr¹©HHrŲK“Hswz|Hs“r,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421379DV114213791142AŠMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WN1MFLSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-28ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹©HHs“r,Hr¹©HHrŲK“Hswz|Hs“r,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421379DV114213791142AŠMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSWW3POther Informed Consent Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-04-29B{DW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¹©HHs“r,Hr¹©HHrŲK“Hswz|Hs“r,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421380DV114213801142AšMASIAN DWDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WN1MGBSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-28ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ÕŠHsźƒ<Hr¹ÕŠHrÖöģHsŃuHsźƒ<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÓYC4591001C4591001 1142 11421380DV114213801142AšMASIAN DWDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WN1MGHSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-28ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ÕŠHsźƒ<Hr¹ÕŠHrÖöģHsŃuHsźƒ<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÓYC4591001C4591001 1142 11421380DV114213801142AšMASIAN DWDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WN1MGXRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-23B:DW> YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ÕŠHsźƒ<Hr¹ÕŠHrÖöģHsŃuHsźƒ<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÓYC4591001C4591001 1142 11421380DV114213801142AšMASIAN DWDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WN1MH3Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-23B:DW> YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ÕŠHsźƒ<Hr¹ÕŠHrÖöģHsŃuHsźƒ<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÓYC4591001C4591001 1142 11421380DV114213801142AšMASIAN DWDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1YBHJHZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK18 NO Non-Important2021-06-06B”DW„ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ÕŠHsźƒ<Hr¹ÕŠHrÖöģHsŃuHsźƒ<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÓYC4591001C4591001 1142 11421380DV114213801142AšMASIAN DWDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1YYTKQ3Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK20 NO Non-Important2021-06-20BÆDW³ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ÕŠHsźƒ<Hr¹ÕŠHrÖöģHsŃuHsźƒ<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÓYC4591001C4591001 1142 11421380DV114213801142AšMASIAN DWDWģPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1Z6XAPVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK24 NO Non-Important2021-07-14BĒDWĖ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¹ÕŠHsźƒ<Hr¹ÕŠHrÖöģHsŃuHsźƒ<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWÓYC4591001C4591001 1142 11421383DV114213831142AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WN1MJVSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-29ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŗśPHrÖš\HrŗśPHrÖš\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1142 11421383DV114213831142AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WN1MKBSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-29ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŗśPHrÖš\HrŗśPHrÖš\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1142 11421383DV114213831142AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WOKL39Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK12 NO Non-Important2021-03-05BCDWH YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŗśPHrÖš\HrŗśPHrÖš\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1142 11421383DV114213831142AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1YYTKQ6Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK16 NO Non-Important2021-05-28B—DWœ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŗśPHrÖš\HrŗśPHrÖš\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1142 11421384DV114213841142AŠFNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WN1MLLSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-29ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»5ŲHrŲI˜Hr»5ŲHrŲI˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421384DV114213841142AŠFNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WN1MLRSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-29ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»5ŲHrŲI˜Hr»5ŲHrŲI˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421384DV114213841142AŠFNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHGLJ4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142V4_MONTH6_L NO Non-Important2021-08-05BÜDWį YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»5ŲHrŲI˜Hr»5ŲHrŲI˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421385DV114213851142AšMNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1WN1MMRSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-31ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr½¢xHrŚ˜ģHr½¢xHrŚ˜ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421385DV114213851142AšMNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1WN1MMXSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-31ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr½¢xHrŚ˜ģHr½¢xHrŚ˜ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421385DV114213851142AšMNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WN1MN3Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-22B6DW= YYPhase 3A@ . . .Y. A12-15 YearsNAšHr½¢xHrŚ˜ģHr½¢xHrŚ˜ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421385DV114213851142AšMNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WN1MN9Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-22B6DW= YYPhase 3A@ . . .Y. A12-15 YearsNAšHr½¢xHrŚ˜ģHr½¢xHrŚ˜ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421385DV114213851142AšMNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1Z7X5NYNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK16 NO Non-Important2021-06-15B§DW® YYPhase 3A@ . . .Y. A12-15 YearsNAšHr½¢xHrŚ˜ģHr½¢xHrŚ˜ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421385DV114213851142AšMNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZD1SGLNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK22 NO Non-Important2021-07-26BŠDW× YYPhase 3A@ . . .Y. A12-15 YearsNAšHr½¢xHrŚ˜ģHr½¢xHrŚ˜ģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1142 11421386DV114213861142AŠMNOT REPORTED DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WN1MNFSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-31ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr½¤XHs‡FdHr½¤XHrŚšĢHsn?ĄHs‡FdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421386DV114213861142AŠMNOT REPORTED DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WN1MNVSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2020-12-31ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr½¤XHs‡FdHr½¤XHrŚšĢHsn?ĄHs‡FdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421386DV114213861142AŠMNOT REPORTED DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WN1MO1Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-22B6DW= YYPhase 3A@ . . .N. A12-15 YearsNAŠHr½¤XHs‡FdHr½¤XHrŚšĢHsn?ĄHs‡FdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421386DV114213861142AŠMNOT REPORTED DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WN1MOHRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-22B6DW= YYPhase 3A@ . . .N. A12-15 YearsNAŠHr½¤XHs‡FdHr½¤XHrŚšĢHsn?ĄHs‡FdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421386DV114213861142AŠMNOT REPORTED DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZBK2E5Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1142V103_MONTH1 NO Non-Important2021-07-20BŹDWŃ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr½¤XHs‡FdHr½¤XHrŚšĢHsn?ĄHs‡FdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421388DV114213881142AšMWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WN1MPTSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ4HrßķģHrÄ4Hrßķģ..Placebo Placebo .DWŒYC4591001C4591001 1142 11421388DV114213881142AšMWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WN1MPZSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ4HrßķģHrÄ4Hrßķģ..Placebo Placebo .DWŒYC4591001C4591001 1142 11421388DV114213881142AšMWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZF2FU7Serology sample not collected Laboratory FOLLOW-UP 1142V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-17BHDWT YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ4HrßķģHrÄ4Hrßķģ..Placebo Placebo .DWŒYC4591001C4591001 1142 11421388DV114213881142AšMWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1SK9U82Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142COVID_A1 NO Non-Important2021-03-17BHDWT YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ4HrßķģHrÄ4Hrßķģ..Placebo Placebo .DWŒYC4591001C4591001 1142 11421388DV114213881142AšMWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1T3P3R3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-17BHDWT YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ4HrßķģHrÄ4Hrßķģ..Placebo Placebo .DWŒYC4591001C4591001 1142 11421388DV114213881142AšMWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA€1-1ZNJN3VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK8 NO Non-Important2021-04-08B^DWj YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ4HrßķģHrÄ4Hrßķģ..Placebo Placebo .DWŒYC4591001C4591001 1142 11421388DV114213881142AšMWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XT0RD0Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK10 NO Non-Important2021-04-22BlDWx YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ4HrßķģHrÄ4Hrßķģ..Placebo Placebo .DWŒYC4591001C4591001 1142 11421388DV114213881142AšMWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z94BDENasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1142SSWAB_WEEK14 NO Non-Important2021-05-20BˆDW” YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄ4HrßķģHrÄ4Hrßķģ..Placebo Placebo .DWŒYC4591001C4591001 1142 11421389DV114213891142AąMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WN1MQFSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrʼn Hrį*Hrʼn Hrį*..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421389DV114213891142AąMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WN1MQLSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrʼn Hrį*Hrʼn Hrį*..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421389DV114213891142AąMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1VM3J63Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK6 NO Non-Important2021-03-22BLDWY YYPhase 3A@ . . .Y. A12-15 YearsNAąHrʼn Hrį*Hrʼn Hrį*..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421389DV114213891142AąMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1VM3J66Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK6 NO Non-Important2021-04-05BZDWg YYPhase 3A@ . . .Y. A12-15 YearsNAąHrʼn Hrį*Hrʼn Hrį*..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421390DV114213901142AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZK0800Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŋxHrą3LHrŋxHrą3L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421390DV114213901142AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZK0806Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŋxHrą3LHrŋxHrą3L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421390DV114213901142AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1ZK07ZOSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŋxHrą3LHrŋxHrą3L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421390DV114213901142AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1ZK07ZUSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-06ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŋxHrą3LHrŋxHrą3L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421390DV114213901142AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1WKFUQNRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-24B2DW? YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŋxHrą3LHrŋxHrą3L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421390DV114213901142AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1WKFUZFRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-24B2DW? YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŋxHrą3LHrŋxHrą3L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421390DV114213901142AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA€1-1Z6XAPZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1142SSWAB_WEEK22 NO Non-Important2021-07-07B·DWÄ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŋxHrą3LHrŋxHrą3L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421390DV114213901142AŠFWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZK0816Other Informed Consent Informed Consent REPEAT SCREENING 1 1142Consent NO Non-Important2021-07-20BÄDWŃ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŋxHrą3LHrŋxHrą3L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1142 11421391DV114213911142AŠMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WKFUZLRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-23B1DW> YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅ«ŠHsŗPHrÅ«ŠHrć’øHsu.čHsŗPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421391DV114213911142AŠMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WKFV0CRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-23B1DW> YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅ«ŠHsŗPHrÅ«ŠHrć’øHsu.čHsŗPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421391DV114213911142AŠMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1QZZX5ZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-23B1DW> YYPhase 3A@ . . .N. A12-15 YearsNAŠHrÅ«ŠHsŗPHrÅ«ŠHrć’øHsu.čHsŗPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1142 11421392DV114213921142AšMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WKFV0IRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-05B9DWH YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČ)Hrä(¼HrČ)Hrä(¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1142 11421392DV114213921142AšMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WKFV0ORevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-05B9DWH YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČ)Hrä(¼HrČ)Hrä(¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1142 11421393DV114213931142AŠMWHITE DWDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XQCFYSSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-08ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČW|Hsž8HrČW|Hrā†`Hsž8Hsž8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1142 11421393DV114213931142AŠMWHITE DWDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XQCFYYSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-08ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČW|Hsž8HrČW|Hrā†`Hsž8Hsž8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1142 11421393DV114213931142AŠMWHITE DWDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QWCS4LOther Informed Consent Informed Consent VACCINATION 1142Consent NO Non-Important2021-02-02BDW) YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČW|Hsž8HrČW|Hrā†`Hsž8Hsž8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1142 11421393DV114213931142AŠMWHITE DWDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WKFV0URevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-26B2DWA YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČW|Hsž8HrČW|Hrā†`Hsž8Hsž8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1142 11421393DV114213931142AŠMWHITE DWDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WKFV10Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-02-26B2DWA YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČW|Hsž8HrČW|Hrā†`Hsž8Hsž8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1142 11421393DV114213931142AŠMWHITE DWDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA€1-1ZNJN3YVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK12 NO Non-Important2021-04-28BoDW~ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČW|Hsž8HrČW|Hrā†`Hsž8Hsž8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1142 11421393DV114213931142AŠMWHITE DWDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XE4N3NNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1142SSWAB_WEEK14 NO Non-Important2021-05-12B}DWŒ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČW|Hsž8HrČW|Hrā†`Hsž8Hsž8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1142 11421393DV114213931142AŠMWHITE DWDWūPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1ZHFHBAPotential COVID-19 illness visit not done when required per protocol. Visit Schedule REPEAT SCREENING 1 1142Potential COVID Illness Visit NO Non-Important2021-08-05BŅDWį YYPhase 3A@ . . .N. A12-15 YearsNAŠHrČW|Hsž8HrČW|Hrā†`Hsž8Hsž8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŲYC4591001C4591001 1142 11421394DV114213941142AąMNOT REPORTED DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XQCFZ4Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĢ%PHré$HrĢ%PHré$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421394DV114213941142AąMNOT REPORTED DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1XQCG4KSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĢ%PHré$HrĢ%PHré$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421394DV114213941142AąMNOT REPORTED DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1PFEHMJSerology sample not collected Laboratory VACCINATION 1142V201_SURVEIL_CONSENT NO Non-Important2021-02-08BDW/ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĢ%PHré$HrĢ%PHré$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421394DV114213941142AąMNOT REPORTED DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WKFV16Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-09B:DWL YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĢ%PHré$HrĢ%PHré$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421394DV114213941142AąMNOT REPORTED DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WKFV1CRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-09B:DWL YYPhase 3A@ . . .Y. A12-15 YearsNAąHrĢ%PHré$HrĢ%PHré$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1142 11421395DV114213951142AŠMMULTIPLE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1XQHBTZSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢ'lHrēŹųHrĢ'lHrēŹų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWąYC4591001C4591001 1142 11421395DV114213951142AŠMMULTIPLE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1XQHBYBSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢ'lHrēŹųHrĢ'lHrēŹų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWąYC4591001C4591001 1142 11421395DV114213951142AŠMMULTIPLE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WKFV1IRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-03B4DWF YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢ'lHrēŹųHrĢ'lHrēŹų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWąYC4591001C4591001 1142 11421395DV114213951142AŠMMULTIPLE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1WKFV1ORevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-03B4DWF YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĢ'lHrēŹųHrĢ'lHrēŹų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWąYC4591001C4591001 1142 11421396DV114213961142AšFWHITE DWDWöPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XQHBYHSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢBŲHs÷z8HrĢBŲHrēŪ$HsŪ܈Hs÷z8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1142 11421396DV114213961142AšFWHITE DWDWöPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XQHC6FSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1142Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢBŲHs÷z8HrĢBŲHrēŪ$HsŪ܈Hs÷z8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1142 11421396DV114213961142AšFWHITE DWDWöPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XRQKV8Other Informed Consent Informed Consent VACCINATION 1142Consent NO Non-Important2021-02-01BDW( YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢBŲHs÷z8HrĢBŲHrēŪ$HsŪ܈Hs÷z8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1142 11421396DV114213961142AšFWHITE DWDWöPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WKFV1URevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-01B2DWD YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢBŲHs÷z8HrĢBŲHrēŪ$HsŪ܈Hs÷z8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1142 11421396DV114213961142AšFWHITE DWDWöPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WKFV2ARevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1142Consent NO Non-Important2021-03-01B2DWD YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢBŲHs÷z8HrĢBŲHrēŪ$HsŪ܈Hs÷z8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1142 11421396DV114213961142AšFWHITE DWDWöPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1WXBDM3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1142SSWAB_WEEK8 NO Non-Important2021-03-30BODWa YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢBŲHs÷z8HrĢBŲHrēŪ$HsŪ܈Hs÷z8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1142 11421396DV114213961142AšFWHITE DWDWöPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZF2K70Serology sample not collected Laboratory REPEAT SCREENING 1 1142V4_MONTH6_L NO Non-Important2021-08-03BĶDWß YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢBŲHs÷z8HrĢBŲHrēŪ$HsŪ܈Hs÷z8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŁYC4591001C4591001 1147 11471263DV114712631147AĄMWHITE DVīDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PGIV5FVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-06B@DW- YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr›ZˆHr¹ĒĄHr›ZˆHr¹ĒĄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471264DV114712641147AąMWHITE DVīDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OPUKCKProcedure/Test not performed per protocol Procedures/Tests VACCINATION 1147V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr›h\Hs‰ā˜Hr›h\Hr¹§¤Hsn2dHs‰ā˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471264DV114712641147AąMWHITE DVīDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YWWQYKLab performed out of window Laboratory OPEN LABEL TREATMENT1147COVID_A NO Non-Important2021-06-23BÉDW¶ YYPhase 3A@ . . .N. A12-15 YearsNAąHr›h\Hs‰ā˜Hr›h\Hr¹§¤Hsn2dHs‰ā˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471271DV114712711147AšFWHITE DVīDWVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1O91Z5BSerology sample not collected Laboratory VACCINATION 1147V1_DAY1_VAX1_L NO Non-Important2020-12-05ADVī YYPhase 3A@ . . .N. A12-15 YearsNAšHr›†˜Hs$dōHr›†˜Hr¹ŽøHs…ÄHs$dōPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW8YC4591001C4591001 1147 11471274DV114712741147AĄFWHITE DVīDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1O91Z5FSerology sample not collected Laboratory VACCINATION 1147V1_DAY1_VAX1_L NO Non-Important2020-12-05ADVī YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr›šHHr¹¶¤Hr›šHHr¹¶¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471274DV114712741147AĄFWHITE DVīDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1VM4BZ3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1147COVID_A1 NO Non-Important2021-04-22B‹DWx YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr›šHHr¹¶¤Hr›šHHr¹¶¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471275DV114712751147AŠFBLACK OR AFRICAN AMERICAN DVīDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTC3JCVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1147V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHr›žDHs‰īPHr›žDHr¹µ<Hsn:ŌHs‰īPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471275DV114712751147AŠFBLACK OR AFRICAN AMERICAN DVīDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z7IGBBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-08BBDW/ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr›žDHs‰īPHr›žDHr¹µ<Hsn:ŌHs‰īPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471277DV114712771147AšFWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z3X4SMSerology sample not collected Laboratory REPEAT SCREENING 1 1147V4_MONTH6_L NO Non-Important2021-06-22BÅDWµ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŸŗ$Hr¹ĆÄHrŸŗ$Hr¹ĆÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471279DV114712791147AĄFWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z7FGGSNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1147SSWAB_WEEK10 NO Non-Important2021-07-02BĻDWæ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŸ¹¬Hr¹ļŌHrŸ¹¬Hr¹ļŌ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471282DV114712821147AąFWHITE DVõDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z2PN8JVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147SSWAB_WEEK8 NO Non-Important2021-06-24BĆDW· YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¤ŸHrĆČHr¤ŸHrĆČ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471283DV114712831147AĄFWHITE DVõDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z3T79GVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147V4_MONTH6_L NO Non-Important2021-06-25BÄDWø YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¤£THrĀŪHr¤£THrĀŪ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471284DV114712841147AšFWHITE DVõDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZGLOXLReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V4_MONTH6_L YES-POP2,YES-POP3Important 2021-05-30BŖDWž YYPhase 3A@ . . .N. A12-15 YearsNAšHr¤¦œHrƐHr¤¦œHrƐ..Placebo Placebo .DWŒYC4591001C4591001 1147 11471284DV114712841147AšFWHITE DVõDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZGLOXOReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V4_MONTH6_L YES-POP2,YES-POP3Important 2021-06-23BĀDW¶ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¤¦œHrƐHr¤¦œHrƐ..Placebo Placebo .DWŒYC4591001C4591001 1147 11471284DV114712841147AšFWHITE DVõDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZGLOMCVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147V4_MONTH6_L NO Non-Important2021-08-09BńDWå YYPhase 3A@ . . .N. A12-15 YearsNAšHr¤¦œHrƐHr¤¦œHrƐ..Placebo Placebo .DWŒYC4591001C4591001 1147 11471285DV114712851147AĄFWHITE DVõDWŸPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XTRFMTVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1147V102_VAX4 NO Non-Important2021-05-31B«DWŸ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr¤ŸXHs„ÓpHr¤ŸXHrĀéąHsm(`Hs„ÓpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471290DV114712901147AŠFWHITE DVüDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PKJ0OLSerology sample not collected Laboratory FOLLOW-UP 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-06B2DW- YYPhase 3A@ . . .N. A12-15 YearsNAŠHr­ŁœHsˆ™ˆHr­ŁœHrÉl Hsm1HHsˆ™ˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471291DV114712911147AšFWHITE DVüDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OH6W9TSubject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1147Consent NO Non-Important2020-12-19ADVü YYPhase 3A@ . . .N. A12-15 YearsNAšHr­ČųHsv?øHr­ČųHrɦ¤HsY‹\Hsv?øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWUYC4591001C4591001 1147 11471291DV114712911147AšFWHITE DVüDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1R01D7WVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1147COVID_A1 NO Non-Important2021-03-03BKDWF YYPhase 3A@ . . .N. A12-15 YearsNAšHr­ČųHsv?øHr­ČųHrɦ¤HsY‹\Hsv?øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWUYC4591001C4591001 1147 11471291DV114712911147AšFWHITE DVüDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZP3JNIRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1147Consent NO Non-Important2021-04-28BƒDW~ YYPhase 3A@ . . .N. A12-15 YearsNAšHr­ČųHsv?øHr­ČųHrɦ¤HsY‹\Hsv?øPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWUYC4591001C4591001 1147 11471296DV114712961147AąFWHITE DVüDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z2PN8MVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147V4_MONTH6_L NO Non-Important2021-07-02BÄDWæ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr­įHrɒ|Hr­įHrɒ|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471300DV114713001147AąFWHITE DVüDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PG66KMSerology sample not collected Laboratory FOLLOW-UP 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-10B6DW1 YYPhase 3A@ . . .N. A12-15 YearsNAąHr­ģ Hs—%ĄHr­ģ HrɊ Hsw£¼Hs—%ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471300DV114713001147AąFWHITE DVüDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XKAPZ9Visit not done Visit Schedule FOLLOW-UP 1147V101_VAX3 NO Non-Important2021-04-02BiDWd YYPhase 3A@ . . .N. A12-15 YearsNAąHr­ģ Hs—%ĄHr­ģ HrɊ Hsw£¼Hs—%ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471300DV114713001147AąFWHITE DVüDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YBHJI2Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1147V102_VAX4 NO Non-Important2021-06-14B²DW­ YYPhase 3A@ . . .N. A12-15 YearsNAąHr­ģ Hs—%ĄHr­ģ HrɊ Hsw£¼Hs—%ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471300DV114713001147AąFWHITE DVüDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZHW9PFVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1147V103_MONTH1 NO Non-Important2021-08-17BņDWķ YYPhase 3A@ . . .N. A12-15 YearsNAąHr­ģ Hs—%ĄHr­ģ HrɊ Hsw£¼Hs—%ĄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471301DV114713011147AŠMWHITE DVüDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PG66KPSerology sample not collected Laboratory FOLLOW-UP 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-10B6DW1 YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr­ņģHrɦ¤Hr­ņģHrɦ¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471301DV114713011147AŠMWHITE DVüDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1XD5Z2NVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147COVID_A1 NO Non-Important2021-05-26BŸDWš YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr­ņģHrɦ¤Hr­ņģHrɦ¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471307DV114713071147AŠMWHITE DVžDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YWWQYNLab performed out of window Laboratory OPEN LABEL TREATMENT1147COVID_A NO Non-Important2021-06-19BµDW² YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°v HsˆåšHr°v HrɃøHsmHøHsˆåšPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471308DV114713081147AšFWHITE DVžDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YVHD2WVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1147V103_MONTH1 NO Non-Important2021-07-01BĮDW¾ YYPhase 3A@ . . .N. A12-15 YearsNAšHr°HsŠ2„Hr°HrÉ”@HsnŒ HsŠ2„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471309DV114713091147AąMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z2PN8PVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147SSWAB_WEEK8 NO Non-Important2021-06-30BĄDW½ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr°’,HrÉ؄Hr°’,HrÉ؄..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471310DV114713101147AšFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QT6M9JVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1147COVID_A1 NO Non-Important2021-02-22B@DW= YYPhase 3A@ . . .Y. A12-15 YearsNAšHr° Hrɲ\Hr° Hrɲ\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471310DV114713101147AšFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZBK2F0Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147V4_MONTH6_L NO Non-Important2021-07-19BÓDWŠ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr° Hrɲ\Hr° Hrɲ\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471311DV114713111147AŠMWHITE DVžDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBK2F3Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1147V103_MONTH1 NO Non-Important2021-07-20BŌDWŃ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr°ŸˆHs…õ˜Hr°ŸˆHrÉ°@Hsm1 Hs…õ˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471313DV114713131147AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YIR5JCVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147SSWAB_WEEK4 NO Non-Important2021-05-26BDWš YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°ŗ|HrɟœHr°ŗ|Hrɟœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471313DV114713131147AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1Z2PN8SVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147SSWAB_WEEK6 NO Non-Important2021-07-02BĀDWæ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°ŗ|HrɟœHr°ŗ|Hrɟœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471313DV114713131147AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZGP4BNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147V4_MONTH6_L NO Non-Important2021-08-13BģDWé YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°ŗ|HrɟœHr°ŗ|Hrɟœ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471314DV114713141147AąMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OT46YOSerology sample not collected Laboratory VACCINATION 1147V1_DAY1_VAX1_L NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .Y. A12-15 YearsNAąHr°¼\HrɀčHr°¼\Hrɀč..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471315DV114713151147AšFWHITE DW DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QY6FK9Serology sample not collected Laboratory FOLLOW-UP 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-22B2DW= YYPhase 3A@ . . .Y. A12-15 YearsNAšHrƤHrÜōHrƤHrÜō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471318DV114713181147AšMWHITE DW DW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z3T79TVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1147V2_VAX2_L NO Non-Important2021-01-28BDW$ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĆFģHsv†DHrĆFģHrāāøHsYŒÄHsv†DPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWvYC4591001C4591001 1147 11471321DV114713211147AšMBLACK OR AFRICAN AMERICAN DW DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBK2F6Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1147V103_MONTH1 NO Non-Important2021-07-13B¾DWŹ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÄohHsīÄHrÄohHrā°HssŠHHsīÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471322DV114713221147AĄMWHITE DW DW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1R1TFSFSerology sample not collected Laboratory VACCINATION 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-26B5DWA YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄtTHrį'„HrÄtTHrį'„..Placebo Placebo .DWŒYC4591001C4591001 1147 11471322DV114713221147AĄMWHITE DW DW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1U1RUSTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-08B?DWK YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄtTHrį'„HrÄtTHrį'„..Placebo Placebo .DWŒYC4591001C4591001 1147 11471322DV114713221147AĄMWHITE DW DW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X92J3TReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14B‚DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄtTHrį'„HrÄtTHrį'„..Placebo Placebo .DWŒYC4591001C4591001 1147 11471322DV114713221147AĄMWHITE DW DW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZZ5Q2JReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-04B—DW£ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄtTHrį'„HrÄtTHrį'„..Placebo Placebo .DWŒYC4591001C4591001 1147 11471322DV114713221147AĄMWHITE DW DW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZHGWCJNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1147COVID_C NO Non-Important2021-08-06BÖDWā YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄtTHrį'„HrÄtTHrį'„..Placebo Placebo .DWŒYC4591001C4591001 1147 11471322DV114713221147AĄMWHITE DW DW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZE8ETFProcedure/Test not performed per protocol Procedures/Tests REPEAT SCREENING 1 1147POT_COVID_ILL|649956386396030 NO Non-Important2021-08-06BÖDWā YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÄtTHrį'„HrÄtTHrį'„..Placebo Placebo .DWŒYC4591001C4591001 1147 11471323DV114713231147AąMWHITE DW DW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X92J3WReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14B‚DWŽ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĉäHrį•4HrĉäHrį•4..Placebo Placebo .DWŒYC4591001C4591001 1147 11471323DV114713231147AąMWHITE DW DW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z94B1JReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-04B—DW£ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĉäHrį•4HrĉäHrį•4..Placebo Placebo .DWŒYC4591001C4591001 1147 11471324DV114713241147AŠFWHITE DW DW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QWNWKMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1147COVID_A1 NO Non-Important2021-02-25B4DW@ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĊ˜HsŽxHrĊ˜Hrį•čHsrjdHsŽxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471327DV114713271147AąMWHITE DW DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1QZCKCSProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-25B4DW@ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĔčHrĔčHrĔčHrĔč..BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471327DV114713271147AąMWHITE DW DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHXSQVReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-07B{DW‡ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĔčHrĔčHrĔčHrĔč..BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471327DV114713271147AąMWHITE DW DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHXSQZReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-04B—DW£ YYPhase 3A@ . . .N. A12-15 YearsNAąHrĔčHrĔčHrĔčHrĔč..BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471328DV114713281147AšFWHITE DW DWŌPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z6704FSubject/LAR signed and dated ICD after screen/enroll date Informed Consent OPEN LABEL TREATMENT1147Consent NO Non-Important2021-07-01B²DW¾ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒHsŹ×ųHrĒHrāHHs­čČHsŹ×ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1147 11471328DV114713281147AšFWHITE DW DWŌPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z6704HProcedure/Test not performed per protocol Procedures/Tests OPEN LABEL TREATMENT1147V101_VAX3 NO Non-Important2021-07-19BÄDWŠ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒHsŹ×ųHrĒHrāHHs­čČHsŹ×ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1147 11471328DV114713281147AšFWHITE DW DWŌPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZIGGBQVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1147V103_MONTH1 NO Non-Important2021-08-18BāDWī YYPhase 3A@ . . .N. A12-15 YearsNAšHrĒHsŹ×ųHrĒHrāHHs­čČHsŹ×ųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW•YC4591001C4591001 1147 11471330DV114713301147AšFWHITE DW DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z07BD1Urine pregnancy test not performed. Laboratory OPEN LABEL TREATMENT1147V102_VAX4 NO Non-Important2021-06-14B”DW­ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĞHHs—lÄHrĞHHrāę“Hssé˜Hs—lÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471330DV114713301147AšFWHITE DW DW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YBHJI5Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1147V102_VAX4 NO Non-Important2021-06-14B”DW­ YYPhase 3A@ . . .N. A12-15 YearsNAšHrĞHHs—lÄHrĞHHrāę“Hssé˜Hs—lÄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471332DV114713321147AąMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBK2FJVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1147V103_MONTH1 NO Non-Important2021-07-16BĄDWĶ YYPhase 3A@ . . .N. A12-15 YearsNAąHrōŠHs‘ö@HrōŠHrāʘHssŚ˜Hs‘ö@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471332DV114713321147AąMWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZQO1V2Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1147COVID_A NO Non-Important2021-08-17BąDWķ YYPhase 3A@ . . .N. A12-15 YearsNAąHrōŠHs‘ö@HrōŠHrāʘHssŚ˜Hs‘ö@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471333DV114713331147AšMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1R7E23CVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1147V2_VAX2_L NO Non-Important2021-02-03BDW* YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŔŲHrźÉ$HrŔŲHrźÉ$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471334DV114713341147AŠFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YVHD2ZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147SSWAB_WEEK6 NO Non-Important2021-06-22BØDWµ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖHrį#HrŖHrį#..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471334DV114713341147AŠFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIML8SNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1147SSWAB_WEEK8 NO Non-Important2021-07-10BŗDWĒ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrŖHrį#HrŖHrį#..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471335DV114713351147AšMWHITE DWDW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZHW9SHVisit not done Visit Schedule REPEAT SCREENING 1 1147COVID_A1 NO Non-Important2021-05-07BzDW‡ YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖōHrį$<HrŖōHrį$<..Placebo Placebo .DWŒYC4591001C4591001 1147 11471335DV114713351147AšMWHITE DWDW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z94B1MReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-20B‡DW” YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖōHrį$<HrŖōHrį$<..Placebo Placebo .DWŒYC4591001C4591001 1147 11471335DV114713351147AšMWHITE DWDW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z94B33Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-10BœDW© YYPhase 3A@ . . .N. A12-15 YearsNAšHrŖōHrį$<HrŖōHrį$<..Placebo Placebo .DWŒYC4591001C4591001 1147 11471336DV114713361147AšFWHITE DWDW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZBJFDNLab performed out of window Laboratory REPEAT SCREENING 1 1147COVID_A NO Non-Important2021-07-14B¾DWĖ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÅØHrįEĄHrÅØHrįEĄ..Placebo Placebo .DWŒYC4591001C4591001 1147 11471336DV114713361147AšFWHITE DWDW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZHXSRDReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-07-22BĘDWÓ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÅØHrįEĄHrÅØHrįEĄ..Placebo Placebo .DWŒYC4591001C4591001 1147 11471336DV114713361147AšFWHITE DWDW#Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZHXSRAReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1147V2_VAX2_L YES-POP2,YES-POP3Important 2021-08-12BŪDWč YYPhase 3A@ . . .N. A12-15 YearsNAšHrÅØHrįEĄHrÅØHrįEĄ..Placebo Placebo .DWŒYC4591001C4591001 1147 11471337DV114713371147AŠMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z2PN8VVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1147SSWAB_WEEK8 NO Non-Important2021-07-02B²DWæ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÅ®ÜHrįüHrÅ®ÜHrįü..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471338DV114713381147AŠMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1QZR7VPOther Informed Consent Informed Consent FOLLOW-UP 1147Consent NO Non-Important2021-03-01B7DWD YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÅĮ`Hrį&HrÅĮ`Hrį&..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471338DV114713381147AŠMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIML95Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1147SSWAB_WEEK12 NO Non-Important2021-07-18BĀDWĻ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrÅĮ`Hrį&HrÅĮ`Hrį&..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471340DV114713401147AĄFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1XKAPZCVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1147POT_COVID_ILL|643560399562058 NO Non-Important2021-05-03BvDWƒ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅŚ°HrįqHrÅŚ°Hrįq..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471340DV114713401147AĄFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YWUHXELab performed out of window Laboratory REPEAT SCREENING 1 1147COVID_A NO Non-Important2021-05-24B‹DW˜ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅŚ°HrįqHrÅŚ°Hrįq..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471340DV114713401147AĄFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIML98Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1147SSWAB_WEEK8 NO Non-Important2021-06-25B«DWø YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅŚ°HrįqHrÅŚ°Hrįq..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471340DV114713401147AĄFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZIML9BNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1147SSWAB_WEEK10 NO Non-Important2021-07-13B½DWŹ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅŚ°HrįqHrÅŚ°Hrįq..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471341DV114713411147AąMASIAN DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZGO9CGVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1147V103_MONTH1 NO Non-Important2021-08-04BÓDWą YYPhase 3A@ . . .N. A12-15 YearsNAąHrÅå“Hs˜¤|HrÅå“HrįgDHs|ś`Hs˜¤|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1147 11471342DV114713421147AĄMASIAN DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZGO9CBVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1147V103_MONTH1 NO Non-Important2021-08-04BÓDWą YYPhase 3A@ . . .N. A12-15 YearsNAĄHrÅå<Hs˜„0HrÅå<HrįfHs|śŲHs˜„0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1147 11471344DV114713441147AĄFWHITE DWDW3BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P93Z07Subject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1147V1_DAY1_VAX1_L NO Non-Important2021-01-13A€DW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅėHröŖdHrÅėHröŖd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1147 11471345DV114713451147AšMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBK2FMVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1147V103_MONTH1 NO Non-Important2021-07-16BĄDWĶ YYPhase 3A@ . . .N. A12-15 YearsNAšHrÅģųHsĆ8HrÅģųHrāä˜Hsu#ØHsĆ8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŒYC4591001C4591001 1147 11471346DV114713461147AĄFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1SJSPLJSerology sample not collected Laboratory FOLLOW-UP 1147V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-26B4DWA YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrÅņŌHrį^˜HrÅņŌHrį^˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501118DV115011181150AŠMWHITE DV»DVĪBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1NUUOMEOther Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2020-10-15ADV» YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrX ŠHrqHrX ŠHrq..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501118DV115011181150AŠMWHITE DV»DVĪBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1X206YJVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK4 NO Non-Important2021-04-07BÆDWi YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrX ŠHrqHrX ŠHrq..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501118DV115011181150AŠMWHITE DV»DVĪBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZCKER9Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1150Potential ReVax Initial Contact NO Non-Important2021-05-13BÓDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrX ŠHrqHrX ŠHrq..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501120DV115011201150AšMWHITE DV»DW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1NUTN4OOther Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2020-10-15ADV» YYPhase 3A@ . . .N. A12-15 YearsNAšHrXDšHs’„HrXDšHru7,Hsv|ØHs’„Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501121DV115011211150AšFWHITE DV»DW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCKERCUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1150Potential ReVax Initial Contact NO Non-Important2021-05-13BÓDW YYPhase 3A@ . . .N. A12-15 YearsNAšHrXq“Hs’?ŲHrXq“Hrq,ąHsv6Hs’?ŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501125DV115011251150AąMBLACK OR AFRICAN AMERICAN DVæDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P9XMA1Procedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1150POT_COVID_ILL NO Non-Important2020-12-20B?DVż YYPhase 3A@ . . .N. A12-15 YearsNAąHr]qdHs‘å$Hr]qdHryg¬Hssē@Hs‘å$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501126DV115011261150AĄFMULTIPLE DVæDVŌBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1NPX56QUrine pregnancy test not performed. Laboratory VACCINATION 1150V1_DAY1_VAX1_L NO Non-Important2020-10-19ADVæ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr]|¤HrymÄHr]|¤HrymÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501127DV115011271150AšMWHITE DVæDVÖBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1NUUWVWOther Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2020-10-19ADVæ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr]’¬Hr| ¼Hr]’¬Hr| ¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501129DV115011291150AĄFWHITE DVĄDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1NNFIZPUrine pregnancy test not performed. Laboratory VACCINATION 1150V1_DAY1_VAX1_L NO Non-Important2020-10-20ADVĄ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr^›„Hs†YpHr^›„HrzCüHslļØHs†YpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501129DV115011291150AĄFWHITE DVĄDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X206YMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK4 NO Non-Important2021-04-09B¬DWk YYPhase 3A@ . . .N. A12-15 YearsNAĄHr^›„Hs†YpHr^›„HrzCüHslļØHs†YpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501129DV115011291150AĄFWHITE DVĄDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X20LTPVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK6 NO Non-Important2021-04-17B“DWs YYPhase 3A@ . . .N. A12-15 YearsNAĄHr^›„Hs†YpHr^›„HrzCüHslļØHs†YpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501129DV115011291150AĄFWHITE DVĄDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1X20LTSVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK8 NO Non-Important2021-04-23BŗDWy YYPhase 3A@ . . .N. A12-15 YearsNAĄHr^›„Hs†YpHr^›„HrzCüHslļØHs†YpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501129DV115011291150AĄFWHITE DVĄDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1Z3T873Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1150V103_MONTH1 NO Non-Important2021-07-07CPDWÄ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr^›„Hs†YpHr^›„HrzCüHslļØHs†YpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501132DV115011321150AąMWHITE DVĄDVŌBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZAMFPJOther Informed Consent Informed Consent FOLLOW-UP 1150Consent NO Non-Important2021-02-09BqDW0 YYPhase 3A@ . . .Y. A12-15 YearsNAąHr_ĢHry Hr_ĢHry ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501132DV115011321150AąMWHITE DVĄDVŌBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1UCO558Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150COVID_A1 NO Non-Important2021-04-06B©DWh YYPhase 3A@ . . .Y. A12-15 YearsNAąHr_ĢHry Hr_ĢHry ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501134DV115011341150AšMWHITE DVĮDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCKERFUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1150Potential ReVax Initial Contact NO Non-Important2021-05-13BĶDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr`"°HsŽ:“Hr`"°HrzyäHsrvXHsŽ:“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501135DV115011351150AąMWHITE DVĮDVŲBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZCKERSUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1150Potential ReVax Initial Contact NO Non-Important2021-05-13BĶDW YYPhase 3A@ . . .Y. A12-15 YearsNAąHr`%DHr~pųHr`%DHr~pų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501168DV115011681150AŠMWHITE DVėDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P9XMBOVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-01B>DW( YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr——øHr³&¤Hr——øHr³&¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501168DV115011681150AŠMWHITE DVėDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XA1US1Participant entered into asymptomatic swabbing part of study after they were unblinded Other REPEAT SCREENING 1 1150V201_SURVEIL_CONSENT NO Non-Important2021-05-20BŖDW” YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr——øHr³&¤Hr——øHr³&¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501168DV115011681150AŠMWHITE DVėDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YBHJIVVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-06-11BĄDWŖ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr——øHr³&¤Hr——øHr³&¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501171DV115011711150AąFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZZ5Q2MReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1150V2_VAX2_L YES-POP2,YES-POP3Important 2021-09-01CDWü YYPhase 3A@ . . .Y. A12-15 YearsNAąHr˜«”Hr“iŲHr˜«”Hr“iŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501183DV115011831150AąMWHITE DVńDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z67CGFSerology sample not collected Laboratory REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-06-25BČDWø YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŸn¬Hr¹°PHrŸn¬Hr¹°P..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501187DV115011871150AŠMWHITE DVņDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z9VJXEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-07-23BćDWŌ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr ŅģHr¹—“Hr ŅģHr¹—“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501189DV115011891150AšFWHITE DVóDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X20LTVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK8 NO Non-Important2021-04-07BwDWi YYPhase 3A@ . . .N. A12-15 YearsNAšHr”āTHsŽSHr”āTHr»VlHsr\HsŽSPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501190DV115011901150AŠFWHITE DVóDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X20LTYVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK8 NO Non-Important2021-04-07BwDWi YYPhase 3A@ . . .N. A12-15 YearsNAŠHr”įÜHsŽRŲHr”įÜHr»UōHsr\THsŽRŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501191DV115011911150AąFWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1X20LW9Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK2 NO Non-Important2021-02-19BHDW: YYPhase 3A@ . . .Y. A12-15 YearsNAąHr”öōHr¼gšHr”öōHr¼gš..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501193DV115011931150AąFWHITE DVóDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OAY4GMOther Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2020-12-10ADVó YYPhase 3A@ . . .N. A12-15 YearsNAąHr¢/čHs…ę\Hr¢/čHr½ž|HsmhHs…ę\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501195DV115011951150AĄMWHITE DVōDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X20LWCVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK6 NO Non-Important2021-04-06BuDWh YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£6,HsŽP¼Hr£6,Hr½‘\Hsr€ØHsŽP¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501195DV115011951150AĄMWHITE DVōDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X20LWFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK8 NO Non-Important2021-04-15B~DWq YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£6,HsŽP¼Hr£6,Hr½‘\Hsr€ØHsŽP¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501196DV115011961150AąMWHITE DVōDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X20LX2Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK6 NO Non-Important2021-04-06BuDWh YYPhase 3A@ . . .N. A12-15 YearsNAąHr£6¤HsŽQ4Hr£6¤Hr½‘ Hsr€lHsŽQ4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501196DV115011961150AąMWHITE DVōDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X20LX5Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK8 NO Non-Important2021-04-15B~DWq YYPhase 3A@ . . .N. A12-15 YearsNAąHr£6¤HsŽQ4Hr£6¤Hr½‘ Hsr€lHsŽQ4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501200DV115012001150AĄMWHITE DVōDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZNJNARVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK6 NO Non-Important2021-04-05BtDWg YYPhase 3A@ . . .N. A12-15 YearsNAĄHr£ŽLHs†\Hr£ŽLHr½æLHsm$(Hs†\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501201DV115012011150AšFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1X20LX8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK6 NO Non-Important2021-04-05BtDWg YYPhase 3A@ . . .Y. A12-15 YearsNAšHr£ŽHr½æˆHr£ŽHr½æˆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501203DV115012031150AšMWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YIQWD8Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150SSWAB_WEEK16 NO Non-Important2021-06-10B³DW© YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§(HrĀĪ°Hr§(HrĀĪ°..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501205DV115012051150AšFWHITE DV÷DW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PKTXS8Other Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2021-01-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHr§B”HrĆI¼Hr§B”HrĆI¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501209DV115012091150AĄMWHITE DVųDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YM0M5NVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150SSWAB_WEEK20 NO Non-Important2021-06-22B¾DWµ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr؅ŒHrĆXHr؅ŒHrĆX..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501214DV115012141150AĄMWHITE DVųDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTBWEIVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1150V2_VAX2_L NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrØó“Hs’GXHrØó“HrĒ0ąHssų Hs’GXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501214DV115012141150AĄMWHITE DVųDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y29BTBVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1150POT_COVID_CONVA|645108273204030 NO Non-Important2021-06-11B³DWŖ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrØó“Hs’GXHrØó“HrĒ0ąHssų Hs’GXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501221DV115012211150AšFWHITE DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YO3CUCVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-06-22B¼DWµ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr«S¬HrČT4Hr«S¬HrČT4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWMYC4591001C4591001 1150 11501228DV115012281150AšFWHITE DVūDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSHW4KVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1150V102_VAX4 NO Non-Important2021-06-03BØDW¢ YYPhase 3A@ . . .N. A12-15 YearsNAšHr¬Ē HsˆŌ\Hr¬Ē HrÅēHsiģHsˆŌ\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŠYC4591001C4591001 1150 11501233DV115012331150AĄMWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBK2FPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-07-26BŚDW× YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°_HrĢDHr°_HrĢD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501237DV115012371150AšFWHITE DVžDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONF58GOther Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2020-12-21ADVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr°ŠüHs“‹Hr°ŠüHrĻųHsu$Hs“‹Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501237DV115012371150AšFWHITE DVžDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X20M03Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK2 NO Non-Important2021-02-22B@DW= YYPhase 3A@ . . .N. A12-15 YearsNAšHr°ŠüHs“‹Hr°ŠüHrĻųHsu$Hs“‹Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501237DV115012371150AšFWHITE DVžDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XD90VXOther Informed Consent Informed Consent OPEN LABEL TREATMENT1150Consent NO Non-Important2021-05-19B–DW“ YYPhase 3A@ . . .N. A12-15 YearsNAšHr°ŠüHs“‹Hr°ŠüHrĻųHsu$Hs“‹Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501238DV115012381150AĄFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONFNDSOther Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2020-12-22ADV’ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr±¶¬HrŠd”Hr±¶¬HrŠd”..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501238DV115012381150AĄFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZIK1D5Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150SSWAB_WEEK26 NO Non-Important2021-08-13BėDWé YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr±¶¬HrŠd”Hr±¶¬HrŠd”..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501238DV115012381150AĄFWHITE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHW9QWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-08-17BļDWķ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr±¶¬HrŠd”Hr±¶¬HrŠd”..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501239DV115012391150AŠFMULTIPLE DV’DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1X20M06Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK8 NO Non-Important2021-04-13BqDWo YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr² ÜHrĻ˜Hr² ÜHrĻ˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501240DV115012401150AąMWHITE DV’DW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R1PD1HOther Informed Consent Informed Consent FOLLOW-UP 1150Consent NO Non-Important2021-02-26BCDWA YYPhase 3A@ . . .N. A12-15 YearsNAąHr²Hs‡“Hr²HrŠm|HsnwˆHs‡“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501242DV115012421150AšMWHITE DWDWgPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1VI83AXVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1150V102_VAX4 NO Non-Important2021-04-05BhDWg YYPhase 3A@ . . .N. A12-15 YearsNAšHr³,Hs:ļHr³,HrŃl|HsфHs:ļPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWEYC4591001C4591001 1150 11501245DV115012451150AąFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1SK9ULRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150COVID_A1 NO Non-Important2021-03-17BPDWT YYPhase 3A@ . . .Y. A12-15 YearsNAąHr¹Č8Hr× Hr¹Č8Hr× ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW”YC4591001C4591001 1150 11501246DV115012461150AšMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PJ7AMQVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1150V2_VAX2_L NO Non-Important2021-01-29B!DW% YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŗhHrćŽčHrŗhHrćŽč..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501246DV115012461150AšMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1T3Q4BUVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-12BKDWO YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŗhHrćŽčHrŗhHrćŽč..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501246DV115012461150AšMWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHGW7XVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-08-11BćDWē YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŗhHrćŽčHrŗhHrćŽč..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501247DV115012471150AąMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YE2OTTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V202_SURVEIL_SWAB|643812986479058NO Non-Important2021-05-27B–DW› YYPhase 3A@ . . .Y. A12-15 YearsNAąHrŗīŌHrÖ¼HrŗīŌHrÖ¼..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501250DV115012501150AŠFNOT REPORTED DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ONY5KBOther Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2020-12-29ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr»/ĄHr׹Hr»/ĄHr׹..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501252DV115012521150AšMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z2PN8YVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150SSWAB_WEEK18 NO Non-Important2021-07-05B½DWĀ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr»FHrՃčHr»FHrՃč..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501256DV115012561150AĄMMULTIPLE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OW74D1Other Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr¼dØHr՛Hr¼dØHr՛..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501258DV115012581150AąFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XE2UPOOther Informed Consent Informed Consent OPEN LABEL TREATMENT1150Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAąHr¼¢ÄHs“{PHr¼¢ÄHrŚ„XHsu6ąHs“{PPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501259DV115012591150AŠMWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XE2URNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1150Consent NO Non-Important2021-05-19BDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¼£Hs“{ŒHr¼£HrŚ„ŠHsu7Hs“{ŒPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501262DV115012621150AĄFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHGW81Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-08-05BŚDWį YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr½šųHrŲZxHr½šųHrŲZx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501263DV115012631150AĄMWHITE DW DWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OW74ILOther Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2021-01-04ADW YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĀÓ$Hs“"@HrĀÓ$HrąäHsu,Hs“"@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501268DV115012681150AŠFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XFTTSAVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V202_SURVEIL_SWAB|643035587307058NO Non-Important2021-05-15B„DW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĆ?lHrŽÖPHrĆ?lHrŽÖP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501269DV115012691150AĄFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZHGW84Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-08-04BÕDWą YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĆAHrą7HHrĆAHrą7H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501276DV115012761150AšMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z97VPRVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150SSWAB_WEEK16 NO Non-Important2021-07-08B¹DWÅ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrƜHrą<čHrƜHrą<č..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501278DV115012781150AĄMWHITE DW DW“Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YO3CUFVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1150V102_VAX4 NO Non-Important2021-06-21BØDW“ YYPhase 3A@ . . .N. A12-15 YearsNAĄHrĞüHs ³8HrĞüHrąE”Hs~u˜Hs ³8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501280DV115012801150AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 126899801IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1150Vax 1 NO Non-Important2021-01-06ADW YYPhase 3A@ . . .N. A12-15 YearsNAąHrŒ¼Hs’8”HrŒ¼Hrāā|Hsu dHs’8”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501280DV115012801150AąFWHITE DWDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1T5WLA4Other Informed Consent Informed Consent FOLLOW-UP 1150Consent NO Non-Important2021-03-02B8DWE YYPhase 3A@ . . .N. A12-15 YearsNAąHrŒ¼Hs’8”HrŒ¼Hrāā|Hsu dHs’8”Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501285DV115012851150AšMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P23R7GOther Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2021-01-07ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĒäHrįUģHrĒäHrįUģ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501286DV115012861150AŠFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P25HU7Other Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2021-01-07ADW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĒ\HrįV(HrĒ\HrįV(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501289DV115012891150AšFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P25I70Other Informed Consent Informed Consent VACCINATION 1150Consent NO Non-Important2021-01-08ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrČ^ĄHsˆõ¤HrČ^ĄHräģHsn˜XHsˆõ¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501289DV115012891150AšFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X7PJ4LOther Informed Consent Informed Consent OPEN LABEL TREATMENT1150Consent NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrČ^ĄHsˆõ¤HrČ^ĄHräģHsn˜XHsˆõ¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501289DV115012891150AšFWHITE DWDW¢Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X7PJ13Subject/LAR signed consent but did not date it Informed Consent OPEN LABEL TREATMENT1150Consent NO Non-Important2021-05-14BDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHrČ^ĄHsˆõ¤HrČ^ĄHräģHsn˜XHsˆõ¤Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501293DV115012931150AšMWHITE DWDW3BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P93Z1CSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1150V1_DAY1_VAX1_L NO Non-Important2021-01-15APDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢ4PHrö‹tHrĢ4PHrö‹t..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWDYC4591001C4591001 1150 11501293DV115012931150AšMWHITE DWDW3BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1P29DM0Subject was vaccinated despite meeting temporary delay criterion #3 (anticipation of receiving seasonal or pandemic influenza vaccine within 14 days or any other non-study vaccine within 28 days afterIP administration) Investigational ProductVACCINATION 1150V1_DAY1_VAX1_L NO Non-Important2021-01-15APDW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĢ4PHrö‹tHrĢ4PHrö‹t..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWDYC4591001C4591001 1150 11501295DV115012951150AĄMWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBK2GCVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1150V4_MONTH6_L NO Non-Important2021-07-20BæDWŃ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrĢTlHrč(@HrĢTlHrč(@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501296DV115012961150AšMWHITE DWDW”Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X20M09Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK6 NO Non-Important2021-04-07BWDWi YYPhase 3A@ . . .N. A12-15 YearsNAšHrĢ|€Hs‡›šHrĢ|€HrźĖ@Hsn„äHs‡›šPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1150 11501298DV115012981150AŠMASIAN DWDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X20M0CVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1150SSWAB_WEEK4 NO Non-Important2021-04-05BTDWg YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĶ|4Hs…öHrĶ|4HrēÉHsmOüHs…öPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1152 11521604DV115216041152AšMWHITE DVėDWbPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128259601IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-02ADVė YYPhase 3A@ . . .N. A12-15 YearsNAšHr—„ČHs4C$Hr—„ČHr°­ŌHsņDHs4C$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWFYC4591001C4591001 1152 11521604DV115216041152AšMWHITE DVėDWbPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 128265901Other IP deviation Investigational ProductVACCINATION 1152Vax 2 NO Non-Important2020-12-21BDVž YYPhase 3A@ . . .N. A12-15 YearsNAšHr—„ČHs4C$Hr—„ČHr°­ŌHsņDHs4C$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWFYC4591001C4591001 1152 11521605DV115216051152AšMWHITE DVėDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128259701IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-02ADVė YYPhase 3A@ . . .Y. A12-15 YearsNAšHr—³$Hr±ĆĢHr—³$Hr±ĆĢ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWTYC4591001C4591001 1152 11521607DV115216071152AąFWHITE DVģDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128264301IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .N. A12-15 YearsNAąHr˜ĘLHsš ,Hr˜ĘLHr³ŲHs~f\Hsš ,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1152 11521607DV115216071152AąFWHITE DVģDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 128266701Other IP deviation Investigational ProductVACCINATION 1152Vax 2 NO Non-Important2020-12-23BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr˜ĘLHsš ,Hr˜ĘLHr³ŲHs~f\Hsš ,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1152 11521608DV115216081152AĄFWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128362901IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr˜Ä0Hr³!øHr˜Ä0Hr³!ø..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1152 11521611DV115216111152AąMWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128363201IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr˜õhHr±ņ4Hr˜õhHr±ņ4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1152 11521612DV115216121152AŠFWHITE DVģDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128363301IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜ń0Hs¾źˆHr˜ń0Hr±ōČHs£FHHs¾źˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1152 11521612DV115216121152AŠFWHITE DVģDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 128267301Other IP deviation Investigational ProductVACCINATION 1152Vax 2 NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜ń0Hs¾źˆHr˜ń0Hr±ōČHs£FHHs¾źˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1152 11521612DV115216121152AŠFWHITE DVģDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZLQIC3Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1152V103_MONTH1 NO Non-Important2021-08-25C DWõ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜ń0Hs¾źˆHr˜ń0Hr±ōČHs£FHHs¾źˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1152 11521612DV115216121152AŠFWHITE DVģDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZQN69BVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1152V103_MONTH1 NO Non-Important2021-08-25C DWõ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜ń0Hs¾źˆHr˜ń0Hr±ōČHs£FHHs¾źˆPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1152 11521613DV115216131152AŠFWHITE DVģDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128363501IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜ļŒHs¾ģąHr˜ļŒHr±ųHs£D¤Hs¾ģąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1152 11521613DV115216131152AŠFWHITE DVģDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 128267501Other IP deviation Investigational ProductVACCINATION 1152Vax 2 NO Non-Important2020-12-22BDV’ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜ļŒHs¾ģąHr˜ļŒHr±ųHs£D¤Hs¾ģąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1152 11521613DV115216131152AŠFWHITE DVģDWĖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZLQIC7Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1152V103_MONTH1 NO Non-Important2021-08-25C DWõ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜ļŒHs¾ģąHr˜ļŒHr±ųHs£D¤Hs¾ģąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW®YC4591001C4591001 1152 11521614DV115216141152AąFWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128363601IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr˜’|Hr±Ź˜Hr˜’|Hr±Ź˜..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1152 11521615DV115216151152AšMWHITE DVģDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128363701IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .N. A12-15 YearsNAšHr™ Hs‘ŌųHr™ Hr²ųHswuĢHs‘ŌųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1152 11521615DV115216151152AšMWHITE DVģDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XN7TO0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1152SSWAB_WEEK2 NO Non-Important2021-05-05BšDW… YYPhase 3A@ . . .N. A12-15 YearsNAšHr™ Hs‘ŌųHr™ Hr²ųHswuĢHs‘ŌųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1152 11521615DV115216151152AšMWHITE DVģDW©Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YLW4O5Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL TREATMENT1152COVID_A NO Non-Important2021-06-01BµDW  YYPhase 3A@ . . .N. A12-15 YearsNAšHr™ Hs‘ŌųHr™ Hr²ųHswuĢHs‘ŌųPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1152 11521617DV115216171152AŠMWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128364001IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™¼Hr¹–ÄHr™¼Hr¹–Ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĖYC4591001C4591001 1152 11521617DV115216171152AŠMWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1PJ7AMTVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1152V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™¼Hr¹–ÄHr™¼Hr¹–Ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĖYC4591001C4591001 1152 11521617DV115216171152AŠMWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z6ZZNBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1152V4_MONTH6_L NO Non-Important2021-07-14BąDWĖ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™¼Hr¹–ÄHr™¼Hr¹–Ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĖYC4591001C4591001 1152 11521617DV115216171152AŠMWHITE DVģDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z7IG17Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1152V4_MONTH6_L NO Non-Important2021-07-14BąDWĖ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr™¼Hr¹–ÄHr™¼Hr¹–Ä..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWĖYC4591001C4591001 1152 11521619DV115216191152AąMWHITE DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128364301IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-03ADVģ YYPhase 3A@ . . .Y. A12-15 YearsNAąHr™!Hr² dHr™!Hr² d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1152 11521625DV115216251152AĄMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128258301IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHršHr³+HršHr³+..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1152 11521625DV115216251152AĄMWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZCKEYZUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1152Potential ReVax Initial Contact NO Non-Important2021-06-23BŹDW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHršHr³+HršHr³+..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1152 11521626DV115216261152AĄMWHITE DVķDWÓPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128258401IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr™žōHsÉu˜Hr™žōHr³'ŠHs« HsÉu˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1152 11521626DV115216261152AĄMWHITE DVķDWÓPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZCKEZ2Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1152Potential ReVax Initial Contact NO Non-Important2021-06-23BŹDW¶ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr™žōHsÉu˜Hr™žōHr³'ŠHs« HsÉu˜Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW¶YC4591001C4591001 1152 11521628DV115216281152AąFWHITE DVķDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128258601IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrš 4Hr³2\Hrš 4Hr³2\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWØYC4591001C4591001 1152 11521629DV115216291152AšMWHITE DVķDW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128258701IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-04ADVķ YYPhase 3A@ . . .N. A12-15 YearsNAšHrš |HrŽ‡ĢHrš |Hr³_ŌHrÄ'tHrŽ‡ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1152 11521629DV115216291152AšMWHITE DVķDW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA0128724801Other IP deviation Investigational ProductOPEN LABEL TREATMENT1152Vax 3 NO Non-Important2021-01-05B!DW YYPhase 3A@ . . .N. A12-15 YearsNAšHrš |HrŽ‡ĢHrš |Hr³_ŌHrÄ'tHrŽ‡ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1152 11521629DV115216291152AšMWHITE DVķDW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1PGIV5OVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1152V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-05B!DW YYPhase 3A@ . . .N. A12-15 YearsNAšHrš |HrŽ‡ĢHrš |Hr³_ŌHrÄ'tHrŽ‡ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1152 11521629DV115216291152AšMWHITE DVķDW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 128706301IP documentation error - IRT Confirmation Report Error Investigational ProductOPEN LABEL TREATMENT1152Vax 4 NO Non-Important2021-01-27B7DW# YYPhase 3A@ . . .N. A12-15 YearsNAšHrš |HrŽ‡ĢHrš |Hr³_ŌHrÄ'tHrŽ‡ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1152 11521629DV115216291152AšMWHITE DVķDW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZBJNGVNasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1152COVID_A NO Non-Important2021-07-16BįDWĶ YYPhase 3A@ . . .N. A12-15 YearsNAšHrš |HrŽ‡ĢHrš |Hr³_ŌHrÄ'tHrŽ‡ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW YC4591001C4591001 1152 11521633DV115216331152AšMWHITE DVšDW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128256201IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .N. A12-15 YearsNAšHržxHs›^°HržxHr¹ę8Hs}ĢHs›^°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1152 11521633DV115216331152AšMWHITE DVšDW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 128269301Other IP deviation Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .N. A12-15 YearsNAšHržxHs›^°HržxHr¹ę8Hs}ĢHs›^°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1152 11521633DV115216331152AšMWHITE DVšDW°Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZH2NMRVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1152V103_MONTH1 NO Non-Important2021-07-28BźDWŁ YYPhase 3A@ . . .N. A12-15 YearsNAšHržxHs›^°HržxHr¹ę8Hs}ĢHs›^°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW‘YC4591001C4591001 1152 11521635DV115216351152AšFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128256601IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .Y. A12-15 YearsNAšHržXHr¹¶¤HržXHr¹¶¤..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1152 11521636DV115216361152AŠMBLACK OR AFRICAN AMERICAN DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128256701IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .Y. A12-15 YearsNAŠHržüHr¹‘ŲHržüHr¹‘Ų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWēYC4591001C4591001 1152 11521636DV115216361152AŠMBLACK OR AFRICAN AMERICAN DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZGN7TEUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1152Potential ReVax Initial Contact NO Non-Important2021-08-11BųDWē YYPhase 3A@ . . .Y. A12-15 YearsNAŠHržüHr¹‘ŲHržüHr¹‘Ų..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWēYC4591001C4591001 1152 11521637DV115216371152AŠFWHITE DVšDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128256801IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž!(HsŅ°Hrž!(Hr¹ŹĢHsvF HsŅ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1152 11521637DV115216371152AŠFWHITE DVšDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 128269701Other IP deviation Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž!(HsŅ°Hrž!(Hr¹ŹĢHsvF HsŅ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1152 11521637DV115216371152AŠFWHITE DVšDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1X20M20Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1152SSWAB_WEEK10 NO Non-Important2021-04-21BˆDWw YYPhase 3A@ . . .N. A12-15 YearsNAŠHrž!(HsŅ°Hrž!(Hr¹ŹĢHsvF HsŅ°Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1152 11521638DV115216381152AšMWHITE DVšDWwPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128257001IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .N. A12-15 YearsNAšHrž¤HsP2 Hrž¤Hrŗ°Hs5É`HsP2 Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW`YC4591001C4591001 1152 11521638DV115216381152AšMWHITE DVšDWwPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 128269901Other IP deviation Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .N. A12-15 YearsNAšHrž¤HsP2 Hrž¤Hrŗ°Hs5É`HsP2 Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW`YC4591001C4591001 1152 11521639DV115216391152AĄFWHITE DVšDW§Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128257301IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1152Vax 1 NO Non-Important2020-12-07ADVš YYPhase 3A@ . . .N. A12-15 YearsNAĄHržŌHrɅŌHréa`Hs|ą Hs—>ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1223 12231277DV122312771223AĄMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1PDKG7FVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1223V2_VAX2_L NO Non-Important2021-02-02BDW) YYPhase 3A@ . . .N. A12-15 YearsNAĄHrɅŌHs—>ŌHrɅŌHréa`Hs|ą Hs—>ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1223 12231277DV122312771223AĄMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGCVI9Other Informed Consent Informed Consent FOLLOW-UP 1223Consent NO Non-Important2021-04-06BXDWh YYPhase 3A@ . . .N. A12-15 YearsNAĄHrɅŌHs—>ŌHrɅŌHréa`Hs|ą Hs—>ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1223 12231277DV122312771223AĄMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YM0M81Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1223SSWAB_WEEK2 NO Non-Important2021-04-27BmDW} YYPhase 3A@ . . .N. A12-15 YearsNAĄHrɅŌHs—>ŌHrɅŌHréa`Hs|ą Hs—>ŌPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1223 12231278DV122312781223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA0127784801IP documentation error - Confirmation of blind error Investigational ProductVACCINATION 1223Vax 1 NO Non-Important2021-01-09ADW YYPhase 3A@ . . .Y. A12-15 YearsNAšHrɐœHré‡HrɐœHré‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231278DV122312781223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1PJL0WIVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1223V2_VAX2_L NO Non-Important2021-02-02BDW) YYPhase 3A@ . . .Y. A12-15 YearsNAšHrɐœHré‡HrɐœHré‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231278DV122312781223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1XGCVU6Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1223Consent NO Non-Important2021-04-01BSDWc YYPhase 3A@ . . .Y. A12-15 YearsNAšHrɐœHré‡HrɐœHré‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231278DV122312781223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XGCVUCOther Informed Consent Informed Consent FOLLOW-UP 1223Consent NO Non-Important2021-04-11B]DWm YYPhase 3A@ . . .Y. A12-15 YearsNAšHrɐœHré‡HrɐœHré‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231278DV122312781223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1Z8PR8XVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1223V4_MONTH6_L NO Non-Important2021-07-22BĆDWÓ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrɐœHré‡HrɐœHré‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231278DV122312781223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZGPHVVNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK18 NO Non-Important2021-08-05BŃDWį YYPhase 3A@ . . .Y. A12-15 YearsNAšHrɐœHré‡HrɐœHré‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231278DV122312781223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZMUK3GNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK20 NO Non-Important2021-08-19BßDWļ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrɐœHré‡HrɐœHré‡..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231279DV122312791223AŠFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OZPPIZOther Informed Consent Informed Consent VACCINATION 1223Consent NO Non-Important2021-01-09ADW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrɑŒHs“;ĢHrɑŒHréxHstÜhHs“;ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231279DV122312791223AŠFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZEQEFRRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1223Consent NO Non-Important2021-05-19BƒDW“ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrɑŒHs“;ĢHrɑŒHréxHstÜhHs“;ĢPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231280DV122312801223AŠFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZNJNIIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1223V4_MONTH6_L NO Non-Important2021-08-30BźDWś YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrɘ”HrāĘŌHrɘ”HrāĘŌ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1223 12231281DV122312811223AąFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1PJL0WLVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1223V2_VAX2_L NO Non-Important2021-02-02BDW) YYPhase 3A@ . . .Y. A12-15 YearsNAąHrɟ`HréPHrɟ`HréP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231281DV122312811223AąFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZHWD5AVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1223SSWAB_WEEK8 NO Non-Important2021-06-18B”DW± YYPhase 3A@ . . .Y. A12-15 YearsNAąHrɟ`HréPHrɟ`HréP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231281DV122312811223AąFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z7IV9FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1223SSWAB_WEEK10 NO Non-Important2021-07-16B½DWĶ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrɟ`HréPHrɟ`HréP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231281DV122312811223AąFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZIQVW7Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK12 NO Non-Important2021-08-03BĻDWß YYPhase 3A@ . . .Y. A12-15 YearsNAąHrɟ`HréPHrɟ`HréP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231283DV122312831223AąMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WOJWZZOther Informed Consent Informed Consent FOLLOW-UP 1223Consent NO Non-Important2021-04-02BTDWd YYPhase 3A@ . . .N. A12-15 YearsNAąHrɧHsŠHrɧHrä$Hsv.ŲHsŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231283DV122312831223AąMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WYZMNBOther Informed Consent Informed Consent FOLLOW-UP 1223Consent NO Non-Important2021-04-02BTDWd YYPhase 3A@ . . .N. A12-15 YearsNAąHrɧHsŠHrɧHrä$Hsv.ŲHsŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231283DV122312831223AąMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGFIRSRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1223Consent NO Non-Important2021-04-02BTDWd YYPhase 3A@ . . .N. A12-15 YearsNAąHrɧHsŠHrɧHrä$Hsv.ŲHsŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231283DV122312831223AąMWHITE DWDWØPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGFITHOther Informed Consent Informed Consent OPEN LABEL TREATMENT1223Consent NO Non-Important2021-05-20B„DW” YYPhase 3A@ . . .N. A12-15 YearsNAąHrɧHsŠHrɧHrä$Hsv.ŲHsŠPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231284DV122312841223AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1VM3ZS4Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1223Consent NO Non-Important2021-03-09B9DWL YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ»HrédlHrĶ»Hrédl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231284DV122312841223AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YO3VACLab performed out of window Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK10 NO Non-Important2021-06-06B’DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ»HrédlHrĶ»Hrédl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231284DV122312841223AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA`1-1Z4GUORNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK12 NO Non-Important2021-06-25B„DWø YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ»HrédlHrĶ»Hrédl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231284DV122312841223AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1Z4GUONLab performed out of window Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK14 NO Non-Important2021-07-08B²DWÅ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ»HrédlHrĶ»Hrédl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231284DV122312841223AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1ZHUFWGLab performed out of window Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK18 NO Non-Important2021-08-13BÖDWé YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ»HrédlHrĶ»Hrédl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231284DV122312841223AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAp1-1ZNJNILVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1223V4_MONTH6_L NO Non-Important2021-08-25BāDWõ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ»HrédlHrĶ»Hrédl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231284DV122312841223AŠFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZOAQNUNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK20 NO Non-Important2021-08-30BēDWś YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĶ»HrédlHrĶ»Hrédl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231285DV122312851223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XGFIU9Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1223Consent NO Non-Important2021-03-09B9DWL YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŗHrée\HrĶŗHrée\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231285DV122312851223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA@1-1Z4A0YGVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1223SSWAB_WEEK12 NO Non-Important2021-07-08B²DWÅ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŗHrée\HrĶŗHrée\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231285DV122312851223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZMUK4ANasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK14 NO Non-Important2021-07-26BÄDW× YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŗHrée\HrĶŗHrée\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231285DV122312851223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAAP1-1ZNJNIOVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1223V4_MONTH6_L NO Non-Important2021-08-25BāDWõ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŗHrée\HrĶŗHrée\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231285DV122312851223AšFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-201SLGDNasal swab collected at a visit where it was not required Laboratory REPEAT SCREENING 1 1223SSWAB_WEEK18 NO Non-Important2021-08-30BēDWś YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĶŗHrée\HrĶŗHrée\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW’YC4591001C4591001 1223 12231286DV122312861223AšFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P59PJ3Other Informed Consent Informed Consent SCREENING 1223Consent NO Non-Important2021-01-11ĮDWYNYPhase 3A@ . . .N. A12-15 YearsNAšHrĶÅHs“,HrĶÅHrź¹čHsw€ŠHs“,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1223 12231286DV122312861223AšFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P59PK3Other Informed Consent Informed Consent VACCINATION 1223Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶÅHs“,HrĶÅHrź¹čHsw€ŠHs“,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1223 12231286DV122312861223AšFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGJWOPOther Informed Consent Informed Consent FOLLOW-UP 1223Consent NO Non-Important2021-04-01BPDWc YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶÅHs“,HrĶÅHrź¹čHsw€ŠHs“,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1223 12231286DV122312861223AšFWHITE DWDWŖPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGJWRDOther Informed Consent Informed Consent OPEN LABEL TREATMENT1223Consent NO Non-Important2021-05-21B‚DW• YYPhase 3A@ . . .N. A12-15 YearsNAšHrĶÅHs“,HrĶÅHrź¹čHsw€ŠHs“,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW“YC4591001C4591001 1235 12351236DV123512361235AąMWHITE DVėDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1O7D0BLOther Informed Consent Informed Consent SCREENING 1235Consent NO Non-Important2020-11-30Į DVéYNYPhase 3A@ . . .N. A12-15 YearsNAąHr—˜ØHsŽ'@Hr—˜ØHr±·$HsrmpHsŽ'@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1235 12351236DV123512361235AąMWHITE DVėDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZQONP9Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1235COVID_A NO Non-Important2021-08-27CŠDW÷ YYPhase 3A@ . . .N. A12-15 YearsNAąHr—˜ØHsŽ'@Hr—˜ØHr±·$HsrmpHsŽ'@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1235 12351238DV123512381235AšMASIAN DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1P2FFO3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1235COVID_A1 NO Non-Important2021-01-29B6DW% YYPhase 3A@ . . .Y. A12-15 YearsNAšHrūlHr¹¬THrūlHr¹¬T..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1235 12351238DV123512381235AšMASIAN DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZHW9PCVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1235V4_MONTH6_L NO Non-Important2021-08-05BņDWį YYPhase 3A@ . . .Y. A12-15 YearsNAšHrūlHr¹¬THrūlHr¹¬T..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1235 12351244DV123512441235AŠMWHITE DVńDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS3F82Lab performed out of window Laboratory VACCINATION 1235COVID_A NO Non-Important2020-12-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAŠHrŸnpHr¼UØHrŸnpHr¼UØ..Placebo Placebo .DWŽYC4591001C4591001 1235 12351251DV123512511235AŠFWHITE DVūDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSJ0G5Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1235V102_VAX4 NO Non-Important2021-06-04B©DW£ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬u Hs‰Ü¼Hr¬u HrČ0XHsr+XHs‰Ü¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1235 12351253DV123512531235AšFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA127036001IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1235Vax 2 NO Non-Important2021-01-28BDW$ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrČvØHrā™ HrČvØHrā™ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1270 12701184DV127011841270AŠFWHITE DVėDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS3FLWLab performed out of window Laboratory VACCINATION 1270COVID_A NO Non-Important2021-01-15B-DW YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr—ÆdHr³,DHr—ÆdHr³,D..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701187DV127011871270AšFASIAN DVģDV’BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1PBHT89Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1270V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-29B:DW% YYPhase 3A@ . . .Y. A12-15 YearsNAšHr˜š<Hr±­Hr˜š<Hr±­..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701188DV127011881270AŠMASIAN DVģDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PBHT8CVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1270V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-29B:DW% YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜š“Hs—%HHr˜š“Hr±­LHss½ÄHs—%HPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701188DV127011881270AŠMASIAN DVģDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YCOMH1Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1270V102_VAX4 NO Non-Important2021-06-14BĀDW­ YYPhase 3A@ . . .N. A12-15 YearsNAŠHr˜š“Hs—%HHr˜š“Hr±­LHss½ÄHs—%HPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701194DV127011941270AŠFWHITE DVķDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z7K672Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1270V102_VAX4 NO Non-Important2021-06-16BĆDWÆ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrš2üHs™ŽČHrš2üHr³ üHsw³čHs™ŽČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701198DV127011981270AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1VIS4UBNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1270V201_SURVEIL_CONSENT NO Non-Important2021-04-01BtDWc YYPhase 3A@ . . .Y. A12-15 YearsNAąHržHr¼cōHržHr¼cō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701198DV127011981270AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YY3V1HVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK4 NO Non-Important2021-05-19B¤DW“ YYPhase 3A@ . . .Y. A12-15 YearsNAąHržHr¼cōHržHr¼cō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701198DV127011981270AąFWHITE DVšDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1ZNKOP3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK6 NO Non-Important2021-06-16BĄDWÆ YYPhase 3A@ . . .Y. A12-15 YearsNAąHržHr¼cōHržHr¼cō..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701200DV127012001270AŠMWHITE DVóDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1WOTD9QVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1270COVID_A1 NO Non-Important2021-05-04B’DW„ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHr¢@PHr»IÄHr¢@PHr»IÄ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701201DV127012011270AšFWHITE DVōDW…Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTN73BVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1270V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAšHr£<€HsbS|Hr£<€HrĀŽÜHsIØ|HsbS|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWqYC4591001C4591001 1270 12701201DV127012011270AšFWHITE DVōDW…Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCJKLFNasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1270COVID_C NO Non-Important2021-08-02BėDWŽ YYPhase 3A@ . . .N. A12-15 YearsNAšHr£<€HsbS|Hr£<€HrĀŽÜHsIØ|HsbS|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWqYC4591001C4591001 1270 12701203DV127012031270AšFWHITE DVōDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBJFDQLab performed out of window Laboratory REPEAT SCREENING 1 1270COVID_A NO Non-Important2021-07-21BßDWŅ YYPhase 3A@ . . .Y. A12-15 YearsNAšHr£q“Hr¼T@Hr£q“Hr¼T@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701204DV127012041270AĄMNOT REPORTED DVųDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OE55RWOther Informed Consent Informed Consent VACCINATION 1270Consent NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .N. A12-15 YearsNAĄHrØrHsŽ"HrØrHrÅĪHsrtHsŽ"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701205DV127012051270AŠFMULTIPLE DVųDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YO3VBFVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1270V102_VAX4 NO Non-Important2021-06-14B¶DW­ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrؾHs—¼HrؾHrĉØHsr%ōHs—¼Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701206DV127012061270AšFWHITE DVųDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OE55SROther Informed Consent Informed Consent VACCINATION 1270Consent NO Non-Important2020-12-15ADVų YYPhase 3A@ . . .N. A12-15 YearsNAšHrØĒąHsšąHrØĒąHrÅŅøHs~^ HsšąPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701208DV127012081270AąFWHITE DVłDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PG793ENasal swab not collected for the visit where it is required Laboratory VACCINATION 1270COVID_A NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr©łHs—m“Hr©łHrű¬Hstī8Hs—m“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701208DV127012081270AąFWHITE DVłDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YCOMH4Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1270V102_VAX4 NO Non-Important2021-06-14BµDW­ YYPhase 3A@ . . .N. A12-15 YearsNAąHr©łHs—m“Hr©łHrű¬Hstī8Hs—m“Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701210DV127012101270AšFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1TT78WPNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1270COVID_A NO Non-Important2021-03-22BaDWY YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŖ$ÜHrĆ)dHrŖ$ÜHrĆ)d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW[YC4591001C4591001 1270 12701210DV127012101270AšFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZGQ4W5Serology sample not collected Laboratory REPEAT SCREENING 1 1270V201_SURVEIL_CONSENT NO Non-Important2021-04-21BDWw YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŖ$ÜHrĆ)dHrŖ$ÜHrĆ)d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW[YC4591001C4591001 1270 12701210DV127012101270AšFWHITE DVłDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1X916JOParticipant entered into asymptomatic swabbing part of study after they were unblinded Other REPEAT SCREENING 1 1270V201_SURVEIL_CONSENT NO Non-Important2021-04-21BDWw YYPhase 3A@ . . .Y. A12-15 YearsNAšHrŖ$ÜHrĆ)dHrŖ$ÜHrĆ)d..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW[YC4591001C4591001 1270 12701213DV127012131270AĄFWHITE DVśDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZGQ4W8Serology sample not collected Laboratory FOLLOW-UP 1270V201_SURVEIL_CONSENT NO Non-Important2021-03-15BYDWR YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«čHs—58Hr«čHrĘÄ Hsr%Hs—58Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701213DV127012131270AĄFWHITE DVśDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YO3EWDVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1270V102_VAX4 NO Non-Important2021-06-14B“DW­ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«čHs—58Hr«čHrĘÄ Hsr%Hs—58Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701215DV127012151270AĄFASIAN DVśDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1OS50B2Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1270V2_VAX2_L NO Non-Important2021-01-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr«K“HrŠB Hr«K“HrŠB ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701217DV127012171270AĄFWHITE DVśDWÆPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YCOMH7Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1270V102_VAX4 NO Non-Important2021-06-16B¶DWÆ YYPhase 3A@ . . .N. A12-15 YearsNAĄHr«lüHs™ŽČHr«lüHrČbDHsru¤Hs™ŽČPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701218DV127012181270AąFMULTIPLE DVśDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YO3EWHVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1270V102_VAX4 NO Non-Important2021-06-15BµDW® YYPhase 3A@ . . .N. A12-15 YearsNAąHr«} Hs˜£Hr«} HrĒ- Hsu¼Hs˜£Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701223DV127012231270AŠMWHITE DVūDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YCOMHAVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1270V102_VAX4 NO Non-Important2021-06-15B“DW® YYPhase 3A@ . . .N. A12-15 YearsNAŠHr¬ŃxHs˜m,Hr¬ŃxHrČ}ģHsvxčHs˜m,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701224DV127012241270AĄFWHITE DVžDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA128599201IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1270Vax 2 NO Non-Important2021-01-12BDW YYPhase 3A@ . . .Y. A12-15 YearsNAĄHr°”üHrĶĄ,Hr°”üHrĶĄ,..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701225DV127012251270AąFASIAN DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA128599501IP documentation error – IP preparation form errors Investigational ProductVACCINATION 1270Vax 2 NO Non-Important2021-01-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAąHr»”Hs˜uŲHr»”HrÕj\Hs|ĢčHs˜uŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1270 12701225DV127012251270AąFASIAN DWDW®Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YKK1KGNasal swab not collected for the visit where it is required Laboratory OPEN LABEL TREATMENT1270COVID_B NO Non-Important2021-05-25B”DW™ YYPhase 3A@ . . .N. A12-15 YearsNAąHr»”Hs˜uŲHr»”HrÕj\Hs|ĢčHs˜uŲPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWŽYC4591001C4591001 1270 12701232DV127012321270AąFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZCE9T6Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK16 NO Non-Important2021-07-20BÅDWŃ YYPhase 3A@ . . .Y. A12-15 YearsNAąHrÄ}“Hrį€ŠHrÄ}“Hrį€Š..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701234DV127012341270AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1ZBKAZ0Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK16 NO Non-Important2021-07-20BÄDWŃ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrÅv`Hrār°HrÅv`Hrār°..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701235DV127012351270AĄFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1YY3V1KVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK14 NO Non-Important2021-06-28B®DW» YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŇ|HrātHrŇ|Hrāt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701235DV127012351270AĄFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1ZNKOP6Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK16 NO Non-Important2021-07-20BÄDWŃ YYPhase 3A@ . . .Y. A12-15 YearsNAĄHrŇ|HrātHrŇ|Hrāt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701239DV127012391270AŠFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1Z3U36UVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK12 NO Non-Important2021-07-01B°DW¾ YYPhase 3A@ . . .Y. A12-15 YearsNAŠHrĘūpHrā“HrĘūpHrā“..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701240DV127012401270AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA1-1XTRFN2Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK10 NO Non-Important2021-06-07B˜DW¦ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĒČHrāĆHrĒČHrāĆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701240DV127012401270AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA 1-1YVHD7LVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK12 NO Non-Important2021-06-16B”DWÆ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĒČHrāĆHrĒČHrāĆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701240DV127012401270AšMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)A€A€12-15 YearsAA01-1YVHDIJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1270SSWAB_WEEK14 NO Non-Important2021-06-23BØDW¶ YYPhase 3A@ . . .Y. A12-15 YearsNAšHrĒČHrāĆHrĒČHrāĆ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701241DV127012411270AŠMWHITE DWDW­Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YCOMHDVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1270V102_VAX4 NO Non-Important2021-06-14BŸDW­ YYPhase 3A@ . . .N. A12-15 YearsNAŠHrĒ%(Hs—eHrĒ%(HrįxœHstŽHHs—ePlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701242DV127012421270AąFWHITE DWDW£Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1TZ3WJPVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1270V2_VAX2_L NO Non-Important2021-02-03BDW* YYPhase 3A@ . . .N. A12-15 YearsNAąHrČN”HsŠ(čHrČN”HrźwŠHsna€HsŠ(čPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1270 12701244DV127012441270AąFWHITE DWDW¦Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P93YUJUrine pregnancy test not performed. Laboratory VACCINATION 1270V2_VAX2_L NO Non-Important2021-01-12A DW YYPhase 3A@ . . .N. A12-15 YearsNAąHrĢqøHsŽ:xHrĢqøHréQ4HssÕčHsŽ:xPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWY